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Abstract 
 
The Metabolic Fate and Bioactivity of Anthocyanins in Humans 
 
Rachel M. de Ferrars 
 
Anthocyanins, the class of flavonoid responsible for giving a red hue to many berries, have 
been associated with a decreased risk of cardiovascular disease. However, numerous 
intervention studies feeding anthocyanin-rich foods report limited (<1%) bioavailability of 
the parent anthocyanins in vivo. Due to the instability of anthocyanins at neutral pH, it is 
postulated that degradation products and metabolites of anthocyanins may be responsible for 
the perceived bioactive effects. The aims of the present thesis were: (1) To model and 
establish analytical methods for the extraction and quantification of putative anthocyanin 
metabolites in urine, serum and faecal samples. (2) To identify and explore the 
pharmacokinetics of anthocyanin metabolites via the analysis of urine, serum and faecal 
samples from two human interventions, feeding either (a) 500 mg of isotopically (
13
C5) 
labelled anthocyanin or (b) 500 mg elderberry anthocyanins for 12 wks. (3) To explore the 
impact of acute (500 mg) versus chronic (500 mg/day for 12 wks) anthocyanin consumption 
on their metabolism and (4) To investigate the anti-inflammatory activity of six anthocyanin 
metabolites at physiologically relevant concentrations (0.01 µM to 10 µM) using human 
umbilical vein endothelial cells (HUVECs). Following the consumption of 500 mg 
elderberry anthocyanins, 28 anthocyanin metabolites were identified in urine and 21 in 
plasma, with the phenolic metabolites within plasma identified at 45 fold higher levels than 
their parent compounds. Similar results were observed within the 
13
C-labelled anthocyanin 
intervention, where 17 
13
C-labelled compounds were identified in serum and 31 in urine. 
However, chronic consumption of anthocyanins had no impact on the formation of the 
metabolites. The cardiovascular bioactivity of anthocyanins may be linked to the anti-
inflammatory activity of their metabolites. IL-6 and VCAM-1 are cytokines and adhesion 
molecules integral to the initiation and progression of inflammation. In vitro, anthocyanin 
metabolites reduced CD40L and TNF-α stimulated expression of the inflammatory markers, 
sVCAM-1 and IL-6, indicating that the anti-inflammatory effects of anthocyanins are likely 
attributed to their metabolites. In conclusion, the present thesis provides a new 
understanding into the metabolism and bioactivity of anthocyanins, which should provide an 
informative insight into how the consumption of higher intakes of anthocyanins may 
contribute to optimising human health.  
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Flavonols Flavanones Isoflavonoids
Chapter 1. Anthocyanins: Review of the 
scientific literature 
 
1.1. Introduction 
In recent years, polyphenols have become a major focus of many epidemiological and 
bioavailability studies. Initially the focal reason for this interest was the identification of 
their potential antioxidant properties. Whilst this concept is no longer accepted, evidence 
suggests they may have several properties, which make them potentially important 
compounds for the prevention of multiple diseases (cardiovascular, neurodegenerative, 
obesity and cancer) (Baur et al., 2006; de Pascual-Teresa et al., 2010; Feng et al., 2007; 
Hooper et al., 2008; Ramassamy, 2006; Vauzour et al., 2008; Wallace, 2011). Polyphenols 
can be divided into three main groups: tannins, lignins and flavonoids. Flavonoids comprise 
the largest and most renowned division of polyphenols and consist of several thousand 
compounds, consumed as part of an everyday plant-rich diet. Flavonoids can be classified 
into six main subgroups based on the variation in their heterocyclic C-ring: anthocyanidins, 
flavan-3-ols, flavonols, flavones, flavanones and isoflavonoids (Hollman, 2004; Zamora-Ros 
et al., 2010) (Figure 1.1). The following review summarises the current literature pertaining 
to the metabolism, degradation, bioavailability and bioactivity of anthocyanidins, which in 
plants are found as glycosylated structures termed ‘anthocyanins’. 
 
Figure 1.1 General structures of common dietary flavonoids.  
 
Adapted from (Hollman, 2004; Zamora-Ros et al., 2010). 
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Anthocyanins (Greek; anthos=flower, kyanos=blue) are common water-soluble pigments, 
widely distributed in plant tissues, found in the leaves, flowers and fruits, and are partially 
responsible for giving many plants a characteristic red to purple hue (Chalker-Scott, 1999). 
Anthocyanins have a number of properties, which may produce health benefits. They have 
been shown to reduce risk factors of cardiovascular and inflammatory diseases (de Pascual-
Teresa et al., 2010; Hooper et al., 2008; Wallace, 2011), neurodegenerative diseases such as 
Alzheimer’s and Parkinson’s disease and cognitive function (Tarozzi et al., 2007), cancer 
(Feng et al., 2007) and obesity (Sasaki et al., 2007). For example, a 14 year follow-up study 
of 157,000 people, found an increase in anthocyanin intake from 6 mg/day to 19 mg/day was 
associated with an 8% reduction in the relative risk of hypertension (Cassidy et al., 2011) 
and an increase in anthocyanin intake from 8 to 24 mg/day was associated with a 3 mm Hg 
reduction in central systolic blood pressure (Jennings et al., 2012). The present work focuses 
on the bioactivity and the beneficial properties of anthocyanin metabolites against 
cardiovascular disease (CVD).  
 
1.2. Anthocyanin chemistry 
The basic structure of anthocyanins is based on the flavylium ion (2-phenylchromenylium) 
and consists of cationic oxygen-containing heterocycle pyran with a fused benzene ring. 
There are six predominant anthocyanidins (cyanidin, delphinidin, pelargonidin, peonidin, 
petunidin and malvidin) found in plants, which account for over 90% of the 625 
anthocyanins currently identified (Wallace, 2011). Anthocyanins differ according to their 
types of glycosylation and acylation and the number and position of hydroxyl- and methoxy-
groups on their B-ring  (Wu et al., 2006) (Figure 1.2). Glycosylation commonly occurs with 
glucose, galactose, rhamnose, arabinose and xylose, with anthocyanins most frequently 
forming 3-monosides, 3-biosides (disaccharides), 3-triosides and 3,5-diglycosides of these 
sugars (Castañeda-Ovando et al., 2009; McGhieandWalton, 2007). Cyanidin-3-glucoside is 
the most common anthocyanin within the UK diet, with cyanidin accounting for 50% of 
anthocyanidins in fruit and vegetables (Figure 1.2). Anthocyanins have a maximum 
absorbance in the visible range, between 465 and 550 nm, with a second maxima between 
270 and 280 nm. 
 
1.3. Anthocyanins in plants 
The synthesis of an anthocyanin from its precursors, 4-coumaroyl-CoA and malonyl-CoA, 
requires over seven enzymes and a monosaccharide molecule (Gould, 2004; Shirley, 1996). 
Anthocyanins play a vital role in a plant’s survival. The red colour of anthocyanins plays a 
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role in attracting and repelling various animals, and can protect photosynthetic apparatus 
from photoinhibition resulting from overloading of the photosynthetic electron transport 
chain in strong light (Gould, 2004). Furthermore, the induction of anthocyanins in cold 
temperatures can reduce the risk of photo-oxidative damage to leaves as they senesce in 
autumn, which would otherwise decrease the efficiency of nutrient retrieval (Feild et al., 
2001). Similarly, a high anthocyanin content in leaves increases the osmotic potential, 
thereby delaying freezing to protect the leaf from a late frost, or minimising 
evapotranspiration to increase the plants hardiness to drought (Chalker-Scott, 1999).  
 
Figure 1.2 Structural identification of anthocyanidins and their approximate distribution in 
nature. 
R1 and R2 represent functional groups. Adapted from (Castañeda-Ovando et al., 2009; Wu et 
al., 2006). 
 
1.4. Dietary consumption of anthocyanins 
Anthocyanins are naturally abundant constituents within our diets, regularly consumed in 
red vegetables and berries (Neveu et al., 2010). Typical anthocyanin concentrations within 
berries range from 72 to 500 mg/100 g fresh fruit, but in some berries, can reach 
concentrations of 1300 mg/100 g fresh fruit (Neveu et al., 2010) (Table 1.1). Anthocyanin 
content varies considerably between species and are highly dependent upon many factors 
such as environmental conditions, ripeness, cultivar, cultivation site, processing and storage 
(Del Rio et al., 2010). Furthermore, anthocyanin intake varies considerably depending on 
socio-demographic and lifestyle factors (Chun et al., 2007) and can range several-fold 
depending on individual dietary patterns (Burton-Freeman, 2010).  
 
Estimates of habitual anthocyanin intake are poorly established, principally due to a lack of 
available data in food composition databases and variations of estimated intake between 
method of dietary assessment (Manach et al., 2005). However, estimates range from 3 to 47 
mg/day [3.1 mg/day, United States (Chun et al., 2007); 12.5 mg/day, United States (Wu et 
al., 2006); 18 mg/day, Spain (Zamora-Ros et al., 2010) and 47 mg/day, Finland (Ovaskainen 
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Petunidin -OH -OCH3 7%
Malvidin -OCH3 -OCH3 7%
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et al., 2008)]. In addition, large doses (> 500 mg) of anthocyanins can be obtained from 
single servings of some anthocyanin rich berries, vegetables and juices (Table 1.1). 
 
Table 1.1 Anthocyanin content within common foods.  
 
Numbers represent total of all glycoslated forms of anthocyanins. Cy, cyanidin; Pel, 
pelargonidin; peo, peonidin; del, delphinidin; pet, petunidin; mal, malvidin. Data derived 
from (Neveu et al., 2010). 
 
1.5. Anthocyanin stability 
Isolated anthocyanidins are unstable and are susceptible to factors including light, pH, 
temperature and oxygen (Fossen et al., 1998).  Anthocyanidins can form several different 
pH-dependent structural isoforms depending on the pH of the solution (Manach et al., 2005). 
The pH dependent transformation of anthocyanidins can be observed through the dramatic 
colour change, which is caused by their unique positive charge and chromophore giving 
them their characteristic pH dependent colour. The relative abundance of each isoform at 
equilibrium varies with pH and the structure of the anthocyanidin (MazzaandBrouillard, 
1987), however in general, the red-blue coloured flavylium cation is the predominate species 
at pH 1 (Figure 1.3A). As the pH increases to pH 2-4, the blue coloured quinoidal species 
can be observed (Figure 1.3B-D). At pH 5-6, a colourless carbinol pseudobase forms (Figure 
1.3E) followed by a pale yellow chalcone (Figure 1.3F), and a highly reactive α-diketone, 
formed when the C-ring structure of the carbinol pseudobase opens (Fossen et al., 1998).  
 
Within plants, warm climates result in lower anthocyanin content. This is best observed 
within red wines, where hot regions, such as California, do not produce grapes containing 
the same anthocyanin content as those produced in cooler regions, due to decreased 
synthesis and increased catabolism of the anthocyanins at higher temperatures (Shaked-
Sachray et al., 2002). Within a laboratory setting, the temperature stability of anthocyanins 
is of importance as it can affect the identification and recovery of anthocyanins and the 
consistency of data during processing and storage. At constant pH, the degradation of 
Food
Mean Content (mg) per 100 g FW
Cy Pel Peo Del Pet Mal Total
Black elderberry 1315 2 - - - - 1317
Blackberry 173 - - - - - 173
Blackcurrant 187 2 1 392 10 - 592
Highbush blueberry 10 - 2 46 29 48 134
Black grape 1 - 6 3 3 59 72
Strawberry 5 68 - - - - 73
Red Onion 3 - - 7 - - 9
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anthocyanins increases within increasing temperature (Kırca et al., 2007; Patras et al., 2010). 
This has been observed during sample processing, and during storage. For example, black 
carrot anthocyanins stored at pH 4.3 demonstrated a half-life of 71.8 weeks at 4 ºC, 4.1 
weeks at 37 ºC, 17 h at 70 ºC and 4.5 h at 60 ºC (Kırca et al., 2007).  
 
The stability of glycosylated anthocyanins is greatly increased over anthocyanidin 
aglycones; in a degradation study, 100% loss in anthocyanidins aglycones was observed for 
samples stored in buffer at 37 °C, pH 7 for 2 h, in contrast, the anthocyanin glycosides 
demonstrated a loss of 20 to 100% over a 12 h period (Woodward et al., 2009). The stability 
of anthocyanins is also influenced by their B-ring moieties; in vitro pelargonidin-3-
glucoside, cyanidin-3-glucoside and delphinidin-3-glucoside demonstrated a loss of 20%, 
40% and 100% respectively over 12 h (Woodward et al., 2009). Therefore, whilst the 
presence of a sugar moiety infers increased stability, this is also influenced by the B-ring 
moieties, with the presence of additional hydroxyl and methoxy groups appearing to 
decrease the molecules stability (Fossen et al., 1998; Woodward et al., 2009). 
 
Figure 1.3 Anthocyanins pH dependent chemical structures.  
 
Adapted from  (Castañeda-Ovando et al., 2009). 
 
Following exposure to neutral pH, temperature or enzymes (β-glucosidase) anthocyanins 
degrade to form phenolic acid and phloroglucinaldehyde components in vitro (Kay et al., 
2009; Piffaut et al., 1994; Seeram et al., 2001; Woodward et al., 2009). Due to variations in 
their B-ring, cyanidin degrades to form protocatechuic acid whilst peonidin forms vanillic 
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acid (Figure 1.4). These results suggest that due to the warm, basic physiochemical 
conditions found in the gastrointestinal tract (GIT) (Fallingborg, 1999), a large proportion of 
ingested anthocyanins may also be degraded into phenolic acids and aldehyde. Yet there is 
still considerable uncertainty as to what occurs in vivo. In one paper, protocatechuic acid 
was reported to be a major metabolite of cyanidin glycoside in humans (Vitaglione et al., 
2007), yet subsequent papers have failed to detect protocatechuic acid in rat blood plasma, 
stating protocatechuic acid is not a major intestinal metabolites of cyanidin glycosides 
(Ichiyanagi et al., 2007). Reasons for these discrepancies may be due to substantial 
degradation reactions within the small intestine and colon and further conjugation reactions 
occurring in the intestine, kidneys or liver.  
 
Figure 1.4 Degradation of anthocyanidins into reactive α-diketone and monomeric phenolic 
acids and aldehyde.  
 
R1 and R2 represent functional groups. Adapted from (Fleschhut et al., 2006; 
KepplerandHumpf, 2005; Woodward et al., 2009). 
 
The pH of urine is also of significance, as it can affect the elimination of an analytes. The pH 
of urine is typically acidic, but can range from pH 4.5 to 8, depending on fluid ingestion and 
diet, with more acidic urine caused by the consumption of acidic fruits such as cranberries 
(Freudenthaler et al., 1998; Hertrampf et al., 1991; Miller et al., 2009; Roy et al., 1987). For 
example, the renal excretion of salicylate is highly dependent upon pH, and in order to treat 
an aspirin overdose, urine is alkalinised in order to enhance the elimination of salicylate 
(Miller et al., 2009; Proudfoot et al., 2003). In brief, this may occur because the ionisation of 
weak acids, such as salicyclic acid, is increased in an alkali environment, this results in a 
decrease in their reabsorption with increasing pH, following filtration at the glomeruli 
(Proudfoot et al., 2003) 
 
  
Anthocyanidin Phenolic acid R1 R2
Cyanidin Protocatechuic acid -OH -H
Delphinidin Gallic acid -OH -OH
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1.6. Anthocyanin bioavailability 
In contrast to flavanones and flavanols such as epicatechin, which can reach micromolar 
concentrations, anthocyanins are present at nanomolar concentrations in plasma (Manach et 
al., 2005; WilliamsonandManach, 2005). Anthocyanins are rapidly absorbed and reach 
maximum plasma concentration within 30 min to 4 h in humans depending on the contents 
of the stomach and the compounds ingested (Table 1.2). In a study feeding 400 mL red 
grape juice containing 284 mg anthocyanins, anthocyanins reached maximal plasma 
concentrations of 223 nM, 0.5 h following consumption (Bitsch et al., 2004a). Similarly, a 
study feeding blackcurrant concentrate containing 2380 mg anthocyanins detected maximal 
plasma concentrations of 147 nM, 1.5 h following consumption (Matsumoto et al., 2001).  
 
The recovery of anthocyanins and anthocyanin metabolites in urine has also been low, 
typically ranging from 0.004 to 0.11% of the ingested dose (Bub et al., 2001; Kay et al., 
2005; Manach et al., 2005). Whilst a few studies have measured levels of anthocyanin 
excretion up to 5% after strawberry, red wine and cranberry consumption (Felgines et al., 
2003; Lapidot et al., 1998; Ohnishi et al., 2006), these cases are exceptions, and still only 
comprise a small proportion of total anthocyanin ingested (Table 1.2).  
 
Table 1.2 Summary of key pharmacokinetic data derived from selected human anthocyanins 
bioavailability studies. 
Food 
consumed 
Anthocyanin 
dose 
(mg) 
Study 
duration 
(h) 
Plasma 
Cmax 
(nM) 
Plasma 
Tmax 
(h) 
Urinary 
excretion 
(%) 
Reference 
Red wine 68 6 1 0.3 0.03 (Bub et al., 2001) 
Red wine 95 24 4 1.8 0.05 
(Garcia-Alonso et al., 
2009) 
Strawberry 179 24 - - 1.80 (Felgines et al., 2003) 
Strawberry 222 24 274 1.1 0.75 (Mullen et al., 2008a) 
Red grape 284 7 223 0.5 0.23 (Bitsch et al., 2004a) 
Purple sweet 
potato 
311 24 2 1.5 0.02 (Harada et al., 2004) 
Purple carrots 416 24 6 2.0 0.03 (Kurilich et al., 2005) 
Cranberry 651 24 - - 5.00 (Ohnishi et al., 2006) 
Elderberry 720 24 97 1.2 0.05 (Cao et al., 2001) 
Chokeberry 721 24 96 2.8 0.15 (Kay et al., 2005) 
Elderberry 722 7 95 1.0 0.04 (Netzel et al., 2005) 
Blueberry 1200 4 29 4.0 0.003 (Mazza et al., 2002) 
Chokeberry 1300 24 351 2.0 - (Kay et al., 2004) 
Blackcurrant 2380 8 147 1.5 0.11 
(Matsumoto et al., 
2001) 
Cmax, maximum concentration; Tmsx, time of maximum concentration. 
 
As of yet, no conclusive explanation has been given for the low anthocyanin recovery 
observed within these studies. It is possible that due to their unstable nature, the 
anthocyanins are present as degradation products, intermediates or metabolites, which 
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remain undetected. This remains a possibility despite the best efforts of many researchers, 
due to numerous potential structures, the complex profiles formed following conjugation and 
a lack of analytical standards. It is also probable that plasma and urine samples may give an 
inaccurate assessment of anthocyanin bioavailability due to the rapid removal of 
anthocyanins from the bloodstream or the requisition of anthocyanins by body tissues 
(Crozier et al., 2010). The large number of structures present in food sources and the ability 
of anthocyanin metabolism to convert their form (i.e 3'-methylation of cyanidin results in the 
formation of peonidin) further complicates the elucidation of the bioavailability of 
anthocyanins (Del Rio et al., 2010).  
 
1.7. Anthocyanin metabolism and absorption 
In order for anthocyanins to elicit biological effects in vivo, sufficiently high concentrations 
of the bioactive molecule must be present within the circulation for a sufficient length of 
time. However, there are considerable gaps in our knowledge concerning the metabolism of 
anthocyanins. Following consumption, anthocyanins enter the stomach, followed by the 
small intestine and colon, where they may undergo extensive degradation, metabolism and 
catabolism. This may be followed by absorption and subsequent phase I and II metabolism 
(Levsen et al., 2005; WangandHo, 2009) within body tissues such as the liver and kidneys 
(Wang et al., 2009), before excretion through the bilary or urinary routes.  
1.7.1. Anthocyanin stability and absorption in the stomach.  
The acidic condition of the gastric content provides a favourable environment for 
anthocyanins (He et al., 2009; Hollman et al., 1995; McDougall et al., 2005a; McDougall et 
al., 2005b), which have a structure which is highly influenced by pH (Miyazawa et al., 
1999). In simulated gastrointestinal digestion studies, where red wine (McDougall et al., 
2005b), raspberry (McDougall et al., 2005a), chokeberry (Bermúdez-Soto et al., 2007) and 
red cabbage (McDougall et al., 2007) anthocyanins were incubated with pepsin and 
hydrochloric acid for 2 h at 37 °C, total anthocyanin content remained stable. However, as in 
vitro digestion simulations cannot mimic possible uptake of anthocyanins via active 
transport processes, a number of investigations on the fate of anthocyanins in the stomach in 
murines have been conducted (Passamonti et al., 2003; Talavéra et al., 2003). A study 
injecting the stomach (with a ligated pylorus) of fasted (24 h) and anesthetised rats with a 
physiologic buffer containing 14 µM anthocyanin extract found a high proportion (19-37% 
depending on anthocyanin structure) of anthocyanin mono-glycosides were absorbed intact, 
based on analysis of stomach contents and plasma after 30 min (Talavéra et al., 2003). 
Similar results were obtained, with anthocyanins detected in the plasma within 6 min, when 
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1 mM grape anthocyanins were introduced into the sealed stomach of rats through a tube 
entering via the duodenum (Passamonti et al., 2003).  
 
A proposed method for the uptake of anthocyanins within the stomach is via the 
bilitranslocase transporter (Passamonti et al., 2003), an anion carrier located within the liver 
and gastric mucosa, as anthocyanins have been shown to inhibit its activity (Passamonti et 
al., 2002). Absorption of anthocyanins within the stomach would explain the intact and rapid 
absorbance of anthocyanins in plasma, which can appear within a few minutes of oral 
administration in murines (He et al., 2009; Matsumoto et al., 2001; Tsuda et al., 1999) and 
within 60 min in humans (Bub et al., 2001; Matsumoto et al., 2001), yet the plausibility of 
this theory is uncertain. Anthocyanins are present as cations in gastric conditions, the 
absorbance of nutrients from the stomach is unusual and the rapid appearance of 
anthocyanins within the circulatory system in humans may solely result from absorbance in 
the upper small intestine, particularly considering most studies dose fasted volunteers with 
liquid solutions of anthocyanins. Rat studies which have directly measured anthocyanin 
absorbance within the stomach, were carried out under exceptionally unnatural conditions, 
with high concentrations of aqueous anthocyanins administered directly to the sealed 
stomachs of fasted and anaesthetised murines by intubation (Passamonti et al., 2003) or 
injection (Talavéra et al., 2003). It is therefore uncertain as to how relevant these studies are 
when looking at anthocyanin metabolism in humans. 
1.7.2. Anthocyanin absorption in the small intestine.  
Upon entry into the small intestine, anthocyanins are subjected to an increased pH and a 
gradually increasing array of bacteria (Berg, 1996). Within humans, absorption studies 
conducted using ileostomy volunteers provide the clearest picture of the passage of 
anthocyanins prior to reaching the colon. A study feeding 300 g raspberries to patients who 
had an ileostomy obtained an average recovery of 40% of the ingested dose within the ileal 
fluid. However, this ranged from 6% for cyanidin-3-glucoside to 75% recovery for 
pelargonidin-3-glucoside ( onz lez-Barrio et al., 2010), thereby emphasising the impact 
additional hydroxyl groups have on the molecules stability in vivo. Similar results were 
obtained from a study feeding volunteers with an end ileostomy 300 g blueberries, where 
recoveries of the ingested anthocyanins included 28% for cyanidin-3-glucoside, 45% for 
cyanidin-3-arabinoside and 85% for malvidin-3-arabinoside (Kahle et al., 2006).  These 
results indicate that anthocyanins containing few hydroxyl or methoxy groups within their 
B-ring and attached to complex sugar moieties likely remain intact until the large intestine; 
however, in the case of anthocyanins such as cyanidin-3-glucoside, a high proportion of the 
degradation, metabolism and/or absorption appears to occur before the large intestine. 
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Nevertheless, there are limitations involved with these studies; ileostomy patients often have 
an increased gut permeability, electrolyte imbalance, lower production of urine and the 
terminal gut often develops its own microflora (WilliamsonandClifford, 2010). In addition, 
the fate of the anthocyanins remains unknown, as only their disappearance from the small 
intestine is monitored.  
 
In contrast to other flavonoids, such as quercetin which require deglycoslation prior to 
absorption, the absorption of intact anthocyanin glycosides has been confirmed through the 
presence of low concentrations of anthocyanins identified in the plasma of rats and humans 
(McGhie et al., 2003; Milbury et al., 2002; Miyazawa et al., 1999; Mülleder et al., 2002; 
Wu et al., 2002). Furthermore, a study which continually perfused the intestinal lumen of 
anesthetised rats with physiological buffer (pH 6.6) containing 10 µM anthocyanins for 45 
min noted an absorption of 11 to 22% of the perfused dose (Talavéra et al., 2004). The 
mechanism of absorption for anthocyanins through the epithelial cells of the intestinal lumen 
is uncertain, but may be aided by lactase phlorizin hydrolase (LPH), sodium dependent 
glucose transporter (SGLT1) or glucose transporters 2 (GLUT2) (Crozier et al., 2009; Del 
Rio et al., 2010). 
 
LPH, a β-glycosidase enzyme found on the brush border of the intestinal epithelial cells, is 
thought to hydrolyse a range of flavonoid glycosides, including the structurally similar 
flavonol, quercetin (Day et al., 2000). The hydrolysis of quercetin glycosides releases the 
more lipophilic aglycone form, which may subsequently enter the endothelial cells by 
passive diffusion (Figure 1.5) (Crozier et al., 2009; Day et al., 2000; Del Rio et al., 2010). 
The hydrolysis of anthocyanins by LPH is probable, as anthocyanidin aglycones have been 
reported within rat jejunum (Tsuda et al., 1999), although not in plasma. As the aglycone 
structures are unstable at neutral pH, the anthocyanidins likely subsequently degrade to form 
phenolic acid and aldehyde. Alternatively, glycosides may be actively transported into the 
epithelial cells and subsequently hydrolysed by cytosolic β-glucosidase (CG). SGLT1 has 
been proposed to play a role in the active transport of flavonoid glycosides (Gee et al., 2000; 
Gee et al., 1998; Hollman et al., 1999). Quercetin glycosides have been found to interact 
with intestinal glucose transporters in rat jejunum (Gee et al., 1998) and studies on the 
absorption of quercetin-4'-glucoside and quercetin-3'-glucoside demonstrated a reduction in 
flavonoid transport when glucose or phlorizin (SGLT1 inhibitors) were present, thus 
suggesting SGLT1 may have a role in mucosal uptake of the flavonoids (Walgren et al., 
2000; Wolffram et al., 2002). However, there have been a number of contradictory studies 
attesting to the role of SGLT1 in the transport of flavonoids. The reduction in flavonoid 
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transport in the presence of SGLT1 inhibitors may be caused by the flavonoids interacting 
with, rather than being transported by SGLT1, especially considering sequential studies 
using Xenopus oocytes expressing human SGLT1 found none of the tested flavonoids were 
transported by SGLT1 (Arts et al., 2002; KottraandDaniel, 2007).  
 
Another possible mechanism for the absorption of anthocyanins through intestinal epithelial 
is via glucose transporters 2 (GLUT2) (Del Rio et al., 2013; Faria et al., 2009; 
ManzanoandWilliamson, 2010). An experiment conducted using caco-2 cells found that 
anthocyanin transport across cells pretreated with anthocyanins was increased compared to 
control cells, and the expression of GLUT2 expression was significantly increased in these 
cells (Faria et al., 2009). Following absorption into the epithelial cell, anthocyanins and 
anthocyanin metabolites may enter the portal circulation via diffusion, or via a transporter 
such as GLUT2. The use of the GLUT2 transporter is supported by evidence which shows 
polyphenols inhibiting GLUT2 facilitated glucose efflux on the basolateral side of cells 
(Manzano et al., 2010) (Figure 1.5). Alternatively, flavonoid conjugates formed in the 
intestinal mucosa may be secreted back into the gut lumen using the multiresistant protein 2 
(MRP2) transporter and P-glycoproteins (Figure 1.5) (Crozier et al., 2009; Del Rio et al., 
2010; Del Rio et al., 2013).  
 
Figure 1.5 Potential mechanisms for anthocyanin absorption 
 
 
CG, cytosolic β-glucosidase; GLUT2, glucose transporters 2; LPH, lactase phlorizin 
hydrolase; MRP2, multiresistant protein 2; SGLT1, sodium dependent glucose transporter; 
SULT, sulfotransferase; UDPDG, uridine-5'-diphospho-glucuronosyltransferase. Adapted 
from (Day et al., 2000; Gee et al., 2000; McGhie et al., 2007; Walgren et al., 2000). 
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1.7.3. Anthocyanin metabolism and absorption in the colon 
Anthocyanins not absorbed, degraded or metabolised within the small intestine reach the 
large intestine, where they are exposed to a large array of microflora; over 400 species and 
10
10
 – 1011 microbes per gram intestinal contents are predicted to be present (Arumugam et 
al., 2011; Berg, 1996; Qin et al., 2010), with Bacteroides species, Clostridium species and 
Eubacterium species making up the majority of the microflora within the intestines 
(WilliamsonandClifford, 2010).  Ex vivo faecal fermentation studies of anthocyanins have 
reported the deglycosylation of anthocyanins and the appearance of their aglycones, 
phloroglucinaldehyde and their corresponding B-ring degradation products following 
incubation with a human faecal suspension within an anaerobic chamber (Aura et al., 2005; 
Fleschhut et al., 2006;  onz lez-Barrio et al., 2010; Hassimotto et al., 2008; Keppler et al., 
2005). Only a slight decrease in the anthocyanin content was observed in the heat-
inactivated faecal suspension, indicating the bacteria were primarily responsible for the 
disappearance of anthocyanins (Fleschhut et al., 2006).  
 
In addition to the parent anthocyanins, the microbial metabolism of the phenolic degradation 
products has also been investigated. A faecal fermentation study, which incubated phenolic 
acids and phloroglucinaldehyde in sterilised caecum inoculum from pigs found phenolic 
acids were stable within the sterilised samples whilst phloroglucinaldehyde was degraded 
extensively, with only small amounts remaining detectable after 24 h. The possible reactions 
involved in the degradation of aldehydes include condensation with free amine (NH2) groups 
of amino acids or proteins or the formation of an imine (Keppler et al., 2005).  
 
Despite the detection of B-ring degradation product in a number of in vitro fermentation 
studies, the measured amounts of phenolic degradation products formed do not account for 
the entire starting concentration of anthocyanin, therefore, it is likely that further unknown 
anthocyanin intermediates are present or that further microbial metabolism takes place 
(Keppler et al., 2005). In addition to the Odeglycosylation and degradation of anthocyanins, 
the microflora are capable of C-deglycosylation, hydrolysis of esters and deglucuronidation. 
The resulting aglycones are susceptible to aromatic dehydroxlation, demethoxylation and 
demethylation, hydrogenation, and α- and β-oxidation of the aliphatic elements generated 
following the rupture of the heterocyclic oxygen ring (WilliamsonandClifford, 2010). The 
dehydroxylation of ortho-dihydroxy substrates, such as protocatechuic acid, can occur either 
at a meta (3-OH) or para (4-OH) position, however dehydroxylation at the meta  position is 
less efficiently removed, so meta hydroxyl catabolites often predominate 
(WilliamsonandClifford, 2010). Demethylation of anthocyanin degradation products has 
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been reported in vitro, with a pig faecal fermentation study observing the demethylation of 
vanillic acid and sinapic acid to from gallic acid and protocatechuic acid respectively 
(Keppler et al., 2005). Therefore, the degradation and transformation of anthocyanins by 
colonic microflora can result in the formation of a complex range of phenolic structures. 
 
Comparatively few of the bacterial enzymes responsible for the transformation of phenolic 
compounds within the GIT have been characterised. However, hydroxylation of the 
flavonoid A-ring has been demonstrated with Pseudomonas species and Eubacterium species 
are known to degrade flavonoids anaerobically via deglycosylation and cleaving the C-ring 
(WilliamsonandClifford, 2010). 
1.7.4. Phase II metabolism of anthocyanins.  
Prior to passage into the portal circulation from the small intestine, anthocyanins may 
undergo metabolism, forming glucuronidated, sulfated and methylated metabolites, through 
the action of uridine-5’-diphospho-glucuronosyltransferase (UDPDG), sulfotransferase 
(SULT) and catechol-O-methyltransferase (COMT) enzymes respectively (Crozier et al., 
2009; PiskulaandTerao, 1998; Tsuda et al., 1999), which are abundant within the 
gastrointestinal tract (Riches et al., 2009; Zhang et al., 2007). Within the portal circulation, 
anthocyanin metabolites may be subjected to further phase II metabolism by UDPDG, SULT 
and COMT enzymes within the liver, and following entry into the systemic circulation, may 
be further metabolised within tissues such as the kidneys and lungs (Talavéra et al., 2005). 
Following administration of anthocyanins to humans, glucuronidated, sulfated and 
methylated metabolites of anthocyanins have been found within urine and plasma (Azzini et 
al., 2010; Bitsch et al., 2004b; Carkeet et al., 2008; Felgines et al., 2003; Felgines et al., 
2005; Hollands et al., 2008; Kay et al., 2005; Mullen et al., 2008a). In general, the formation 
of glucuronide conjugates is considered the most common phase II metabolic route for 
water-soluble metabolites, and accounts for the majority of conjugated metabolites found in 
the urine and bile. 
 
A study feeding 200 g strawberries identified four conjugated anthocyanin metabolites, 
including three mono-glucuronides and one sulfoconjugate of pelargonidin within urine. The 
glucuronide conjugates were excreted at concentrations up to 2675 nM/24 h, whilst the 
sulfate conjugate reached 134 nM/24 h (Felgines et al., 2003). Animals studies have 
observed similar results (Talavéra et al., 2005; Talavéra et al., 2004). In a study which 
perfused the intestinal lumen of anesthetised rats with high concentrations of blackberry 
anthocyanins, they observed the methylation of cyanidin-3-glucoside to peonidin-3-
glucoside, and glucuronidation to cyanidin and peonidin monoglucuronide in urine and 
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plasma (Talavéra et al., 2004). Similarly, a study feeding chokeberry to weanling  pigs 
observed methylation and glucuronidation of cyanidin-3-glucoside (Wu et al., 2005).  
 
Alternatively prior to conjugation, anthocyanins may be degraded into their phenolic acid 
and aldehyde within the small intestine lumen or epithelial cells or by microflora within the 
colon (Pérez-Vicente et al., 2002). A study feeding cyanidin-3-glucoside to rats identified 
higher concentrations of protocatechuic acid than the parent anthocyanin within plasma 
(Tsuda et al., 1999) and a study in caco-2 cells found protocatechuic acid and 
phloroglucinaldehyde were metabolised to glucuronide and sulfate conjugates (Kay et al., 
2009). 
 
In addition to methylation, sulfation and glucuronidation, anthocyanins are speculated to 
undergo conjugation with glutathione (GSH), a tripeptide present in millimolar 
concentrations within intracellular fluid (Figure 1.6). The formation of GSH conjugates of 
quercetin has been observed within murine hepatic suspensions, and GSH related 
metabolites of quercetin degradation products have been observed in  human urine 
(HongandMitchell, 2006). Furthermore, a quercetin GSH adduct has been putatively 
identified within human plasma (Lee et al., 2012). GSH has a nucleophilic cysteinyl thiol 
group, which allows it to be added to activated double bonds, such as those found at the 
ortho-position of a phenolic group or aromatic ring (Levsen et al., 2005), therefore such 
anthocyanins are also probable candidates for GSH conjugation.  
1.7.1. Enterohepatic circulation and urinary excretion 
Following their absorption and metabolism, anthocyanins may be eliminated through the 
urinary (Felgines et al., 2003) or biliary routes (Ichiyanagi et al., 2006; Talavéra et al., 2003; 
Talavéra et al., 2004). Compounds eliminated within bile are generally large (>375 Da) and 
lipophilic (Millburn et al., 1967). Therefore conjugates formed through phase II metabolism 
are more likely to be enter the enterohepatic circulation, to be modified, secreted back into 
the small intestine, and possibly reabsorbed, whereas smaller, polar conjugates follow the 
urinary route. Analysis of bile samples from rats with high concentrations of anthocyanins 
injected into their intestinal lumen, found anthocyanins and methylated anthocyanins present 
within the bile within 20 min (Ichiyanagi et al., 2006; Talavéra et al., 2003; Talavéra et al., 
2004). 
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Figure 1.6 Structure of glutathione 
 
 
1.7.2. Distribution of anthocyanins  
The use of radioactive [such as carbon-14 (
14
C)] or stable isotopes [such as carbon-13 (
13
C) 
and deuterium (
2
H)] can facilitate the elucidation of metabolite structures in vivo (Mutlib, 
2008). Radiolabeled analogues are widely used to provide a qualitative and quantitative 
assessment of a drugs’ distribution and excretion patterns in humans and animals, whilst 
stable isotopes can facilitate the elucidation of a metabolites structure using HPLC-MS/MS 
by separating the molecular weight of the labelled and unlabelled analogues by a couple of 
mass units (Mutlib, 2008). However to date, few studies have used isotopically labelled 
anthocyanins to determine the absorption, metabolism, distribution and elimination (ADME) 
of anthocyanins in humans. Previously, a flavonol intervention study administered 4-
14
C-
quercetin either orally (100 mg) or intravenously (0.3 mg) to human volunteers (Walle et al., 
2001). The dose was predominantly recovered in the form of CO2, which is likely primarily 
due to the position of the 
14
C label on the C=O bond, at the 4-position in the C-ring. In 
contrast, a 2-
14
C-quercetin-4’-glucoside study, containing the labelled carbon at the 2-
position in the C-ring, detected minimal radioactivity outside of the gastrointestinal tract in 
rats, with the majority of the compound absorbed within the colon and rapidly removed from 
the circulation by the kidneys or excreted within faeces (Mullen et al., 2008b). An 
anthocyanin labelled study which fed 
14
C-cyanidin-3-glucoside with the labelling on the six 
carbons within the B-ring, by direct stomach intubation to mice, obtained 92% recovery of 
the label in mice which were sacrificed after 3 h. The majority of the label was within the 
gastrointestinal tract, suggesting cyandin-3-glucoside is poorly absorbed in mice and that 
anthocyanins have a limited systemic bioavailability (Felgines et al., 2010). 
 
1.8. Anthocyanins and cardiovascular disease 
CVD is responsible for an estimated 17.3 million deaths worldwide every year (WHO, 2013) 
and is caused by disorders of the heart and blood vessels, and includes coronary heart 
disease, cerebrovascular disease and peripheral artery disease. Whilst the evidence for the 
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protective effects of anthocyanin rich diets on cardiovascular protection is mixed, a 
significant amount of epidemiological studies (Cassidy et al., 2013; Cassidy et al., 2011; 
McCullough et al., 2012; Mink et al., 2007; Rissanen et al., 2003; Sesso et al., 2007) and 
randomised control trials (Basu et al., 2010; Rodriguez-Mateos et al., 2013; Zhu et al., 2013) 
generally support the concept that high intakes of anthocyanins are associated with a 
decreased risk of cardiovascular disease. A study of 157,000 people, with 14 years of follow 
up found that a high anthocyanin intake was associated with an 8% reduction in the relative 
risk of hypertension (Cassidy et al., 2011), similarly a prospective study of 93,600 women, 
with 18 years follow up, found an association between a higher anthocyanin intake and a 
decreased risk of death due to CVD (Cassidy et al., 2013). Mechanistic studies suggest that 
the benefits of high anthocyanin intake may be due to their effects on endothelial 
dysfunction and inflammation (BellandGochenaur, 2006; García-Lafuente et al., 2009; Heiss 
et al., 2010; Libby et al., 2002; Xu et al., 2004a; Xu et al., 2004b). 
1.8.1. Endothelial Dysfunction 
Many anthocyanin bioactivity studies have focused on the protective effects of anthocyanins 
against endothelial dysfunction. Endothelial dysfunction can be broadly defined as the 
imbalance of vasodilating and vasoconstricting substances within the endothelium (Bell et 
al., 2006; Heiss et al., 2010; Xu et al., 2004a; Xu et al., 2004b). Nitric oxide (NO) is a 
powerful vasodilator and cellular signalling molecule responsible for maintaining 
endothelium homeostasis; within the endothelium it is produced by endothelial nitric oxide 
synthase (eNOS), which uses L-arginine, oxygen and reduced nicotinamide-adenine-
dinucleotide phosphate (NADPH) as co-substrates (FörstermannandSessa, 2012). The 
bioavailability of NO is reduced by increased superoxide (O2
•-
) production, as O2
•-
 reacts 
with NO to produce peroxynitrite (ONOO
-
). A major source of O2
•-
 in the endothelium is 
NADPH oxidase 2 (NOX2), which belongs to the family of enzymes capable of generating 
O2
•-
 by transferring electrons from NADPH. NO and O2
•-
 can react to form ONOO
-
, which 
can oxidise the essential cofactor of eNOS, tetrahydrobiopterin (BH4), to form BH3• and 
BH2, which lead to the uncoupling of eNOS (Figure 1.7). Functional, NO generating eNOS 
is converted into a dysfunctional, O2
•-
 generating enzyme that contributes to vascular 
oxidative stress (Förstermann et al., 2012). Therefore, impairment of NO or eNOS, in 
conjunction with increased levels of reactive oxygen species (ROS) is a significant step 
towards the development of endothelium dysfunction and ultimately CVD (Bell et al., 
2006).  
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Figure 1.7 Potential mechanisms by which cardiovascular risk factors lead to eNOS 
uncoupling and oxidative stress. 
 
BH4, tetrahydrobiopterin; eNOS, endothelial nitric oxide synthase; NOX, NADPH oxidase; 
SOD, superoxide dismutase. Adapted from (Förstermann et al., 2012). 
 
One of the mechanisms by which anthocyanins are thought to help prevent the progress of 
CVD is by up-regulating the activity of eNOS, resulting in an increased presence of 
bioavailable NO (Wallace, 2011; Xu et al., 2004b). A significant increase in flow mediated 
dilation (FMD), a technique that measures NO mediated brachial artery dilation in 
hypercholesterolemic individuals, was detected in a randomised, double blind, placebo 
controlled crossover study, following a 12-week intervention feeding 320 mg berry 
anthocyanins, thus demonstrating an improved vasodilatory response from anthocyanin 
consumption (Zhu et al., 2011). Similarly, an ex vivo study conducted using porcine 
coronary arterial rings found berry anthocyanins using concentrations of 0.005 mg/L to 5 
mg/L induced dose responsive endothelium-dependent vasorelaxation, which was prevented 
by the application of NO2-L-arginine, a known inhibitor of eNOS (Bell et al., 2006). This 
suggests the endothelial NO system is involved in the relaxation response to anthocyanins. 
Cellular evidence has also supported this hypothesis; 0.1 µM cyanidin-3-glucoside applied to 
bovine artery endothelial cells for 8 h was found to up-regulate eNOS, inducing a two-fold 
increase in NO production  (Xu et al., 2004a; Xu et al., 2004b).  
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1.8.2. Inflammation 
Inflammation is a defence mechanism whereby leukocytes migrate into damaged tissues, to 
destroy agents which may potentially cause further tissue damage (García-Lafuente et al., 
2009). Acute inflammation is a limited, generally beneficial response whilst chronic 
inflammation is more persistent, and is involved in the development of many diseases, 
including arteriosclerosis, diabetes and cancer (García-Lafuente et al., 2009). Inflammation 
drives the formation, and progression of atherosclerotic plaques through initiating the 
expression of adhesion molecules and cytokines, which leads to the recruitment and 
aggregation of leukocytes (Libby et al., 2002). Several mechanisms explaining the link 
between a decrease in risk factors associated with inflammation and anthocyanins have been 
described. These include modulation of inducible nitric oxide synthase (iNOS), modulation 
and regulation of pro-inflammatory molecules such as adhesion molecules and cytokines and 
modulation of arachidonic acid related enzymes (García-Lafuente et al., 2009).  
 
Modulation of iNOS 
In contrast to eNOS which is constitutively expressed in most cells, iNOS is regulated at the 
transcriptional level, and highly activated by inflammatory stimuli such as 
lipopolysaccharide (LPS) and inflammatory cytokines, in cells such as macrophages and is 
responsible for the overproduction of NO during inflammation. Damage to healthy cells, as 
well as invading microbes can be caused by the NO radical, or by the interaction of NO with 
superoxide leading to the formation of peroxynitrite.  Excessive NO production by iNOS can 
lead to arteriolar vasodilation, microvascular damage and septic shock (García-Lafuente et 
al., 2009). Therefore, compounds which can reduce NO production through interacting with 
iNOS without affecting eNOS can be important in regulating inflammation (García-Lafuente 
et al., 2009). Anthocyanins, including blackberry extract, cyanidin-3-glucoside and 
pelargonidin-3-glucoside, have been reported to inhibit iNOS protein and mRNA expression 
in a dose-dependent manner in macrophages (Hämäläinen et al., 2007; Pergola et al., 2006; 
Wang et al., 2008) and microglia (Jeong et al., 2013) exposed to the inflammatory stimulus 
LPS. 
 
Modulation of adhesion molecules 
The recruitment of adhesion molecules responsible for the arrest, adherence, transmigration 
and accumulation of leukocytes is one of the earliest events in the initiation of 
atherosclerosis, and occurs at arterial sites following pro-atherogenic stimuli such as 
oxidised LDL (oxLDL) or free radicles (EpsteinandRoss, 1999; García-Lafuente et al., 
2009). The endothelium reacts to proatherogenic stimuli by expressing two classes of 
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adhesion molecule, selectins and cell adhesion molecules (Fotis et al., 2012).  Selectins 
participate in the early stages of leukocyte recruitment, rolling and tethering at the 
endothelial surface by interacting with their ligands to create weak bonds between activated 
endothelial cells (P- and E-selectins) and leukocytes (L-selectins) (Blankenberg et al., 2003), 
whilst cell adhesion molecules aid the arrest and extravasation of leukocytes. Intercellular 
adhesion molecules (ICAM) bind to multiple β2 integrins, platelet endothelial cellular 
adhesion molecule-1 (PECAM-1) are dense at junctions between endothelial cells and 
participate in homophilic binding and vascular cell adhesion molecule-1 (VCAM-1) is 
transcriptionally induced on endothelial cells and participates in the firm adhesion of 
leukocytes to the endothelium. VCAM-1 also interacts with integrin α4β1, which induces 
signals within endothelial cells, including the activation of NADPH oxidase to catalyse the 
production of ROS, thus triggering endothelial shape change and allowing leukocyte 
emigration (Figure 1.8) (Matheny et al., 2000). Anthocyanins have been reported to 
modulate the expression of VCAM-1 (Chao et al., 2013; Kim et al., 2006; Miyazaki et al., 
2008; Nizamutdinova et al., 2009; Xia et al., 2009). Humans fed 320 mg/day anthocyanins 
for 24 weeks (Zhu et al., 2013) and mice fed purple sweet potato for four weeks  (Miyazaki 
et al., 2008) had significantly lower plasma VCAM-1 levels. Similarly, in vitro, pre-
treatment of TNF-α challenged endothelial cells with black soybean anthocyanins (Chao et 
al., 2013; Kim et al., 2006; Nizamutdinova et al., 2009) and grape seed extract 
(SenandBagchi, 2001) has been shown to reduce VCAM-1 expression.  
 
Modulation of cytokines and chemokines 
Cytokines and chemokines are mediators of local and intercellular communications required 
for the response to a wide range of stimuli in immune and inflammatory processes (Wallace, 
2011). Several cytokines, such as tumour necrosis factor-α (TNF-α), interleukin (IL)-6 and 
IL-1β, and chemokines such as monocyte chemoattractant protein-1 (MCP-1), are 
predominately produced by activated macrophages, dendritic cells and T-cells, and are 
strongly associated with the chronic inflammatory response (BaudandKarin, 2001; García-
Lafuente et al., 2009). These pro-inflammatory molecules contribute to atherogenesis by 
triggering attachment and transendothelial migration of leukocytes into the endothelium and 
by maintaining the inflammation inside atherosclerotic lesions and promoting the 
proliferation and migration of smooth muscle cells (García-Lafuente et al., 2009). Moreover, 
in target cells, cytokines interact with their receptor protein to stimulate the activation of 
pro-inflammatory signalling pathways such as the mitogen activated protein kinases 
(MAPK) and nuclear factor-κB (NF-κB) pathways (Baud et al., 2001; García-Lafuente et 
al., 2009).  
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Figure 1.8 Schematic diagram of the leukocyte-endothelial interactions and the roles of 
selectins and adhesion molecules in the early stages of atherosclerosis.   
 
ICAM, intercellular adhesion; PECAM-1platelet endothelial cellular adhesion molecule-1; 
VCAM-1, vascular cell adhesion molecule-1. Adapted from (Blankenberg et al., 2003; Fotis 
et al., 2012). 
 
NF-κB is activated by numerous pro-inflammatory stimuli and controls the expression of 
numerous genes involved in inflammatory response and secretion of cytokines and 
chemokines (BremnerandHeinrich, 2002). It is generally represented by subunits p65 and 
p50 and in its inactive form resides in the cytoplasm bound to the inhibitory protein, NF-κB 
inhibitory protein (IκB) (Min et al., 2010). The up-regulation of effector proteins by NF-κB 
is initiated by upstream signalling cascades, such as the TNF-α or CD40L signalling 
cascades. CD40L or TNF-α released from macrophages, bind with their receptors (CD40 
and TNFR1), thus activating the recruitment of multiple protein kinases, leading to the 
activation of the IkB kinase (IKK) complex (Bremner et al., 2002). The IKK complex 
triggers the phosphorylation of IκB, which is recognised by an ubiquitin protein ligase and 
undergoes poly-ubiquitination, which targets the protein from rapid degradation (Figure 
1.9). The free NF-κB is translocated into the nucleus where NFκB binding sites are found in 
the promoter regions of cell adhesion molecules and cytokines including IL-1, IL-6, IL-8 
and TNF-α (Bremner et al., 2002). One of the mechanism by which anthocyanins and their 
degradation products are thought to reduce inflammation is through the inhibition of the 
activation of NF-κB (Karlsen et al., 2007; Wang et al., 2010). Anthocyanins have been 
shown to suppress LPS and CD40L stimulated NF-κB activation through inhibiting IκBα 
phosphorylation and the translocation of NF-κB (p65) into the nucleus (Min et al., 2010; Xia 
et al., 2009).  
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Figure 1.9 Activation of NF-κB and MAPK signalling pathways by CD40-CD40L and 
TNF-α.  
 
 
CD40L, Cluster of differentiation 40 ligand; ERK, extracellular-signal-regulated kinases; IKK, 
inhibitory-κB kinase; JNK, c-Jun N-terminal kinases; MAPK, mitogen-activated protein 
kinase complex; NF-κB, nuclear factor-κB; P, phosphate; p38, mitogen-activated protein 
kinase;  p50, NF-κB p50 subunit; p65, NF-κB  p65 subunit; TNF-α, tumour necrosis factor-α; 
TNFR1, TNF receptor-1; ub, ubiquitination. Adapted from (Bremner et al., 2002; Pamukcu et 
al., 2011). 
 
The MAPK family consists of three members: extracellular signal regulated kinase (ERK), 
p38 and c-jun NH2-terminal kinase (JNK), and its activation can lead to the degradation of 
the IκB-α protein and subsequent activation of NF-κB (Figure  1.9) (Hirano et al., 1996). 
Endothelial cells pre-treated with anthocyanins have been shown to reduce CD40L induced 
production of pro-inflammatory molecules and decreased the activation of JNK and p38 
(Xia et al., 2009) and protocatechuic acid has also been shown to reduce the LPS stimulated 
production of inflammatory cytokines through inhibiting the activation of JNK, ERK and 
p38 in macrophages (Min et al., 2010).  
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1.9. Summary 
Anthocyanins can constitute major dietary components of phytochemical intake, with intake 
in excess of 500 mg being feasible for those who follow a diet rich in berries, red vegetables 
and red wine (Del Rio et al., 2013). Moreover, a high intake of anthocyanins has been linked 
to a decrease in risk factors associated with CVD (Cassidy et al., 2013; Cassidy et al., 2011; 
McCullough et al., 2012; Mink et al., 2007; Rissanen et al., 2003; Sesso et al., 2007). 
However, anthocyanins have an exceptionally low bioavailability, with intervention studies 
identifying low nanomolar concentrations present within the systemic circulation, which 
rarely equates to more than 1% of the ingested dose (Felgines et al., 2005; Garcia-Alonso et 
al., 2009; Kay et al., 2005; Kay et al., 2004). Due to their unstable nature at physiological 
pH, it has been proposed that anthocyanins are likely present in the circulation, as 
unidentified degradation products and metabolic intermediates (Kay, 2010), and that these 
metabolites may be responsible for the perceived bioactivity of anthocyanins against CVD. 
The foregoing review therefore highlighted the gaps in our current understanding of 
anthocyanins, particularly their absorption, metabolism and ultimately their bioactivity in 
vivo. 
 
The key to establishing the bioactivity of anthocyanins in vivo is to first gain a complete 
understanding their absorption, distribution and metabolism, and subsequently incorporate 
this understanding into establishing their bioactivity. Since anthocyanins are unstable at 
physiological pH, attention must turn to the possible bioactivity of unknown anthocyanin 
degradation products and metabolites. To date, few studies have search for anthocyanin 
degradants and those that have, generally had difficulties separating anthocyanin degradation 
products from phenolics present within the bolus. The reason the metabolic pathway of 
anthocyanin remains elusive, may in part be due to the lack of studies using pure or labelled 
anthocyanins and in part due to the lack of intrinsic methods developed for the detection of 
anthocyanin degradation products and metabolites. Therefore, the current thesis set out to: 
 
1. Develop methods for the detection of anthocyanin metabolites. 
2. Identify novel anthocyanin metabolites in human biological samples from 
anthocyanin intervention trials. 
3. Establish the bioactivity of identified metabolites in vitro, with a specific focus on 
inflammation.  
 
As initial data from our lab suggests that the metabolites of anthocyanins are not bioactive 
against biomarkers for vascular activity, such as eNOS and NO (unpublished data), the 
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present thesis focused on the anti-inflammatory activity of anthocyanins metabolites on the 
production of VCAM-1 and IL-6 in human umbilical vein endothelial cells (HUVECs) 
following stimulation with either CD40L or TNF-α. VCAM-1 and IL-6 were selected for 
analysis as they play key roles in the progression of inflammation, VCAM-1 aids leukocyte 
attachment and transmigration (Blankenberg et al., 2003), and IL-6 is responsible for the 
recruitment of multiple pro-inflammatory molecules, and in combination with its receptor 
can dictate the transition from acute to chronic inflammation (Gabay, 2006). Therefore, 
strategies targeting these molecules can lead to an effective prevention of chronic 
inflammatory diseases. 
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Chapter 2. Methods for isolating, identifying 
and quantifying known and predicted 
anthocyanin metabolites in clinical samples 
 
2.1. Introduction 
Epidemiological evidence suggests an association between the consumption of fruits and 
vegetables rich in anthocyanins and a decreased risk of cardiovascular disease (Cassidy et 
al., 2011; McCullough et al., 2012; Mink et al., 2007). However, there is a distinct lack of 
information regarding the bioavailability and metabolic fate of anthocyanins in humans, 
which is predominantly due to anthocyanin bioavailability studies demonstrating extremely 
low recoveries of anthocyanins post ingestion  (Kay et al., 2005; Manach et al., 2005; 
Williamson et al., 2005). This low recovery of anthocyanins led to the notion that 
anthocyanin may degrade and be extensively metabolised (via phase I and II metabolism or 
bacterial catabolism) in vivo, and it is postulated that these products of anthocyanin 
degradation are likely to be responsible for their associated health-promoting properties (Del 
Rio et al., 2010; Tsuda, 2011; WilliamsonandClifford, 2010).  
 
A limited number of previous in vitro studies have reported the degradation of anthocyanins 
into phenolic acids and aldehydes (Kay et al., 2009; Woodward et al., 2009) and their 
subsequent methyl, glucuronide and sulfate conjugation (Woodward et al., 2011). This has 
been observed in vivo, with a few studies reporting the presence of the phenolic acid 
degradation products in serum and urine (Azzini et al., 2010; Czank et al., 2013; Hassimotto 
et al., 2008; Ichiyanagi et al., 2007; Nurmi et al., 2009; Vitaglione et al., 2007). However, 
there are still conflicting reports in the literature regarding the identity and prevalence of the 
major metabolites present following the consumption of anthocyanin-rich foods and until 
these are realised, the mechanisms associated with their health effects will remain undefined.  
 
The major challenges associated with the recovery and detection of anthocyanins relate to 
their instability under neutral pH (Fossen et al., 1998) and heat (Fleschhut et al., 2006; 
Keppler et al., 2005; Woodward et al., 2009), their extensive metabolic conjugation in vivo 
(Mullen et al., 2008a) and their probable catabolism by intestinal microflora 
(WilliamsonandClifford, 2010).  It is therefore likely that after consumption of anthocyanin 
rich foods, a complex mixture of intact anthocyanins, phenolic degradation products, phase 
II metabolic conjugates and colonic metabolites exist in tissues and biological fluids (Czank 
et al., 2013). Whilst a number of methods have been developed for the analysis of flavonoids 
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and flavonoid derived phenolics (Kylli et al., 2010; Plazonić et al., 2009; ZhangandZuo, 
2004), the vast majority of reported methods for anthocyanin analysis (in particular) have 
concentrated on quantification of parent/precursor forms or their respective metabolic 
conjugates (methyl, glucuronide and sulfate derivatives of anthocyanins). There are limited 
reports where quantitative analytical methods have been optimised for the analysis of 
anthocyanins and their phenolic acid and aldehyde degradation products and metabolites 
together (Kay, 2010; Nurmi et al., 2009; WilliamsonandClifford, 2010). 
 
Developing an appropriate method for this purpose presents many challenges, as there is an 
extremely large diversity of metabolic by-products, whose structures and physicochemical 
properties make extraction and quantification in complex matrices problematic. In addition, 
many phase II conjugates of phenolic acids are not commercially available for use as 
reference standards for method development. In order to facilitate the development of a 
suitable method, in-house synthesis is therefore often necessary. The objective of the present 
chapter was firstly to model the putative metabolites formed from the metabolism of 
anthocyanins and secondly to develop and validate extraction and detection methods suitable 
for determining the absorption, distribution, metabolism and elimination (ADME) of 
anthocyanins, including their degradation products and metabolites, in clinical samples. 
HPLC and MS variables such as organic modifier, ionic modifier concentration, mobile 
phase gradient, flow rate, column, ion source and multiple reaction monitoring (MRM) 
parameters were assessed to optimise analytical performance. Analytical methods were 
validated for the 45 analytes and four internal standards and confirmed using clinically 
derived urine and serum samples, for linearity, precision and accuracy using the U.S. 
Department of Health and Human Services Food and Drug Administration (FDA) guidance 
for industry bioanalytical methods validation (FDA, 2001). 
 
When working with biological samples, it is often necessary to isolate the analytes of interest 
from their matrices. This allows the analyte to be detected within a ‘clean’ chromatogram by 
reducing the signal to noise ratio, thus improving the detection of analytes present in low 
concentrations. In addition, extracted samples can be concentrated, further increasing the 
detection limits of the analytes of interest. Typically, individual classes of (poly)phenolic 
compounds can be extracted from human matrices using either protein precipitation (Marks 
et al., 2009; Mullen et al., 2009; Stalmach et al., 2009a; Stalmach et al., 2009b), liquid-
liquid extraction (LLE) (Graf et al., 2006; Mullen et al., 2002) or solid phase extraction 
(SPE) (Kay et al., 2005; Kay et al., 2004; Mazza et al., 2002; Woodward et al., 2009). The 
present study will focus on developing and validating a method for SPE of urine, serum and 
faecal samples, as it allows sample concentration and the removal of ion suppressing solutes 
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such as salts, urea and proteins, whilst retaining the analytes of interest, anthocyanins and 
phenolic acids (Kraemer-Schafhalter et al., 1998; Mazza et al., 2004). The analytes explored 
in the present chapter include anthocyanins (cyanidin-3-glucoside, C3G; pelargonidin-3-
glucoside, P3G), their degradation products (protocatechuic acid, PCA; 4-hydroxybenzoic 
acid; phloroglucinaldehyde, PGA), phase II conjugates (protocatechuic acid-3-glucuronide, 
protocatechuic acid-4-glucuronide, vanillic acid-4-glucuronide, benzoic acid-4-glucuronide, 
isovanillic acid-3-glucuronide, protocatechuic acid-3-sulfate,  protocatechuic acid-4-sulfate, 
vanillic acid-4-sulfate, isovanillic acid-3-sulfate and benzoic acid-4-sulfate) and probable 
colonic metabolites (2-hydroxybenzoic acid, 3-hydroxybenzoic acid, 4-hydroxybenzoic acid, 
2,3-dihydroxybenzoic acid, 2,4-dihydroxybenzoic acid, protocatechuic acid, 3,5-
dihydroxybenzoic acid, gallic acid, 2-methoxybenzoic acid, 4-methoxysalicylic acid, 6-
methoxysalicyclic acid, vanillic acid, isovanillic acid, syringic acid, 3-methylgallic acid, 
methyl-3,4-dihydroxybenzoate, methyl-3,4-dimethoxybenzoate, methyl vanillate, methyl 
gallate, 4-hydroxybenzyl alcohol, p-coumaric acid, caffeic acid, ferulic acid, sinapic acid, 
phloroglucinaldehyde, 4-hydroxybenzaldehyde, 3,4-dihydroxybenzaldehyde, 4-
hydroxyphenylacetic acid, homoprotocatechuic acid, homovanillic acid, hippuric acid, 3-
methylhippuric acid, 4-methylhippuric acid) and four internal standards (scopoletin, 
phloridzin, taxifolin and 7,8-dihydroxycourmarin). The present chapter therefore describes 
methods for the identification and quantification of an extensive series of anthocyanin 
metabolites for use in future clinical intervention studies. 
 
2.2. Materials and Methods 
2.2.1. Chemicals 
Cyanidin-3-glucoside, pelargonidin-3-glycoside, peonidin-3-glucoside, cyanidin-3-
sambubioside, cyanidin-3-rutinoside and cyanidin-3,5-diglucoside were obtained from 
Extrasynthese (Genay, France). Phase II conjugates of phenolic acids (protocatechuic acid-3-
glucuronide, protocatechuic acid-4-glucuronide, vanillic acid-4-glucuronide, benzoic acid-4-
glucuronide, isovanillic acid-3-glucuronide, protocatechuic acid-3-sulfate,  protocatechuic 
acid-4-sulfate, vanillic acid-4-sulfate, isovanillic acid-3-sulfate and benzoic acid-4-sulfate) 
were synthesised were synthesised at St Andrews University as part  of a BBSRC 
collaborative project, via recently published methods (Zhang et al., 2012). Formic acid, 
hydrochloric acid and the remaining compounds (2-hydroxybenzoic acid, 3-hydroxybenzoic 
acid, 4-hydroxybenzoic acid, 2,3-dihydroxybenzoic acid, 2,4-dihydroxybenzoic acid, 
protocatechuic acid, 3,5-dihydroxybenzoic acid, gallic acid, 2-methoxybenzoic acid, 4-
methoxysalicylic acid, 6-methoxysalicyclic acid, vanillic acid, isovanillic acid, syringic acid, 
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3-methylgallic acid, methyl-3,4-dihydroxybenzoate, methyl-3,4-dimethoxybenzoate, methyl 
vanillate, methyl gallate, 4-hydroxybenzyl alcohol, p-coumaric acid, caffeic acid, ferulic 
acid, sinapic acid, phloroglucinaldehyde, 4-hydroxybenzaldehyde, 3,4-
dihydroxybenzaldehyde, 4-hydroxyphenyl-acetic acid, homoprotocatechuic acid, 
homovanillic acid, hippuric acid, 3-methyl hippuric acid, 4-methyl hippuric acid, phloridzin, 
scopoletin, taxifolin and 7,8-dihydroxycourmarin) were purchased from Sigma-Aldrich 
(Dorset, UK).  HPLC grade methanol, acetonitrile and ethyl acetate were purchased from 
Fisher Scientific (Loughborough, UK). All water utilised was of Milli-Q grade (18.2 MΩ 
cm
-1
). 
2.2.2. Materials 
Strata-X™ SPE columns (6 mL, 500 mg, 88 Å),  HPLC columns [Kinetex pentafluorophenol 
(PFP) reverse phase (RP) (2.6 µm, 100 × 4.6 mm, 100 Å), Synergi Max RP (4 µm, 250 × 4.6 
mm, 80 Å), Luna C18 (2) RP (4 µm, 250 × 4.6 mm, 100 Å), Synergi Polar RP (4 µm, 250 × 
4.6 mm, 80 Å)] and SecurityGuard
®
 cartridges (PFP and C18, 4 × 2.0 mm) were purchased 
from Phenomenex (Macclesfield, UK). Bond Elute C18 SPE columns (20 mL, 5 g, 70 Å) 
and Eclipse XDB-C18 HPLC (5 µm, 150 × 4.6 mm, 80 Å) columns were from Agilent 
(Wokingham, UK). Sterile filtered human male serum from AB plasma, Discovery® DSC-
18 SPE columns (6 mL, 1 g), Acrodisc PTFE syringe filters (13 mm, 0.45 µm) were 
purchased from Sigma-Aldrich (Dorset, UK). Human faeces and urine were collected 
following internal protocols, approved by the Norfolk Research Ethics Committee (Norfolk, 
UK).   
2.2.3. Metabolite Modelling  
To identify target compounds for method development, a model of the putative metabolism 
of anthocyanins was developed in ACD ChemSketch 2.0 (ACD Labs, UK) based on 
published and predicted phase I, phase II and colonic metabolites for anthocyanins, their 
derived phenolic acids and as well as other common flavonoid metabolites (Aura et al., 
2005; CheminatandBrouillard, 1986; Donovan et al., 1999; Donovan et al., 2002; Fernandes 
et al., 2008; Mazza et al., 1987; Mazza et al., 2002; Moridani et al., 2001; Williamson et al., 
2010). 
2.2.4. Stock Standards 
Stock solutions of pure standards were prepared at 5 mg/mL in dimethyl sulfoxide (DMSO) 
and used to produce a mixture of standards diluted to the appropriate concentration in 0.1% 
formic acid in methanol.   
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2.2.5. HPLC-ESI-MS/MS conditions 
HPLC-ESI-MS/MS  analysis was carried out on an Agilent (Wokingham, UK) 1200 series 
HPLC with the inclusion of an ABSciex (Warrington, UK) 3200 series Q-trap MS/MS, 
attached to a Turbo V electrospray ionisation (ESI) source. The column temperature was set 
at 37 °C with a 5 µL injection volume and absorbance was recorded at 265, 280, 300, 320, 
360 and 525 nm. The following variables were further evaluated: column type [Eclipse 
XDB-C18 (5 µm, 150 × 4.6 mm, 80 Å), Kinetex PFP (2.6 µm, 100 × 4.6 mm, 100 Å), 
Synergi Max (4 µm, 250 × 4.6 mm, 80 Å), Luna C18 (2) (4 µm, 250 × 4.6 mm, 100 Å) and 
Synergi Polar (4 µm, 250 × 4.6 mm, 80 Å)], organic modifier (acetonitrile or methanol), 
ionic modifier (0.1 to 1.0% formic acid), flow rate (0.5 to 1.5 mL/min), HPLC mobile phase 
gradient elution and MS source and multiple reaction monitoring (MRM) related parameters.  
 
Source parameters were manually optimised for flow rates of 1.5 mL/min using flow assisted 
syringe infusion; the HPLC flow gradient was set to 10% mobile phase B and the syringe 
infusion of the analyte (50 µM in 0.1% formic acid/methanol) was set to 10 µL/min. The 
source parameters were optimised based on the conditions which resulted in the most intense 
ion, and optimised parameters include temperature (200 to 750 °C), nebulizer gas (0 to 90 
psi) and auxiliary gas (0 to 90 psi), curtain gas (CUR; 10 to 50 psi) and ion spray voltage (IS; 
-1000 to -4500 V; +1000 to +5500 V). The optimised method for HPLC-ESI-MS/MS 
analysis utilised a PFP column and guard cartridge with the  mobile phase consisting of 0.1% 
formic acid (v/v) in water (mobile phase A) and 0.1% formic acid (v/v) in acetonitrile 
(mobile phase B) at a flow rate of 1.5 mL/min at 0 min, 1 mL/min
 
 at 7 to 14 min and 1.5 
mL/min at 14 to 28 min. The gradient consisted of 1% B at 0 min, 7.5% B at 7 min, 7.6% B 
at 14 min, 10% B at 17 min, 12% B at 18.5 min, 12.5% B at 20 min, 30% B at 24 min, 90% 
B at 25 to 28 min, 1% B at 29 to 32 min. Optimal MS/MS source parameters included 
curtain gas 40, ion spray voltage (IS) -4000 V (or IS +5500 V), temperature 700 °C and 
nebulizer and auxiliary gas 60 psi.  
 
MRM mode was used to identify and quantify analytes. MRM related parameters, including 
declustering potential (DP), entrance potential (EP), collision energy (CE) and collision exit 
potential (CXP), were individually optimised for each compound via direct syringe infusion 
using a Hamilton syringe pump (Bonaduz, Switzerland). Individual standards (50 µM in 
0.1% formic acid/methanol) were injected at a constant flow rate of 10 µL/min. The ions in 
MRM mode were produced by collision-activated dissociation (CAD) of the selected 
precursor ions in the collision cell. The optimum CAD (N2) was 3 arbitrary units. MRM 
analysis of mixed standards at 50 µM was used to verify the final method in positive and 
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negative mode and MRM related parameters were considered optimised when MRM 
intensities were above 5.0 × 10
4 
counts
 
per second. 
2.2.6. Extraction chromatography 
The SPE procedure was based on previously published methods (Woodward et al., 2009) 
and optimised at the Institute of Food Research (Norwich, UK) for the following variables: 
SPE sorbent bed material (DSC-18 or Strata-X™), addition of preservative (with or without 
10% ascorbate w/v in 10 mM ethylenediaminetetraacetic acid [EDTA]), acid modifier 
(formic acid or HCl), elution volume (1 to 9 mL) and final concentration [i.e. complete or 
incomplete (≈ 50 µL remaining) evaporation]. The final SPE method for urine and serum 
consisted of the samples being diluted 2:1 with 1% formic acid in milliQ water (pH 2.4) and 
loaded onto either DSC-18 (6 mL, 1 g, urine) or Strata-X™ (6 mL, 500 mg, serum) SPE 
columns. The columns had previously been conditioned with one column volume of 1% 
formic acid in methanol followed by one column volume of 1% formic acid in water (pH 
2.4). After the samples were loaded, the columns were washed with two column volumes of 
1% formic acid in water, dried under vacuum for 30 min and ‘soaked’ in one third of a 
column volume of 1% formic acid in methanol for 10 min. Extracts were eluted under 
gravity with 7 mL of 1% formic acid in methanol, concentrated to approximately 50 µL 
using a Speedvac® centrifugal evaporator and reconstituted with 200 µL 1% formic acid in 
water. A post-extraction volume marker (5 µL of 1 mM scopoletin) was added and used to 
accurately calculate volume.  
 
Faecal samples were extracted using an identical process, except samples were first 
prepared, which included autoclaving at 121 °C for 30 min, lyophilisation and rehydration at 
20% wet weight/volume as previously described (Graf et al., 2006).  Samples were then 
extracted via a two-stage methanol extraction (30 min vortex of 1:1 sample-to-solvent ratio) 
and evaporated to 2 mL, using a Speedvac® centrifugal evaporator.  Samples were then 
loaded onto a conditioned Bond Elute C18 (20 mL, 5 g) SPE column, washed with two 
column volumes of acidified water (pH 2.4), eluted with 20 mL 1% formic acid in methanol 
and concentrated to approximately 1 mL using a Speedvac® centrifugal evaporator.  
 
In order to establish the extraction efficiencies of the SPE methods, baseline urine, serum 
and faecal homogenates were spiked with the analytes of interest at 50 µM and allowed to 
stand for 20 min prior to extraction. All samples were syringe filtered [Acrodisc PTFE 
syringe filters (13 mm, 0.45 µm)] and stored at -80 °C prior to analysis. Extractions were 
conducted in triplicate. 
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2.2.7. Methods validation  
Validation of the HPLC-MS/MS method was carried out in terms of the linearity, precision 
and accuracy of compounds spiked into mobile phase, using the guidelines set out by the 
Food and Drug Administration for Bioanalytical Methods Validation (2001) (FDA, 2001). 
Six-point calibration curves (0 to 20 µM) were prepared, by diluting the stock solutions to 
the appropriate concentration with mobile phase. The method was validated based on the 
mean, standard deviation and coefficient of variation (CV) of the slope after each 
concentration was injected six times. 
 
The limit of detection (LOD) of an analytical method represents the lowest concentration of 
the test compound that remains acceptably detectable. LODs were established by calculating 
the concentration of analyte yielding a peak height signal-to-noise ratio of 3:1 (signal-to-
noise method) when the analyte was spiked into urine, serum and faecal matrices at 
concentrations of 0.34 µM to 4 µM post extraction. Where the analytes of interest were 
endogenously present in the baseline matrix, peak heights were corrected for baseline 
concentrations.  
 
The extraction methods were validated by calculating the extraction efficiencies of the 
compounds of interest spiked into baseline urine, serum and faecal homogenates prior to 
SPE, relative to matrix-matched (urine, serum, faeces) control samples spiked with the same 
mixture of the standards post SPE. Five-point calibration curves (25 µM to 400 µM) were 
constructed for each analyte within a matched-matrix, with coefficient of determination (r
2
) 
established as linear (r
2 ≥ 0.99). Extraction efficiency data are given as mean ± SD of three 
replicates and where stated, statistical comparisons were undertaken using t-tests (p ≤ 0.05, n 
= 3) in SPSS 18 (IBM, UK). 
 
The final urine and serum methods were applied to the analysis of anthocyanin metabolites 
in samples derived from a previous clinical intervention trial feeding participants (n=15) a 
500 mg bolus of elderberry derived anthocyanins, where samples were collected for 3 h post 
bolus (Curtis et al., 2009). The faecal method was applied to samples derived from a study 
feeding participants (n = 8) 500 mg 
13
C-labelled cyanidin-3-glucoside, where samples were 
collected for 48 h post bolus (Czank et al., 2013). The analytes were quantified using the 
optimised extraction and detection methods and the lowest and highest urinary, plasma 
concentrations identified are presented.  
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2.3. Results 
2.3.1. Metabolite modelling 
Target compounds for method development were chosen based on previously published 
studies (Aura et al., 2005; Cheminat et al., 1986; Czank et al., 2013; Donovan et al., 1999; 
Donovan et al., 2002; Fernandes et al., 2008; Mazza et al., 1987; Mazza et al., 2002; 
Moridani et al., 2001; Williamson et al., 2010) and putative metabolites were modelled in 
silico using ACD ChemSketch 2.0 (ACD Labs, UK), based on known phase I and II 
conjugation pathways and colonic metabolism of other similarly structured flavonoids. For 
example, post consumption of a bilberry-lingonberry purée, a metabolism study identified 
benzoic acids including protocatechuic acid, syringic acid and vanillic acid, phenylacetic 
acids including homovanillic acid and homoprotocatechuic acid, and cinnamic acids 
including caffeic acid, ferulic acid and p-courmaric acid (Nurmi et al., 2009). Therefore, 
these metabolites, and also phase II conjugates of these metabolites, such as methyl-3,4-
dihydroxybenzoate, the methylated conjugated of vanillic acid, and 3-hydroxybenzoic acid, 
the dehydroxylated conjugated of protocatechuic acid, were included.  
 
This approach yielded a total of 112 putative metabolites, including the parent structure 
(cyanidin-3-glucoside), its aglycone (cyanidin), two degradation products (protocatechuic 
acid and phloroglucinaldehyde), 97 phase I (oxidation, reduction and hydrolysis) and phase 
II (sulfation, glucuronidation, methylation and cysteine and glutathione conjugation) 
metabolites and 11 possible colonic metabolites based on microbiota degradation and 
conjugation reactions from the literature, including ex vivo (ForesterandWaterhouse, 2008) 
and in vitro fermentation studies (Aura et al., 2005;  onz lez-Barrio et al., 2010).  From 
these, 45 of the most probable metabolites were selected for method validation and utilised 
in the present study; 34 compounds were commercially available and purchased from Sigma-
Aldrich, and ten were synthetically produced (sulfated and glucuronidated conjugates of 
protocatechuic acid, 4-hydroxybenzoic acid, vanillic acid and isovanillic acid) at St Andrews 
University (Zhang et al., 2012) (Table 2.1). 
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Table 2.1 Structures of the optimised anthocyanins, degradation products and putative metabolites.  
Structure Common Name IUPAC Name Configuration
a
 
Anthocyanin  
 
Cyanidin-3-glucoside 
 
Pelargonidin-3-glucoside 
 
 
Peonidin-3-glucoside  
(2S,3R,4S,5R,6R)-2-[2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-
chromen-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol  
(2S,3R,4S,5R,6R)-2-[5,7-Dihydroxy-2-(4-
hydroxyphenyl)chromen-3-yl]oxy-6-(hydroxymethyl)oxane-
3,4,5-triol 
(2S,3R,4S,5S,6R)-2-[5,7-dihydroxy-2-(4-hydroxy-3-
methoxyphenyl)chromenylium-3-yl]oxy-6-
(hydroxymethyl)oxane-3,4,5-triol 
R
1
,R
2
 = OH 
 
R
2
 = OH 
 
R
1
=OCH3, R
2
=OH,  
 
Benzoic acids 
 
 
 
 
2-Hydroxybenzoic acid  
3-Hydroxybenzoic acid  
4-Hydroxybenzoic acid  
2,3-Dihydroxybenzoic acid  
2,4-Dihydroxybenzoic acid  
Protocatechuic acid  
Protocatechuic acid-3-glucuronide  
 
Protocatechuic acid-4-glucuronide 
 
Protocatechuic acid-3-sulfate 
Protocatechuic acid-4-sulfate  
3,5-Dihydroxybenzoic acid  
Gallic acid 
2-Methoxybenzoic acid  
3-Methoxybenzoic acid  
4-Methoxybenzoic acid  
4-Methoxysalicyclic acid 
6-Methoxysalicyclic acid  
Vanillic acid  
Vanillic acid-4-glucuronide 
 
2-Hydroxybenzoic acid 
3-Hydroxybenzoic acid 
4-Hydroxybenzoic acid 
2,3-Dihydroxybenzoic acid  
2,4-Dihydroxybenzoic acid  
3,4-Dihydroxybenzoic acid 
6-(5-Carboxy-2-hydroxyphenoxy)-3,4,5-trihydroxytetrahydro-
2H-pyran-2-carboxylic acid 
6-(4-Carboxy-2-hydroxyphenoxy)-3,4,5-trihydroxytetrahydro-
2H-pyran-2-carboxylic acid 
5-Carboxy-2-hydroxyphenyl sulfate 
4-Carboxy-2-hydroxyphenyl sulfate 
3,5-Dihydroxybenzoic acid  
3,4,5-Trihydroxybenzoic acid  
2-Methoxybenzoic acid  
3-Methoxybenzoic acid  
4-Methoxybenzoic acid  
2-Hydroxy-4-methoxybenzoic acid  
2-Hydroxy-6-methoxybenzoic acid 
4-Hydroxy-3-methoxybenzoic acid 
6-(4-Carboxy-2-methoxyphenoxy)-3,4,5-trihydroxytetrahydro-
2H-pyran-2-carboxylic acid 
R
1
 = OH 
R
2
 = OH 
R
3
 = OH 
R
1
,R
2
 = OH 
R
1
,R
3
 = OH 
R
2
,R
3
 = OH 
R
2
 = O-GlcA,  R
3
 = OH 
 
R
2
 = OH,  R
3
 = O-GlcA 
 
R
2
 = OSO3
-
,  R
3
 = OH 
R
2
 = OH,  R
3
 = OSO3
-
 
R
2
, R
4
 = OH 
R
2
,R
3
,R
4
 = OH 
R
1
 = OCH3 
R
2
 = OCH3 
R
3
 = OCH3 
R
1
=OH, R
3
=OCH3 
R
1
 = OH, R
5
 = OCH3 
R
2
 = OCH3, R
3
 = OH 
R
2
 = OCH3, R
3
 = O-GlcA 
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Vanillic acid-4-sulfate 
Isovanillic acid 
Isovanillic acid-3-glucuronide 
 
Isovanillic acid-3-sulfate 
Syringic acid  
3-Methylgallic acid  
Benzoic acid-4-glucuronide 
 
Benzoic acid-4-sulfate 
4-Carboxy-2-methoxyphenyl sulfate 
3-Hydroxy-4-methoxybenzoic acid  
6-(5-Carboxy-2-methoxyphenoxy)-3,4,5-trihydroxytetrahydro-
2H-Pyran-2-carboxylic acid 
5-Carboxy-2-methoxyphenyl sulfate 
4-Hydroxy-3,5-dimethoxybenzoic acid  
3,5-Dihydroxy-4-methoxybenzoic acid  
6-(4-Carboxyphenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-
2-carboxylic acid 
4-Carboxyphenyl sulfate 
R
2
 = OCH3, R
3
 = OSO3
-
 
R
2
 = OH, R
3
 = OCH3 
R
2
 = O-GlcA, R
3
 = OCH3 
 
R
2
 = OSO3
-
, R
3
 = OCH3 
R
2
,R
4 
= OCH3, R
3 
= OH 
R
3
,R
5 
= OH, R
4
 = OCH3 
R
3 
= O-GlcA 
 
R
3 
= OSO3
-
 
Benzoates 
 
Methyl-3,4-dihydroxybenzoate  
Methyl-3,4-dimethoxybenzoate  
Methyl vanillate  
Methyl gallate 
Methyl 3,4-dihydroxybenzoate  
Methyl 3,4-dimethoxybenzoate  
Methyl 4-hydroxy-3-methoxybenzoate  
Methyl 3,4,5-trihydroxybenzoate 
R
1
,R
2
 = OH 
R
1
,R
2 
= OCH3 
R
1 
= OCH3, R
2 
= OH 
R
1
,R
2
,R
3 
= OH 
Benzyl alcohol 
 
4-Hydroxybenzyl alcohol 
 
 
(4-Acetyloxyphenyl)methyl acetate 
 
R
1 
= OH 
 
Phenylpropenoic acids  
 
p-Coumaric acid  
Caffeic acid 
Ferulic acid  
Sinapic acid  
3-(4-Hydroxyphenyl)prop-2-enoic acid 
3-(3,4-Dihydroxyphenyl)prop-2-enoic acid 
3-(4-Hydroxy-3-methoxyphenyl)-prop-2-enoic acid 
3-(4-Hydroxy-3,5-dimethoxyphenyl)prop-2-enoic acid 
R
2 
= OH 
R
1
,R
2 
= OH 
R
1 
= OCH3, R
2 
= OH 
R
1
, R
3 
= OCH3, R
2 
= OH 
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Benzaldehydes 
 
Phloroglucinaldehyde  
4-Hydroxybenzaldehyde  
3,4-Dihydroxybenzaldehyde 
Vanillin  
  
2,4,6-Trihydroxybenzaldehyde 
4-Hydroxybenzaldehyde  
3,4-Dihydroxybenzaldehyde  
4-Hydroxy-3-methoxybenzalehyde 
R
1
,R
3
,R
5 
= OH 
R
3 
= OH 
R
2
,R
3 
= OH 
R
2 
= OCH3, R
3 
= OH 
 
 
Phenylacetic acids 
 
4-Hydroxyphenylacetic acid  
Homoprotocatechuic acid
 
Homovanillic acid  
2-(4-Hydroxyphenyl)acetic acid 
2-(3,4-Dihydroxyphenyl)acetic acid 
2-(4-Hydroxy-3-methoxy-phenyl)acetic acid  
R
2 
= OH 
R
1
,R
2 
= OH 
R
1 
= OH, R
2 
= OCH3 
Hippuric acids 
 
Hippuric acid 
3-Methylhippuric acid 
4-Methylhippuric acid 
2-Benzamidoacetic acid 
3-Methylhippuric acid 
4-Methylhippuric acid 
R
1
,R
2 
=H 
R
1 
= CH3 
R
2 
= CH3 
R
1
-R
5
 represents hydrogen (H) or position of 
a
functional group. OH, hydroxyl; OCH3, methoxy; CH3, methyl; O-GlcA, O-glucuronide; OSO3
-
, sulfate. 
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2.3.2. HPLC-ESI-MS/MS 
To obtain the optimal separation of the analytes of interest by HPLC-UV/vis, system 
conditions including column type, flow rate, acid modifier and organic modifier were 
investigated. Five HPLC columns commonly utilised in flavonoid analysis (Eclipse XDB 
C18, Kinetex PFP, Synergi Max, Luna C18 and Synergi Polar RP) were selected to establish 
the chromatographic separation of the target compounds. The PFP column resulted in 29 ± 
14% to 45 ± 15% reduction in peak width (Figure 2.1A) and 42 ± 22% to 77 ± 45% increase 
in peak height (Figure 2.1B) compared to the Eclipse C18, Synergi Max, Luna C18 and 
Synergi Polar RP columns. The PFP column thereby yielded the highest selectivity for 
aromatic and polar compounds, giving the best separation of the structurally similar aromatic 
compounds. This was particularly evident for the sulfated compounds; the Eclipse and Luna 
C18 columns resulted in very poor resolution and separation of the sulfated compounds, the 
Synergi Max and Polar RP columns resulted in improved resolution, however, the PFP 
column provided the greatest resolution, with two to tenfold improvement in peak intensity 
relative to the other stationary phases (Figure 2.2). No column tested was capable of 
sufficiently separating the isomers of protocatechuic acid-sulfate under the explored 
conditions. 
 
Figure 2.1 HPLC column optimisation 
 
.  
 
 
 
 
 
 
 
(A) Peak width relative to column type, (B) peak height relative to column type. Graphs are 
depicted as mean +SD of n=10 compounds (cyanidin-3-glucoside, pelargonidin-3-glucoside, 
scopoletin, p-courmaric acid, phloroglucinaldehyde, ferulic acid, benzoic acid-4-glucuronide, 
sinapic acid, isovanillic acid and gallic acid).  
 
  
A.                                   B. 
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Figure 2.2 MRM chromatograms of sulfated metabolites using Eclipse C18, Luna C18, 
Synergi max RP, Synergi Polar RP and Kinetex PFP HPLC columns. 
 
Flow rate: 1 mL/min; Solvent A: 0.1% formic acid in water (v/v); Solvent B: 0.1% formic 
acid in acetonitrile (v/v); gradient: 1-15% B at 0 minutes, 15% B at 15 minutes; 99% B at 
17 to 20 minutes. 
1
PCA-4-sulfate; 
2
PCA-3-sulfate; 
3
benzoic acid-4-glucuronide; 
4
vanillic 
acid-4-glucuronide; 
5
isovanillic acid-3-glucuronide. 
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Flow rates between 1.0 mL/min and 1.5 mL/min were tested on the PFP column, to establish 
the optimal flow rate for the separation and resolution of the analytes of interest. The 
maximum flow rate (1.5 mL/min) within the systems pressure limits (400 bar) was selected 
as it provided optimal peak resolution (reduced peak broadening), resulting in a 40% reduced 
peak width relative to 1 mL/min (Figure 2.3). A flow rate of 1.5 mL/min decreasing to 1 
mL/min
 
from 7 to 14 min was necessary to achieve optimal separation while staying within 
the pressure limitations of the HPLC system utilised. 
 
Figure 2.3 HPLC flow rate optimisation 
 
 
 
 
 
 
 
 
 
 
 
(A) Peak height and (B) peak width of n=10 compounds (cyanidin-3-glucoside, 
pelargonidin-3-glucoside, scopoletin, p-courmaric acid, phloroglucinaldehyde, ferulic acid, 
benzoic acid-4-glucuronide, sinapic acid, isovanillic acid and gallic acid) with flow rates of 
0.8 mL/min to 1.5 mL/min. Graphs are depicted as mean +SD. 
 
Acid modifier concentration of 0%, 0.1%, 0.5% and 1% formic acid were tested on the PFP 
column, to establish the optimal flow rate for the separation and resolution of the analytes of 
interest. The peak intensities and the peak widths of the phenolic analytes decreased with 
increasing formic acid within the mobile phase; 0.1% formic acid resulted in a 389 ± 530% 
increase in peak height relative to 1% formic acid (Figure 2.4A). Furthermore, a lower 
increase in peak width (i.e. decrease in peak resolution) was observed using 0.1% formic 
acid (144 ± 44% increase relative to 1% formic acid) compared to 0% formic acid (216 ± 
87% increase relative to 1% formic acid) (Figure 2.4C). A similar effect was observed for 
the anthocyanins peak width, which demonstrated a significantly lower increase in peak 
width (i.e. decrease in peak resolution) using 0.1% formic acid (213 ± 23% increase relative 
to 1% formic acid)  compared to 0% formic acid (1150 ± 60% increase relative to 1% formic 
acid) (Figure 2.4E). In contrast, the anthocyanin peak intensities (Figure 2.4B) decreased 
with decreasing formic acid (Figure 2.4D). In the current study, 0.1% formic acid was 
A.                        B. 
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selected for HPLC-ESI-MS/MS analysis as it provided overall the optimal resolution for 
phenolic analytes and anthocyanins.  
 
Figure 2.4 HPLC optimisation of acid modifier in mobile phase 
 
 
 
 
 
 
 
Peak height of (A) phenolic analytes and (B) anthocyanins, and peak widths of (C) phenolic 
analytes and (D) anthocyanins with 0%, 0.1%, 0.5% and 1% formic acid within the mobile 
phase. Flow rate: 1 mL min-1; gradient: 1-15% B at 0 minutes, 15% B at 15 minutes; 99% B 
at 17 to 20 minutes. Values are represented as mean % change relative to 1% formic acid 
+SD [phenolic analytes, n=19: protocatechuic acid (PCA), vanillic acid (VA), PCA-4-
sulfate, VA-4-sulfate, benzoic acid (BA)-4-glucuronide (GlcA), PCA-4-GlcA, VA-4-GlcA, 
BA-4-sulfate, Methyl-3,4-dihydroxybenzoate, homoPCA, caffeic acid, hippuric acid, ferulic 
acid, phloroglucinaldehyde, p-courmaric acid, 4-hydroxyBA, 3,4-dihydroxybenzaldehyde, 
gallic acid and phloridzin; anthocyanins, n=3: cyanidin-3-glucoside, cyanidin-3-rutinoside, 
pelargonidin-3-glucoside]. (E) Extracted MRM chromatograms for cyanidin-3-glucoside 
with i) 1%, ii) 0.5, iii) 0.1% and iv) 0% formic acid in the mobile phase. 
 
 
i   ii   iii      iv 
A. Phenolic analytes                             B. Anthocyanins 
C. Phenolic analytes                   D. Anthocyanins 
 
 
 
 
 
 
 
 
E. Anthocyanins 
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The organic modifiers, methanol and acetonitrile were compared for their suitability for use 
with anthocyanin and putative anthocyanin metabolites. Acetonitrile provided a 138 ± 78% 
increase in peak intensity (Figure 2.5A) and a 20 ± 31% decrease in peak width (Figure 
2.5C) for the phenolic analytes compared to methanol. However, the opposite effect was 
observed for the anthocyanins tested, with a 78 ± 83% increase in peak intensities (Figure 
2.5C) and (81 ± 25%)  decrease in peak widths (Figure 2.5D) observed with methanol 
compared to acetonitrile. Acetonitrile was selected as the optimal organic modifiers, as it 
was optimal for the separation and detection of the phenolic analytes. 
 
Figure 2.5 HPLC optimisation of organic modifier in mobile phase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peak height of (A) phenolic analytes and (B) anthocyanins and peak widths of (C) phenolic 
analytes and (D) anthocyanins with the mobile phase containing 0.1% formic acid in 
acetonitrile or methanol. [Phenolic metabolites, n=19: protocatechuic acid (PCA), vanillic 
acid (VA), PCA-4-sulfate, VA-4-sulfate, benzoic acid (BA)-4-glucuronide (GlcA), PCA-4-
GlcA, VA-4-GlcA, BA-4-sulfate, Methyl-3,4-dihydroxybenzoate,  homoPCA, caffeic acid, 
hippuric acid, ferulic acid, phloroglucinaldehyde, p-courmaric acid, 4-hydroxyBA, 3,4-
dihydroxybenzaldehyde, gallic acid and phloridzin; anthocyanins, n=3: cyanidin-3-
glucoside, cyanidin-3-rutinoside, pelargonidin-3-glucoside]. Values are represented as mean 
+SD. 
 
 
A. Phenolic analytes                               B. Anthocyanins 
C. Phenolic analytes                              D. Anthocyanins 
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The source parameters for the electrospray ionisation (ESI) Turbo V source were manually 
optimised to provide the optimal nebulisation, evaporation and ionisation for a flow rate of 
7% acetonitrile at 1.5 mL/min using flow assisted syringe infusion (FIA). Optimised source 
parameters were established as a CUR of 40 psi, which prevented solvent entering the 
orifice, a temperature of 700 °C, which ensured evaporation at 1.5 mL/min and gas flows of 
60 psi (nebulizer and auxiliary gas) for optimal nebulisation of the solvent. The position of 
the ionisation needle was optimised to give the highest ion intensity at x=5, y=5. 
 
The MRM related parameters, consisting of declustering potential (DP), entrance potential 
(EP), collision energy (CE) and collision exit potential (CXP), were optimised for each 
individual compound separately in positive or negative mode in order to select the most 
abundant ion pairs and the optimal declustering and entrance potentials and collision 
energies for fragmenting and focusing the ions through the quadruples. Compound 
parameters were optimised for the three most intense ion transitions (Table 2.2) and MRM 
analysis of a 50 µM mixed standard of the 45 analytes was used to verify the final method in 
positive and negative mode (Figure 2.6). 
2.3.3. HPLC-ESI-MS/MS method validation 
The final HPLC-MS/MS method was validated across 45 analytes for linearity, precision 
and accuracy using six-point calibration curves in mobile phase following six repeat 
injections. All calibration curves were linear over the concentration ranges (1.25 to 20 µM), 
with correlation coefficients (r
2
) ranging from 0.991 to 1.000 (CV, 0.2%) (Table 2.2). The 
CV of the slope ranged from 1.4% for vanillic acid-4-sulfate to 9.6% for pelargonidin-3-
glucoside. The sensitivity of the method was established using baseline serum, urine and 
faecal samples derived from previously conducted anthocyanin intervention trials (Czank et 
al., 2013; de Ferrars et al., 2013; de Ferrars et al., 2014), which were spiked post extraction. 
The HPLC-ESI-MS/MS LODs ranged from 1 nM for phloridzin to 2604 nM for 
homovanillic acid in urine, 0.3 nM for phloridzin to 2340 nM for homovanillic acid in serum 
and 1 nM for phloridzin to 2238 nM for 4-hydroxyphenylacetic acid in faeces (Table 2.3). 
  
 
Table 2.2 Optimised multiple reaction monitoring (MRM) transitions and parameters of target analytes
a 
Analyte 
MRM 
mode 
λmax 
(nm) 
Rt 
(min) 
MW 
Precursor 
ion (m/z)
b
 
MS
2
 Fragments 
(m/z) 
CE 
(V) 
DP 
(V) 
EP 
(V) 
CXP 
(V) 
Anthocyanins 
Cyanidin-3-glucoside + 514 11.7 449.4 449 287
c
,241,213,137 30,70,70,70 60 5 2 
Pelargonidin-3-glucoside + 502 14.6 433.3 433 271
c
,197,121,65 30,70,70,120 50 5 2 
Peonidin-3-glucoside + 518 16.9 463.4 463 301
c
 10 30 5 2.5 
Cyandin-3-sambubioside + 516 12.0 581.5 581 287
c
 10 30 5 2.5 
Cyanidin-3-rutinoside + 518 13.32 595.5 595 287
c
 10 30 5 2.5 
Cyanidin-3,5-diglucoside + 512 7.18 611.5 611 287
c
 10 30 5 2.5 
Benzoic acids 
2-Hydroxybenzoic acid - 300 19.0 138.1 137 93
c
,75,65 -25,-50,-40 -30 -7 -2 
3-Hydroxybenzoic acid - 298 8.6 138.1 137 93
c
,65 -18,-16 -40 -9 0 
4-Hydroxybenzoic acid - 258 6.8 138.1 137 93
c
,65 -20,-22 -35 -5 0 
2,3-Dihydroxybenzoic acid - 315 9.3 154.1 153 109
c
,91 -22,-32 -60 -2 0 
2,4-Dihydroxybenzoic acid - 258 10.1 154.1 153 109,65
c
 -22,-26 -35 -5 0 
Protocatechuic acid (PCA) - 260 4.5 154.1 153 108
c
,91,81 -31,-31,-31 -42 -10 0 
PCA-3-glucuronide - 256 4.2 330.2 329 175,153
c
,113,109 -21,-25,-25,-50 -45 -5 -3 
PCA-4-glucuronide - 252 3.1 330.2 329 175,153
c
,113,109 -21,-25,-25,-50 -45 -5 -3 
PCA-3 and 4-sulfate - 256 5.0 233.0 231 189,153,109
c
,97 -15,-25,-40,-30 -38 -3 -2 
3,5-Dihydroxybenzoic acid - 250 4.5 154.1 153 109
c
,67,65, -16, -16,-18 -35 -9 0 
Gallic acid - 276 2.5 170.1 169 125
c
,107,79 -15,-15,-15 -50 -7 0 
2-Methoxybenzoic acid + 296 13.4 152.1 153 135
c
,92,77,63 16,35,30,70 40 7 6 
4-Methoxysalicylic acid - 256 21.8 168.1 167 123,108
c
,80 -15,-25,-35 -34 -3 -2 
6-Methoxysalicyclic acid - 254 23.7 168.1 167 123
c
,109 -20,-30 -21 -8 -2 
Vanillic acid - 262 9.6 168.1 167 152
c
,123,108 -20,-14,-20 -30 -2 0 
Vanillic acid-4-glucuronide - 254 4.5 344.3 343 175,167,152,113
c
,108 -15,-20,-40,-20,-55 -60 -4 -2 
Vanillic acid-4-sulfate - 252 7.4 247.0 245 167
c
,152,123,108 -20,-25,-30,-30 -33 -4 -2 
Isovanillic acid + 260 9.8 168.1 169 151
c
,125,93,65 19,12,19,34 27 6 6 
Isovanillic acid-3-glucuronide - 260 5.8 344.3 343 175,167,152,113
c
,108 -15,-30,-40,-20,-55 -66 -4 -2 
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Isovanillic acid-3-sulfate - 254 6.8 233.0 231 167
c
,152,108,80 -25,-30,-40,-45 -33 -4 -2 
Syringic acid + 274 12.2 198.2 199 155,140
c
,125,77 13,21,39,35 34 5 6 
3-Methylgallic acid - 272 7.5 184.1 183 168
c
,139 -16,-16 -36 -3 -5 
Benzoic acid-4-glucuronide - 248 2.7 314.2 313 175,137,113,93
c
 -15,-20,-20,-54 -54 -7 -2 
Benzoic acid-4-sulfate - 248 6.4 217.0 217 173,137
c
 -10,-21 -31 -3 -2 
Benzoates 
Methyl 3,4-dihydroxybenzoate - 260 13.9 168.1 167 108
c
,91 -28,-30 -45 -8 0 
Methyl 3,4-dimethoxybenzoate + 260 24.7 196.2 197 165,153,138
c
 17,15,15 36 9 4 
Methyl vanillate + 262 21.2 182.2 183 151
c
,124,107,77 18,20,40,40 38 6 2 
Methyl gallate - 272 7.9 184.1 183 124
c
,106,78 -28,-38,-42 -45 -4 0 
Benzyl alcohols  
4-Hydroxybenzyl alcohol - 276 5.1 124.1 123 105,77
c
 -15,-20 -24 -10 -2 
Phenylpropenoic acids 
p-Coumaric acid - 310 15.5 164.2 163 119
c
,117,93 -20,-42,-40 -30 -10 0 
Caffeic acid - 324 10.6 180.2 179 135
c
,106,89 -20,-40,-40 -45 -6 -2 
Ferulic acid - 320 18.9 194.2 193 178,149,134
c
 -20,-20,-20 -30 -6 -2 
Sinapic acid - 322 20.4 224.2 223 208
c
,193,164,149,121 -18,-28,-22,-28,-40 -38 -2 -2 
Benzaldehydes  
Phloroglucinaldehyde - 292 18.2 154.1 153 151
c
,125,107,83 -20,-20,-20,-20 -88 -7 -2 
4-Hydroxybenzaldehyde - 285 9.4 122.1 121 108
c
,92,65 -31,-34,-35 -47 -7 -10 
3,4-Dihydroxybenzaldehyde - 280 6.5 138.1 137 108
c
,92,81 -30,-30,-26 -40 -10 0 
Vanillin - 280 12.6 152.2 151 136
c
,108,92 -20,-30,-30 -25 -6 0 
Phenylacetic acids  
4-Hydroxyphenylacetic acid - 275 7.4 152.1 151 123,107
c
,93,79 -25,-17,-25,-25 -50 -7 -2 
Homoprotocatechuic acid - 280 5.1 168.1 167 123
c
,108,95 -20,-30,-40 -20 -8 -2 
Homovanillic acid - 280 10.1 182.2 181 137
c
,122 -10,-20 -43 -2 -4 
Hippuric acids  
Hippuric acid - 246 6.9 179.2 178 134
c
,132,77 -18,-22,-22 -40 -3 0 
3-Methylhippuric acid - 246 14.1 193.2 192 148
c
,146,91 -16,-22,-26 -35 -10 0 
4-Methylhippuric acid - 246 13.8 193.2 192 148
c
,146,91 -16,-22,-26 -35 -5 0 
Internal Standards  
Phloridzin - 286 24.2 436.4 435 273
c
,167,123,81 -26,-40,-50,-80 -40 -4 -2 
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Scopoletin
 
- 350 19.1 192.2 192 148,120,104
c
 -32,-28,-34 -35 -10 0 
Scopoletin + 350 19.1 192.2 193 133
c
,122,94 27,37,43 56 4 4 
Taxifolin - 288 20.8 304.2 303 285,151,125
c
 -17,-30,-30 -50 -5 0 
7,8-Dihydroxycourmarin - 322 10.6 178.1 177 121
c
,105,93 -30,-26,-32 -50 -8 0 
a
A dwell time of 50 ms was used across all transitions;
 b
Precursor and 
c
daughter transition used for MRM quantitation. Rt, retention time; CE, collision 
energy corresponding to MS
2 
fragment; DP, declustering potential; MW, molecular weight; V, Volts;  
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Figure 2.6 Multiple reaction monitoring (MRM) chromatogram showing the ion pairs used 
for quantification for the optimised negative (A) and positive (B) HPLC-MS/MS methods.  
 
(A) 
1
Gallic acid, 
2
benzoic acid (BA)-4-glucuronide, 
3
protocatechuic acid (PCA)-4-glucuronide, 
4
PCA-3-glucuronide, 
5
vanillic acid (VA)-4-glucuronide, 
6
PCA, 
7
3,5-dihydroxy BA,
 8
PCA-3 and 
4-sulfate, 
9
4-hydroxybenzyl alcohol, 
10
homoPCA, 
11
isoVA-3-glucuronide, 
12
 BA-4-sulfate, 
13
3,4-dihydroxybenzaldehyde, 
14
isoVA-3-sulfate, 
15
4-hydroxyBA, 
16
hippuric acid, 
17
4-
hydroxyphenylacetic acid, 
18
VA-4-sulfate, 
19
methyl gallate, 
20
3-hydroxyBA, 
21
2,3-
dihydroxyBA, 
22
4-hydroxybenzaldehyde,  
23
VA, 
24
2,4-dihydroxyBA, 
25
homoVA, 
26
caffeic acid, 
27
7,8-dihydroxycourmarin, 
28
4-methylhippuric acid, 
29
methyl-3,4-dihydroxybenzoate, 
30
3-
methylhippuric acid, 
31
p-coumaric acid, 
32
phloroglucinaldehyde, 
33
ferulic acid, 
34
2-hydroxyBA, 
35
sinapic acid, 
36
taxifolin, 
37
4-methoxysalicylic acid, 
38
6-methoxysalicyclic acid, 
39
phloridzin. 
(B) 
1
3-methylgallic acid, 
2
cyanidin-3-glucoside,
 3
isoVA, 
4
syringic acid, 
5
pelargonidin-3-
glucoside, 
5
2-methoxyBA, 
7
methyl vanillate, 
8
methyl-3,4-dimethoxybenzoate. 
XIC of -MRM (33 pairs): 167.0/123.0 Da ID: *3,4-dihydroxyphenylacetic acid from Sample 17 (20uM Stdcurve27007) of Data121212 valid... Max. 2.3e5 cps.
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Table 2.3 Validation of HPLC-MS/MS methods within urine, serum and faecal matrices. 
Analyte 
Slope (a)
a 
Mean ± SD 
CV 
(%) 
R² LOD (nM) 
Urine Serum Faeces 
Anthocyanins 
Cyanidin-3-glucoside 594,473 ± 39,888 6.71 0.998 2 4 4 
Pelargonidin-3-glucoside 1,034,231 ± 98,822 9.56 0.996 2 1 2 
Benzoic acids 
2-Hydroxybenzoic acid 189,231 ± 4,334 2.29 0.998 116 86 136 
3-Hydroxybenzoic acid 60,138 ± 2,698 4.49 0.999 173 191 214 
4-Hydroxybenzoic acid 167,981 ± 7,078 4.21 0.995 139 74 86 
2,3-Dihydroxybenzoic acid 78,108 ± 1,819 2.33 0.999 92 29 126 
2,4-Dihydroxybenzoic acid 19,681 ± 746 3.79 0.999 98 68 112 
Protocatechuic acid (PCA) 15,128 ± 760 5.02 0.997 41 1 9 
PCA-3-glucuronide 174,408 ± 5711 3.27 0.999 6 1 4 
PCA-4-glucuronide 102,003 ± 4,943 4.85 0.999 5 2 4 
PCA-3 and 4-sulfate 378,495 ± 13,989 3.70 0.998 1 2 1 
3,5-Dihydroxybenzoic acid 234,649 ± 8,897 3.79 0.996 24 31 150 
Gallic acid 34,012 ± 907 2.67 0.997 15 29 20 
2-Methoxybenzoic acid 400,431 ± 20,139 5.03 0.996 16 23 22 
4-Methoxysalicylic acid 300,116 ± 9,224 3.07 0.998 23 29 375 
6-Methoxysalicyclic acid 15,687 ± 583 3.72 0.999 116 25 333 
Vanillic acid 11,322 ± 337 2.97 0.999 53 16 45 
Vanillic acid-4-glucuronide 56,069 ± 2,416 4.31 0.999 37 6 11 
Vanillic acid-4-sulfate  214,295 ± 3,041 1.42 0.999 2 3 3 
Isovanillic acid 30,715 ± 1,362 4.44 0.998 47 77 94 
Isovanillic acid-3-glucuronide 67,871 ± 3,294 4.85 1.000 9 5 9 
Isovanillic acid-3-sulfate 308,646 ± 7,864 2.55 0.999 2 3 3 
Syringic acid 61,287 ± 2,709 4.42 0.998 16 45 21 
3-Methylgallic acid 1,584 ± 69 4.37 0.997 360 121 400 
Benzoic acid-4-glucuronide  66,978 ± 2,529 3.78 0.998 4 10 21 
Benzoic acid-4-sulfate  143,079 ± 4,552 3.18 0.998 1 4 2 
Benzoates 
Methyl 3,4-dihydroxybenzoate 230,527 ± 10,659 4.62 0.996 2 3 6 
Methyl 3,4-dimethoxybenzoate 93,306 ± 5,946 6.37 0.999 8 23 22 
Methyl vanillate 33,814 ± 3,204 9.47 0.999 43 68 36 
Methyl gallate 257,934 ± 19,070 7.39 1.000 1 2 3 
Benzyl alcohols 
4-Hydroxybenzyl alcohol 963 ± 40 4.16 0.995 62 246 424 
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Phenylpropenoic acids 
p-Coumaric acid 111,853 ± 8,169 7.30 0.994 46 51 30 
Caffeic acid 333,099 ± 8,610 2.58 0.992 67 122 100 
Ferulic acid 40,588 ± 1,939 4.78 1.000 14 9 67 
Sinapic acid 7,806 ± 638 8.17 0.999 39 7 20 
Phenylaldehydes 
Phloroglucinaldehyde  23,907 ± 1,126 4.71 0.992 13 5 40 
4-Hydroxybenzaldehyde 1,235 ± 63 5.11 0.998 25 40 14 
3,4-Dihydroxybenzaldehyde 43,960 ± 1,288 2.93 0.993 10 4 2 
Phenylacetic acids 
4-Hydroxyphenylacetic acid 30,535 ± 1,017 3.33 0.998 116 938 2,238 
HomoPCA 2,146 ± 65 3.03 0.999 108 117 413 
Homovanillic acid 23,907 ± 1,126 4.71 0.992 2,604 2,340 727 
Hippuric acids 
Hippuric acid 92,688 ± 3,528 3.81 0.996 4 0.4 70 
3-Methylhippuric acid 160,138 ± 5,016 3.13 0.999 99 43 105 
4-Methylhippuric acid 99,126 ± 4,512 4.55 0.999 77 43 122 
Internal standards 
Phloridzin 292,333 ± 6,420 2.20 0.991 1 0.3 1 
Scopoletin 10,817 ± 536 4.96 0.999 23 11 30 
Taxifolin 124,601 ± 3,176 2.55 0.995 5 5 6 
7,8-Dihydroxycourmarin 28,696 ± 1,308 4.56 0.994 19 20 3 
a
Linear regression analysis with a regression equation of y = ax + b, where x is the concentration in µM, b is 
equal to 0 and y is the peak area. LOD, the limit of detection (Signal/Noise = 3); R
2
, correlation coefficient of 
regression equations 
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2.3.4. Extraction chromatography 
SPE methods were previously optimised for five compounds (cyanidin-3-glucoside, 
protocatechuic acid, protocatechuic acid-4-glucuronide, phloroglucinaldehyde and taxifolin) 
at the Institute of Food Research (Norwich, UK). Methods were optimised for sorbent bed 
material (DSC-18 or Strata-X™), addition of preservative (with or without 10% ascorbate 
w/v in 10 mM (EDTA), acid modifier (formic acid or HCl), elution volume (1-9 mL) and 
final concentration [i.e. complete or incomplete (≈ 50 µL remaining) evaporation]. Two 
sorbents were tested (DSC-18 and Strata-X™). The DSC-18 SPE cartridges were found to be 
more suitable for use with the urine, whilst within the serum matrix, the Strata-X™ sorbent 
resulted in higher extraction efficiencies, with improved reproducibility and repeatability 
compared to samples extracted using the DSC-18 sorbent. The addition of a preservative 
(10% ascorbate w/v in 0.5 mM EDTA) prior to SPE and the change of acid modifier from 
formic acid to HCl during SPE had little impact on analyte recovery (p ≥ 0.05, n = 3). 
Therefore, no preservative was utilised in the present analyses and formic acid was selected 
as the appropriate acid modifier due to its suitability with ESI-MS methods. An elution 
volume of 7 mL of 1% formic acid in methanol was selected, as it provided the lowest 
elution volume with the maximum retention of analytes from serum using both the strata-X 
(Figure 2.7) and DCS-18 (Figure 2.8) columns. Complete evaporation of eluent to dryness 
significantly reduced the recovery of some compounds (including anthocyanins and PGA). 
Therefore, samples were dried to approximately 50 µL, reconstituted with 200 µL acidified 
water and a marker (scopoletin) was added to allow calculation of the exact volume: 
       
                 
       
 
Where V1 is the desired volume, V2 is predicted volume of the sample, C1 is predicted 
concentration of the sample and C2 is the known concentration of the volume control 
standard. 
 
The extraction of the analytes of interest from the faecal matrix required a two-stage 
extraction process due to the complexity of the matrix. The optimised method for faecal 
extraction involved a combination of methanol extraction, partial evaporation to remove 
residual methanol followed by SPE of the remaining aqueous phase using Bond Elute C18 
(20 mL, 5 g) cartridges with 100% aqueous wash and an elution volume of 20 mL.  
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Figure 2.7 Effect of elution volume on the recovery of analytes by solid phase extraction 
using Strata-X columns with serum. 
 
 
 
 
 
 
 
 
 
 
 
Analytes include cyanidin-3-glucoside, cyanidin-3-rutinoside, pelargonidin-3-glucoside, 
protocatechuic acid (PCA), vanillic acid (VA),  PCA-4-sulfate, VA-4-sulfate, benzoic acid 
(BA)-4-glucuronide (GlcA), PCA-4-GlcA, VA-4-GlcA, BA-4-sulfate, Methyl-3,4-
dihydroxy-benzoate, homoPCA, caffeic acid, hippuric acid, ferulic acid, 
phloroglucinaldehyde, p-courmaric acid, 4-hydroxyBA, 3,4-dihydroxybenzaldehyde, gallic 
acid and phloridzin. 
 
Figure 2.8 Effect of elution volume on the recovery of analytes by solid phase extraction 
using DSC-18 columns with urine. 
 
 
 
 
 
 
 
 
 
 
Analytes include cyanidin-3-glucoside, cyanidin-3-rutinoside, pelargonidin-3-glucoside, 
protocatechuic acid (PCA), vanillic acid (VA), PCA-4-sulfate, VA-4-sulfate, benzoic acid 
(BA)-4-glucuronide (GlcA), PCA-4-GlcA, VA-4-GlcA, BA-4-sulfate, Methyl-3,4-
dihydroxy-benzoate, homoPCA, caffeic acid, hippuric acid, ferulic acid, 
phloroglucinaldehyde, p-courmaric acid, 4-hydroxyBA, 3,4-dihydroxybenzaldehyde, gallic 
acid and phloridzin. 
 
2.3.5. Extraction methods validation 
Extraction methods were validated using the 45 phenolic analyte mixture spiked into urine, 
serum and faecal (as a homogenate) matrices, then extracted using the optimised methods 
and analysed via HPLC-ESI-MS/MS. The mean recovery of the 45 analytes from urine, 
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serum and faeces was 88.3 ± 17.8%, 86.5 ± 11.1% and 80.6 ± 20.9% respectively (Table 
2.4). Of the total 45 analytes, 34, 34, and 26 compounds were extracted with greater than 
80% recovery (urine, serum and faeces, respectively). Poor recoveries (<50%) were 
exhibited for 4-methoxysalicyclic acid, gallic acid and benzoic acid-4-glucuronide in the 
faeces. The recovery of protocatechuic acid-sulfate, benzoic acid-4-glucuronide and gallic 
acid from the urine when using DSC-18 SPE cartridges were also poor, but were improved 
when using Strata X™ columns where the extraction efficiencies of the analytes within 
serum were all >60% (Table 4). The CV of the extraction efficiency across the 45 analytes 
averaged 7.9 ± 5.3% for urine, 6.8 ± 5.0% for serum and 14.1 ± 7.9% for faeces. 
 
Table 2.4 Extraction efficiencies of compounds in urine, serum and faecal matrices. 
Analyte 
Extraction Efficiency (% recovery) 
Urine  Serum Faeces  
Anthocyanins 
Cyanidin-3-glucoside 97.8 ± 6.2 72.1 ± 4.6 55.4 ± 9.0 
Pelargonidin-3-glucoside 101.9 ± 6.0 74.0 ± 3.4 64.5 ± 11.0 
Benzoic acids 
2-Hydroxybenzoic acid 89.6 ± 1.1 81.2 ± 3.0 71.2 ± 7.0 
3-Hydroxybenzoic acid 85.8 ± 10.5 92.9 ± 7.6 82.9 ± 10.1 
4-Hydroxybenzoic acid 86.2 ± 2.0 86.6 ± 9.8 121.1 ± 41.5 
2,3-Dihydroxybenzoic acid 86.8 ± 3.0 73.9 ± 4.4 86.6 ± 7.8 
2,4-Dihydroxybenzoic acid 79.1 ± 10.0 97.4 ± 3.0 79.9 ± 6.4 
Protocatechuic acid (PCA) 89.7 ± 10.7 89.3 ± 6.4 80.4 ± 4.3 
PCA-3-glucuronide 94.9 ± 5.0
a
 92.0 ± 6.3 78.4 ± 5.8 
PCA-4-glucuronide 91.8 ± 5.1 93.2 ± 1.3 84.8 ± 23.4 
PCA-3 and 4-sulfate 92.9 ± 1.9
a
 67.4 ± 11.5 111.0 ± 13.6 
3,5-Dihydroxybenzoic acid 91.3 ± 16.9 80.9 ± 16.7 82.0 ± 13.7 
Gallic acid 72.8 ± 3.9
a
 85.0 ± 7.6 10.2 ± 4.6 
2-Methoxybenzoic acid 90.6 ± 3.5 89.6 ± 6.3 93.7 ± 10.9 
4-Methoxysalicylic acid 92.7 ± 2.2 85.3 ± 3.6 9.3 ± 2.7 
6-Methoxysalicyclic acid 95.9 ± 1.9 85.3 ± 3.1 67.7 ± 3.0 
Vanillic acid 91.6 ± 3.9 87.3 ± 3.7 76.0 ± 8.2 
Vanillic acid-4-glucuronide 74.5 ± 12.8 93.6 ± 2.6 85.9 ± 12.8 
Vanillic acid-4-sulfate  87.3 ± 7.1 92.6 ± 2.6 96.2 ± 16.8 
Isovanillic acid 110.7 ± 10.2 101.8 ± 5.8 79.4 ± 11.6 
Isovanillic acid-3-glucuronide 89.6 ± 5.0 86.7 ± 12.0 76.6 ± 8.2 
Isovanillic acid-3-sulfate 96.2 ± 6.3 92.6 ± 9.3 84.2 ± 13.0 
Syringic acid 104.5 ± 8.3 87.7 ± 2.6 82.7 ± 4.7 
3-Methylgallic acid 79.6 ± 17.4 95.3 ± 3.7 75.2 ± 3.8 
Benzoic acid-4-glucuronide  85.8 ± 1.9
a
 103.5 ± 5.6 42.0 ± 11.6 
Benzoic acid-4-sulfate  77.3 ± 7.1 94.2 ± 3.3 89.6 ± 15.3 
Benzoates 
Methyl 3,4-dihydroxybenzoate 87.2 ± 9.4 82.6 ± 17.8 79.2 ± 6.1 
Methyl 3,4-dimethoxybenzoate 96.8 ± 3.9 73.3 ± 3.2 73.0 ± 7.2 
Methyl vanillate 101.5 ± 11.8 83.6 ± 2.1 80.9 ± 13.6 
Methyl gallate 87.7 ± 13.0 64.9 ± 5.3 101.4 ± 23.0 
Hydroxybenzyl alcohol 
4-Hydroxybenzyl alcohol 72.9 ± 8.7 80.0 ± 3.9 92.7 ± 12.2 
Phenylpropenoic acids 
p-Coumaric acid 93.5 ± 10.2 88.1 ± 6.0 87.6 ± 9.4 
Caffeic acid 78.6 ± 9.1 75.7 ± 6.0 98.6 ± 12.8 
Ferulic acid 105.3 ± 2.1 100.0 ± 4.4 74.3 ± 6.8 
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Sinapic acid 110.1 ± 5.6 88.7 ± 0.5 79.6 ± 9.8 
Benzaldehydes 
Phloroglucinaldehyde  64.5 ± 5.9 79.7 ± 8.4 66.4 ± 7.0 
4-Hydroxybenzaldehyde 85.8 ± 8.7 73.7 ± 6.1 97.0 ± 13.4 
3,4-Dihydroxybenzaldehyde 77.8 ± 7.9 83.8 ± 9.2 109.4 ± 26.8 
Phenylacetic acids 
4-Hydroxyphenylacetic acid 87.2 ± 2.8 87.6 ± 7.9 82.1 ± 19.9 
Homoprotocatechuic acid 60.0 ± 11.6 72.0 ± 3.2 88.2 ± 11.8 
Homovanillic acid 81.9 ± 9.7 107.3 ± 1.1 63.4 ± 7.3 
Hippuric acids 
Hippuric acid NQ
b 
98.9 ± 2.4 87.3 ± 11.5 
3-Methylhippuric acid 76.6 ± 9.6 95.4 ± 0.4 85.4 ± 10.5 
4-Methylhippuric acid 92.5 ± 1.7 90.3 ± 6.2 77.1 ± 6.2 
Internal standards 
Phloridzin 81.6 ± 6.4 77.2 ± 15 75.5 ± 7.4 
Scopoletin
c
 VC
 
VC
 
VC
 
Taxifolin 96.6 ± 0.9 88.6 ± 4.4 76.6 ± 11.0 
7,8-Dihydroxycourmarin 88.8 ± 0.8 87.5 ± 5.4 98.0 ± 12.5 
Data expressed as mean ± SD; VC, volume control. 
a
Extracted using Strata-X™ as opposed to 
DSC-18 SPE columns. 
b
NQ, Not quantified due to high background concentrations in urine. 
c
Scopoletin was used as a volume control standard and was therefore added post extraction 
only. 
 
2.3.6. Validation using clinically derived samples. 
Validation of the urine and plasma extraction methods was established using samples 
collected from a previously undertaken anthocyanin intervention study where participants 
consumed 500 mg of elderberry derived anthocyanins (Chapter 4) (Curtis et al., 2009), 
whilst the faecal method was validated using samples collected from a previous study where 
participants consumed 500 mg 
13
C5-cyanidin-3-glucoside (Chapter 3) (Czank et al., 2013). 
The lowest metabolite concentration detected in samples taken at 1, 2 and 3 h post-
consumption was investigated, where 36 of the 45 putative compounds were detected in 
human samples, 26 within urine, 25 within plasma and 24 with faeces. The minimum 
concentrations identified ranging from 0.4 nM for vanillic acid-sulfate to 0.1 mM for 
hippuric acid in urine, 2 nM for methyl-3,4-dihydroxybenzoate to 6 µM for hippuric acid in 
plasma and 0.3 nM for benzoic acid-4-glucuronide to 7 µM for 2,3-dihydroxybenzoic acid in 
faeces (Table 2.5). The maximum concentrations identified within participant samples 
ranged from 3 m M in urine to 10 µ M in plasma for hippuric acid and 211 µM for ferulic 
acid in faeces. 
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Table 2.5 Minimum and maximum concentrations of analytes detected in spot urine, serum 
and faecal samples post consumption of 500 mg anthocyanins. 
Analyte 
Urine (nM) Plasma (nM) Faeces (nM) 
Min
a 
Max
b 
Min
a 
Max
b 
Min
c
 Max
d
 
Anthocyanins 
Cyanidin-3-glucoside 2 6,348 4 7 2,017 2,017 
Benzoic acids 
2-Hydroxybenzoic acid 37 2,919 173 211 ND ND 
3-Hydroxybenzoic acid 60 21,024 21 36 ND ND 
4-Hydroxybenzoic acid 656 9,892 30 39 34 3,026 
2,3-Dihydroxybenzoic acid 12 12,360 ND ND 6,974 21,044 
Protocatechuic acid (PCA) 31 8,117 11 24 8 33,081 
PCA-3-glucuronide 2 8,161 3 15 20 713 
PCA-4-glucuronide 7 2,771 4 14 9 1,127 
PCA-3 and 4-sulfate 14 29,403 734 358 2 872 
3,5-Dihydroxybenzoic acid 134 21,328 18 50 ND ND 
4-Methoxysalicylic acid ND ND 0.3 2 29 11,420 
Vanillic acid (VA) 66 18,076 6 62 282 16,663 
VA-4-glucuronide 74 18,929 16 120 29 285 
VA-4-sulfate  0.4 75,259 23 161 0.3 1,968 
IsoVA ND ND ND ND 177 230 
IsoVA-3-glucuronide 4 15,680 10 24 18 241 
IsoVA-3-sulfate 0.4 75,259 23 161 1 4,993 
Syringic acid ND ND 5 22 ND ND 
Benzoic acid-4-glucuronide  3 623 7 10 0.3 1,477 
Benzoic acid-4-sulfate  ND ND 66 196 ND ND 
Benzoates 
Methyl-3,4-dihydroxybenzoate ND ND 2 6 58 7,425 
Methyl gallate ND ND 3 5 ND ND 
Methyl vanillate ND ND ND ND 2726 2726 
Hydroxybenzyl alcohol 
4-Hydroxybenzyl alcohol 228 17,663 ND ND ND ND 
Phenylpropenoic acids 
p-Coumaric acid 13 3,040 ND ND ND ND 
Caffeic acid ND ND ND ND 4,168 9,285 
Ferulic acid 15 9,908 7.7 28 131 211,194 
Sinapic acid 5 8,842 ND ND ND ND 
Benzaldehydes 
Phloroglucinaldehyde  7 3,477 4 103 10 11,216 
4-Hydroxybenzaldehyde ND ND 97 182 9 105 
3,4-Dihydroxybenzaldehyde ND ND 17.3 23 11 724 
Phenylacetic acids 
HomoPCA 309 22,045 ND ND 8 1,879 
HomoVA 1,493 289,697 ND ND ND ND 
Hippuric acids 
Hippuric acid 127,899 3,102,601 5,771 10,106 13 748 
3-Methylhippuric acid 29 5,831 ND ND ND ND 
4-Methylhippuric acid 16 2,963 ND ND ND ND 
a
Minimum and 
b
maximum analyte concentration detected within baseline, 1, 2 and 3 h post 
bolus spot urine and plasma samples of participants (n=15) fed 500 mg elderberry anthocyanins. 
c
Minimum and 
d
maximum analyte concentration detected within faecal samples, where 
participants (n=8) were fed 500 mg 
13
C-labelled cyanidin-3-glucoside and samples were 
collected for 48 h post bolus. ND, not detected. 
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2.4. Discussion 
The metabolic fate of anthocyanins in vivo has remained elusive despite a large number of 
studies aimed at quantifying them within biological fluids, predominantly due to the low 
bioavailability of the parent structures and a shortage of quantitative analytical methods 
optimised for the analysis of anthocyanin metabolites. The objective of the present chapter 
was to develop methods suitable for establishing the ADME of anthocyanins, including the 
clearance of their degradation products and metabolites. The present investigation strategy 
was to first model putative metabolites of anthocyanins to establish a range of targets for 
method validation, second establish fit for purpose methods for detecting and quantifying the 
putative metabolites, and third validate the developed methods. 
 
The analytes used in this study were selected based on modelling the products of 
degradation, phase I, phase II and colonic metabolism of anthocyanins and other similarly 
structured flavonoids based on previously published studies (Aura et al., 2005; Cheminat et 
al., 1986; Donovan et al., 1999; Donovan et al., 2002; Fernandes et al., 2008; Forester et al., 
2008; Kay et al., 2004; Mazza et al., 1987; Mazza et al., 2002; Moridani et al., 2001; 
Williamson et al., 2010; Woodward et al., 2009). This approach provided an extensive 
library of 112 compounds for the optimisation of extraction and detection methodology that 
can be applied to future studies of ADME. Synthesis of  glucuronide and sulfate conjugates 
of phenolic metabolites was necessary (Zhang et al., 2012) as analytical standards of these 
phase II metabolites were not commercially available. To the best of the author’s knowledge, 
this comprehensive approach has not been previously published for anthocyanin analysis. 
The internal standards utilised in this method were selected as they are not endogenously 
present within humans and have a similar structure to anthocyanins. Phloridzin comprises of 
two linked phenyl rings, with a glucopyranoside attached and is found in tree bark. Taxifolin 
is a flavanonol and can be found in conifers such as Chinese yew. It is also found in the açaí 
palm, in the silymarin extract from the milk thistle seeds.Scopoletin is a coumarin found in 
the roots of plants in the genus Scopolia. It can also be found in vinegar and dandelion 
coffee. 
 
Initially, chromatographic conditions for the separation and identification of putative 
anthocyanin metabolites were explored using HPLC-UV/vis, which is routinely used for the 
detection of intact anthocyanins in biological matrices. Unfortunately, the concentrations of 
many phenolics found in the biological samples were often below the detection limit of 
UV/vis detection (data not shown). In addition, numerous phenolic metabolites of 
anthocyanins absorb at wavelengths common to many compounds naturally present in 
Rachel M. de Ferrars © 2013  
 
66/215 
 
baseline biological samples, in contrast to their parent structures which have a relatively 
unique peak absorbance (525 nM), thus precluding the use of UV/vis detection methods. 
Therefore, incorporation of MS/MS was necessary for the detection and quantification of the 
phenolics in the highly complex mixtures of analytes as explored in the present investigation. 
The HPLC-ESI-MS/MS method was optimised for common parameters, including column, 
ionic modifier concentration, organic modifier, mobile phase gradient and flow rate. HPLC 
columns vary according to their sorbent material, pore size and column dimensions whilst 
analyte retention is influenced by its surface area, polarity and size. Suitable 
chromatographic separation when using HPLC-MS/MS is difficult when dealing with 
complex mixtures, and in particular, where compounds of equal mass (isomeric compounds) 
are present. The majority of studies using RP-HPLC to analyse anthocyanins have utilised 
C18 packing materials (Felgines et al., 2003; Garcia-Alonso et al., 2009; Kay et al., 2009; 
Valentova et al., 2007). C18 columns consist of silica particles coated with C18H37 alkyl 
groups, which provide good hydrophobic retention. The Synergi Max RP column is similar 
to C18, but contains a C12 bonded phase with trimethylsilyl (TMS) end capping, giving it 
similar hydrophobic selectivity, with less steric hindrance than C18. The Luna C18(2) 
column contains octadecyl silane ligands bound to the silica surface and the Synergi polar 
RP column contains ether linked phenyl groups with polar endcaps, giving it high retention 
of polar and aromatic compounds, especially in the presence of methanol which facilitates π-
π bonding. The PFP column is a relatively new stationary phase and incorporates fluorine 
atoms on the periphery of a phenyl ring, resulting in good peak resolution of aromatic 
compounds. Of the five columns tested, the present study identified the PFP column as 
providing the greatest chromatographic separation efficiency under the present conditions. 
The PFP stationary phase also demonstrated superior resolution of the sulfated conjugates 
(Figure 2.2), resulting in higher peak intensities (2-10 fold increase) compared to the other 
stationary phases tested. No column tested was able to effectively separate the isomers of 
PCA sulfate under the explored conditions. 
 
The pH of the mobile phase can have a large impact on the peak resolution of acids and 
bases depending on their pKa. Due to the differing behaviours of ions and neutral molecules 
within a chromatographic column, it is preferred to have a high percentage of the molecule 
in the same state of ionisation, to prevent the ions gradually separating (Le Chatelier’s 
principle) resulting in the elution of wide peaks. In the present study, the use of 0.1% formic 
acid within the mobile phase increased peak resolution and resulted in a 389 ± 530% 
increase in peak height relative to 1% formic acid for the phenolic compounds (Figure 2.4A). 
The resolution of the analytes was further improved by decreasing the flow rate from 1.5 
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mL/min to 1 mL/min from 7 to 14 min within the run-time, where the majority of the 
structurally similar compound were eluting. Moreover, selecting acetonitrile as the organic 
solvent rather than methanol improved peak resolution, as acetonitrile has a stronger elution 
strength and lower backpressure than methanol. 
 
The MS source and MRM related parameters were optimised for the analytes of interest in 
positive and negative mode in order to select the optimum method (i.e. due to their positive 
change, anthocyanins ionise better in positive mode, whilst phenolic acids tend to provide 
higher ion intensities in negative mode). Source parameters are responsible for controlling 
the temperature, voltages and gas flows responsible for nebulising, evaporating, ionising and 
directing the solvent towards the curtain plate orifice. Therefore, they are important in 
controlling ion intensity. Source parameters were kept constant throughout an experiment, 
thus common optimal values for all compounds were used. A high temperature (700 °C) and 
gas flow (60 psi) appeared particularly important to ensure ionisation of the compounds at 
this relatively high flow rate. Conversely, MRM related parameters were optimised 
separately for each compound. They are responsible for fragmenting, selecting and focusing 
the ions by controlling the potential through the quadruples and therefore control the 
fragmentation of the compound. However, it should be noted that MS optimisation is 
instrument specific and the presented values (Table 2.2) should only be used as a guide for 
method development or validation and most other sources and MS platforms may not be able 
to deal with flow rates in this range. 
 
LOD represent the lowest concentration at which the test compound that remains detectable, 
or specifically the concentration at which the analyte yields a peak height signal-to-noise 
ratio of 3:1. The LODs of the final method ranged from 0.3 nM (for phloridzin in serum) to 
2604 nM (for homovanillic acid in urine) (Table 2.5). The LODs of the majority of the 
compounds were below 100 nM; however, the LODs of 8, 7 and 15 compounds in urine, 
serum and faeces respectively were above 100 nM, generally a result of poor ionisation and 
high baseline interference, and should be considered unacceptable. The LOD for 
homovanillic acid was extremely poor, suggesting the described HPLC-MS/MS method is 
not optimal for its detection, and alternative techniques such as derivatization followed by 
GC-MS may be more suitable; yet despite this, it was detected within urine, due to the 
extremely high concentrations present (1.5 µM). Homoprotocatechuic acid and 2, 3- and 4-
hydroxybenzoic acid in urine and 3-hydroxybenzoic acid in serum were also detected in 
biological samples, despite having a detection limit above 100 nM. However, future clinical 
studies using these methods should be aware that if undetected, these compounds may still 
be present at concentrations below 100 nM.  
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SPE is often the preferred extraction method when using HPLC-MS/MS as it removes salts 
that may affect ionisation, resulting in a matrix free from interfering elements (Kataoka et 
al., 2010). It should be noted however that dilution, acidification and syringe filtration 
(Marks et al., 2009; Mullen et al., 2009; Stalmach et al., 2009a), protein precipitation (Graf 
et al., 2006; Kay et al., 2004; Marks et al., 2009; Mullen et al., 2009; Stalmach et al., 2009a; 
Woodward et al., 2009) and liquid-liquid extraction (Graf et al., 2006; Mullen et al., 2002) 
are also often commonly used techniques in the analysis of polyphenols. These methods 
were also initially and exhaustively explored, however, due to issues with poor recovery, 
extremely high variability (inter- and intra-extraction) and insufficient chromatographic 
resolution of some analytes, they were abandoned in favour of SPE. Thus, SPE was the 
optimal method for the extraction of anthocyanin metabolites, resulting in mean extraction 
efficiencies of 88.3 ± 17.8% for urine, 86.5 ± 11.1% for serum and 80.6 ± 20.9% for faeces 
for the 45 modelled metabolites. In addition, the methods provided acceptable repeatability 
as the extraction efficiencies averaged from 7.9 ± 5.3% for urine, 6.8 ± 5.0% for serum and 
14.1 ± 7.9% for faeces (Table 2.3). For urine extraction, the DSC-18 and Strata-X™ SPE 
cartridges yielded similar recoveries for cyaniding-3-glucoside, phloroglucinaldehyde and 
the internal standard (taxifolin), however the binding characteristics of the polymeric 
divinylbenzene Strata-X™ sorbent allowed large amounts of polar compounds to remain 
bound to the column after the aqueous wash, resulting in poor resolution of the analytes of 
interest from co-eluting compounds in the background matrix and thus resulting in higher 
limits of detection. Therefore, DSC-18 SPE cartridges were selected as they gave superior 
recoveries for compounds from urine. Within serum, the more selective Strata-X™ 
cartridges were optimal for the extraction of target analytes, as they afforded significantly 
higher extraction efficiencies and improved repeatability (77.9 ± 5.2% to 89.2 ± 6.2%) 
relative to the DSC-18 cartridges (54.1 ± 3.5% to 77.2 ± 14.3%). Within the faecal matrix, 
the SPE recoveries of the 45 compounds of interest ranged from 9.3 ± 2.7% to 121 ± 41.5% 
with a high mean recovery of 80.6 ± 20.9%. Recoveries above 100% are commonly 
observed in SPE methods and can result from the accumulation of error during the extraction 
process, particularly when the analyte is endogenously present within the sample. The lowest 
recoveries were observed within the faeces, with 4-methoxysalicylic acid and gallic acid 
having a recovery of 9% and 10% respectively. The lower recoveries observed within the 
faecal matrix were likely due to the complexity of the faecal matrix; a proportion of the 
spiked analyte likely remained bound to the solid matter and the presence of the vast array of 
microflora may also contribute to the lower recoveries. Together these results demonstrate 
that despite the complexity of the biological matrices, the presented method is suitable for 
the recovery of the target analytes.  
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Validation of the methods for use with clinical samples was carried out on urine and plasma 
samples derived from 15 participants in a human intervention study feeding 500 mg 
elderberry anthocyanins (Curtis et al., 2009). The methods described herein were successful 
in identifying 36 metabolites, comprising of 26 analytes within urine, 25 within serum, and 
24 within faeces. The lowest concentrations of the metabolites identified in the urine samples 
ranged from 0.4 nM for vanillic acid-4-sulfate to 0.1 mM for hippuric acid, while 
concentrations in the plasma ranged from 2 nM for methyl-3,4-dihydroxybenzoate to 6 µM 
for hippuric acid and concentrations in the faeces ranged from 0.3 nM for benzoic acid-4-
glucuronide to 7 µM for 2,3-dihydroxybenzoic acid (Table 2.5). The identification of these 
metabolites within clinical samples demonstrates the methods are suitable and have 
acceptable LODs for the detection of anthocyanin metabolites in clinically relevant samples. 
Furthermore, quantification was carried out using matrix-matched standard curves rather 
than standard curves prepared in mobile phase (a common approach), which provides an 
extra degree of precision as the matrix associated ionisation efficiencies and baseline 
deviation of the sample and standards are more similar.  
 
2.5. Conclusion 
The present study describes the development of analytical methods that are suitable for the 
separation, detection and quantification of a large number of structurally diverse anthocyanin 
metabolites in clinical samples. The sample extraction and analyte detection methods 
described are suitable for analysis of the majority of the compounds examined, which 
included several metabolites that were not available commercially and for which reliable 
methods had not previously been reported. This work has resulted in the development of 
methods that are expected to enhance the quality of future studies of anthocyanin ADME, 
which may in turn identify novel targets for future investigations exploring the biological 
activity of anthocyanins.  
  
Rachel M. de Ferrars © 2013  
 
70/215 
 
Chapter 3. The pharmacokinetics of 
anthocyanins following the ingestion of 
13
C5-
cyanidin-3-glucoside in humans 
 
3.1. Introduction  
In order for anthocyanins to exert protective effects, as reported in many epidemiological 
studies (Cassidy et al., 2013; Cassidy et al., 2011; Mink et al., 2007), randomised controlled 
trials (Zhu et al., 2013; Zhu et al., 2011), animal (Wang et al., 2011) and in vitro 
(Edirisinghe et al., 2011; Xu et al., 2004b) studies, they need to be absorbed and reach target 
tissues in a bioactive form. However, ambiguity has arisen concerning the absorption, 
distribution, metabolism and elimination (ADME) of anthocyanins, as their recovery from 
biological samples has been poor, often with nanomolar concentrations observed in plasma. 
Furthermore, interventions feeding anthocyanin rich foods, including blackberries, 
strawberries, blackcurrants or cranberries, containing up to 2.4 g anthocyanins, rarely 
recover more than 1% of the ingested dose (Bub et al., 2001; Cao et al., 2001; Felgines et 
al., 2005; Kay et al., 2005; Kay et al., 2004; Manach et al., 2005; Matsumoto et al., 2001; 
Milbury et al., 2002; Milbury et al., 2010; Mullen et al., 2008a; Murkovic et al., 2001).  This 
raises questions regarding the metabolic fate of anthocyanins and similarly the 
compounds/metabolites responsible for their potential cardio-protective effects. 
 
Due to their unstable nature, it has been proposed that anthocyanins are likely present in the 
circulation, as degradation products and metabolic intermediates (Kay, 2010). The 
degradation of anthocyanins to their phenolic acid and aldehyde constituents has been 
observed in vitro, with the degradation products observed within gastric (Woodward et al., 
2009) and microbial fermentation studies (Gonzalez-Barrio et al., 2011; Williamson et al., 
2010); yet only a few human studies have detected these degradation products within 
biological samples (Azzini et al., 2010; Czank et al., 2013; Nurmi et al., 2009; Russell et al., 
2009; Vitaglione et al., 2007). It is therefore possible that the degradation products are 
further metabolised in vivo, forming a large number of potentially bioactive metabolites.   
 
A study feeding 71 mg anthocyanins within 1 L blood orange juice, implicated the phenolic 
acid degradation product, protocatechuic acid, as a major anthocyanin metabolite (Vitaglione 
et al., 2007). In addition, a range of phenolic acids, including vanillic, syringic, caffeic and 
ferulic acid have been identified within serum, reaching maximum concentrations 4-6 h after 
the consumption of a bilberry-lingonberry puree (Nurmi et al., 2009). However, the complex 
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flavonoid and phenolic profile of the intervention food, limited the ability to trace the 
metabolites back to their source. Further, in vitro and human studies indicate that such 
phenolic acids undergo phase II conjugation (Nardini et al., 2009; Nardini et al., 2006; 
Woodward et al., 2011), suggesting anthocyanin degradation products can undergo extensive 
metabolism in vivo. Recent evidence also suggests that the major metabolites of 
anthocyanins are likely to be derived from bacterial fermentation and absorption from the 
colon (Del Rio et al., 2010; McGhie et al., 2007; Williamson et al., 2010) .  
 
The extensive degradation and metabolism of anthocyanins was recently confirmed in a 
stable isotope-labelled cyanidin-3-glucoside feeding study in which the relative 
bioavailability of cyanidin-3-glucoside was established as 12.38 ± 1.38%, based on the 
recovery of the 
13
C-label in the urine and breath (Czank et al., 2013), thus suggesting that the 
extent of anthocyanin absorption and metabolism had been previously underestimated.  
Furthermore, given the degradation, short t½ and low Cmax of the parent anthocyanins, the 
observed cardiovascular benefits of anthocyanin consumption (Cassidy et al., 2013; Cassidy 
et al., 2011; Erdman et al., 2007; Mink et al., 2007) are likely the consequence of the 
metabolites, which are present within the circulation for significantly longer and at higher 
concentrations than the parent anthocyanins. The present study aimed to identify the unique 
pharmacokinetic profiles of each anthocyanin metabolite, following the consumption of a 
500 mg oral bolus dose of 
13
C-labelled cyanidin-3-glucoside. The findings from this work 
will inform the design of future clinical interventions and mechanistic studies exploring the 
biological activity of anthocyanins.  
 
3.2. Materials and methods 
3.2.1. Chemicals and materials 
Unlabelled cyanidin-3-glucoside and peonidin-3-glucoside were obtained from 
Extrasynthese (Genay, France) as analytical standards. Phase II conjugates of phenolic acids 
(protocatechuic acid-3-glucuronide, protocatechuic acid-4-glucuronide, vanillic acid-4-
glucuronide, isovanillic acid-3-glucuronide, benzoic acid-4-glucuronide, protocatechuic 
acid-3-sulfate, protocatechuic acid-4-sulfate, vanillic acid-4-sulfate and isovanillic acid-3-
sulfate) were synthesised in the School of Chemistry and Centre for Biomolecular Sciences, 
University of St. Andrews (UK) via recently published methods (Zhang et al., 2012). All 
other standards (caffeic acid, p-courmaric acid, ferulic acid, sinapic acid, 3,4-
dihydroxybenzaldehyde, homoprotocatechuic acid and homovanillic acid) were purchased 
from Sigma-Aldrich (Dorset, UK). Kinetex pentafluorophenol (PFP) HPLC column (2.6 µM, 
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100 x 4.6 mm) and SecurityGuard
®
 cartridges (PFP, 4.0 x 2.0mm) were purchased from 
Phenomenex (Macclesfield, UK). HPLC grade methanol and acetonitrile were purchased 
from Fisher Scientific (Loughborough, UK). Discovery® DSC-18 SPE columns (6 mL, 1 g) 
and Acrodisc 13 mm, 0.45 µm PTFE syringe filters, ascorbic acid, formic acid and all other 
chemicals, were purchased from Sigma-Aldrich (Dorset, UK). All water utilised was of 
Milli-Q grade (18.2 MΩ cm-1). 
3.2.2. Clinical Design 
Eight healthy men (n = 8; age, 27.8 ± 8.1 y; BMI, 23.2 ± 1.5 kg/m²) were recruited from the 
University of East Anglia and local community of Norwich, UK to take part in the study in 
June-September 2011. In order to maintain a homogenous study population and minimise 
metabolic variation, male participants were selected, who were non-smokers, moderate 
drinkers and were not taking any dietary supplements. The protocol was explained to the 
participants and they provided informed consent. The study was conducted at the Clinical 
Research and Trials Unit at the University of East Anglia according to the principles 
expressed in the Declaration of Helsinki and was approved by the local Research Ethics 
Committee (REC ref: 10/110 H0306/42) and  registered at clinicaltrials.gov as 
NCT01106729. 
 
Cyanidin-3-glucoside was synthesised and isotopically labelled at positions 6, 8, 10, 3’ and 
5’ (Figure 3.1) at the University of St. Andrews, Scotland, so that three 13C atoms (13C3) 
were present on the A-ring and two 
13
C atoms (
13
C2) were present on the B-ring (Zhang et 
al., 2011). The molecule was established as 99.8% pure, with an enrichment of 99 atom 
percent at each position and was accurately weighed and encapsulated (250 mg 
anthocyanin/gelatin capsule) at the Ipswich Hospital Pharmaceutical Manufacturing unit 
(Czank et al., 2013; Zhang et al., 2011). 
 
Figure 3.1 Structure and labelling 
configuration of 6,8,10,3',5'-
13
C5-cyanidin-3-
glucoside. 
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3.2.3. Study Protocol 
For a seven-day washout period prior to the trial and throughout the three study days, 
volunteers limited their intake of foods rich in anthocyanins and with a high natural 
abundance of 
13
C (For exclusion list, refer to Appendix 1). In order to monitor compliance, 
food diaries were completed during the washout period (three days), the study day and 
during the 48 h follow-up. Following an overnight fast, baseline faecal (up to 72 h prior to 
the study day), urine (total morning void of study day), blood and breath samples were 
collected. Participants were given a single, oral 500 mg bolus of encapsulated 
13
C5-cyanidin-
3-glucoside (2 x 250 mg capsules), followed by a standardised anthocyanin free breakfast. 
Blood and breath samples were collected at 0.5 h, 1 h, 2 h, 4 h, 6 h, 24 h and 48 h following 
the anthocyanin bolus. Individual urine and faecal total voids were collected throughout the 
study day (0-6 h) and pooled for 6-24 h and 24-48 h time points (Figure 3.2). 
 
Figure 3.2 Clinical study design summarising the collection of blood and urine samples. 
 
 
 
3.2.4. Sample collection 
Total urine voids were collected into Urisafe® collection containers (VWR, UK) with 100 
mg ascorbic acid added to each sample prior to collection and an addition 100 mg was added 
for every additional 500 mL. In order to prevent degradation of the anthocyanins, the pH of 
the samples was established using a pH meter (Omega, UK) and manually adjusted to pH 2.4 
± 0.08 with formic acid. Blood samples were collected into sterile, untreated 10 mL 
vacutainers® (BD, UK). For whole blood isotope ratio mass spectrometry (IRMS) analysis, 
blood was immediately aliquoted into 1 mL cryogenic vials and flash frozen using liquid 
nitrogen, whilst for serum collection, blood was inverted and left to clot at room temperature 
-7 
days
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Rachel M. de Ferrars © 2013  
 
74/215 
 
for 1 h, then centrifuged at 4°C, 1300 g for 10 min. 7.5 mL serum was collected, the pH was 
measured, 10%vv of 10% acorbate was added to the serum and the pH was manually 
(dropwise) adjusted to pH 2.4 (final pH, 2.4 ± 0.08) with formic acid. Breath samples were 
collected using the Alveosampler™ system (QuinTron, Italy) and stored in 10 mL 
vacutainer® (BD, UK) tubes at room temperature for IRMS. Faecal voids were collected 
into custom-made stool collection kits, weighed and transferred to cryogenic storage 
containers (Nalgene, UK) for storage. Following processing, all blood, serum and faeces 
samples were stored at -80°C until analysis. Note, breath samples were analysed using 
continuous-flow IRMS (AP 2003; Iso-Prime) and the data are described by Czank et al. 2013 
(Czank et al., 2013). 
3.2.5. Sample preparation 
Urine and plasma samples were extracted and concentrated at the Institute of Food Research 
(Norwich, UK) as previously described (Chapter 2). Briefly samples were extracted using 
DSC-18 (for urine) and Strata-X™ (for plasma) SPE cartridges, evaporated to approximately 
50 µL using a Thermo speedvac and diluted with 200 uL of acidified water. 10 µL of 1 
mg/mL phloridzin was added as a volume control standard and samples were then syringe 
filtered prior to analysis.  
 
3.2.6. HPLC-MS/MS analysis 
HPLC-MS/MS analysis was conducted at the Institute of Food Research (Norwich, UK) 
using an Agilent 1200 series HPLC system coupled with a ABSciex 4000 MS/MS system, 
with samples injected onto a Kinetex PFP column as previously described (Chapter 2). 
(Note: the analysis described in the present chapter was conducted by the Institute of Food 
Research, using the conditions as described in Chapter 2. Retention times were adjusted for 
the 4000 Q-trap system). Briefly, the mobile phase consisted of 0.1% formic acid (v/v) in 
water (A) and 0.1% formic acid (v/v) in acetonitrile (B), at a flow rate of 1.5 mL/min at 0 
min, 1 mL/min at 7 to 14 min and 1.5 mL/min at 14 to 28 min. The gradient consisted of 1% 
B at 0 min, 7.5% B at 7 min, 7.6% B at 14 min, 10% B at 17 min, 12% B at 18.5 min, 12.5% 
B at 20 min, 30% B at 24 min and 90% B at 25 to 28 min. MS/MS source parameters 
included curtain gas 40 psi, ion spray voltage -4000 V/+5500 V, temperature 700°C and 
nebulizer and auxiliary gas 60 psi. The system was controlled by Analyst software (v. 1.5, 
Applied Biosystems/MDS Sciex). Metabolite identification was performed by multiple 
reaction monitoring (MRM) optimised for the detection of pure standards with m/z of the 
parent and daughter fragments adjusted to +2,+3,+5 Da to allow identification of the 
13
C-
labelled metabolites derived from the B-ring, A-ring or the parent structure, respectively. 
Rachel M. de Ferrars © 2013  
 
75/215 
 
Metabolites were confirmed on the basis of retention time (using authentic and synthesised 
standards where possible) and three or more parent-daughter ion transitions.  
3.2.7. Statistics 
Pharmacokinetic modelling of metabolites in the serum was performed with the PKSolver 
‘add-on’ for Excel 2010 (Microsoft, California) (Zhang et al., 2010) using non-
compartmental analysis with AUC calculated using the trapezoidal rule. Pharmacokinetic 
parameters were established for each individual analyte and presented as mean ± SD. Urine 
samples collected during the first 6 h post bolus were grouped together to the nearest hour 
for graphical interpretation and to calculate total cumulative recovery. The concentration of 
metabolites was converted to amount recovered from the urine by accounting for the 
molecular weight of the individual 
13
C-labelled metabolites and the volume of the individual 
participants void and averaged across participants. Recovery of metabolites in the faeces was 
established from the molecular weight of the 
13
C-labelled metabolite and the weight of the 
individual participants void adjusting for faecal water content as previously described 
(Czank et al., 2013). Urine and faecal recovery amounts are presented as mean ± SD, n = 8 
unless otherwise stated.   
 
3.3. Results 
3.3.1. Metabolite identification 
A total of 35 
13
C-labelled analytes (including the parent 
13
C5- cyanidin-3-glucoside) were 
identified in serum, urine and faecal samples collected over 48 h post-consumption. The 
metabolites identified included the degradation products of cyanidin-3-glucoside 
(protocatechuic acid and phloroglucinaldehyde), phase I (dehydroxylation, reduction) and 
phase II (methyl, sulfate, glycine and glucuronyl) conjugates of cyanidin-3-glucoside, 
protocatechuic acid and phloroglucinaldehyde and probable bacterial metabolites, including 
carboxylic, phenylacetic and phenylpropenoic acids. Of the 35 analytes identified, six 
metabolites (two isomers of cyanidin-glucuronide, methyl-cyanidin-glucuronide and three 
isomers of methyl-cyanidin-3-glucose-glucuronide; Table 3.1) were tentatively identified as 
having a neutral loss of 176 m/z (glucuronide) whilst sharing common daughter ion 
transitions with cyanidin-3-glucoside or peonidin-3-glucoside. The remaining 29 metabolites 
were confirmed by comparison of retention time and MS/MS fragmentation patterns to that 
of pure standards (Table 3.1). 
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Table 3.1 HPLC-MS/MS identification (MRM) of 
13
C-labelled cyanidin-3-glucoside (C3G) and its metabolites in the serum, urine and faeces of healthy 
volunteers (n=8) after the consumption of 500 mg of 
13
C-labelled C3G.  
Metabolite 
Compound identification Analytical standards 
Rt 
(min) 
MRM ion transitions 
(m/z)
a
 
Location # 
13
C
b
 
MS
2
 fragments 
(m/z) 
Parent anthocyanins       
Cyanidin-3-glucoside (C3G) 12.6 454/292, 246, 218, 133 Urine, serum, faeces +5 449/287, 241, 213, 128 
Cyanidin-glucuronide  11.7 468/292 Urine +5 NA
c 
Cyanidin-glucuronide 16.5 468/292 Urine +5 NA
c
 
Peonidin-3-glucoside 16.6 468/306 Urine +5 463/301 
Methyl-cyanidin-glucuronide 16.7 482/306 Urine +5 NA
c
 
Methyl-C3G-glucuronide 5.7 644/306 Urine +5 NA
c
 
Methyl-C3G-glucuronide 8.0 644/306 Urine +5 NA
c
 
Methyl-C3G-glucuronide 9.6 644/306 Urine +5 NA
c
 
Degradants      
Protocatechuic acid (PCA) 4.3 155/111, 93, 83 Urine, serum, faeces +2 153/109, 91, 81 
Phloroglucinaldehyde 7.4 156/155, 128, 110, 86 Urine, serum, faeces +3 153/151, 125, 107, 83 
Metabolites      
3-Hydroxybenzoic acid 8.1 138/95, 67 Urine, faeces +2 136/93, 65 
4-Hydroxybenzoic acid 6.5 138/95, 67 Urine, faeces +2 136/93, 65 
Benzoic acid-4-glucuronide 3.0 317/175, 155, 113, 95 Urine, serum, faeces +2 315/175, 153, 113, 93 
PCA-3-glucuronide 4.3 331/175, 155, 113, 111 Urine, serum, faeces +2 329/175, 153, 113, 109 
PCA-4-glucuronide 3.3 331/175, 155, 113, 111 Urine, serum, faeces +2 329/175, 153, 113, 109 
PCA-3-sulfate 6.5 235/191, 155, 111 Urine, serum, faeces +2 233/189, 153, 109, 97 
PCA-4-sulfate 6.2 235/191, 155, 111 Urine, serum, faeces +2 233/189, 153, 109, 97 
Vanillic acid (VA) 9.5 169/154, 125, 110 Urine, serum, faeces +2 167/152, 123,108 
IsoVA 9.9 171/153, 127, 95 Urine, serum, faeces +2 169/151, 125, 93, 65 
IsoVA-3-glucuronide 6.2 347/175, 171, 154, 113 Urine, serum, faeces +2 345/175, 169, 152, 113 
VA-4-glucuronide 4.9 347/175, 171, 154, 113 Urine, serum, faeces +2 345/175, 169, 152, 113 
IsoVA-3-sulfate 8.8 247/169, 154, 125, 110 Urine, serum, faeces +2 245/167, 152, 123, 108 
VA-4-sulfate 8.6 247/169, 154, 125, 110 Urine, serum, faeces +2 245/167, 152, 123, 108 
4-Hydroxyphenylacetic acid 6.8 154/125, 109, 95 Urine, faeces +2 152/123, 107, 93, 79 
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HomoPCA 4.6 171/127, 111, 97 Urine, faeces +2 169/125, 109, 95 
4-Hydroxybenzaldehyde 8.5 123/110, 94, 67 Urine, serum, faeces +2 121/108, 92, 65 
3,4-Dihydroxybenzaldehyde 5.8 139/110, 94, 83 Urine, faeces +2 137/109, 92, 81 
Caffeic acid 10.4 183/139, 110, 93 Faeces +2 181/137, 108, 91 
Ferulic acid 18.8 
195/180, 150, 136 
196/181, 151, 137 
Urine, serum, faeces 
Urine, serum, faeces 
+2 
+3 
193/178, 148, 134 
Hippuric acid 6.3 179/136, 134, 79 Urine, serum, faeces +2 177/134 ,132, 77 
4-Methoxybenzaldehyde 19.6 169/125, 110, 81 Faeces +2 167/123, 108, 79 
4-Methoxysalicyclic acid 20.1 
155/94, 79, 65 
156/95, 80, 66 
Faeces 
Urine 
+2 
+3 
153/92,77, 63 
Methyl vanillate 21.4 185/153, 125, 109 Faeces +2 183/151, 123, 107, 77 
Methyl-3,4-dihydroxybenzoate 12.9 170/111, 93 Urine, serum, faeces +2 168/109, 91 
a
Mass spectra fragments for 
13
C labelled metabolites with +2, +3 and +5 m/z. 
b
 +2, +3 and +5 m/z refer to metabolites derived from PCA, PGA and cyanidin 
respectively. 
c
NA, no analytical standard available for confirmation. 
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3.3.2. Serum pharmacokinetics  
In serum, a total of 17 
13
C-labelled compounds, comprising cyanidin-3-glucoside, 
protocatechuic acid, phloroglucinaldehyde, 13 derivatives of protocatechuic acid, and one 
derivative of phloroglucinaldehyde were detected (Table 3.2; Figure 3.3; Figure 3.4). The 
Cmax of the analytes ranged from 11 ± 6 nM for protocatechuic acid-3-glucuronide (Figure 
2B) to 2.0 ± 3.9 µM for hippuric acid (Figure 3A), with tmax between 1.8 ± 0.4 h for 
cyanidin-3-glucoside and 30.1 ± 22.8 h for vanillic acid-sulfate. Elimination half-lives (t½) 
also ranged from 0.4 h for cyanidin-3-glucoside to 96.5 ± 134.7 h for the A-ring derived 
ferulic acid (Table 3.2). protocatechuic acid-3-glucuronide was the least abundant metabolite 
present in serum with an AUC of 60 ± 86 nmol·hL
-1
 while hippuric acid was the most 
abundant metabolite with an AUC of 46 ± 86 µmol·hL
-1 
(Table 3.2).
  
 
Table 3.2 Serum pharmacokinetic profiles of cyanidin-3-glucoside (C3G), its degradation products 
and derived metabolites in humans after the consumption of 500 mg 
13
C-labelled C3G
a
.  
Metabolite n
b Cmax 
(nM) 
tmax 
(h) 
t ½ 
(h) 
AUC0-48 
(nmol·hL
-1
) 
Parent anthocyanins 
Cyanidin-3-glucoside
e
  5 141 ± 156 1.8 ± 0.4 0.4 278 ± 380 
Degradants 
Protocatechuic acid (PCA)
g
 8 146 ± 209 3.3 ± 2.0 9.9 ± 9.0 1,377 ± 2,150 
Phloroglucinaldehyde
d
 4 582 ± 1072 2.8 ± 2.2 NQ
c
 7,882 ± 15,535 
Protocatechuic acid derived 
Benzoic acid-4-glucuronide
f
 7 74 ± 52 10.9 ± 9 17.1 ± 6.0 1,467 ± 1,295 
Methyl-3,4-dihydroxybenzoate
g
 8 12 ± 15 8.4 ± 16.1 21.6 ± 10.3 171 ± 197 
PCA-3-glucuronide
g
 5 11 ± 6 2.7 ± 2.3 18.0 ± 22.0 60 ± 86 
PCA-4-glucuronide
f
 8 68 ± 171 3.8 ± 2.1 19.4  ± 8.1 618 ± 1,384 
PCA-sulfates
g
 8 157 ± 329 11.4 ± 10.6 31.9 ± 38.2 1,180 ± 987 
Vanillic acid (VA)
c
 2 1,845 ± 1,185 12.5 ± 16.3 6.4 23,319 ± 29,203 
IsoVA
b
 1 195 2.0 NQ
c
 189 
VA-4-glucuronide
g
 8 24 ± 11 4.8 ± 1.0 NQ
c
 74 ± 31 
IsoVA-3-glucuronide
g
 8 34 ± 14 4.3 ± 1.7 1.6 ± 0.2 103 ± 37 
VA-sulfates
d
 4 430 ± 598 30.1 ± 22.8 NQ
c
 10,689 ± 15,503 
4-Hydroxybenzaldehyde
f
 7 667 ± 1,727 5.6 ± 8.3 17.9 ± 17.6 663 ± 1,336 
Ferulic acid
f
 7 827 ± 982 8.2 ± 10.9 21.4 ± 15.7 17,422 ± 29,246 
Hippuric acid 
g
 8 1,962 ± 3,928 15.7 ± 11.5 95.6 ± 134.7 46,568 ± 85,731 
Phloroglucinaldehyde derived 
Ferulic acid
e
 6 87 ± 93 13.3 ± 19.2 96.5 ± 127.2 1,815 ± 2,581 
a
Values are expressed as mean ± SD. 
b
Metabolite detected in n = number of participants. 
c
 NQ, not 
quantifiable as compounds remained sufficiently above baseline at 48h. 
d
PCA-sulfate and VA-
sulfate isomers could not be separated sufficiently by HPLC to allow individual quantitation and 
the values presented are cumulative concentration of both isomers. 
e
Alternative isomers of ferulic 
acid include 2-hydroxy-4-methoxycinnamic acid or 4-hydroxy-2-methoxycinnamic acid. 
 
Cyanidin-3-glucoside reached a maximum serum concentration of 141 ± 156 nM (Figure 
3.3A), while its degradation products, protocatechuic acid and phloroglucinaldehyde were 
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present at 146 ± 209 nM (Figure 3.3B) and 0.6 ± 1.1 µM (Figure 3.4C) respectively, with 
their tmax occurring 2-3 h later than that of cyanidin-3-glucoside (3.3 ± 2.0 h and 2.8 ± 2.2 h, 
respectively; Table 3.2). The metabolites of protocatechuic acid were the dominant species 
detected in the serum, with hippuric acid, vanillic acid and the B-ring derived ferulic acid 
representing the most abundant metabolites, having a Cmax of 2.0 ± 3.9 µM (Figure 3.4A), 1.8 
± 1.2 µM (Figure 3.3C), and 827 ± 982 nM (Figure 3.4B) respectively. Hippuric acid (t½ , 
95.6 ± 134.7 h), protocatechuic acid-sulfate (t½,  31.9 ± 38.2 h) and ferulic acid (t½  21. ± 15.7 
h) had significantly longer elimination half-lives than protocatechuic acid (t½  9.9 ± 9.0 h; 
Table 3.2). 
 
Eight sulfated and glucuronidated forms of protocatechuic acid and methylated 
protocatechuic acid (vanillic acid) were identified within the serum (Figure 2B,C), with the 
conjugations occurring at both the meta and para positions. Of these, vanillic acid-sulfate 
was present in the highest concentration (Cmax, 430 ± 598 nM; tmax, 30.1 ± 22.8 h) followed by 
protocatechuic acid-4-glucuronide (Cmax, 68 ± 171 nM; tmax, 3.8 ± 2.1 h) and protocatechuic 
acid-sulfate (Cmax, 157 ± 329 nM; tmax, 11.4 ± 10.6 h) (Table 3.2). In contrast, only one A-ring 
derived metabolites was identified within the serum, namely ferulic acid (Cmax, 87 ± 93 nM; 
tmax, 13.3 ± 19.2 h) (Figure 3.4C; Table 3.2). 
3.3.1. Urinary elimination  
In the urine, 31 
13
C-labelled compounds were identified, comprising of cyanidin-3-glucoside, 
seven methylated and glucuronidated conjugates of cyanidin-3-glucoside and cyanidin, 
protocatechuic acid, phloroglucinaldehyde, 19 derivatives of protocatechuic acid, and two 
derivatives of phloroglucinaldehyde (Table 3.3). Maximum concentrations of cyanidin-3-
glucoside (334 ± 382 nM) and its conjugated derivatives (ranging from 6 ± 5 nM to 206 ± 
234 nM) were identified between 1 and 2 h post consumption (Figure 3.5A). Protocatechuic 
acid also reached its maximum concentration (337 ± 332 nM) at 1-2 h (Figure 3.5B), while 
phloroglucinaldehyde reached its peak concentration (170 ± 118 nM) considerably later (6 to 
24 h) (Figure 3.6C). The phenolic metabolites were excreted in much higher concentrations 
than the parent anthocyanins, ranging from 24 ± 17 nM for 3,4-dihydroxybenzaldehyde 
(Figure 3.6C)  to 5.4 ± 13.9 µM for hippuric acid (Figure 3.6A), with peak excretions 
observed from 0-1 h to 24-48 h post consumption (Table 3.3). 
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Figure 3.3 Serum pharmacokinetic profiles of (A) cyanidin-3-glucoside, (B) protocatechuic 
acid and its metabolites and (C) methylated protocatechuic acid and its metabolites after the 
consumption of 500 mg 
13
C5- cyanidin-3-glucoside. 
 
All data is mean ± SD. C3G, cyanidin-3-glucoside; GlcA, glucuronide; M34dhbz, methyl-
3,4-dihydroxybenzoate; PCA, protocatechuic acid; VA, vanillic acid.  
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Figure 3.4  Serum pharmacokinetic profiles of (A) benzoic acid metabolites, (B) propenoic 
acid metabolites and (C) A-ring derived and aldehyde metabolites of cyanidin-3-glucoside 
after the consumption of 500 mg 
13
C5- cyanidin-3-glucoside. 
 
All data is mean ± SD. BA, benzoic acid; BAL, benzaldehyde; GlcA, glucuronide; PGA, 
phloroglucinaldehyde. 
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Table 3.3 Urinary recovery of cyanidin-3-glucoside, its degradation products and derived 
metabolites in humans after the consumption of 500 mg 
13
C-labelled cyanidin-3-glucoside
 a
. 
Metabolite n
b 
Maximum 
concentration  
 (nM) 
Time at 
maximum 
concentration
c 
Total recovery  
 (µg) 
Parent anthocyanin 
Cyanidin-3-glucoside (C3G)
h
 7 334 ± 382 1-2 h 120 ± 159 
Cyanidin-glucuronide
d
 5 88 ± 94 1-2 h 24 ± 25 
Cyanidin-glucuronide
d
 3 19 ± 12 1-2 h 12 ± 12 
Peonidin-3-glucoside 7 76 ± 113 1-2 h 23 ± 28 
Methyl cyanidin-glucuronide
e
 5 206 ± 234 1-2 h 75 ± 80 
Methyl C3G-glucuronide
e
 4 6 ± 5 1-2 h 2 ± 2 
Methyl C3G-glucuronide
e
 4 14 ± 13 1-2 h 7 ± 7 
Methyl C3G-glucuronide
e
 5 20 ± 19 1-2 h 10 ± 12 
Degradants 
Protocatechuic acid (PCA) 8 337 ± 332 1-2 h 72 ± 59 
Phloroglucinaldehyde 8 170 ± 118 6-24 h 67 ± 60 
Protocatechuic acid derived 
Hydroxybenzoic acid
f
 5 49 ± 24 1-2 h 13 ± 8 
Vanillic acid (VA) 4 3412 ± 624 1-2 h 960 ± 700 
IsoVA 4 212 ± 290 1-2 h 80 ± 108 
Methyl-3,4-dihydroxybenzoate 8 108 ± 111 3-4 h 21 ± 23 
Benzoic acid-4-glucuronide 7 129 ± 124 4-5 h 53 ± 48 
PCA-3-glucuronide 8 301 ± 204 1-2 h 198 ± 117 
PCA-4-glucuronide 8 233 ± 184 1-2 h 100 ± 86 
PCA-3-sulfate 8 1,112 ± 900 1-2 h 322 ± 247 
PCA-4-sulfate 8 1,244 ± 941 1-2 h 492 ± 546 
VA-4-glucuronide 8 762 ± 351 4-5 h 618 ± 310 
IsoVA-3-glucuronide 8 699 ± 254 5-6 h 527 ± 261 
VA-4-sulfate 7 1,682 ± 2,379 3-4 h 449 ± 297 
IsoVA-3-sulfate 5 822 ± 1,246 3-4 h 183 ± 208 
Hippuric acid 8 5,417 ± 13,876 6-24 h 2,416 ± 6,288 
Ferulic acid 8 1,840 ± 1,858 24-48 h 798 ± 836 
4-Hydroxyphenylacetic acid 3 391 ± 197 4-5 h 50 ± 3 
HomoPCA 1 82 24-48 h 28 
4-Hydroxybenzaldehyde 2 97 ± 133 5-6 h 10 ± 13 
3,4-Dihydroxybenzaldehyde 6 24 ± 17 0-1 h 6 ± 7 
Phloroglucinaldehyde derived 
Ferulic acid
g
 8 474 ± 770 0-1 h 225 ± 496 
4-Methoxysalicyclic acid 1 172 3-4 h 65 
a
Values are expressed as mean ± SD. 
b
Metabolites detected in n= number of  participants. 
c
Samples were pooled within participants urine voids, for t=0-1 h (n=3), t=1-2 h (n=5), t=2-3 h 
(n=6), t=3-4 h (n=6), t=4-5 h (n=4), t=5-6 h (n=8), t=6-24 h (n=8) and t=24-48 h (n=8). 
d
Quantified relative to C3G. 
e
Quantified relative to peonidin-3-glucoside. 
f
Includes both 
isomers (3-hydroxybenzoic acid and 4-hydroxybenzoic acid). 
h
Alternative isomers of ferulic 
acid include 2-hydroxy-4-methoxycinnamic acid or 4-hydroxy-2-methoxycinnamic acid. 
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Figure 3.5 Urinary elimination profiles of (A) cyanidin-3-glucoside and its metabolites, 
(B) protocatechuic acid and its metabolites and (C) methylated protocatechuic acid and 
its metabolites after the consumption of 500 mg 
13
C5- cyanidin-3-glucoside.  
 
All data is mean ± SD. C3G, cyanidin-3-glucoside; Cy, cyanidin; GlcA, glucuronide; 
M34dhbz, methyl-3,4-dihydroxybenzoate; Me, methylated; P3G, peonidin-3-glucoside; 
PCA, protocatechuic acid; VA, vanillic acid. 
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Figure 3.6 Urinary elimination profiles of (A) benzoic acid metabolites, (B) propenoic 
acid metabolites and (C) A-ring derived and aldehyde metabolites of cyanidin-3-
glucoside after the consumption of 500 mg 
13
C5- cyanidin-3-glucoside.  
 
All data is mean ± SD. 4-HBAL, 4-hydroxybenzaldehyde; BA, benzoic acid; BAL, 
benzaldehyde; GlcA, glucuronide; PAA, phenylacetic acid; PGA, phloroglucinaldehyde. 
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3.3.2. Recovery of faecal metabolites 
A total of 28 
13
C-labelled compounds were detected in the faeces, including cyanidin-3-
glucoside, protocatechuic acid, phloroglucinaldehyde, 24 B-ring derived metabolites and one 
A-ring derived metabolite (Table 3.4). B-ring derived ferulic acid was present at the highest 
concentrations within the faeces, with a maximum recovery of 2.4 ± 5.8 mg at 6-24 h post 
bolus, followed by the A-ring derived ferulic acid (470 ± 972 µg) and protocatechuic acid 
(361 ± 622 µg; Table 3.4).  
 
Table 3.4 Total faecal recovery of cyanidin-3-glucoside its degradation products and derived 
metabolites at 0-6 h, 6-24 h and 24-48 h after the consumption of 500 mg 
13
C-labelled C3G
a
.  
Metabolite 
Recovery (µg)  
0-6 h 6-24 h 24-48 h 
Parent anthocyanin 
Cyanidin-3-glucoside ND 70 
b
 20 
b
 
Degradants 
Protocatechuic acid ND 361 ± 622 
f
 222 ± 357 
h
 
Phloroglucinaldehyde ND 2 ± 3
 e
 111 ± 193
 g
 
Protocatechuic acid derived 
Hydroxybenzoic acid ND ND  22 ± 20
 d
 
2,3-Dihydroxybenzoic acid ND ND  440 ± 540
 c
 
4-Methoxysalicyclic acid ND 1 
b
 273 ± 386
 c
 
Vanillic acid ND 55 ± 2
 c
 49 ± 37
 d
 
Isovanillic acid ND 11
 b
 9 
b
 
Methyl-3,4-dihydroxybenzoate ND 167 ± 174
 d
 92 ± 121 
g
 
Methyl vanillate ND 35
 b
 ND  
Benzoic acid-4-glucuronide  2
b
 7 ± 7
 f
 15 ± 23 
i
 
Protocatechuic acid-3-glucuronide ND 23 ± 38
 d
 49 
b
  
Protocatechuic acid-4-glucuronide ND 16 ± 43
 g
 20 ± 46
 i
 
Protocatechuic acid-3-sulfate 0.1
b
 30 ± 39
 c
 12 ± 21
 e
 
Protocatechuic acid-4-sulfate ND 23 ± 3
 d
 12 ± 18
 d
 
Vanillic acid-4-glucuronide 4
b
 3 
b
 10 ± 14
 d
 
Isovanillic acid-3-glucuronide 2
b
 1 
b
 13 ± 15
 c
 
Vanillic acid-4-sulfate 1
b
 ND 69 ± 68
 d
 
Isovanillic acid-3-sulfate ND 1 ± 0.4
c
 176 ± 247
 c
 
Hippuric acid ND 12 ± 20
 d
 28 ± 39
 c
 
Caffeic acid         ND 25 
b 
355 ± 177
 c
 
Ferulic acid    ND 2,373 ± 5,811
 e
 1,455 ± 3,336
 g
 
4-Hydroxyphenylacetic acid ND 7
 b
 55 
b
 
Homoprotocatechuic acid 2
b
 10 ± 8
 e
 13 ± 17
f
 
4-Hydroxybenzaldehyde ND 1 ± 1
 c
 0.1
b
 
4-Methoxybenzaldehyde ND 21
 b
  ND 
3,4-Dihydroxybenzaldehyde ND 3 ± 5
 c
 5 ± 5 
i
 
Phloroglucinaldehyde derived 
Ferulic acid
j 
ND 470 ± 972 
c
 241 ± 345 
f
 
a
For 0-6 h, n=2; 6-24 h, n=8 and 24-48 h, n=8 participants provided samples; Values are 
expressed as mean ± SD, where metabolites were detected in 
b
n=1,
 c
n=2, 
d
n=3, 
e
n=4, 
f
n=5, 
g
n=6, 
h
n=7, 
i
n=8 participants; ND, not detected; 
j
could alternatively represent 2-hydroxy-4-
methoxycinnamic acid or 4-hydroxy-2-methoxycinnamic acid. 
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3.4.  Discussion 
Interest in anthocyanins continues to grow as a result of their reported cardiovascular activity 
(Cassidy et al., 2013; Cassidy et al., 2011; Mink et al., 2007). The present chapter describes 
the first anthocyanin intervention trial to use an isotopically labelled marker to establish the 
pharmacokinetics of anthocyanins and anthocyanin metabolites in humans (Czank et al., 
2013). In previous labelled flavonoid studies, 4-
14
C-quercetin has been fed to human 
volunteers (Walle et al., 2001), and was recovered predominantly in the form of CO2. This 
was likely primarily due to the position of the 
14
C label on the C=O bond of the C-ring. In 
contrast, a 2-
14
C-quercetin-4’-glucoside study conducted in rats detected minimal 
radioactivity outside of the gastrointestinal tract, with the majority of the label observed 
within the colon and rapidly removed from circulation by the kidneys or excreted within 
faeces (Mullen et al., 2008b). An anthocyanin labelled study which fed 
14
C-cyanidin-3-
glucoside with the labelling on the six carbons within the B-ring, by direct stomach 
intubation to mice (Felgines et al., 2010) obtained 92% recovery of the label in mice which 
were sacrificed after 3 h, most of which was within the gastrointestinal tract. This is the first 
study to feed an isotopically labelled anthocyanin to humans, and improves on previous 
tracer studies by increasing the number of positions containing a labelled carbon to enable 
the degradation of anthocyanins A- and B-ring to be traced. Furthermore, as the A ring 
contains three 
13
C labelled carbons, whilst the B-ring has two, the origin of the labelled 
metabolites in the present study could be defined.   
 
Metabolite identification in previous human studies feeding anthocyanins has generally been 
limited to phase II conjugates of cyanidin-3-glucoside or cyanidin (Felgines et al., 2003; 
Felgines et al., 2005; Kay et al., 2005; Kay et al., 2004; Manach et al., 2005), with only a 
limited number of human and animal studies identifying phenolic acid degradation products 
and/or colonic metabolites  (Kim et al., 1998; McGhie et al., 2007; Nurmi et al., 2009; 
Vitaglione et al., 2007). By utilising the targeted labelling of the A- and B-rings of cyanidin-
3-glucoside (Figure 1), the present study was able to confirm the pharmacokinetics of the 
phenolic conjugates of anthocyanins, through the identification of 
13
C5, 
13
C3 and 
13
C2 derived 
metabolites of the parent structure. This strategy allowed for the establishment of 
pharmacokinetic profiles of 17 metabolites in the circulation as well as the elimination of 31 
and 28 metabolites in the urine and faeces respectively. In addition, we have tentatively 
identified sulfate and glucuronide conjugates of phenylacetic and phenylpropenoic acids 
using MS
3
, however standards were not available to confirm their identity with certainty, so 
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they have not been included in the present pharmacokinetic analysis. To our knowledge, this 
diversity of anthocyanin metabolites has not been demonstrated previously in humans.   
 
In the present study, cyanidin-3-glucoside reached a maximum serum concentration of 141 ± 
70 nM at 1.8 ± 0.2 h (Figure 3.3A). In addition, seven methylated and glucuronidated 
conjugates of cyanidin-3-glucoside and cyanidin were identified within the urine, reaching 
cumulative concentrations of 425 ± 72 nM at 1-2 h post bolus (Figure 3.5A), which is in 
accordance with previous studies (Kay et al., 2004; Manach et al., 2005; McGhie et al., 
2007). However, the parent anthocyanin only represented 2% of the total metabolites found 
in the circulation, and was only present for a relatively short period of time (t½, 0.4 h; Table 
3.2), thus suggesting anthocyanin bioactivity is likely to be mediated by high concentrations 
of its phenolic intermediates as opposed to the parent structure. 
 
It is well established that cyanidin-3-glucoside degrades to protocatechuic acid and 
phloroglucinaldehyde when incubated at neutral pH (Kay et al., 2009; Woodward et al., 
2009) and this is corroborated by the present data, as protocatechuic acid (tmax, 3.3 ± 0.7 h; 
Figure 3.3B) and phloroglucinaldehyde (tmax, 2.8 ± 1.1 h; Figure 3.4C) were some of the 
earliest phenolic metabolites identified in the circulation (Table 3.2). In a previous study in 
which blood orange juice was fed, protocatechuic acid was identified as the major metabolite 
of cyanidin-3-glucoside, with concentrations reaching 492 ± 62 nM; around 250 fold higher 
than the cyanidin-3-glucoside reported in the serum (Vitaglione et al., 2007). In the present 
study protocatechuic acid was observed at maximum concentrations of 147 ± 74 nM, thus 
suggesting it is not the major metabolite of anthocyanins. Interestingly, the A-ring derived 
degradation product, phloroglucinaldehyde, was present at concentrations greater than either 
cyanidin-3-glucoside or protocatechuic acid in the serum, exhibiting a Cmax of 582 ± 536 nM 
(Table 3.2 & Figure 3.4C). However, it was not detected in urine at any appreciable 
concentration (Cmax, 170 ± 42 nM; Table 3.3 & Figure 3.6C), suggesting it was further 
metabolised prior to elimination. 
 
Multiple phase II metabolites of protocatechuic acid were detected in early (0.5 h to 1 h) 
serum samples, suggesting that the degradation of anthocyanins in vivo is swiftly followed 
by further biotransformation, and this is likely to be an important pathway for the clearance 
of anthocyanins from the body. 
 
Hippuric acid was identified as the major metabolite of anthocyanins in the present study, 
reaching maximum concentration of 1962 ± 1389 nM in serum (Table 3.2) and 5,417 ± 4,507 
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nM in urine (Table 3.3).  Hippuric acid has been speculated to be a common metabolite for 
many flavonoids (Pero, 2010) but it is a challenging metabolite to identify without the use of 
a carbon-label, due to its high background levels derived from other dietary and endogenous 
(i.e., protein metabolism and amino acid catabolism) sources, where it is reported to reach 1-
2 mM concentrations in human urine (Pero, 2010; Toromanović et al., 2008). The detection 
of 
13
C2-labelled hippuric acid in the present study indicates hippuric acid is likely formed by 
the dehydroxylation of protocatechuic acid to benzoic acid, and its subsequent conjugation 
with glycine, or alternatively from the alpha-oxidation and dehydroxylation of 
hydroxyphenylacetic acids  (Mullen et al., 2008b). This suggests that glycine conjugation is 
a key conjugation process responsible for the clearance of phenolic metabolites of cyanidin-
3-glucoside from the body.  
 
Vanillic acid, the methylated metabolite of protocatechuic acid, was also present in the 
serum in high concentrations (Cmax, 1.8 ± 0.8 µM; Table 3.2 & Figure 3.3C); however, it was 
only identified in the serum of two participants. In the majority of participants, sulfation 
appeared to be the preferential metabolic process for the clearance of protocatechuic acid, as 
protocatechuic acid-sulfate (Cmax, 157 ± 116 nM; Figure 3.3B) and vanillic acid-sulfate (Cmax, 
430 ± 299 nM; Figure 2C) were detected in much higher concentrations than their 
unconjugated or glucuronide counterparts. Protocatechuic acid-4-glucuronide (Cmax, 68 ± 61 
nM), vanillic acid-4-glucuronide (Cmax, 24 ± 4 nM) and isovanillic acid-3-glucuronide (Cmax, 
35 ± 5 nM) were also present, albeit at much lower concentrations (Table 3.2 & Figure 
3.3B,C).  This pattern of elimination of protocatechuic acid metabolites in the serum was 
mirrored in the urine, with vanillic acid detected at the highest concentrations (Cmax, 3.4 ± 0.3 
µM), followed by meta and para sulfated and glucuronidated conjugates of protocatechuic 
acid and vanillic acid (detected at concentrations ranging from 234 ± 65 nM to 1.7 ± 0.9 µM; 
Table 3.3). Di-methylation of protocatechuic acid was also observed by the presence of 
methyl-3,4-dihydroxybenzoate and methyl vanillate, however, methyl vanillate was only 
detected in the faeces (Table 3.4), suggesting that di-methylation of protocatechuic acid 
results in biliary elimination or is an exclusive product of microbial metabolism. Therefore, a 
primary route of metabolism and subsequent elimination of cyanidin-3-glucoside appears to 
be through degradation to protocatechuic acid, followed by rapid methylation of the catechol 
group to form vanillic acid, and subsequent sulfate and glucuronide conjugation, thus 
increasing its polarity and elimination from the body. This finding is supported by previous 
studies feeding catechin to rats and guinea pigs, where unconjugated metabolites represented 
only 3.5-4.4% of the recovered phenolic metabolites (DasandGriffiths, 1969). Minimal 
amounts of Phase I metabolites of protocatechuic acid were also detected in this study, 
Rachel M. de Ferrars © 2013  
 
89/215 
 
including 3,4-dihydroxybenzaldehyde (Cmax, 24 ± 7 nM; Figure 3.6C) and hydroxybenzoic 
acid (Cmax, 49 ± 11 nM; Figure 3.6A) within urine and 4-hydroxybenzaldehyde within serum 
(Cmax, 667 ± 653 nM; Figure 3.4C ) and urine (Cmax, 97 ± 94 nM; Figure 3.6C), suggesting 
that phase I metabolism may not be a highly utilised pathway for anthocyanin metabolism.  
 
Many metabolites of cyanidin-3-glucoside in the present study appeared to follow biphasic 
serum kinetics, displaying an initial serum peak between 0-5 h followed by a second peak 
after 6-48 h (Figure 3.3 & Figure 3.4). Biphasic absorption of delphinidin-3-glucoside has 
previously been reported in rats, with maximum plasma concentrations reported at 15 and 60 
min (Ichiyanagi et al., 2004) and also within human studies feeding flavonoids, where 
metabolites including caffeic acid, ferulic acid and ferulic acid-sulfate were reported to 
follow biphasic plasma kinetic patterns (Azzini et al., 2007; Rodriguez-Mateos et al., 2013; 
Stalmach et al., 2009a; Wittemer et al., 2005). The biphasic profiles most likely results from 
metabolism occurring in different tissues, including the liver and at different sites within the 
intestine. For example, the initial peak in protocatechuic acid concentrations may result from 
the rapid degradation and absorption of cyanidin-3-glucoside following exposure to the 
higher pH found within the small intestine. In contrast, the second peak at 6-24 h post bolus 
may result from the catabolic cleavage of the C-ring of anthocyanins by microflora within 
the large intestine or alternatively from enterohepatic recirculation. 
 
A total of three A-ring derived metabolites were identified in serum, urine and faeces 
(phloroglucinaldehyde, ferulic acid and 4-methoxysalicyclic acid) in the present study. 
However, the route of elimination of the A-ring derived metabolites is less clear than for 
protocatechuic acid. Interestingly, the A-ring derived metabolite, tentatively identified as 
ferulic acid within the serum, urine and faeces, matched the molecular weight (+3), 
fragmentation pattern, and had a similar retention time to the ferulic acid standard (Table 
3.1). However, the exact structural conformation of 
13
C3-ferulic acid cannot be established 
with certainty, as other probable isomers could result from the methylation of the A-ring 
hydroxyl to form either 2-hydroxy-4-methoxyphenyl prop-2-enoic acid or 4-hydroxy-2-
methoxy phenyl prop-2-enoic acid (also known as 2-hydroxy-4-methoxycinnamic acid and 
4-hydroxy-2-methoxycinnamic acid, respectively). These compounds have the same 
molecular formula as ferulic acid and could be formed without structural rearrangements of 
methoxy or hydroxyl moieties, as required to form ferulic acid from phloroglucinaldehyde. 
We are not aware of previous studies reporting 2-hydroxy-4-methoxycinnamic acid or 4-
hydroxy-2-methoxy cinnamic acid metabolites of flavonoids and more work is required to 
confirm the exact structural identity of the metabolite, as presently there are no available 
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commercial standards for these phenylpropenoic isomers. In addition, A-ring derived 3,4-
dihydroxybenzaldehyde and methyl 3,4-dihydroxybenzoate were tentatively identified 
within post bolus samples; however due to the low concentrations observed, they were not 
included in the present analyses. The absence of phloroglucinaldehyde derived metabolites 
of anthocyanins is not surprising considering the high reactivity of aldehydes (Keppler et al., 
2005). An in vitro faecal fermentation study which incubated phenolic acids and 
phloroglucinaldehyde in sterilised caecum inoculum filtrate from pigs at the physiological 
conditions found in the intestine (pH 6.4, 37 ºC), found phenolic acids were stable within the 
sterilised samples. However phloroglucinaldehyde was degraded extensively, with only 
small amounts remaining detectable after 24 h. Possible pathways for aldehyde instability 
include condensation with free amine groups of amino acids or proteins and formation of 
imine (Keppler et al., 2005). However, at present little is known about the metabolism of 
phloroglucinaldehyde and further studies are required to delineate the mechanisms involved 
in its metabolism and clearance. 
 
Colonic metabolism has long been speculated to be a major contributor to the overall 
metabolism of anthocyanins (Cardona et al., 2013; Williamson et al., 2010) and our 
13
C-
labelled cyanidin-3-glucoside study reported 32 ± 6% of the recovered 
13
C-label  in  faeces 
(Czank et al., 2013). It has been proposed that phenylpropenoic acids arise from cyanidin-3-
glucoside as a result of bacterial cleavage of the C-ring in the colon (Forester et al., 2008; 
 onz lez-Barrio et al., 2010), which is supported by the detection of caffeic acid and its 
methyl metabolite, ferulic acid, within the faeces in the present investigation. The absence of 
caffeic acid from the serum and urine despite its abundance within the faeces (Table 3.4) 
suggests the catechol group of caffeic acid is rapidly methylated to yield ferulic acid, either 
during intestinal absorption, prior to entry into the systemic circulation or by the liver. The 
rapid metabolism of caffeic acid has been observed in previous phenolic acid intervention 
studies, where caffeic acid is reported at significantly lower concentrations than its methyl, 
glucuronyl and sulfate conjugates (Nardini et al., 2006). In addition, ferulic acid was 
detected within serum and urine within 4 h of consumption, indicating that ferulic acid may 
in part be formed proximal to the colon (i.e., the mid and lower small intestine). 
 
Based on the findings of this study, the metabolism of anthocyanins can be summarised as 
undergoing a combination of multiple biotransformations . The parent compound appears to 
undergo methylation and glucuronidation to some extent, however it primarily undergoes 
degradation, followed by significant phase II conjugation, particularly methylation and 
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Figure 3.7 Proposed pathway for the metabolism of cyanidin-3-glucoside in humans.  
 
*Conjugates represent unknown structural position. BA, benzoic acid; BAL, benzaldehyde; 
C3G, cyanidin-3-glucoside; Cy, cyanidin; GlcA, glucuronide; Me, methoxy; M34dhbz, 
methyl-3,4-dihydroxybenzoate; P3G, peonidin-3-glucoside; PAA, phenylacetic acid; PGA, 
phloroglucinaldehyde. 
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sulfation. Given the early timing and high concentrations of protocatechuic acid and 
phloroglucinaldehyde observed in this study, it is clear that cyanidin-3-glucoside 
spontaneously degrades to protocatechuic acid and phloroglucinaldehyde in the small 
intestine; however, colonic metabolism is also likely to play a significant role. 
Dehydroxylation by colonic bacteria, to form hydroxybenzoic acid, followed by conjugation 
with glycine to form hippuric acid, appears to be the definitive elimination pathway. Finally, 
the metabolism of phloroglucinaldehyde to phenylpropenoic acids, which are similar to, or 
include ferulic acid, may be responsible for the detoxification and elimination of 
phloroglucinaldehyde. 
 
The major limitation of the present method is its targeted approach, which relies on pure 
standards and MRM for identification. This approach is highly sensitive, however, it does 
not allow for the identification of unknown/untargeted metabolites. Additionally, synthesis 
of the speculated metabolites is necessary to confirm their identities. Alternative 
spectroscopy techniques, such as GC-MS/MS and high resolution time of flight (TOF) MS 
would aid in identifying further metabolites not captured by the present method. As many of 
the metabolites did not completely returned to baseline by 48 h, a longer blood, urine and 
faecal sampling time may have increased the recovery of metabolites.  Despite these 
limitations, this human study has demonstrated for the first time that a wide array of 
metabolites are recovered by the described extraction and detection methods and these data 
represent a considerable advancement in our understanding of anthocyanin ADME.  
 
3.5. Conclusion 
In conclusion, the present chapter describes the identification of an extensive number of 
anthocyanin metabolites. The appearance of multiple peaks across the 48 h time period, and 
their wide range of elimination half-lives, suggest that the clearance of anthocyanins 
involves multiple processes, including enterohepatic recirculation, hepatic recycling, and 
microbial metabolism, with an extended period of intestinal absorption from both the small 
and large intestine. This study provides new insights into the metabolism of anthocyanins, 
which should inform the design of future clinical studies exploring the bioactivity of these 
potentially important dietary compounds.  
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Chapter 4. Identification of anthocyanin 
metabolites following the ingestion of an 
extract derived from elderberries in humans 
 
4.1. Introduction 
As discussed in the foregoing chapter, despite the body of evidence for the cardioprotective 
effects of dietary anthocyanins (Cassidy et al., 2013; Cassidy et al., 2011; Erdman et al., 
2007; Mink et al., 2007), the mechanisms involved remain poorly understood due to an 
incomplete understanding of their bioavailability and metabolism. Anthocyanins are reported 
to have a low bioavailability, with the majority of studies reporting a recovery of <1% of the 
ingested anthocyanin dose (Kay et al., 2005; Manach et al., 2005; McGhie et al., 2007). 
Numerous human feeding studies have explored the absorption, distribution, metabolism and 
elimination (ADME) of anthocyanins, however most studies reported conjugated derivatives 
(methyl, glucuronide, sulfate) of parent anthocyanins to be the major metabolites in the 
circulation post consumption, with maximum serum concentrations ranging from 1.4 nM to 
547 nM, between 0.5 h and 1.5 h (tmax) post consumption (Kay et al., 2004; Manach et al., 
2005; McGhie et al., 2007). At neutral pH, anthocyanins are susceptible to degradation 
( onz lez-Barrio et al., 2010; Woodward et al., 2009), especially if their sugar moiety is 
hydrolysed, which may occur due to the action of lactase phlorizin hydrolase or cytosolic β-
glucosidase within the intestinal epithelial cells (Crozier et al., 2009; Day et al., 2000; Del 
Rio et al., 2010). Therefore, it has been proposed that anthocyanins are likely present in the 
circulation, as degradation products and metabolic intermediates (Kay, 2010).  
 
Previously, human interventions feeding dried cranberry juice, strawberry or bilberry-
loganberry extracts to humans identified potential metabolites of anthocyanins in plasma and 
urine including hippuric acid, benzoic acid, 4-hydroxybenzoic acid, protocatechuic acid, 
dihydroxybenzoic acids, caffeic acid, p-courmaric acid, ferulic acid, sinapic acid, 2-
hydroxyphenylacetic acid, homovanillic acid, vanillic acid and 4-hydroxyphenlyacetic acid 
(Nurmi et al., 2009; Russell et al., 2009; Valentova et al., 2007; Zhang et al., 2004). 
However, a limitation of these data is that the origin of the phenolics could not be traced 
with certainty to the anthocyanins fed. Until recently, this was predominantly due to a lack of 
human anthocyanin studies feeding a labelled bolus. In addition, the varied and complex 
boluses of polyphenol rich food as utilised in previous interventions, further complicates the 
elucidation of the metabolic pathway of anthocyanins. However, as described previously 
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(Chapter 3), we recently conducted an isotopic labelled anthocyanin intervention study, 
which fed 500 mg 
13
C-labelled cyanidin-3-glucoside to eight men and reported >40% 
recovery of the 500 mg anthocyanin bolus in serum, urine breath and faeces. The dose was 
recovered as 25 phenolic metabolites, attaining total peak concentrations of 5.97 ± 2.14 μM 
in  the serum and 10.77 ± 4.52 μM in the urine (Czank et al., 2013). The present study aimed 
to progress this work by confirming the metabolism of anthocyanins derived from an 
anthocyanin rich dietary source (elderberries; Sambucus nigra), as opposed to a pure 
synthetic anthocyanin, in order to explore the metabolism of anthocyanin derived phenolics 
from a food source. Elderberries provide a suitable source of anthocyanins as unlike fruits 
such as blueberries, which contain many different forms of anthocyanins, elderberries are 
specifically rich in in one form, namely cyanidin glycosides, and predominantly cyanidin-3-
glucoside and cyanidin-3-sambubioside (Neveu et al., 2010). Cyanidin-3-sambubioside-5-
glucoside, cyanidin-3,5-diglucoside, cyanidin-3-rutinoside, pelargonidin-3-glucoside and 
pelargonidin-3-sambubioside are also found in low concentrations  making up generally less 
than 7% of the total anthocyanins (Neveu et al., 2010; Wu et al., 2004). 
 
Here we used stored samples from a previously completed 12 week anthocyanin 
intervention, where healthy post-menopausal women were fed 500 mg/day of anthocyanins 
derived from 2 g of elderberry extract (Curtis et al., 2009). The present study investigated 
the impacts of a single bolus (500 mg anthocyanins; acute postprandial effect) and repeated 
daily doses (postprandial effect after 12 weeks chronic supplementation) on metabolite 
excretion, to establish if chronic exposure altered metabolism or elimination. To the best of 
our knowledge this is the first study to describe the impact of acute versus chronic 
anthocyanin exposure on anthocyanin derived phenolic metabolites within postprandial 
samples. 
 
4.2. Materials and methods 
4.2.1. Chemicals  
Cyanidin-3-glucoside, peonidin-3-glucoside, pelargonidin-3-glucoside, cyanidin-3-
sambubioside cyanidin-3-rutinoside and cyanidin-3,5-diglucoside were obtained from 
Extrasynthese (Genay, France). Phase II conjugates of phenolic acids (protocatechuic acid-3-
glucuronide, protocatechuic acid-4-glucuronide, vanillic acid-4-glucuronide, benzoic acid-4-
glucuronide, isovanillic acid-3-glucuronide, isovanillic acid-3-sulfate, protocatechuic acid-4-
sulfate, vanillic acid-4-sulfate, protocatechuic acid-3-sulfate and benzoic acid-4-sulfate) were 
synthesised in the School of Chemistry and Centre for Biomolecular Sciences, University of 
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St. Andrews (UK) via recently published methods (Zhang et al., 2012). All other compounds 
(2-hydroxybenzoic acid, 3-hydroxybenzoic acid, 4-hydroxybenzoic acid, 3,5-dihydroxy-
benzoic acid, protocatechuic acid, 2,3-dihydroxybenzoic acid, 2,4-dihydroxybenzoic acid, 
gallic acid, 2-methoxybenzoic acid, 3-methoxybenzoic acid, 4-methoxybenzoic acid, 6-
methoxysalicyclic acid, vanillic acid, isovanillic acid, methyl-3,4-dihydroxybenzoate, 
methyl-3,4-dimethoxy-benzoate,4-methoxysalicyclic acid methyl vanillate, methyl gallate, 
3-methylgallic acid, syringic acid, caffeic acid, sinapic acid, p-coumaric acid, ferulic acid, 
phloroglucinaldehyde, 4-hydroxybenzaldehyde, 2,4-dihydroxybenzaldehyde, 3,4-dihydroxy-
benzaldehyde, 2-hydroxy-4-methoxybenzaldehyde, 4-methoxybenzaldehyde, homo-vanillic 
acid, 4-hydroxyphenylacetic acid, homoprotocatechuic acid, 4-hydroxybenzyl alcohol, 
hippuric acid, 3-methylhippuric acid, 4-methylhippuric acid, phloridzin and scopoletin) were 
purchase from Sigma-Aldrich (Dorset, UK). HPLC grade methanol, acetonitrile and 
hydrochloric acid (HCl) were purchased from Fisher Scientific (Loughborough, UK) and all 
other chemicals, were purchased from Sigma-Aldrich (Dorset, UK). All water utilised was of 
Milli-Q grade (18.2 MΩ cm-1). 
4.2.2. Materials 
Strata-X™ solid phase extraction (SPE) columns (6 mL, 500 mg),  Kinetex 
pentafluorophenol (PFP) HPLC column (2.6 µm, 100 x 4.6 mm, 100 Å) and SecurityGuard
®
 
cartridges (PFP, 4.0 x 2.0 mm) were purchased from Phenomenex (Cheshire, UK). 
Discovery® DSC-18 SPE columns (6 mL, 1 g) and Acrodisc 13mm, 0.45 µm PTFE syringe 
filters were purchased from Sigma-Aldrich (Dorset, UK). 
4.2.3. Analysis of elderberry extract  
The anthocyanin content of the elderberry (Sambucus nigra) extract (standardised to 25% 
anthocyanins) obtained from Artemis International (Fort Wayne, Indianapolis) was 
previously established as 500 mg anthocyanins (cyanidin-3-glucoside and cyanidin-3-
sambubioside, quantified as cyanidin-3-glucoside equivalents) per 2 g extract (Curtis et al., 
2009). The phenolic profile was presently established through HPLC-ESI-MS/MS analysis, 
where prior to analysis, 500 mg of elderberry extract was dissolved in 2 mL of 0.1% HCl and 
5 mL acidified methanol (0.1% vv. HCl) and sonicated for 30 min in a chilled waterbath 
following syringe filtration. The polyphenol content of the breakfast foods was estimated 
using phenol explorer (Neveu et al., 2010). 
Rachel M. de Ferrars © 2013  
 
96/215 
 
4.2.4. Study design 
Samples were analysed from a parallel-designed, randomised, placebo-controlled study 
previously conducted in 2005-2007, which explored the effect of anthocyanins on 
cardiovascular bioactivity and liver function (Curtis et al., 2009). The study fed elderberry 
extract or placebo to 52 (26 in treatment and 26 in placebo group) healthy (age, 58.2 ± 5.6 y; 
BMI, 24.7 ± 0.6 kg/m²) postmenopausal women (Curtis et al., 2009). Participants underwent 
a seven day washout-period (avoiding anthocyanin rich foods and limiting tea and chocolate 
intake) and were then assigned to consume either two elderberry capsules (125 mg 
anthocyanins/tablet) or identically coloured opaque placebo capsules (0 mg 
anthocyanins/tablet) in the morning and evening each day for 12 weeks. Dietary restrictions 
were continued throughout the duration of the 12wk intervention. The elderberry capsules 
provided a daily total of 2 g elderberry extract, containing 500 mg total anthocyanins whilst 
the placebo capsules contained 500 mg of cellulose. Participants were assessed following a 
single bolus dose (week 0, acute) and following 12 weeks of continuous supplementation 
(week 12, chronic), where blood and urine samples were collected in the fasting period 
(baseline) and over 3 h following the consumption of a 500 mg oral bolus dose of 
anthocyanins (equivalent to the daily dose administered throughout the study). An 
anthocyanin and caffeine free breakfast of cereal [Weetabix™ (Weetabix Ltd, UK) or 
Cornflakes (Kelloggs™, UK)], white toast with margarine/butter, milk and water was 
provided ad labitum on the intervention days. Postprandial blood and urine samples (50 mL 
sample) were collected for 3 h (t=1, 2, 3 h) following ingestion (Figure 4.1). Blood was 
collected in EDTA tubes and plasma obtained by centrifugation at 1500 x 3 g for 15 min, 
where urine and plasma samples were acidified with HCl (to a final concentration of 1% vv) 
prior to storage at -80 °C until analysis. The study protocol was approved by the Norfolk 
Research Ethics Committee, conducted at the University Clinical Research and Trials Unit 
and all participants provided written informed consent. In the present analytical 
investigation, a random subset of the banked samples from 15 of the 26 participants on the 
anthocyanin treatment were analysed to explore the effect of 12wks repeated dosing on 
anthocyanin metabolism (the placebo group was not explored). 
4.2.5. Creatinine analysis 
Urine creatinine concentrations were established on an iLab 650 Chemistry Analyzer using 
the IL Test Creatinine-0018257240 kit (Instrumentation Laboratory, Italy). The kit measures 
creatinine based on the colorimetric reaction of creatinine with picric acid under alkali 
conditions (ClarkandThompson, 1949). Quality control samples indicated a CV=4.26%. 
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Urine samples were adjusted for creatinine concentration, and are therefore expressed as 
ratios per mM creatinine.  
 
Figure 4.1 Clinical study design summarising the collection of blood and urine samples. 
 
 
4.2.6. Sample preparation 
The extraction methods used for the purification and concentration of metabolites from 
biological samples were as previously optimised in Chapter 2. Briefly, samples were 
extracted using DSC-18 (for urine) and Strata-X™ (for plasma) SPE cartridges which were 
preconditioned with one column volume (6 mL) of acidified methanol (10% formic acid 
(v/v) in methanol) followed by one column volume of acidified water [10% formic acid (v/v) 
in water (pH 2.4)]. Samples were loaded onto the cartridge with 2 mL water (pH 2.4), 
washed, evaporated to dryness under vacuum, eluted with 7 mL acidified methanol and 
evaporated to approximately 50 µL using a Thermo speedvac. The concentrated extract was 
re-suspended in 200 µL water (pH 2.4), 10 µL of 1 mg/ml scopoletin was added as a volume 
control standard post extraction and samples were then syringe filtered through 0.45 µm 
PTFE syringe filters and stored at -80 ºC until analysis. Individual analysis of the urine 
samples was carried out to establish metabolite variation between participants, whilst plasma 
samples were pooled prior to extraction, by taking 66.7 µL of plasma from each participant 
(n = 15; for a total volume of 1 mL) at each time point, thus providing a ‘snapshot’ of the 
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plasma metabolic profile. The extraction efficiency of the solid phase extraction methods for 
cyanidin-3-glucoside and the 17 phenolic metabolites identified in urine and plasma was 
previously established (Chapter 2) as 88.0 ± 5.4% (CV, 8.6 ± 5.4%) for urine and 86.9 ± 
9.1% (CV, 8.2 ± 5.9%) for plasma, for n = 3 replicates of each analyte. 
4.2.7.  HPLC-ESI-MS/MS analysis 
The HPLC-ESI-MS/MS conditions used for the identification of metabolites in biological 
samples were as previously optimised in Chapter 2. Briefly, HPLC-ESI-MS/MS analysis was 
carried out on an Agilent 1200 series HPLC system coupled with an AB Sciex 3200 Q-trap 
MS/MS system equipped with an electrospray ionisation (ESI) Turbo V source and samples 
were injected onto a Kinetex PFP column. The mobile phase consisted of 0.1% formic acid 
(v/v) in water (A) and 0.1% formic acid (v/v) in acetonitrile (B), at a flow rate of 1.5 
mL/min-1 at 0 min, 1 mL/min at 7 to 14 min and 1.5 mL/min at 14 to 28 min. The gradient 
consisted of 1% B at 0 min, 7.5% B at 7 min, 7.6% B at 14 min, 10% B at 17 min, 12% B at 
18.5 min, 12.5% B at 20 min, 30% B at 24 min, 90% B at 25 to 28 min. MS/MS source 
parameters included curtain gas 40, ionspray voltage -4000V / +5500V, temperature 700 °C, 
nebulizer gas 60 psi and auxiliary gas 60 psi. The system was controlled by Analyst software 
(v. 1.5, Applied Biosystems/MDS Sciex).  
 
Multiple reaction monitoring (MRM) scans were performed using conditions optimised for 
the detection of pure standards (Chapter 2, Table 2.2). Metabolites were confirmed on the 
basis of retention time and the presence of two or more ion transitions. The peak area of the 
most intense ion transition was determined from the chromatograph and used for 
quantification. Seven-point calibration curves ranging from 0 to 10 µM for the analysis of 
the anthocyanin conjugates and from 0 to 50 µM for the analysis of phenolic metabolites 
were utilised for quantification. The calibration curves were prepared by spiking a standard 
mixture of the compounds into a matched-matrix (pooled blank/baseline urine or plasma 
from all participants) and were baseline adjusted to account for any interference from 
analytes present in baseline samples, such as phenolic compounds. For anthocyanin 
conjugates, where the corresponding standards were not available, compounds were 
putatively identified based on the parent-daughter fragmentation pattern (cyanidin-
glucuronide, 463/287; cyanidin-3-glucoside-disulfate, 609/287; cyanidin-diglucuronide, 
639/287; cyanidin-glucuronide-sulfate, 541/285 (negative mode); peonidin-glucuronide, 
477/301; peonidin-3-glucoside-glucuronide, 639/301; cyanidin-3-sambubioside,5-glucoside, 
743/287; pelargonidin-3-sambubioside, 565/271) and quantified relative to cyanidin-3-
glucoside or peonidin-3-glucoside (where appropriate).   
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The HPLC-MS/MS methods were previously validated for linearity and precision across all 
metabolites (Chapter 2). Six point standard curves ranging from 1.25 to 20 µM were 
constructed from analytical standards and injected six times. The precision was established 
as 1.4% to 8.2% and linearity of the standard curves was established as r
2
= 0.991 to 1.000 
(CV, 0.2%) across the identified metabolites. In addition, there was a between run variation 
of 9.17% CV for quality control standards, injected between every eight samples run.  
4.2.8. Statistics 
All statistical analyses were performed using SPSS for Windows statistical software package 
(version 18.0). Within-subject comparisons were analysed using an ANOVA with repeated-
measures general linear model, with Greenhouse-Geisser correction for non-spherical data 
and Bonferroni adjustment (within-subjects, baseline, 0-1 h, 1-2 h, 2-3 h) for pairwise 
comparisons. Between-group comparisons were analysed using ANOVA with repeated-
measures general linear model, with Bonferroni adjustment (within-subjects, week 0 and 
week 12 at baseline, 0-1 h, 1-2 h, 2-3 h). Unless otherwise stated, results are expressed as 
mean ± SD and p<0.05 was considered significant. Baseline refers to the fasting samples 
collected prior to the consumption of the anthocyanin bolus. No statistical analyses were 
possible for the pooled plasma samples (n=1; 15 participants plasma pooled at each 
individual time point). 
 
4.3. Results 
4.3.1. Elderberry extract composition 
Independent analysis of the commercially available elderberry-derived anthocyanin extract 
identified 15 phenolic acids, aldehydes or benzoates (hereafter referred to as phenolics) 
present, accounting for 203 mg total phenolics per gram of elderberry extract (Table 4.1). 
Protocatechuic acid was identified in the highest concentrations, constituting 68.3% of the 
total phenolics identified, followed by phloroglucinaldehyde (7.7%) and caffeic acid (7.3%). 
The anthocyanin content of the elderberry bolus was previously established as 250 mg 
anthocyanin/g extract (Curtis et al., 2009), predominantly consisting  of cyanidin-3-
glucoside (53.5%) and cyanidin-3-sambubioside (39.5%) (Neveu et al., 2010). Elderberries 
are also reported to contain low amounts of cyanidin-3-sambubioside-5-glucoside (6%) and 
cyanidin-3,5-diglucoside (1%) (Neveu et al., 2010). A total proximate analysis of the extract 
was not conducted to establish the composition of the remaining 55% by weight; however 
elderberries have a reported relative composition of 18.4% carbohydrate, 0.7% protein, 0.5% 
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fat, 0.5% organic acids and 6.2% quercetin (Neveu et al., 2010; Saxholt et al., 2008; Veberic 
et al., 2009). 
 
Table 4.1 Phenolics identified via HPLC-ESI-MS/MS within 
elderberry extract standardised to 25% anthocyanins obtained from 
Artemis International. 
Compound 
Concentration 
(mg/g extract) 
% of total 
Protocatechuic acid 138.59 ± 4.48 68.31 
Phloroglucinaldehyde 15.65 ± 1.18 7.71 
Caffeic acid 14.74 ± 1.10 7.27 
4-Hydroxybenzoic acid 11.28 ± 0.28 5.56 
p-Courmaric acid 9.43 ± 0.32 4.65 
Vanillic acid 2.70 ± 0.13 1.33 
4-Hydroxybenzaldehyde 2.51 ± 0.01 1.24 
Methyl-3,4-dihydroxybenzoate 1.85 ± 0.14 0.91 
Gallic acid 1.54 ± 1.18 0.76 
Ferulic acid 1.39 ± 0.08 0.69 
3,4-Dihydroxybenzaldehyde 1.37 ± 0.02 0.68 
Sinapic acid 1.10 ± 0.22 0.54 
Homoprotocatechuic acid 0.38 ± 0.03 0.19 
Isovanillic acid 0.30 ± 0.01 0.15 
Methyl gallate 0.04 ± 0.00 0.02 
Values represent mean ± SD, n=3. 
 
4.3.2. Identification of anthocyanin metabolites in urine and plasma 
Twenty-eight metabolites were identified in the urine following acute and chronic 
anthocyanin consumption. 17 were phenolics and 11 were anthocyanin conjugates (Table 
4.2). Levels of the phenolic metabolites ranged from 145 ± 86 to 7382 ± 5927 nM/mM 
creatinine, whilst the parent anthocyanins were identified at levels of 0.1 ± 0.3 to 309 ± 673 
nM/mM creatinine at 3 h following acute anthocyanin consumption. In plasma, 21 
metabolites were identified, of which 17 were phenolics and four were anthocyanin 
conjugates (Table 4.3), and the cumulative phenolic metabolites were present at 45 fold 
higher concentrations (at a range of 2 to 358 nM at 3 h following acute anthocyanin 
consumption) relative to their parent anthocyanins (at a range of 2 to 11 nM at 3 h following 
acute anthocyanin consumption). Due to a similarity of data following acute and chronic 
anthocyanin consumption, specific figures in the text will now refer solely to data following 
the acute dose unless stated otherwise. 
 
The metabolites identified within the urine (Table 4.2) and plasma (Table 4.3) differed 
substantially. The plasma contained aldehydes (4-hydroxybenzaldehyde and 3,4-
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dihydroxybenzaldehyde), benzoic acids (4-methoxysalicyclic acid, benzoic acid-4-sufate) 
and methyl derivatives of protocatechuic acid (methyl-3,4-dihydroxybenzoate and syringic 
acid), which were absent from the urine. By comparison, the urine contained more 
anthocyanin conjugates, cinnamic acids (p-courmaric and sinapic acid), phenylacetic acids 
[homovanillic acid and homoprotocatechuic acid (also known as 3,4-dihydroxyphenylacetic 
acid)], 3,5-dihydroxybenzoic acid and 4-hydroxybenzyl alcohol, which were absent from the 
plasma.  
4.3.3. Anthocyanins within urine and plasma 
Anthocyanins reached maximal urinary levels of 548 ± 219 nM/mM creatinine 3 h following 
intake of the elderberry extract (Table 4.3). In 3 h post intake urine samples, cyanidin-3-
glucoside was present at levels of 309 ± 673 nM/mM creatinine and cyanidin-3-
sambubioside was identified at levels reaching 99 ± 116 nM/mM creatinine. In addition, nine 
conjugates of cyanidin were putatively identified in urine samples: two cyanidin 
glucuronides, cyanidin-diglucuronide, cyanidin-3-glucoside-disulfate, peonidin-3-glucoside, 
peonidin-glucuronide and three peonidin-3-glucoside-glucuronides, reaching cumulative 
levels of 140 ± 33 nM/mM creatinine 3 h post bolus (Table 4.3 & Figure 4.2).  
 
Within pooled plasma samples, anthocyanins reached a maximum concentration of 34 nM, 2 
h post bolus, where cyanidin-3-glucoside and cyandin-3-sambubioside were present in 
concentrations of 7 nM and 16 nM respectively (Table 4.3). Only two anthocyanin 
conjugates, namely cyanidin-glucuronide and peonidin-glucuronide were identified within 
the plasma and were found at maximum concentrations of 2 nM and 9 nM at 2 h and 3 h post 
bolus respectively (Table 3.4). Furthermore, no anthocyanins were present within week 0 
baseline samples, however, low concentrations (22 ± 5 nM in urine, Table 4.2 and 1 nM in 
plasma, Table 4.3) were identified within week 12 baseline samples, approximately 12 h 
following the previous anthocyanin dose. A high inter-individual variation in anthocyanin 
concentration was observed between participants, with the urinary concentration of cyanidin-
3-glucoside ranging from 21 to 2666 nM/mM creatinine, 3 h following anthocyanin 
supplementation (Figure 4.3).  
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Table 4.2 Ratio of anthocyanins, anthocyanin conjugates and phenolics in urine samples following acute and chronic intake of anthocyanins from an 
elderberry extract, expressed per mM creatinine. 
Compound 
Ratio, nM/mM creatinine (% of total metabolites)
a
 Previously identified 
in urine Baseline t(0-1 h) t(1-2 h) t(2-3 h) Total 
C3G
b 
C3G
c 
ND 
6 ± 11 (0.05) 
5 ± 7 (0.05) 
11 ± 15 (0.05) 
168 ± 317 (0.76) 
151 ± 241 (1.17) 
309 ± 673 (0.93) 
232 ± 303 (1.81)
 
481 ± 385 
400 ± 212 
(Bitsch et al., 2004b; 
Cao et al., 2001; 
Czank et al., 2013; 
Milbury et al., 2002; 
Mülleder et al., 2002; 
Murkovic et al., 2001; 
Wu et al., 2002) 
Cyanidin-3-sambubioside
b
 
Cyanidin-3-sambubioside
c
 
ND 
6 ± 5 (0.05) 
2 ± 4 (0.02) 
9 ± 9 (0.05) 
42 ± 55 (0.19) 
36 ± 28 (0.29) 
99 ± 116 (0.30) 
100 ± 69 (0.79) 
142 ± 75 
152 ± 53 
(Bitsch et al., 2004b; 
Cao et al., 2001; 
Milbury et al., 2002; 
Mülleder et al., 2002; 
Murkovic et al., 2001; 
Wu et al., 2002) 
Cyanidin-glucuronide
b,d
 
Cyanidin-glucuronide
c,d
 
ND 
2 ± 2 (0.01) 
2 ± 5 (0.02) 
5 ± 5 (0.02) 
25 ± 44 (0.12) 
20 ± 14 (0.16) 
41 ± 39 (0.12) 
67 ± 53 (0.53) 
68 ± 33 
94 ± 38 
(Czank et al., 2013) 
Cyanidin-glucuronide
b,d
 
Cyanidin-glucuronide
c,d
 
ND 
1 ± 2 (0.01) 
0.1 ± 0.2 (0) 
1 ± 2 (0.01) 
1 ± 2 (0.01) 
2 ± 2 (0.02) 
4 ± 4 (0.01) 
7 ± 7 (0.06) 
5 ± 3 
11 ± 5 
(Czank et al., 2013) 
Cyanidin-diglucuronide
b,d
 
Cyanidin-diglucuronide
c,d
 
ND 
0 ± 0 (0) 
0 ± 0 (0) 
0 ± 0 (0) 
0.1 ± 0.3 (0) 
0.1 ± 0.1 (0) 
0.1 ± 0.3 (0) 
0.3 ± 0.4 (0) 
0.3 ± 0.2 
0.4 ± 0.3 
NA 
C3G-disulfate
b,d 
C3G-disulfate
c,d
 
ND 
0.03 ± 0.07 (0) 
ND 
0.02 ± 0.06 (0) 
1 ± 1 (0) 
0.5 ± 1.0 (0) 
1 ± 2 (0) 
1 ± 2 (0.01) 
2 ± 1 
1.9 ± 0.3 
NA 
P3G
b
 
P3G
c
 
ND 
1 ± 1 (0.05) 
1 ± 1 (0) 
1 ± 1 (0) 
9 ± 10 (0.04) 
6 ± 5 (0.05) 
18 ± 21 (0.05) 
18 ± 10 (0.14) 
27 ± 13 
25 ± 9 
(Czank et al., 2013; 
Wu et al., 2002) 
Peonidin-glucuronide
b,e 
Peonidin-glucuronide
c,e 
ND 
6 ± 8 (0) 
2 ± 5 (0.02) 
8 ± 7 (0.04) 
35 ± 57 (0.16) 
31 ± 22 (0.24) 
69 ± 61 (0.21) 
120 ± 83 (0.94) 
105 ± 50 
164 ± 63 
(Czank et al., 2013; 
Wu et al., 2002) 
P3G-glucuronide
b,e 
P3G-glucuronide
c,e
 
ND 
0.2 ± 0.3 (0) 
0 ± 0.1 (0) 
0.3 ± 0.3 (0) 
1 ± 2 (0.01) 
1 ± 1 (0.01) 
3 ± 3 (0.01) 
4 ± 2 (0.03) 
4 ± 2 
5 ± 2 
(Czank et al., 2013) 
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P3G-glucuronide
b,e 
P3G-glucuronide
c,e
 
ND 
0.1 ± 0.2 (0) 
0 ± 0.1 (0) 
0.1 ± 0.2 (0) 
1 ± 1 (0) 
0.4 ± 0.4 (0) 
1 ± 1 (0) 
1 ± 1 (0.01) 
2 ± 1 
2 ± 1 
(Czank et al., 2013) 
P3G-glucuronide
b,e 
P3G-glucuronide
c,e
 
ND 
0.4 ± 0.5 (0) 
0.1 ± 0.3 (0) 
0.4 ± 0.4 (0) 
2 ± 2 (0.01) 
2 ± 1 (0.01) 
4 ± 4 (0.01) 
5 ± 3 (0.04) 
6 ± 3 
7 ± 2 
(Czank et al., 2013) 
4-Hydroxybenzoic acid
b
 
4-Hydroxybenzoic acid
c
 
904 ± 694 (9.28) 
781 ± 466 (6.16) 
1386 ± 941 (13.44) 
1251 ± 692 (6.19) 
1897 ± 1026 (8.54)
f 
1275 ± 571 (10.06)
 
1985 ± 985 (5.89)
f 
1451 ± 910 (11.45) 
6172 ± 998 
4758 ± 829 
(Czank et al., 2013; 
Nurmi et al., 2009; 
Russell et al., 2009) 
PCA
b
 
PCA
c
 
70 ± 52 (0.72) 
90 ± 49 (0.71) 
155 ± 209 (1.50) 
194 ± 147 (0.96) 
802 ± 768 (3.61) 
760 ± 514 (6.00) 
1534 ± 1232 (4.55)
f 
1520 ± 940 (12.00) 
2560 ± 929 
2564 ± 949 
(Czank et al., 2013; 
Koli et al., 2010; 
Nurmi et al., 2009; 
Russell et al., 2009; 
Vitaglione et al., 2007) 
3,5-Dihydroxybenzoic 
acid
b
  
3,5-Dihydroxybenzoic 
acid
c
 
258 ± 261 (2.65) 
333 ± 285 (2.63) 
327 ± 220 (3.17) 
421 ± 279 (2.09) 
1015 ± 556 (4.57) 
1119 ± 1108 (8.83) 
1862 ± 1016 (5.52)
f 
1975 ± 1546 (15.58) 
3462 ± 878 
3848 ± 1180 
NA 
VA
b
 
VA
c
 
215 ± 145 (2.21) 
185 ± 116 (1.46) 
321 ± 275 (3.11) 
367 ± 204 (1.82) 
2110  ± 2031 (9.51) 
1762 ± 1257 (13.9) 
4345 ± 3205 (12.88)
f 
3522 ± 2843 (27.79) 
6991 ± 2511 
5835 ± 2566 
(Czank et al., 2013; 
Koli et al., 2010; 
Nurmi et al., 2009; 
Russell et al., 2009) 
Phloroglucinaldehyde
b
 
Phloroglucinaldehyde
c
 
3 ± 3 (0.03) 
41 ± 44 (0.32) 
37 ± 81 (0.35) 
120 ± 181 (0.59) 
309 ± 368 (1.39)
f 
320 ± 245 (2.53) 
602 ± 632 (1.79)
f 
703 ± 510 (5.55) 
951 ± 433 
1184 ± 459 
(Czank et al., 2013) 
HomoVA
b
 
HomoVA
c
 
3695 ± 2647(37.95) 
5833 ± 5379 (46.03) 
3508 ± 2390 (34.03) 
9402 ± 9721 (46.56) 
5403 ± 3880 (24.34) 
7386 ± 4468 (58.29) 
7382 ± 5927 (21.88)
g 
8812 ± 4576 (69.54)
 
19989 ± 4172 
31433 ± 6270 
(Koli et al., 2010; 
Nurmi et al., 2009) 
HomoPCA
b
 
HomoPCA
c
 
870 ± 521 (8.93) 
1289 ± 1205 (10.17) 
1095 ± 902 (10.62) 
2054 ± 1847 (10.17) 
1453 ± 1023 (6.55) 
1755 ± 1154 (13.85) 
1945 ± 1302 (5.77)
f 
2213 ± 2094 (17.46) 
5363 ± 1037 
7312 ± 1557 
(Koli et al., 2010; 
Nurmi et al., 2009) 
4-Hydroxybenzyl alcohol
b
 
4-Hydroxybenzyl alcohol
c
 
716 ± 321 (7.35) 
882 ± 387 (6.96) 
790 ± 420 (7.67) 
1634 ± 1058 (8.09) 
1074 ± 564 (4.84) 
1460 ± 924 (11.52) 
1397 ± 700 (4.14)
f 
1971 ± 2013 (15.56) 
3977 ± 575 
5947 ± 1178 
NA 
p-Courmaric acid
b
 
p-Courmaric acid
c
 
77 ± 82 (0.79) 
61 ± 33 (0.48) 
76 ± 70 (0.74) 
106 ± 117 (0.52) 
132 ± 94 (0.59) 
125 ± 67 (0.98) 
203 ± 144 (0.6)
f 
191 ± 114 (1.51) 
488 ± 112 
483 ± 114 
(Koli et al., 2010; 
Nurmi et al., 2009; 
Russell et al., 2009) 
Ferulic acid
b
 
Ferulic acid
c
 
141 ± 131 (1.44) 
115 ± 128 (0.90) 
408 ± 754 (3.95) 
273 ± 251 (1.35) 
1338 ± 1171 (6.03)
f 
1010 ± 933 (7.97) 
1517 ± 1344 (4.50)
f 
1039 ± 537 (8.20) 
3404 ± 1116 
2436 ± 923 
(Czank et al., 2013; 
Koli et al., 2010; 
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Nurmi et al., 2009; 
Russell et al., 2009) 
Sinapic acid
b
 
Sinapic acid
c
 
110 ± 176 (1.13) 
105 ± 205 (0.83) 
210 ± 232 (2.03) 
342 ± 501 (1.7) 
1120 ± 903 (5.05)
f 
920 ± 644 (7.26) 
1205 ± 943 (3.57)
f 
1102 ± 925 (8.7) 
2645 ± 826 
2470 ± 809 
(Russell et al., 2009) 
PCA-3-glucuronide
b
  
PCA-3-glucuronide
c
  
32 ± 32 (0.33) 
38 ± 18 (0.3) 
30 ± 32 (0.29) 
58 ± 84 (0.29) 
163 ± 157 (0.73) 
179 ± 147 (1.41) 
350 ± 190 (1.04)
f 
460 ± 276 (3.63) 
576 ± 179 
735 ± 233 
(Czank et al., 2013) 
PCA-4-glucuronide
b
 
PCA-4-glucuronide
c
 
44 ± 33 (0.45) 
46 ± 23 (0.36) 
36 ± 37 (0.34) 
57 ± 68 (0.28) 
91 ± 71 (0.41)
f 
87 ± 42 (0.68) 
145 ± 86 (0.43)
f 
177 ± 89 (1.40) 
315 ± 74 
366 ± 83 
(Czank et al., 2013) 
IsoVA-3-glucuronide
b
  
IsoVA-3-glucuronide
c
 
271 ± 479 (2.79) 
241 ± 196 (1.90) 
230 ± 352 (2.23) 
350 ± 515 (1.73) 
660 ± 615 (2.97)
f 
696 ± 442 (5.49)
 
1226 ± 774 (3.64)
f 
1286 ± 788 (10.15) 
2387 ± 692 
2573 ± 717 
(Czank et al., 2013) 
VA-4-glucuronide
b
 
VA-4-glucuronide
c 
427 ± 307 (4.38) 
468 ± 219 (3.69) 
306 ± 157 (2.97) 
585 ± 613 (2.90) 
1154 ± 750 (5.2) 
1001 ± 539 (7.90) 
2296 ± 946 (6.81)
f 
2432 ± 1289 (19.19) 
4183 ± 1005 
4485 ± 1157 
(Czank et al., 2013) 
PCA-sulfate
b,h 
PCA-sulfate
c,h
 
183 ± 291 (1.88) 
240 ± 370 (1.90) 
153 ± 182 (1.48) 
313 ± 574 (1.55) 
885 ± 1215 (3.99) 
1289 ± 1856 (10.17) 
2014 ± 1765 (5.97)
f 
2436 ± 1972 (19.22) 
3235 ± 1303 
4278 ± 1689 
(Czank et al., 2013) 
VA-sulfate
b,i
  
VA-sulfate
c,i
  
1723 ± 1418 (17.69) 
1902 ± 1185 (15.01) 
1231 ± 980 (11.94) 
2632 ± 3661 (13.03) 
2314 ± 2114 (10.42) 
2830 ± 1622 (22.34) 
3176 ± 2478 (9.41)
g 
3638 ± 2090 (28.71)
 
8444 ± 1938 
11003 ± 2372 
(Czank et al., 2013) 
C3G, cyanidin-3-glucoside; ND, not detected; NA, not previously identified following anthocyanin consumption. P3G, peonidin-3-glucoside; PCA, 
protocatechuic acid; VA, vanillic acid 
a
Values represent mean ratios ± SD with % of total metabolites represented in brackets, n=15; all samples have been 
adjusted for creatinine concentration. 
b
Metabolite level following acute (500 mg) anthocyanin consumption (week 0). 
c
Metabolite level following chronic 
(500 mg/day for 12 weeks) anthocyanin consumption (week 12). 
e
No standard available, quantified relative to cyanidin-3-glucoside.
c
No standard available, 
quantified relative to peonidin-3-glucoside. 
f
Significantly increased compared to baseline values (repeated measures, p < 0.05).  
g
Significance indicated by 
ANOVA with Greenhouse-Geisser adjustment but post hoc tests did not reach significance (p > 0.05).  
h
PCA-3-sulfate co-elutes with PCA-4-sulfate. 
i
Vanillic 
acid-4-sulfate co-elutes with isovanillic acid-3-sulfate.   
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Table 4.3 Concentration of anthocyanins, anthocyanin conjugates and phenolics in plasma samples following acute and chronic intake of anthocyanins 
from an elderberry extract. 
Compound 
Concentration, nM (% of total metabolites)
a
 Previously identified 
 in plasma 
Baseline 1 h 2 h 3 h Total 
Cyanidin-3-glucoside
a,f 
Cyanidin-3-glucoside
b 
ND 
1 (0.15) 
4 (0.63) 
1 (0.21) 
7 (0.82) 
7 (1.08) 
5 (0.38) 
6 (0.86) 
16 
15 
(Czank et al., 2013; Milbury et 
al., 2002)
 
Cyanidin-3-sambubioside
 a,f 
Cyanidin-3-sambubioside
b
 
ND 
ND 
10 (1.44) 
8 (1.28) 
16 (1.85) 
18 (2.74) 
11 (0.91) 
15 (2.27) 
38 
41 
(Czank et al., 2013; Milbury et 
al., 2002)
 
Cyanidin-glucuronide
a,d,f 
Cyanidin-glucuronide
b
 
ND 
ND 
ND 
ND 
2 (0.27) 
3 (0.39) 
2 (0.18) 
5 (0.75) 
5 
7 
NA 
Peonidin-glucuronide
a,e,f 
Peonidin-glucuronide 
ND 
1 (0.13) 
2 (0.24) 
3 (0.41) 
8 (0.96) 
15 (2.20) 
9 (0.71) 
21 (3.22) 
19 
39 
NA 
Protocatechuic acid (PCA)
a,f 
PCA
b
 
11 (2.71) 
17 (3.84) 
12 (1.72) 
24 (3.94) 
14 (1.65) 
10 (1.54) 
24 (1.93) 
20 (3.03) 
61 
71 
(Azzini et al., 2010; Czank et 
al., 2013; Koli et al., 2010; 
Russell et al., 2009)
 
3,5-Dihydroxybenzoic acid
a,f 
3,5-Dihydroxybenzoic acid
b
 
20 (5.05) 
26 (5.86) 
18 (2.67) 
23 (3.78) 
8 (4.39) 
25 (3.69) 
50 (3.92) 
31 (4.82) 
126 
105 
NA 
Vanillic acid (VA)
a,f 
VA
b
 
6 (1.64) 
12 (2.70) 
35 (5.13) 
41 (6.58) 
62 (7.03) 
54 (8.05) 
58 (4.60) 
40 (6.24) 
161 
147 
(Czank et al., 2013; Koli et al., 
2010; Russell et al., 2009) 
Syringic acid
a,f 
Syringic acid
b
 
5 (1.16) 
11 (2.41) 
17 (2.44) 
24 (3.95) 
22 (2.56) 
30 (4.43) 
15 (1.20) 
13 (2.01) 
59 
78 
NA 
4-Methoxysalicyclic acid
a,f 
4-Methoxysalicyclic acid
b
 
1 (0.23) 
1 (0.19) 
0.3 (0.05) 
1 (0.17) 
1 (0.07) 
1 (0.12) 
2 (0.13) 
1 (0.15) 
3 
4 
NA 
Methyl-3,4-
dihydroxybenzoate
a,f 
Methyl-3,4-
dihydroxybenzoate
b
 
3 (0.71) 
7 (1.48) 
2 (0.33) 
3 (0.43) 
6 (0.68) 
3 (0.38) 
6 (0.48) 
5 (0.72) 
17 
16 
(Czank et al., 2013) 
Phloroglucinaldehyde
a,f 
Phloroglucinaldehyde
b
 
4 (1.05) 
35 (7.77) 
21 (3.02) 
34 (5.48) 
102 (11.69) 
62 (9.2) 
72 (5.66) 
73 (11.29) 
199 
203 
(Czank et al., 2013) 
3,4-Dihydroxybenzaldehyde
a,f 
3,4-Dihydroxybenzaldehyde
b
 
17 (4.43) 
26 (5.92) 
18 (2.65) 
19 (3.09) 
23 (2.62) 
12 (1.80) 
21 (1.68) 
11 (1.73) 
80 
69 
NA 
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ND, not detected. NA, not previously identified following anthocyanin consumption. 
a
Metabolite concentration following acute (500 mg) anthocyanin 
consumption (week 0); 
b
Metabolite concentration following chronic (500 mg/day for 12 wks) anthocyanin consumption (wk 12). 
c
Values represent 
concentrations of a pooled sample (n=1) from 15 participants samples, with % of total metabolites represented in brackets. 
d
No standard available, quantified 
relative to cyanidin-3-glucoside. 
e
No standard available, quantified relative to peonidin-3-glucoside. 
f
Visual increase in concentration compared to baseline 
values (no statistical analysis possible as a result of using a pooled sample). 
g
PCA-3-sulfate co-elutes with PCA-4-sulfate. 
h
Vanillic acid-4-sulfate co-elutes 
with isovanillic acid-3-sulfate.  
4-Hydroxybenzaldehyde
a,f 
4-Hydroxybenzaldehyde
b
 
97 (24.74) 
120 (26.97) 
146 (21.29) 
109 (17.65) 
182 (20.80) 
120 (17.90) 
150 (11.85) 
95 (14.67) 
575 
444 
NA 
Ferulic acid
a,f 
Ferulic acid
b
 
8 (1.97) 
3 (0.71) 
27 (3.92) 
23 (3.66) 
28 (3.23) 
21 (3.12) 
22 (1.70) 
134 (2.13) 
84 
60 
(Czank et al., 2013; Zhang et 
al., 2004) 
PCA-3-glucuronide
a,f 
PCA-3-glucuronide
b
 
3 (0.79) 
6 (1.24) 
8 (1.10) 
11 (1.78) 
15 (1.75) 
13 (1.97) 
15 (1.22) 
16 (2.43) 
41 
45 
(Czank et al., 2013) 
PCA-4-glucuronide
a,f 
PCA-4-glucuronide
b
 
6 (1.43) 
4 (0.96) 
4 (0.52) 
8 (1.33) 
10 (1.14) 
11 (1.63) 
14 (1.11) 
8 (1.24) 
33 
31 
(Czank et al., 2013) 
IsoVA-3-glucuronide
a,f 
IsoVA-3-glucuronide
b
 
10 (2.65) 
15 (3.42) 
13 (1.97) 
13 (2.15) 
24 (2.71) 
20 (3.03) 
22 (1.71) 
37 (5.68) 
69 
85 
NA 
VA-4-glucuronide
a,f 
VA-4-glucuronide
b
 
16 (4.21) 
22 (4.90) 
33 (4.85) 
30 (4.78) 
78 (8.91) 
90 (13.41) 
120 (9.49) 
115 (17.87) 
248 
256 
NA 
PCA-sulfate
 a,f,g 
PCA-sulfate
b
 
92 (23.55) 
25 (5.53) 
74 (10.78) 
49 (7.91) 
115 (13.17) 
26 (3.81) 
358 (28.31) 
34 (5.30) 
640 
133 
(Czank et al., 2013) 
VA-sulfate
a,f,g 
VA-sulfate
b
 
27 (6.79) 
41 (9.29) 
161 (23.43) 
92 (14.96) 
23 (2.67) 
40 (5.99) 
93 (7.36) 
19 (3.01) 
304 
193 
(Czank et al., 2013) 
Benzoic acid-4-sulfate
a,f 
Benzoic acid-4-sulfate
b
 
66 (16.89) 
74 (16.56) 
81 (11.82) 
102 (16.45) 
97 (11.02) 
91 (13.53) 
196 (15.48) 
68 (10.59) 
439 
334 
NA 
Total anthocyanins
a
 
Total anthocyanins
b
 
0 
1 
16 
12 
34 
43 
28 
46 
78 
102 
 
Total phenolic metabolites
a
 
Total phenolic metabolites
b
 
391 
445 
670 
606 
842 
627 
1238 
599 
3140 
2277 
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Figure 4.2 Structures and HPLC-ESI-MRM traces of anthocyanins identified within 3 h post 
bolus urine samples. 
 
Multiple reaction monitoring (MRM) chromatograms. Structures illustrate possible conjugation 
positions, actual positions are unknown. (A) cyanidin-3-glucoside, m/z 449/287; (B) cyanidin-3-
sambubioside, m/z 581/287; (C) cyanidin-glucuronide, m/z 463/287; (D) peonidin-glucuronide, 
m/z 477/301; (E) peonidin-3-glucoside, m/z 463/301; (F) peonidin-3-glucoside-glucuronide, m/z 
639/301; (G) cyanidin-3-glucoside-disulfate, m/z 609/287; (H) cyanidin-diglucuronide, m/z 
639/287. 
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Figure 4.3 Anthocyanins identified in individual participants urine samples following acute 
(500 mg) anthocyanin consumption. 
 
Solid black lines indicate individual participant excretion (n=15), dashed line illustrates mean. 
Values are adjusted for  creatinine concentrations (nM/mM creatinine). 
 
4.3.4. Phenolic metabolites within urine and plasma 
There was high variability observed in the levels of individual phenolic metabolites, where 
protocatechuic-4-glucuronide (Figure 4.4) and p-courmaric acid (Figure 4.5) were present in 
the lowest ratios, reaching 145 ± 86 and 203 ± 144 nM/mM creatinine respectively (Table 4.2), 
whilst homovanillic acid and vanillic acid reached the highest ratios at 3 h, representing levels 
of 7.4 ± 5.9 and 4.3 ± 3.2 µM/mM creatinine respectively (Figure 4.5). 
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Within plasma, total concentrations of metabolites cumulatively reached 1.2 µM, 3 h post bolus, 
representing an 0.8 µM increase from baseline values (Table 4.3); where protocatechuic acid-
sulfate reached the highest concentration (358 nM) while 4-methoxysalicyclic acid was 
identified at the lowest concentration (2 nM) within plasma. The maximum concentration for 
the majority of the compounds was at 2 h, however, protocatechuic acid, 3,5-dihydroxybenzoic 
acid, 4-methoxysalicyclic acid, protocatechuic acid-4-glucuronide, vanillic acid-4-glucuronide, 
protocatechuic acid-3 & 4-sulfate and benzoic acid-4-sulfate had not reached maximum 
concentration by 3 h. 
 
Figure 4.4 Ratios of glucuronide and sulfate phenolic conjugates identified in individual 
participant urine samples following acute (500 mg) anthocyanin consumption, expressed per 
mM creatinine. 
 
Solid lines indicate individual participant excretion (n=15), dashed line illustrates mean.  
Values are adjusted for  creatinine concentrations (µM/mM creatinine). 
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Figure 4.5 Ratios of phenolic metabolites identified in individual participants urine samples 
following acute (500 mg) anthocyanin consumption.  
 
Solid lines indicate individual participant excretion (n=15), dashed line illustrates mean.  
Values are adjusted for  creatinine concentrations (µM/mM creatinine). 
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12), when comparing individual metabolite levels or when grouping compounds by structure 
(anthocyanins, hydroxybenzoic, hydroxybenzoate, aldehyde, phenylacetic, phenylalcohol or 
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Due to the use of pooled plasma samples (n=1), no statistical comparisons were possible with 
plasma. However there was a visible increase in anthocyanins (78 nM at week 0 versus 100 nM 
at week 12) and decrease in hydroxybenzoic acids (3 nM at week 0 versus 2  nM at week 12) 
following sustained dosing (Figure 4.6); however this was not mirrored in the urine analysis.  
4.3.6. Phenolic compounds not increased from baseline values 
The levels of seven compounds identified in urine and six compounds identified in plasma 
(Table 4.4) did not increase from baseline following the consumption of 500 mg elderberry 
anthocyanins. The compounds included 2-, 3-, and 4-hydroxybenzoic acid, benzoic acid-4-
glucuronide, 2,3-dihydroxybenzoic acid, methylgallate, hippuric acid and 3- and 4-
methylhippuric acid.  
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Figure 4.6 Baseline (BL) and post bolus (0-3 h) anthocyanins and metabolite concentrations in 
plasma.  
 
 
 (A) Concentration of major anthocyanin metabolites (>150 nM) identified in a pooled sample 
from n=15 participants, following a single bolus and (B) following 12-wk supplementation; (C) 
concentration of minor anthocyanin metabolites (<150 nM) identified following a single bolus 
and (D) following 12-wk supplementation. Metabolites are classified by conjugation/ structure 
where hydroxybenzoic acids include protocatechuic acid (PCA), 3,5-dihydroxybenzoic acid, 
vanillic acid (VA), syringic acid, 4-methoxysalicyclic acid, PCA-3-glucuronide, PCA-4-
glucuronide, VA-4-glucuronide, isoVA-3-glucuronide, PCA-sulfate and VA-sulfate; methyl 
conjugates include VA, syringic acid, 4-methoxysalicyclic acid,methyl-3,4-dihydroxybenzoate, 
ferulic acid, VA-4-glucuronide, isoVA-3-glucuronide and VA-sulfate; phenylaldehydes include 
phloroglucinaldehyde, 4-hydroxybenzaldehyde and 3,4-dihydroxybenzaldehyde; glucuronide 
conjugates include PCA-3-glucuronide, PCA-4-glucuronide VA-3-glucuronide and isoVA-3-
glucuronide; sulfate conjugates include PCA-sulfate, VA-sulfate and benzoic acid-4-sulfate; 
anthocyanins include cyanidin-3-glucoside, cyanidin-3-sambubioside, cyanidin-glucuronide and 
peonidin-glucuronide; cinnamic acids include ferulic acid; and benzoates include methyl-3,4-
dihydroxybenzoate. 
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Table 4.4 Phenolic compounds in (A) urine and (B) plasma following acute and chronic intake of anthocyanins from an elderberry 
extract, which demonstrated no increase from baseline ratios. 
A. Urine   
Compound 
Ratio, per mM creatinine ± SD Previously identified in 
urine 
Baseline t(0-1 h) t(1-2 h) t(2-3 h)   
2-Hydroxybenzoic acid
a
 (nM) 
2-Hydroxybenzoic acid
b
 (nM)
 
56 ± 50 
52 ± 33 
54 ± 41 
63 ± 55 
45 ± 35 
38 ± 28 
77 ± 49 
59 ± 48 
(Russell et al., 2009) 
3-Hydroxybenzoic acid
a
 (µM) 
3-Hydroxybenzoic acid
b
 (µM) 
273 ± 316 
734 ± 1007 
259 ± 284 
1215 ± 1384 
365 ± 305 
1147 ± 1362 
319 ± 307 
1014 ± 1189 
(Czank et al., 2013) 
2,3-Dihydroxybenzoic acid
a
 (nM) 
2,3-Dihydroxybenzoic acid
b
 (nM) 
110 ± 210 
70 ± 46 
55 ± 31 
108 ± 115 
75 ± 42 
81 ± 46 
123 ± 80 
108 ± 95 
 
Benzoic acid-4-glucuronide
a
 (nM) 
Benzoic acid-4-glucuronide
b
 (nM) 
17 ± 22 
10 ± 8 
21 ± 34 
41 ± 115 
19 ± 26 
14 ± 16 
19 ± 26 
20 ± 21 
(Czank et al., 2013) 
Hippuric acid
a
 (µM) 
Hippuric acid
b 
(µM) 
246 ± 154 
204 ± 107 
267 ± 177  
300 ± 237 
257 ± 160  
220 ± 106 
227 ± 929 
216 ± 124 
(Czank et al., 2013) 
3-Methylhippuric acid
a
 (nM) 
3-Methylhippuric acid
b
 (nM) 
96 ± 148 
44 ± 29 
125 ± 183 
57 ± 37 
117 ± 162 
47 ± 22 
114 ± 156 
49 ± 32 
 
4-Methylhippuric acid
a
 (nM) 
4-Methylhippuric acid
b
 (nM) 
44 ± 76 
23 ± 18 
54 ± 81 
20 ± 21 
48 ± 54 
20 ± 13 
46 ± 51 
26 ± 21 
 
 
B. Plasma 
     
 
Compound 
Concentration (nM)
 
Previously identified in 
plasma Baseline 1 h 2 h 3 h Total 
Hippuric acid
a 
(µM) 
Hippuric acid
b 
(µM) 
10 
8 
7 
6 
6 
6 
6 
6 
30 
26 
(Czank et al., 2013) 
Methylgallate
a 
(nM) 
Methylgallate
b 
(nM) 
5 
3 
5 
3 
4 
4 
3 
3 
17 
13 
 
Benzoic acid-4-glucuronide
a 
(nM) 10 10 8 7 34 (Czank et al., 2013) 
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a
Metabolite concentration following acute (500 mg) anthocyanin consumption (week 0); 
b
Metabolite concentration following chronic 
(500 mg/day for 12 wks) anthocyanin consumption (wk 12). 
 
 
Benzoic acid-4-glucuronide
b 
(nM) 5 5 3 2 15 
4-Hydroxybenzoic acid
a 
(nM) 
4-Hydroxybenzoic acid
b 
(nM) 
39 
37 
36 
25 
32 
28 
30 
25 
137 
115 
(Azzini et al., 2010; 
Russell et al., 2009; Zhang 
et al., 2004) 
3-Hydroxybenzoic acid
a 
(nM) 
3-Hydroxybenzoic acid
b 
(nM) 
21 
51 
35 
46 
26 
35 
29 
18 
111 
150 
(Zhang et al., 2004) 
2-Hydroxybenzoic acid
a 
(nM) 
2-Hydroxybenzoic acid
b 
(nM) 
173 
186 
211 
149 
191 
80 
172 
102.33 
747 
517 
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4.4. Discussion 
The elderberry extract fed during the present study contained 500 mg anthocyanins, which is 
equivalent to consuming approximately 38 g of elderberries, 84 g blackcurrants or 290 g 
blackberries (Curtis et al., 2009; Neveu et al., 2010). In order to establish the phenolic 
profile of the elderberry extract, the present study carried out a secondary analysis of a recent 
batch of 25% anthocyanin elderberry extract from Artemis, as this was not established in the 
original investigation. Fifteen phenolics (Table 4.1) were identified within the extract, 
including protocatechuic acid (139 ± 4 mg/g extract), phloroglucinaldehyde (16 ± 1 mg/g 
extract), caffeic acid (15 ± 1 mg/g extract) and 4-hydroxybenzoic acid (11  ± 0.3 mg/g 
extract). Therefore, the present study provided a bolus which closely mimicked a dietary 
source of anthocyanins, albeit it was derived from dried and ground berries. 
 
In the present investigation, 28 metabolites were identified in urine (11 anthocyanin 
conjugates and 17 phenolic metabolites, Table 4.2) and 21 metabolites were identified in 
plasma (four anthocyanin conjugates and 17 phenolic metabolites, Table 4.3). In addition, 
seven compounds identified in urine and six compounds identified in plasma demonstrated 
no postprandial increase in concentration, suggesting there presence was derived from the 
‘background’ diet or endogenous protein turnover. 
 
Anthocyanins were present at nanomolar levels in urine, with cyanidin-3-glucoside reaching 
309 ± 673 nM/mM creatinine and cyanidin-3-sambubioside reaching 99 ± 116 nM/mM 
creatinine after 3 h; which is in accordance with data derived from previous studies (Bitsch 
et al., 2004b; Cao et al., 2001; Felgines et al., 2005; Garcia-Alonso et al., 2009; Kay et al., 
2005; Kay et al., 2004; Wu et al., 2002). The conjugated anthocyanins reached cumulative 
levels of 140 ± 33 nM/mM creatinine after 3 h. The conjugated metabolites include 
methylated, glucuronidated and disulfated cyanidin-3-glucoside and methylated, 
glucuronidated and diglucuronidated conjugates of the aglycone, cyanidin (Table 4.2). The 
most predominate conjugation reaction for anthocyanins was glucuronidation (seven 
glucuronide conjugates identified), followed by methylation (five methyl conjugates 
identified), with many anthocyanins undergoing multiple conjugation reactions. It should be 
noted that peonidin was not present in the elderberry extract and therefore the identification 
of peonidin conjugates in the plasma and urine is indicative of the methylation of cyanidin. 
However, in the absence of standards for many of the anthocyanin conjugates, the identity 
and conjugation positions cannot be confirmed. Several peaks in the chromatograms with the 
same mass and fragmentation pattern (two transitions) as cyanidin-glucuronide and 
peonidin-glucoside-glucuronide (Figure 4.2) do however provide evidence to suggest 
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conjugations occurred at several positions on the anthocyanin structure. Previous elderberry 
interventions have predominantly identified cyanidin-3-glucoside and cyanidin-3-
sambubioside in post bolus urine samples (Milbury et al., 2002; Mülleder et al., 2002; 
Murkovic et al., 2001). Wu et al. identified four anthocyanin conjugates, including peonidin-
3-sambubioside and cyanidin-3-glucoside-monoglucuronide, which were not identified in the 
present study (Wu et al., 2002). However, to the best of our knowledge the anthocyanin 
conjugates identified here represent the largest number of metabolic conjugates of elderberry 
anthocyanins identified to date. In addition, despite creatinine adjustment, the ratios of total 
anthocyanins quantified within urine after 2-3 h following intake are amongst the highest 
reported to date.  
 
In plasma, lower concentrations of a smaller range of metabolites were identified compared 
to urine. The four most abundant anthocyanin metabolites identified in urine were detected 
in plasma; cyanidin-3-glucoside was present at 7 nM, cyanidin-3-sambubioside at 16 nM, 
cyanidin-glucuronide at 2 nM and peonidin-glucuronide at 8 nM, at the 2 h time point 
following acute anthocyanin consumption (Table 4.3).   
 
The majority of previous investigations into anthocyanin metabolism have predominantly 
focused on identifying intact anthocyanins, however anthocyanins are inherently unstable 
and degrade at neutral pH into their phenolic acid and aldehyde constituents (Kay et al., 
2009; Woodward et al., 2009). The present study focused on the identification of phenolic 
metabolites. Protocatechuic acid and phloroglucinaldehyde, the degradation products of 
cyanidin-3-glucoside, were detected in both urine and plasma. Protocatechuic acid reached 
levels of 1.5 ± 1.2 µM/mM creatinine and 24 nM after 3 h in urine (Table 4.2) and plasma 
(Table 4.3) respectively. Limited previous data has quantified protocatechuic acid following 
anthocyanin consumption. Russell et al. (Russell et al., 2009) and  Nurmi et al. (Nurmi et al., 
2009) identified protocatechuic acid in urine samples following strawberry and bilberry-
loganberry consumption, and reported 2.3 µM at 3 h post bolus; which is similar to the ratios 
observed in the present study. Vitaglione et al. (Vitaglione et al., 2007) also previously 
reported protocatechuic acid to be the major metabolite of cyanidin-glucosides in humans, 
identifying plasma concentrations of 492 nM  following consumption of blood orange juice, 
yet failed to identify it within the urine. Protocatechuic acid is naturally present in many 
fruits, including elderberries, where the present study identified it as the most abundant 
phenolic, present at concentrations of 139 mg/g extract (Table 4.1). The presence of 
protocatechuic acid in the background diet may have led to an overestimation of anthocyanin 
derived protocatechuic acid in this and previous interventions.  
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Phloroglucinaldehyde was identified at maximum ratios of 602 ± 632 nM/mM creatinine at 3 
h and 103 nM at 2 h in urine (Table 4.2) and plasma (Table 4.3) respectively. Protocatechuic 
acid and phloroglucinaldehyde were identified in our study feeding 
13
C-labelled cyanidin-3-
glucoside, where together they reached maximum concentrations of 507 nM/mM creatinine 
in urine and 728 nM in plasma (Chapter 3) (Czank et al., 2013). As would be expected, the 
urinary levels of protocatechuic acid were higher in the present study, likely due to their 
presence within the elderberry extract and the absence of the use of a labelled marker. 
However, the plasma concentrations of the degradation products were lower, possibly due to 
the degradation products reaching maximum concentration at 6 h post bolus within the 
labelled study. To our knowledge, this is the first study where phloroglucinaldehyde has 
been identified in human blood or urine following a fruit derived anthocyanin intervention.  
 
Our data suggest that the degradation products of anthocyanins undergo phase I and II 
metabolism to produce conjugated phenolic acids, where methylated (vanillic acid), 
glucuronidated (protocatechuic acid-3-glucuronide, protocatechuic acid-4-glucuronide, 
vanillic acid-4-glucuronide and isovanillic acid-3-glucuronide), sulfated (protocatechuic 
acid-sulfate and vanillic acid-sulfate) and de/hydroxylated (4-hydroxybenzoic acid and 3,5-
dihydroxybenzoic acid) metabolites of protocatechuic acid were identified. Vanillic acid-4-
glucuronide demonstrated the largest increase from baseline values in urine, reaching levels 
of 2.3 ± 0.9 µM/mM creatinine 3 h post bolus (Table 4.2) and protocatechuic acid-sulfate 
demonstrated the largest increase in concentration from baseline plasma, reaching 
concentrations of 358 nM 3 h following intake (Table 4.3). 4-Hydroxybenzoic acid and 
vanillic acid have previously been identified within biological samples following bilberry-
lingonberry (Nurmi et al., 2009), cranberry juice (Zhang et al., 2004) and strawberry 
consumption (Azzini et al., 2010). Whilst the glucuronidated and sulfated metabolites have 
been identified at concentrations up to 1.9 ± 0.7 µM (for protocatechuic acid-3-glucuronide) 
in our study feeding 
13
C-labelled cyanidin-3-glucoside (Czank et al., 2013); the present study 
is the first to identify them following a fruit derived anthocyanin intervention. 
 
Anthocyanins may alternatively form phenylpropenoic, phenylacetic and phenylalcohol 
structures. Homovanillic acid, homoprotocatechuic acid, 4-hydroxybenzyl alcohol, p-
courmaric acid, ferulic acid and sinapic acid were detected at increased concentrations within 
postprandial urine samples (Table 4.2) and syringic acid, 4-methoxysalicyclic acid, methyl-
3,4-dihydroxybenzoate, 3,4-dihydroxybenzaldehyde, 4-hydroxybenz-aldehyde and ferulic 
acid were detected at increased concentrations within postprandial plasma samples (Table 
4.3). Of these, homovanillic acid, homoprotocatechuic acid, p-courmaric acid, ferulic acid 
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and sinapic acid have been previously detected within urine (Nurmi et al., 2009; Russell et 
al., 2009) and ferulic acid has previously been identified within plasma (Zhang et al., 2004) 
following phenolic rich anthocyanin interventions. The origin of the phenolic metabolites 
identified in the present study cannot be confirmed with certainty without the use of a 
labelled anthocyanin. However, many have recently been confirmed as anthocyanin 
metabolites through the use of a 
13
C-labelled anthocyanin bolus (Czank et al., 2013), where 
metabolites including ferulic acid, 3- and 4-hydroxybenzoic acid, 3,4-
dihydroxybenzaldehyde, 4-hydroxyphenylacetic acid and methyl-3,4-dihydroxybenzoate 
were identified (Table 4.2 & Table 4.3).  
 
A high inter-individual variation in metabolite excretion was observed between participants; 
for example, levels of protocatechuic acid ranged from 0.03 to 4.9 µM/mM creatinine within 
3 h post bolus urine samples of the n=15 participants. This likely results from individual 
biological variations, including variations in gut microflora, enzyme and receptor levels. 
 
Phenolic metabolites were identified reaching ratios of 24 µM/mM creatinine above baseline 
values, whilst concentrations of 5.97 ± 2.14 μM were obtained from feeding the same dose 
of pure 
13
C-labelled cyanidin-3-glucoside (Czank et al., 2013).  Therefore, as would be 
expected with the inclusion of additional phenolics within a natural food bolus, the present 
study shows phenolics to accumulate at higher concentrations following the consumption of 
anthocyanins within a food matrix as opposed to a pure bolus. The phenylacetic structures, 
homovanillic acid and homoprotocatechuic acid,  which together provided a 4762 nM/mM 
creatinine increase from baseline urinary levels appeared to be major anthocyanin 
metabolites in urine, but were absent from plasma. Similarly, p-courmaric acid, sinapic acid, 
3,5-dihydroxybenzoic acid and 4-hydroxybenzyl alcohol were also identified within urine, 
but were absent from the plasma. The presence of some metabolites in the urine but not the 
plasma suggests some compounds in the plasma were below the detection limit of the 
methodology but became detectable as they were concentrated by the kidneys and excreted 
into the urine. Alternatively, conjugation could occur in the kidney prior to excretion. 
 
The plasma contained 4-hydroxybenzaldehyde, 3,4-dihydroxybenzaldehyde, 4-methoxy 
salicyclic  acid, benzoic acid-4-sulfate, methyl-3,4-dihydroxybenzoate and syringic acid 
which were absent from urine samples. The appearance of metabolites in the plasma but not 
in the urine suggests some metabolites may have been metabolised further within the plasma, 
or were eliminated by the biliary route, and either metabolised further by colonic bacteria 
and reabsorbed or excreted. This is supported by the identification of methyl-3,4-
dihydroxybenzoate and 4-methoxysalicyclic acid within faecal samples following our recent 
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human study feeding 
13
C-labelled cyanidin-3-glucoside (Czank et al., 2013). Conjugates of 
phenolic degradation products of anthocyanins appear in the circulation as early as 1 h post 
consumption (Table 4.3) (Czank et al., 2013), suggesting they do not follow the commonly 
reported elimination profiles of other flavonoids, such as quercetin and epicatechin, which 
require bacterial catabolism to liberate free phenolic intermediates, and therefore appear 
much later in the circulation (Aura et al., 2002; GriffithsandBarrow, 1972; Manach et al., 
2005; Mullen et al., 2008b; Selma et al., 2009; Winter et al., 1989). The early appearance of 
phenolic metabolites in the present study likely results from the instability of anthocyanins at 
physiological pH (pH 5-7) ( onz lez-Barrio et al., 2010; Mullen et al., 2008b; Williamson 
et al., 2010), resulting in their rapid degradation and metabolism within the proximal and 
distal small intestine, where bacteria are still present at varying densities (Berg, 1996). 
 
In the present study a number of unconjugated metabolites, including protocatechuic acid, p-
courmaric acid and homoprotocatechuic acid were identified. Although flavonoids are 
generally reported in the circulation as conjugated metabolites  (Hollman, 2004), 
unconjugated phenolic acids have been reported at levels similar to those detected within the 
present intervention study (Czank et al., 2013; Nurmi et al., 2009; Russell et al., 2009) and 
their presence in the current study, likely reflects the instability and rapid degradation of 
anthocyanins. 
 
Several of the putative phenolic metabolites explored (hippuric acid, 2-, 3- and 4-
hydroxybenzoic acid and benzoic acid-4-glucuronide) were not found to significantly 
increase from baseline concentrations (Table 4.4). These compounds were initially explored 
as putative metabolites as they have been previously reported as possible anthocyanin or 
flavonoid metabolites. Hippuric acid, 3-hydroxybenzoic acid, and benzoic acid-4-
glucuronide have been identified as anthocyanin metabolites in our study feeding 
13
C-
labelled cyanidin-3-glucoside (Czank et al., 2013). Hippuric acid, which was present at the 
highest concentration, reaching millimolar levels within urine in the present study, is formed 
from the reaction of benzoic acid with glycine, and is a common product of protein (Pero, 
2010) or dietary polyphenol metabolism (Del Bo’ et al., 2012; Mulder et al., 2005). 
Similarly, 2-, 3- and 4-hydroxybenzoic acids have been reported in multiple anthocyanin 
intervention studies (Azzini et al., 2010; Nurmi et al., 2009; Russell et al., 2009; Zhang et 
al., 2004). Whilst these phenolics did not increase in concentration from baseline levels, and 
are therefore predominantly derived from other source in the ‘background’ diet or 
endogenous protein turnover (Toromanović et al., 2008), anthocyanin metabolism likely 
contributes to their concentrations in biofluids to some extent (as indicated by their presence 
following consumption of a labelled anthocyanin). 
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The present study is the first study to look at postprandial phenolic metabolite excretion 
following chronic anthocyanin intake for 12 weeks. A previous flavonoid intervention found 
two weeks daily quercetin supplementation resulted in increased plasma quercetin 
concentrations (Egert et al., 2008) suggesting reduced clearance of quercetin following 
repeated dosing. However, there was no significant impact of 12wks continuous dosing on 
urinary metabolite excretion in the present study. This is in accordance with a previous 8wk 
berry intervention which found no effect of chronic intake on fasting polyphenol 
concentrations (Koli et al., 2010), and suggests there is little risk of bioaccumulation or 
toxicity associated with the consumption of anthocyanins. There was an increase in plasma 
anthocyanins (78 nM at wk0 versus 100 nM at wk12) and decrease in hydroxybenzoic acids 
(3 nM at wk0 versus 2 nM at wk12) following sustained dosing (Figure 4.6); however, no 
statistical comparisons were possible due to the use of pooled plasma samples (n=1). This 
observation was not apparent in the urine analysis. In addition, based on the large inter-
individual variation in metabolite excretion reported herein, (Figure 4.3, Figure 4.4 & Figure 
4.5) differences in plasma levels of the anthocyanins or hydroxybenzoic acids are not likely 
to have reached statistical significance. 
 
In contrast to our recent intervention study where we fed pure, 
13
C-labelled synthetic 
cyanidin-3-glucoside (Czank et al., 2013), here we administered a matrix which more closely 
mimics a dietary source of anthocyanins, such as that found in a single serving of some 
berries (Curtis et al., 2009; Neveu et al., 2010). Whilst the present study therefore provides a 
comprehensive account of the metabolism of anthocyanins following acute and chronic 
consumption of elderberries, there are certain limitations with this work. Although the use of 
a food source of anthocyanins, as opposed to a pure chemical better represents habitual 
dietary intake, it complicates the elucidation of anthocyanin derived metabolites. Phenolic 
compounds are ubiquitous within plants (DykesandRooney, 2007; Schmitzer et al., 2010) 
and were present at quantities of 0.04 to 139 mg/g within the elderberry extract (Table 4.1) 
and breakfast consisting of Weetabix, Cornflakes or toast. As the intervention meal was fed 
ad labitum, and intakes were not reported, the phenolic intake could not be quantitatively 
established with accuracy. However, database analysis of the main ingredients present within 
the breakfast (unprocessed wheat, barley and maize) indicated that the foods likely contained 
six of the metabolites identified in the present study, at concentrations ranging from 0.01 to 
0.15 mg/100 g FW (Neveu et al., 2010), presuming the phenolics are not degraded during 
processing. In addition, some of the metabolites identified in the present study are typically 
associated with the colonic metabolites of other phenolic compounds 
(WilliamsonandClifford, 2010) and could therefore be derived from the prior consumption of 
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a range of polyphenolic compounds other than anthocyanins. For example, propenoic acids 
and phenylacetic acids are reported metabolites of flavonols and procyanidins (Del Rio et al., 
2013; Selma et al., 2009). However, only metabolites which increased from fasted/baseline 
levels were reported presently and in addition, 19 and 11 of the metabolites identified in 
urine and serum respectively, including ferulic acid and phase II conjugates of 
protocatechuic acid and vanillic acid, were recently reported in a 
13
C-labelled anthocyanin 
feeding study (Czank et al., 2013). Together this suggests that the metabolites identified 
within the present study were derived, at least in part, from the consumed anthocyanins. 
Nevertheless, without the use of a labelled anthocyanin, it is not possible to categorically 
define the origin of all phenolics within the diet, and therefore the contribution of phenolic 
acids from other sources consumed prior to the fast or in the breakfast cannot be definitively 
excluded. 
 
The samples collected in the present study were limited to 3 h post bolus sampling, and 
longer duration sampling following acute exposure would have allowed us to conduct a more 
comprehensive pharmacokinetic analysis. In addition, there are a number of substances 
known to interfere with the creatinine assay (WeberandVan Zanten, 1991), however we 
found no reports in the literature of anthocyanins interfering with creatinine measurements. 
Anthocyanins do absorb at the same wavelength as the assay substrate (510/570 nm), 
however they would have minimal absorbance intensity under the alkaline conditions of the 
assay (Fossen et al., 1998) and are therefore likely to have minor impact on assay sensitivity. 
The collection and measurement of complete urine voids would have allowed total 
recoveries to be calculated as opposed to reporting creatinine adjusted ratios. Finally, as 
polyphenol metabolites are generally more concentrated in the urine, and urinary clearance 
generally reflects the circulating plasma pool of polar metabolites, plasma samples were 
pooled to reduce analytical costs. This may be seen as a further limitation of the present 
analysis as it reduces the intrinsic variability in clearance kinetics between participants. In 
order to determine whether there was an increase in anthocyanin recovery and decrease in 
hydroxybenzoic acid recovery following sustained dosing (Figure 4.6), the present study 
would need to have analysed participant plasma samples individually. 
 
4.5.  Conclusion 
The present study identifies a greater number of anthocyanin metabolites and higher 
metabolite concentrations than previously reported, with phenolic metabolites identified at 
60 and 45 fold higher concentrations than their parent compounds in urine and plasma 
respectively. No significant difference in metabolism or clearance was identified following 
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chronic anthocyanin consumption, suggesting there is no alteration in metabolic processing 
following 12wks repeated dosing. These results therefore indicate that anthocyanins degrade 
and are extensively metabolised in vivo, and adds further weight to the suggestion that it is 
the accumulation of multiple low molecular weight phenolic metabolites within plasma, 
which may be responsible for the reported bioactivity of anthocyanins.   
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Chapter 5. Structural elucidation of novel 
conjugated metabolites of anthocyanins using 
enhanced mass spectrometry scanning (MS
3
) 
 
5.1. Introduction  
High dietary intakes of anthocyanins have been linked to decreased risk of cardiovascular 
disease (Cassidy et al., 2013; Cassidy et al., 2011; Mink et al., 2007; Rissanen et al., 2003). 
However, owing to their apparent low bioavailability, phenolic degradation products of 
anthocyanins may be responsible for their bioactivity. The identification of 29 anthocyanin 
metabolites in urine was previously described based on their retention time and 
fragmentation pattern in relation to analytical standards (de Ferrars et al., 2013) (Chapter 4). 
This was confirmed via a tracer study, where 500 mg isotopically labelled 
13
C5-cyanidin-3-
glucoside was fed to eight male participants (Czank et al., 2013) (Chapter 3). Biological 
samples were collected for 48 h post-bolus and were analysed using isotope-ratio mass 
spectrometry (IRMS) and HPLC-MS/MS. The study identified 35 metabolites of 
13
C5-
cyanidin-3-glucoside, which accounted for 37 ± 14% of the total 
13
C recovered in the urine 
(Czank et al., 2013), however, a significant portion of the label (63%) remained unaccounted 
for.   
 
A limitation of previous analyses was that the methods focused on identifying and 
quantifying metabolites for which standards were commercially available or had been 
synthesised, and methods were not developed to detect or quantify other conjugates. 
Phenolic acids commonly undergo phase II conjugation (methyl, sulfate, O-glucuronide, 
glycine or glutathione) in vivo, to increase their polarity and elimination from the body 
(Hollman, 2004). Therefore, it is likely that the presence of further conjugated metabolites 
accounts for a large proportion of the unidentified label. Sulfation and glucuronidation, two 
prevalent phase II metabolic processes, are mediated by sulfotransferases (SULTs) and 
uridine-5'-diphosphoglucuronosyl-transferases (UDPDG) respectively (Wu et al., 2011). 
Previously, ten sulfated and glucuronidated conjugates of 4-hydroxybenzoic acid, 
protocatechuic acid and vanillic acid were synthesised at the University of St. Andrews 
(UK), which enabled their identification within post bolus urine and serum samples (Czank 
et al., 2013; de Ferrars et al., 2013). The aim of the present study was to use enhanced MS
3
 
scans to detect and elucidate the structure of additional sulfated and glucuronidated 
conjugates of anthocyanin metabolites for which standards are not currently available. Urine 
samples derived from an intervention trial feeding 500 mg elderberry anthocyanins, (de 
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Ferrars et al., 2013) (Chapter 4) and an intervention feeding 500 mg 
13
C5-labelled cyanidin-
3-glucoside (Czank et al., 2013; de Ferrars et al., 2014) (Chapter 3) were utilised in the 
present analysis. 
 
5.2. Materials and methods 
5.2.1. Chemicals and materials 
All standards used for quantification were purchase from Sigma-Aldrich (Dorset, UK). 
Kinetex pentafluorophenol (PFP) HPLC column (2.6 µM, 100 x 4.6 mm) and 
SecurityGuard
®
 cartridges (PFP, 4.0 x 2.0 mm) were purchased from Phenomenex 
(Macclesfield, UK). HPLC grade methanol, acetonitrile and formic acid were purchased 
from Fisher Scientific (Loughborough, UK). Discovery® DSC-18 SPE columns (6 mL, 1 g) 
and Acrodisc 13 mm, 0.45 µm PTFE syringe filters, ascorbic acid, formic acid and all other 
chemicals, were purchased from Sigma-Aldrich (Dorset, UK). All water utilised was of 
Milli-Q grade (18.2 MΩ cm-1). 
5.2.1. Elderberry derived anthocyanin intervention  
Urine samples from a 12 week elderberry extract supplementation trial were collected as 
described previously (de Ferrars et al., 2013) (Chapter 4). Briefly, biological samples were 
derived from a 12 week anthocyanin intervention trial, where following an overnight fast 
healthy post-menopausal women (n=15; age, 58.2 ± 5.6 y; BMI, 24.7 ± 0.6 kg/m²) consumed 
500 mg/day elderberry anthocyanins (Curtis et al., 2009) and blood and urine samples were 
collected at baseline and at 1 h, 2 h and 3 h post bolus. 
5.2.1. Isotopically labelled cyanidin-3-glucoside intervention 
Urine samples from a 
13
C-labelled cyanidin-3-glucoside intervention study were collected as 
described previously (Chapter 3) (Czank et al., 2013). Briefly, following an overnight fast, a 
baseline urine (total morning void of study day) sample was collected. Male participants 
(n=8; age, 27.8 ± 8.1 y; BMI, 23.2 ± 1.5 kg/m²) were given a single, oral 500 mg bolus of 
encapsulated 
13
C5-cyanidin-3-glucoside (2 x 250 mg capsules) followed by a standardised 
anthocyanin free breakfast. Cyanidin-3-glucoside was isotopically labelled at positions 6, 8, 
10, 3’ and 5’ (Figure 5.1) at the University of St. Andrews, Scotland, so that three 13C atoms 
(
13
C3) were present on the A-ring and two 
13
C atoms (
13
C2) were present on the B-ring (Zhang 
et al., 2011). Individual urine voids were collected throughout the study day (0-6 h) and 
pooled for 6-24 h and 24-48 h time points.  
 
Rachel M. de Ferrars © 2013  
 
125/215 
 
Figure 5.1 Structure and labelling configuration 
of 6,8,10,3',5'-
13
C5-cyanidin-3-glucoside. 
 
 
5.2.2. Sample preparation 
Urine samples were extracted and concentrated as previously published (de Ferrars et al., 
2013) Chapter 2. Briefly urine samples were extracted using DSC-18 (6 mL, 1 g) SPE 
cartridges, evaporated to approximately 50 µL using a Thermo speedvac and diluted with 
200 µL of 1% formic acid in milliQ water (pH 2.4). 10 µL of 1 mg/mL scopoletin was added 
as a volume control standard and samples were then filtered using Acrodisc PTFE syringe 
filters (13 mm, 0.45 µm).  
5.2.3. Metabolite modelling/study design 
In order to identify conjugated metabolites of anthocyanins, an approach was used whereby 
the fragmentation patterns of the possible sulfated and glucuronidated conjugates of 
previously identified metabolites [Chapter 3 & 4 (Czank et al., 2013; de Ferrars et al., 2013; 
de Ferrars et al., 2014)] were modelled based on the known fragmentation patterns of 
commercially available phenolic compounds (non-conjugated standards) (Chapter 2) and 
their commonly reported transitions (Table 5.1) (Boss et al., 1999; Farrell et al., 2011; 
Huang et al., 2010; Keski-Hynnilä et al., 2002; Levsen et al., 2005; Liu et al., 2007; Qu et 
al., 2001; Stalmach et al., 2009a; Wong et al., 2010; Woodward et al., 2011; Wu et al., 
2011). Briefly, in negative mode glucuronides produce ions that are 176 Da higher than 
those of the non-conjugated metabolite. Following collision induced fragmentation, an 
abundant fragment [M-H-176]
-
, which correspond to the fragments resulted from the neutral 
loss of a glucuronic acid from the deprotonated molecule, and a less abundant ion at m/z 175 
is typically observed (Farrell et al., 2011; Keski-Hynnilä et al., 2002; Qu et al., 2001; 
Stalmach et al., 2009a; Woodward et al., 2011). In addition, secondary fragment ions at m/z 
113 (resulting from the loss of CO2 and water from the glucuronide ion, m/z 175) and a less 
intense ion at m/z 85 (from the extrusion of CO from m/z 113) may appear (Farrell et al., 
C
13
CH
13
CH
13
O
+
C
13
CH
13
O
OH
OH
OH
OH Glucose
A           C
B
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2011; Levsen et al., 2005; Stalmach et al., 2009a). Therefore, in order to model the MRM 
fragmentation patterns of possible O-glucuronide metabolites used to trigger an information 
dependant acquisition (IDA) MS
3 
scan, the [M-H+176]
-
 parent ion and the [M-H-176]
-
 and 
m/z 175 daughter ions were used (Table 5.1).   
 
Table 5.1 Modelled fragmentation patterns of possible O-glucuronide and O-sulfate 
conjugates of anthocyanin metabolites. 
Conjugate 
Parent 
mass 
Parent ion 
[M-H]
- 
Daughter 
ion 
Putative 
fragments 
Dihydroxybenzoic acid-GlcA 330.24 329 153 285,175,113,109 
Dihydroxybenzoic acid-sulfate 234.18 233 153 189,109,97,80 
Methoxybenzoic acid-GlcA 328.27 327 151 283,175,113,107 
Methoxybenzoic acid-sulfate 232.21 231 151 187,107,97,80 
Hydroxymethoxybenzoic acid-GlcA 344.27 343 167 299,175,123,113 
Hydroxymethoxybenzoic acid-sulfate 248.21 247 167 203,123,97,80 
Hydroxybenzaldehyde-GlcA 298.25 297 121 253,175,113 
Hydroxybenzaldehyde-sulfate 202.18 201 121 157,97,80 
Dihydroxybenzaldehyde-GlcA 314.24 313 137 269,175,113,93 
Dihydroxybenzaldehyde-sulfate 218.18 217 137 173,137,97,93,80 
Hydroxymethoxybenzaldehyde-GlcA 328.27 327 151 283,175,113,107 
Hydroxymethoxybenzaldehyde-sulfate 232.21 231 151 187,107,97,80 
Hydroxyphenylacetic acid-GlcA 328.27 327 151 283,175,113,107 
Hydroxyphenylacetic acid-sulfate 232.21 231 151 203,123,97,80 
Dihydroxyphenylacetic acid-GlcA 344.37 343 167 299,175,123,113 
Dihydroxyphenylacetic acid-sulfate 248.21 247 167 203,123,97,80 
Hydroxymethoxyphenylacetic acid-GlcA 358.30 357 181 313,175,137,113 
Hydroxymethoxyphenylacetic acid-sulfate 262.24 261 181 217,137,97,80 
Hydroxycinnamic acid-GlcA 340.28 339 163 295,175,119,113 
Hydroxycinnamic acid-sulfate 244.22 233 163 189,119,97,80 
Dihydroxycinnamic acid-GlcA 356.28 355 179 311,175,135,113 
Dihydroxycinnamic acid-sulfate 260.22 259 179 215,135,97,80 
Hydroxymethoxycinnamic acid-GlcA 370.31 369 193 325,175,149,113 
Hydroxymethoxycinnamic acid-sulfate 274.25 273 193 229,149,97,80 
Dimethoxyhydroxycinnamic acid-GlcA 400.33 399 223 355,179,175,113 
Dimethoxyhydroxycinnamic acid-sulfate 304.27 303 223 259,179,97,80 
GlcA, glucuronide 
 
Ionisation of intact sulfated conjugates results in the formation of a molecular ion, [M-
H+80]
-
. Collision-induced fragmentation of the molecular ions of sulfate esters results in a 
loss of 80 Da, producing an abundant [M-H-SO3]
-
 fragment. Alternatively, a loss of 98 Da 
may occur from [M-H-H2SO4]
-
 which is represented by a m/z 97 Da (Levsen et al., 2005). If 
the charge resides with the sulfate group, radical ions at m/z -80 from SO3
-•
 and at m/z -97 
from HSO4
-
 may form. Sulfates other than esters only demonstrate the formation the [M-H-
SO3]
-
 and m/z -80 ions, which enables both types of conjugate to be distinguished (Boss et 
al., 1999; Lin et al., 2007). Therefore, in order to model the MRM fragmentation patterns of 
Rachel M. de Ferrars © 2013  
 
127/215 
 
possible sulfate metabolites used to trigger the dependant MS
3 
scan, the [M-H+80]
-
 parent 
ion and the [M-H-80]
-
 and m/z 80 daughter ions were used (Table 5.1).  
5.2.4. HPLC-MS/MS analysis 
HPLC-MS/MS analysis was performed on an Agilent 1200 series HPLC system coupled 
with a ABSciex 3200 Q-trap MS/MS system, with samples injected onto a Kinetex PFP 
column as previously published (de Ferrars et al., 2013) (Chapter 2). Briefly, the mobile 
phase consisted of 0.1% formic acid (v/v) in water (A) and 0.1% formic acid (v/v) in 
acetonitrile (B), at a flow rate of 1.5 mL/min at 0 min, 1 mL/min at 7 to 14 min and 1.5 
mL/min at 14 to 28 min. The gradient consisted of 1% B at 0 min, 7.5% B at 7 min, 7.6% B 
at 14 min, 10% B at 17 min, 12% B at 18.5 min, 12.5% B at 20 min, 30% B at 24 min and 
90% B at 25 to 28 min. MS/MS source parameters included curtain gas 40 psi, ion spray 
voltage -4000 V/+5500 V, temperature 700 °C and nebulizer and auxiliary gas 60 psi. The 
system was controlled by Analyst software (v. 1.5, Applied Biosystems/MDS Sciex). For 
IDA analysis, multiple reaction monitoring (MRM) or neutral loss (NL) survey scans  were 
used, with transitions above 2000 cps triggering  enhanced resolution (ER) and data 
dependent enhanced product ion (EPI) scans (total cycle time, 1.2 s). Quantification was 
carried using MRM, where the peak area of the most intense ion transition was determined 
from the chromatograph and used for quantification. Seven-point calibration curves were 
prepared by spiking the analytes of interest into a matched-matrix, with the coefficient of 
determination (r
2
) established as linear. Unless otherwise stated, all conjugated metabolites 
were quantified relative to their deconjugated, commercially available standard. For samples 
derived from the 
13
C intervention, the concentration of metabolites was converted to amount 
recovered from the urine by accounting for the molecular weight of the individual 
13
C-
labelled metabolites and the volume of the individual participants void and averaged across 
participants. 
 
5.3. Results 
Putative identification of the conjugates was achieved using HPLC-MS
3
 in consecutive 
reaction monitoring mode. MRM of the conjugated parent ion [M-H]
- 
and unconjugated 
daughter fragment (O-glucuronide conjugate [M-H-175]
-
 or O-sulfate conjugate [M-H-80]
- 
) 
was used to select the compounds of interest for further fragmentation via information 
dependent EPI scans. The resulting MS
3
 daughter ions were compared to the fragmentation 
patterns modelled previously based on the known fragmentation pattern of commercially 
available standards and commonly established metabolite fragmentation patterns (Table 5.1). 
A total of 17 novel phase II metabolites of anthocyanins (Table 5.2) were putatively detected 
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within urine samples derived from intervention trials feeding either 500 mg 
13
C-labelled 
cyanidin-3-glucoside or 500 mg elderberry derived anthocyanins. Unless stated otherwise, 
the fragments described below represent the unlabelled mass. 
 
Three peaks were identified as having a parent ion [M-H]
-
 at m/z 247 and a daughter ion at 
m/z 167, which represents the parent-daughter transitions common between sulfated 
conjugates of hydroxymethoxybenzoic acid, dihydroxyphenylacetic acid or methyl-
dihydroxybenzoate. Peak 1 (m/z 247/167; Rt, 4.12 min; Figure 5.2) and peak 2 (m/z 247/167; 
Rt, 12.27 min; Figure 5.3) were identified within urine derived from both the elderberry
 
and 
13
C-labelled anthocyanin trials. Peak 3 (m/z 247/167; Rt, 13.08 min; Figure 5.4) was 
identified within urine from the 
13
C-labelled intervention trial only, with a mass of +2 Da, 
indicating the metabolite was derived from the anthocyanin B-ring (Table 5.2). Further 
fragmentation of peak 1 using MS
3
 produced ions at m/z 123 (elderberry trial) and m/z 125 
(
13
C-labelled intervention trial) representing the loss of the sulfate and carboxylic groups [M-
H-80-44]
-
. In addition, ions were produced at m/z 203 representing the loss of a carboxylic 
group [M-H-44]
-
. Peak 2 yielded fragments at m/z 137 (elderberry trial) and m/z 139 (
13
C-
labelled intervention trial) representing the loss of sulfate and methoxy groups [M-H-80-30]
-
. 
Additionally, peak 2 produced a large daughter fragment at m/z 152 which may correspond 
to the fragment observed following the loss of a methyl CH3 group producing a [M-H-15]
-
 
anion radical, thus suggesting that peak 2 likely corresponds to a methoxyhydroxybenzoic 
acid or methyl-dihydroxybenzoates, whilst peaks 1 and 3 likely correspond to a sulfate of 
dihydroxyphenylacetic acid. However, due to the lack of commercially available or synthetic 
standards, the exact identity of these structures cannot be established with certainty. 
 
Peaks 1, 2 and 3 were quantified relative to homoprotocatechuic acid (3,4-
dihydroxyphenylacetic acid), an unconjugated, commercially available standard. Following 
13
C-cyanidin-3-glucoside consumption,  maximum concentrations ranging from 394 ± 268 
nM (peak 3) to 1307 ± 826 nM (peak 2) were identified in urine samples 6-24 h post 
anthocyanin consumption (Table 5.3 & Figure 5.5). In addition, maximum concentrations of 
211 ± 167 nM/mM creatinine (peak 2) to 705 ± 694 nM/mM creatinine (peak 1) were 
observed at 3 h following elderberry anthocyanin consumption (Table 5.4). 
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Table 5.2 HPLC-MS
3
 identification of O-glucuronide and sulfate metabolites in urine of human volunteers from intervention study feeding 500 mg elderberry 
anthocyanins or 500 mg 
13
C5-cyanidin-3-glucoside. 
Peak 
# 
Compound 
Elderberry intervention 
13
C5-cyanidin-3-glucoside intervention 
Rt 
(min) 
[M-H]
- 
(m/z)
a
 
MS
3
 
(m/z)
b
 
Rt 
(min) 
[M-H]
- 
(m/z)
a
 
MS
3
 
(m/z)
b
 
1 Dihydroxyphenylacetic acid-sulfate 4.07 247 203,167
c
,123 4.12 249
c
 203,169
c
,154,125 
2 Methyl-dihydroxybenzoate-sulfate 12.28 247
c
 201,167
c
,137 12.27 249
c
 203,169
c
,154,139,80 
3 Dihydroxyphenylacetic acid-sulfate ND ND ND 13.08 249
c
 203,169
c
,137 
4 Dihydroxybenzoic acid-GlcA 7.75 329
c
 175,153,113,109,85 ND ND ND 
5 Dihydroxybenzoic acid-GlcA 9.53 329
c
 175,153,113 ND ND ND 
6 Dihydroxyphenylacetic acid-GlcA 16.00 343
c
 175,167
c
,123,113 ND ND ND 
7 Dihydroxycinnamic acid-sulfate 11.30 259
c 
215,179
c
,147,135 ND ND ND 
8 Dihydroxycinnamic acid-sulfate 13.50 259
c
 215,179
c
,135,97 ND ND ND 
9 Dihydroxycinnamic acid-sulfate 14.10 259
c 215,179c,135 ND ND ND 
10 Dihydroxycinnamic acid-GlcA 9.59 355
c
 311,193,179
c
,175,135,113,85 9.14 357
c
 313,181
c
,175,137,113,109,95,85 
11 Hydroxymethoxycinnamic acid-GlcA 9.90 369
c
 193
c
,178,175,149,137,134,113,85 9.34 371
c
 195
c
,175,113,95,85 
12 Hydroxymethoxycinnamic acid-GlcA 12.37 369
c
 193
c
,178,175,149,137,134,113,85 ND ND ND 
13 Hydroxymethoxycinnamic acid-sulfate 17.95 273
c
 229,193
c
,178,149,134,97 ND ND ND 
14 Dimethoxyhydroxycinnamic acid-sulfate 15.91 303
c
 259,223
c
,208,193,179,164,149,135,97 ND ND ND 
15 Dimethoxyhydroxycinnamic acid-GlcA ND ND ND 7.81 401
c
 357,225
c
,210,195,180,175,113 
16 Dimethoxyhydroxycinnamic acid-GlcA 10.62 399
c
 223
c
,179,175,151,113,85 ND ND ND 
17 Dimethoxyhydroxycinnamic acid-GlcA 11.95 399
c
 223
c
,208,179,175,164,113 12.65 401
c
 225
c
,175,85  
GlcA, glucuronide; ND, not detected; Rt, retention time. 
a
Parent ion. 
b
Daughter fragments, identified via multiple reaction monitoring triggered enhanced 
product ion (MRM-IDA-EPI) scan. 
c
Indicates fragment transitions used for quantification.  
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Figure 5.2 Enhanced product ion (MS3) scan of peak 1, putatively identified as dihydroxyphenylacetic acid-sulfate (Rt, 4.12 min). 
 
Data derived from pooled post bolus urine samples, where participants were fed (A) 500 mg elderberry anthocyanins or (B) 500 mg 
13
C5-cyanidin-
3-glucoside.  
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Figure 5.3  Enhanced product ion (MS
3
) scan of peak 2 putatively identified as dihydroxybenzoic acid-sulfate (Rt, 12.27 min). 
 
Data derived from pooled post bolus urine samples, where participants were fed (A) 500 mg elderberry anthocyanins or (B) 500 mg 
13
C5-cyanidin-
3-glucoside. 
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Figure 5.4 Enhanced product ion (MS
3
) scan of peak 3 putatively 
identified as dihydroxyphenylacetic acid-sulfate (Rt, 13.08 min). 
 
Data derived from pooled post bolus urine samples, where participants 
were fed 500 mg 
13
C5-cyanidin-3-glucoside. 
 
Table 5.3 Concentration of putative metabolites in urine samples following acute intake of 500 
mg bolus 
13
C5-cyanidin-3-glucoside
a
. 
Peak 
# 
Metabolite 
Rt 
(min) 
Cmax 
(nM) 
Tmax 
Total recovery 
(µg) 
1 Dihydroxyphenylacetic acid-sulfate 4.12 1,148 ± 1,193 6-24 h 351 ± 363 
2 Methyl-dihydroxybenzoate-sulfate 12.27 1,307 ± 826 6-24 h 691 ± 507 
3 Dihydroxyphenylacetic acid-sulfate 13.08 394 ± 268 6-24 h 128 ± 121 
4 Dihydroxybenzoic acid-GlcA ND ND ND ND 
5 Dihydroxybenzoic acid-GlcA ND ND ND ND 
6 Dihydroxyphenylacetic acid-GlcA ND ND ND ND 
7 Dihydroxycinnamic acid-sulfate ND ND ND ND 
8 Dihydroxycinnamic acid-sulfate ND ND ND ND 
9 Dihydroxycinnamic acid-sulfate ND ND ND ND 
10 Dihydroxycinnamic acid-GlcA
b
 9.14 738 ± 774 24-48 h 398 ± 394 
11 Hydroxymethoxycinnamic acid-GlcA 9.34 364 ± 160 6-24 h 332 ± 189 
12 Hydroxymethoxycinnamic acid-GlcA ND ND ND ND 
13 Hydroxymethoxycinnamic acid-sulfate ND ND ND ND 
14 Dimethoxyhydroxycinnamic acid-sulfate ND ND ND ND 
15 Dimethoxyhydroxycinnamic acid-GlcA 7.81 430 ± 610 5-6 h 151 ± 172 
16 Dimethoxyhydroxycinnamic acid-GlcA ND ND ND ND 
17 Dimethoxyhydroxycinnamic acid-GlcA 12.65 304 ± 429 24 h 187 ± 271 
GlcA, glucuronide. 
a
Values are expressed as mean ± SD, metabolites were detected in n=8 
participants unless otherwise stated; 
b
detected in n=3. For Tmax, samples were pooled across 
participants for 1 h time periods, for t=0-1 h (n=3), t=1-2 h (n=5), t=2-3 h (n=6), t=3-4 h (n=6), 
t=4-5 h (n=4), t=5-6 h (n=8), t=6-24 h (n=8) and t=24-48 h (n=8). Unless stated otherwise, 
metabolites were quantified relative to the commercially available unconjugated analytical 
standard using their respective quantification transitions.  
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Figure 5.5 Urinary elimination profiles of putative conjugated metabolites of cyanidin-3-
glucoside in eight healthy male participants after the consumption of 500 mg 
13
C5-cyanidin-3-
glucoside.  
 
Broken line indicates mean. Peak numbers refer to metabolites listed in Table 5.2. 
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Table 5.4 Ratio of putative metabolites in urine samples following acute (500 mg) and chronic (500 mg/day for 12 week) intake of anthocyanins from an 
elderberry extract, expressed per mM creatinine. 
Peak 
# 
Compound 
Rt 
(min) 
Ratio nM/mM creatinine (% of total metabolites)
c
 
Baseline t(0-1 h) t(1-2 h) t(2-3 h) Total 
1 
Dihydroxyphenylacetic acid-sulfate
a 
Dihydroxyphenylacetic acid-sulfate
b 4.07 
274 ± 254 
314 ± 272 
334 ± 470 
649 ± 776 
517 ± 784 
552 ± 443 
705 ± 694 
661 ± 553 
1,831 ± 1,937   
2,176 ± 1,620 
2 
Methyl-dihydroxybenzoate-sulfate
a
 
Methyl-dihydroxybenzoate-sulfate
b
 
12.28 
106 ± 140 
101 ± 123 
76 ± 86 
59 ± 68 
162 ± 139 
147 ± 126 
211 ± 167 
174 ± 165 
555 ± 462 
482 ± 350 
3 Dihydroxyphenylacetic acid-sulfate ND ND ND ND ND ND 
4 
Dihydroxybenzoic acid-GlcA
a
 
Dihydroxybenzoic acid-GlcA
b
 
7.75 
78 ± 73 
147 ± 111 
201 ± 338 
318 ± 308 
986 ± 981 
1,043 ± 657 
1,370 ± 868 
1,527 ± 1,126 
2,635 ± 1,515 
3,035 ± 1,678 
5 
Dihydroxybenzoic acid-GlcA
a 
Dihydroxybenzoic acid-GlcA
b
 
9.53 
30 ± 60 
103 ± 59 
103 ± 216 
208 ± 220 
661 ± 679 
642 ± 396 
1,051 ± 802    
1,011 ± 611 
1,845 ± 1,129 
1,964 ± 916 
6 
Dihydroxyphenylacetic acid-GlcA
a 
Dihydroxyphenylacetic acid-GlcA
b
 
16.00 
171 ± 204 
786 ± 1,507 
268 ± 440 
477 ± 349 
1,664 ± 2,150  
1,877 ± 1,351 
2,809 ± 1,913 
3,775 ± 2,549 
4,913 ± 3,999 
6,915 ± 3,269 
7 
Dihydroxycinnamic acid-sulfate
a 
Dihydroxycinnamic acid-sulfate
b
 
11.30 
106 ± 87 
100 ± 73 
78 ± 60 
112 ± 100 
95 ± 79 
93 ± 53 
171 ± 151 
124 ± 106 
449 ± 333 
429 ± 216 
8 
Dihydroxycinnamic acid-sulfate
a
 
Dihydroxycinnamic acid-sulfate
b
 
13.50 
186 ± 273 
46 ± 47 
99 ± 131 
80 ± 90 
138 ± 96 
167 ± 164 
311 ± 297 
278 ± 260 
735 ± 721 
572 ± 432 
9 
Dihydroxycinnamic acid-sulfate
a
 
Dihydroxycinnamic acid-sulfate
b
 
14.10 
63 ± 75 
25 ± 24 
42 ± 42 
40 ± 37 
92 ± 78 
87 ± 49 
170 ± 129 
154 ± 118 
367 ± 243 
306 ± 157 
10 
Dihydroxycinnamic acid-GlcA
a
 
Dihydroxycinnamic acid-GlcA
b
 
9.59 
52 ± 76 
37 ± 63 
34 ± 37 
34 ± 34 
51 ± 91 
32 ± 26 
38 ± 27 
39 ± 27 
175 ± 183 
141 ± 138 
11 
Hydroxymethoxycinnamic acid-GlcA
a
 
Hydroxymethoxycinnamic acid-GlcA
b
 
9.90 
316 ± 334 
267 ± 335 
653 ± 853 
482 ± 540 
2,018 ± 1,773 
1,423 ± 1,089 
2,339 ± 1,472 
1,827 ± 1,470 
5,326 ± 3,959 
3,999 ± 2,649 
12 
Hydroxymethoxycinnamic acid-GlcA
a
 
Hydroxymethoxycinnamic acid-GlcA
b
 
12.37 
1,078 ± 1,965 
379 ± 353 
882 ± 1,353 
534 ± 461 
1,424 ± 1,485 
855 ± 437 
1,730 ± 1,170 
1,333 ± 934 
5,115 ± 5,594 
3,100 ± 1,694 
13 
Hydroxymethoxycinnamic acid-sulfate
a
 
Hydroxymethoxycinnamic acid-sulfate
b
 
17.95 
9,560 ± 11,132    
3,070 ± 2,974 
10,006 ± 11,184 
5,181 ± 5,497 
18,954 ± 18,097 
15,328 ± 13,486 
20,877 ± 15,015   
16,242 ± 11501 
59,397 ± 45,900   
39,821 ± 19,425 
14 
Dimethoxyhydroxycinnamic acid-sulfate
a
 
Dimethoxyhydroxycinnamic acid-sulfate
b
 
15.91 
668 ± 1,104 
556 ± 1,804 
510 ± 678 
362 ± 550 
1,023 ± 1,035 
864 ± 769 
1,086 ± 772   
1,036 ± 1,119 
3,288 ± 2,802   
2,819 ± 2,252 
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15 Dimethoxyhydroxycinnamic acid-GlcA ND ND ND ND ND ND 
16 
Dimethoxyhydroxycinnamic acid-GlcA
a
 
Dimethoxyhydroxycinnamic acid-GlcA
b
 
10.62 
70 ± 188 
1,052 ± 2,857 
114 ± 277 
864 ± 2,425 
297 ± 977 
402 ± 1,088 
61 ± 58 
363 ± 740 
543 ± 1,042 
2,681 ± 7,067 
17 
Dimethoxyhydroxycinnamic acid-GlcA 
Dimethoxyhydroxycinnamic acid-GlcA
b
 
11.95 
52 ± 78 
97 ± 221 
248 ± 451 
331 ± 655 
899 ± 1,052 
808 ± 825 
1,036 ± 892 
917 ± 812 
2,235 ± 2,112 
2,153 ± 1,798 
ND, not detected; GlcA, glucuronide; t, time. Metabolite concentration following 
a
acute (500 mg) anthocyanin consumption (week 0) and 
b
chronic (500 
mg/day for 12 weeks) anthocyanin consumption (week 12); 
c
Values represent mean concentrations ± SD, n=15; all samples have been adjusted for 
creatinine concentration; Unless stated otherwise, metabolites were quantified relative to the commercially available unconjugated analytical standard using 
their respective quantification transitions.  
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In addition to the identification of protocatechuic acid-3-glucuronide and protocatechuic 
acid-4-glucuronide, which were previously described (de Ferrars et al., 2013) (Chapters 3 & 
4), a further two peaks were identified as having a parent ion at m/z 329 and a daughter ion at 
m/z 153 and were tentatively identified as dihydroxybenzoic acid-glucuronide (Figure 5.6). 
Peak 4 (m/z 329/153; Rt, 7.75 min) and peak 5 (m/z 329/153; Rt, 9.53 min) were identified 
within urine derived from the elderberry anthocyanin trial. Fragmentation of the compounds 
using MS
3
 produced ions at m/z 175 (glucuronide ion), 113 (the loss of CO2 and H2O from 
the glucuronide ion), 109 representing the loss of the glucuronide and carboxylic groups [M-
H-176-44]
-
 and 85 (the loss of CO2, H2O and CO from the glucuronide ion) (Table 5.2). 
Peaks 4 and 5 were quantified relative to protocatechuic acid and were identified at 
maximum concentrations of 1427 ± 1126 nM/mM creatinine and 1.1 ± 0.8 µM/mM 
creatinine respectively, 3 h following the consumption of 500 mg elderberry anthocyanins 
(Table 5.4). 
 
Peak 6 (m/z 343/167; Rt, 16.00 min; Figure 5.7) was identified within urine samples from 
the elderberry intervention trial, based on a [M-H]
-
 at m/z 343, which produced a MS
2
 ion at 
m/z 167, representing the loss of the glucuronide group [M-H-176]
-
. These transitions 
correspond to the parent-daughter transitions common between glucuronide conjugates of 
hydroxy-methoxybenzoic acid, dihydroxyphenylacetic acid and methyl-dihydroxybenzoate. 
MS
3
 fragmentation of the molecule produced ions at m/z 175 representing a glucuronide 
anion, 123 [M-H-176-44]
-
 and 113 representing the loss of CO2 and H2O from the 
glucuronide anion (Table 5.2). Due to the lack of ion at m/z 152 [M-H-15]
-
, indicating the 
absence of a methyl CH3 group, peak 6 was putatively identified as a glucuronide of 
dihydroxyphenylacetic acid and quantified relative to homoprotocatechuic acid. It was 
identified at maximum concentrations of 3.8 ± 2.5 µM/mM creatinine, 3 h following 500 mg 
elderberry consumption (Table 5.4). 
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Figure 5.6 Enhanced product ion (MS
3
) scan of peak 4 (Rt, 7.75 min) and peak 5 (Rt, 9.53 min) putatively identified as dihydroxybenzoic 
acid-glucuronides.  
 Data derived from pooled post bolus urine samples, where participants were fed 500 mg elderberry anthocyanins. 
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Figure 5.7  Enhanced product ion (MS
3
) scan of peak 6 putatively 
identified as dihydroxyphenylacetic acid-glucuronide (Rt, 16.00 min). 
 
Data derived from pooled post bolus urine samples, where 
participants were fed 500 mg elderberry anthocyanins. 
 
Peak 7 (m/z 259/179; Rt, 11.30 min), Peak 8 (m/z 259/179; Rt, 13.50 min) and Peak 9 (m/z 
259/179; Rt, 14.10 min) were putatively identified as a dihydroxycinnamic acid-sulfates, 
most likely derived from caffeic acid (Figure 5.8). The peaks were identified based on a [M-
H]
-
 at m/z 259, which produced an MS
2
 ion at m/z 179, representing the loss of the sulfate 
group [M-H-80]
-
. The MS
3
 fragmentation patterns produced ions at m/z 215 representing the 
loss of a carboxylic group [M-H-44]
-
, 135 representing the loss of a sulfate and carboxylic 
group [M-H-80-44]
-
 and 95 indicting the presence of a sulfate anion) (Table 5.2). The 
dihydroxycinnamic acid-sulfates were quantified relative to caffeic acid and found at 
maximum concentrations ranging from 170 ± 129 nM/mM creatinine to 311 ± 297 nM/mM 
creatinine, 3 h post elderberry anthocyanin consumption (Table 5.4). 
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Figure 5.8 Enhanced product ion (MS
3
) scan of (A) peak 7 (Rt, 11.30 min), (B) peak 8  (Rt, 13.50 min) and (C) peak 9 
(Rt, 14.10 min) putatively identified as dihydroxycinnamic acid-sulfate. 
 
Data derived from pooled post bolus urine samples, where participants were fed 500 mg elderberry anthocyanins. 
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Peak 10 (m/z 355/179; Rt, 9.14 min; Figure 5.9) was detected within urine samples from the 
13
C-labelled and elderberry anthocyanin intervention trials and was putatively identified as 
dihydroxycinnamic acid-glucuronide. As it was derived from the B-ring of cyanidin-3-
glucoside (+2 Da), it was most likely a glucuronide conjugate of caffeic acid. The conjugate 
was identified based on a [M-H]
-
 at m/z 355, which produced an MS
2
 ion at m/z 179, 
representing the loss of the glucuronide group [M-H-176]
-
. The MS
3
 fragmentation patterns 
produced ions at m/z 311 representing the loss of a carboxylic group [M-H-44]
-
, 175 
(glucuronide ion), 135, representing the loss of a glucuronide ion and carboxylic group [M-
H-176-44]
-
, 113 (glucuronide ion) and 85 (glucuronide ion) (Table 5.3). Peak 10 was 
quantified relative to caffeic acid and found at maximum concentrations of 51 ± 91 nM/mM 
creatinine, 2 h following the consumption of 500 mg elderberry anthocyanins (Table 5.4) and 
783 ± 774 nM, 48 h post consumption of 500 mg 
13
C-labelled cyanidin-3-glucoside (Figure 
5.5). 
 
Peak 11 (m/z 369/193; Rt, 9.34 min; Figure 5.10), detected within urine samples from the 
13
C-labelled and elderberry anthocyanin intervention trials and peak 12 (m/z 369/193; Rt, 
12.37 min; Figure 5.10), detected within the elderberry urine samples only were putatively 
identified as hydroxymethoxycinnamic acid-glucuronides (Table 5.2), mostly likely derived 
from ferulic acid. The conjugates were detected based on a [M-H]
-
 at m/z 369, which 
produced an MS
2
 ion at m/z 193, representing the loss of the glucuronide group [M-H-176]
-
. 
The MS
3
 fragmentation pattern produced ions at m/z 178 [M-H-176-15]
-
, 175 (glucuronide 
ion), 149 representing the loss of a glucuronide ion and carboxylic group [M-H-176-44]
-
, 137 
representing the loss of the glucuronide ion and cinnamic acid [M-H-176-44-12]
-
, 134 
representing the loss of a glucuronide ion, carboxylic group and methyl CH3 group [M-H-
176-44-15]
-
, 113 (glucuronide ion) and 85 (glucuronide ion). The hydroxymethoxycinnamic 
acid-glucuronides were quantified relative to ferulic acid; peak 11 was identified at 
maximum concentrations of 2.3 ± 1.5 µM/mM creatinine, 3 h following the consumption of 
500 mg elderberry anthocyanins (Table 5.4) and 364 ± 160 nM, 24 h post consumption of 
500 mg 
13
C-labelled cyanidin-3-glucoside (Figure 5.5). Peak 12 was identified at maximum 
concentrations of 1.7 ± 1.2 µM/mM creatinine, 3 h following the consumption of 500 mg 
elderberry anthocyanins (Table 5.4). 
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Figure 5.9 Enhanced product ion (MS
3
) scan of peak 10 putatively identified as dihydroxycinnamic acid-glucuronide (Rt, 9.14 min)  
Data derived from pooled post bolus urine samples, where participants were fed (A) 500 mg elderberry anthocyanins and (B) 500 mg 
13
C5-cyanidin-3-glucoside. 
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Figure 5.10 Enhanced product ion (MS
3
) scan of (A & B) peak 11 (Rt, 9.90 min) and (C) peak 12 (Rt, 12.37 min) 
putatively identified as hydroxymethoxycinnamic acid-glucuronides. 
 
Data derived from pooled post bolus urine samples, where participants were fed (A & C) 500 mg elderberry 
anthocyanins or (B) 500 mg 
13
C5-cyanidin-3-glucoside. 
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Peak 13 (m/z 273/193; Rt, 17.95 min; Figure 5.11) was putatively identified within urine 
samples post elderberry anthocyanin consumption, as a hydroxymethoxycinnamic acid-
sulfate, most likely derived from ferulic acid.  It was identified based on a [M-H]
-
 at m/z 273 
which produced an MS
2
 ion at m/z 193, representing the loss of the sulfate group [M-H-80]
-
. 
The MS
3
 fragmentation patterns produced ions at m/z  229 represent the loss of a carboxylic 
group [M-H-44]
-
, 178 representing the loss of a sulfate and methyl CH3 group [M-H-80-15]
-
, 
149 representing the loss of a sulfate and carboxylic group [M-H-80-44]
-
, and 134 
representing the loss of a sulfate, carboxylic and methyl CH3 group [M-H-80-44-15]
-
. Peak 
13 reached maximum levels of 20.9 ± 15.0 µM/mM creatinine 3 h post bolus when 
quantified relative to ferulic acid, representing a 11.3 µM/mM creatinine increase from 
baseline concentrations (Table 5.4).   
 
Figure 5.11  Enhanced product ion (MS
3
) scan of peak 13 putatively 
identified as hydroxymethoxycinnamic acid-sulfate (Rt, 17.95 min). 
 
 
Data derived from pooled post bolus urine samples, where participants were fed 
500 mg elderberry anthocyanins.  
 
Peak 14 (m/z 303/223; Rt, 15.91 min; Figure 5.12) was putatively identified as a 
dimethoxyhydroxycinnamic acid-sulfate (Table 5.2). It was identified within elderberry 
derived urine samples based on a [M-H]
-
 at m/z 303, which produced an MS
2
 ion at m/z 223, 
representing the loss of the sulfate group [M-H-80]
-
. The MS
3
 fragmentation patterns 
produced ions at m/z  259 representing the loss of a carboxylic group [M-H-44]
-
, 208 
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representing the loss of a carboxylic and methyl group [M-H-44-15]
-
, 193 representing the 
loss of a sulfate and methoxy group [M-H-80-30]
-
, 179 [M-H-80-30-16]
-
, 164 representing 
the loss of a sulfate, carboxylic and methyl group [M-H-80-44-15]
-
, 149 representing the loss 
of a sulfate, carboxylic and methoxy group [M-H-80-44-30]
-
 and 135 representing the loss of 
a sulfate, carboxylic, methoxy and methyl group [M-H-80-44-30-15]
-
. Peak 14 reached 
maximum concentrations of 1.1 ± 0.8 µM/mM creatinine 3 h post bolus when quantified 
relative to sinapic acid, representing an increase of 418 nM/mM creatinine from baseline 
concentrations (Table 5.4).   
 
Figure 5.12 Enhanced product ion (MS
3
) scan of peak 14 putatively identified as 
dimethoxyhydroxycinnamic acid-sulfate (Rt, 15.91 min). 
 
 
Data derived from pooled post bolus urine samples, where participants were fed 
500 mg elderberry anthocyanins. 
 
Peak 15 (m/z 399/223; Rt, 7.81 min) detected within urine samples following 
13
C-cyanidin-3-
glucoside consumption, peak 16 (m/z 399/223; Rt, 10.62 min) detected within elderberry 
derived samples and peak 17 (m/z 399/223; Rt, 12.65 min) detected in urine samples from 
both clinical trials (Table 5.2), were putatively identified as dimethoxyhydroxycinnamic 
acid-glucuronides (Figure 5.13). The conjugates were detected based on a [M-H]
-
 at m/z 399, 
which produced an MS
2
 ion at m/z 223, representing the loss of the glucuronide group [M-H-
176]
-. 
The MS
3
 fragmentation patterns produced multiple ions, including at m/z 355 
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representing the loss of a carboxylic group [M-H-44]
-
, 208 representing the loss of a 
glucuronide ion and methyl group [M-H-176-15]
-
, 175 (glucuronide ion), 164 representing 
the loss of a glucuronide ion, carboxylic and methyl group [M-H-176-44-15]
-
, 113 
(glucuronide ion) and 85 (glucuronide ion). This fragmentation pattern, +2 Da, was matched 
within the 
13
C-samples, indicating the metabolite was derived from the anthocyanin B-ring. 
The conjugates were quantified relative to sinapic acid; peak 15 was identified in the highest 
concentrations within the urine samples from the 
13
C-cyanidin-3-glucoside intervention, 
reaching maximum concentrations of 430 ± 610 nM, 5-6 h post bolus, whilst peak 17 was 
identified at highest concentrations within the elderberry intervention urine samples, 
reaching 1.0 ± 0.9 µM/mM creatinine, 3 h post bolus. 
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Figure 5.13 Enhanced product ion (MS
3
) scan of (A) peak 16 (Rt, 7.81 min), (B) peak 15 (Rt, 10.62 min) and (C 
& D) peak 17 (Rt, 12.65 min) putatively identified as dimethoxyhydroxycinnamic acid-glucuronides. 
 
Data derived from pooled post bolus urine samples, where participants were fed (A & C) 500 mg elderberry 
anthocyanins or (B & D) 500 mg 
13
C5-cyanidin-3-glucoside. 
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5.4.  Discussion 
Our recently conducted 
13
C5-cyanidin-3-glucoside intervention identified 35 metabolites of 
cyanidin-3-glucoside, accounting for 37 ± 14% of the total 
13
C recovered in the urine (Czank 
et al., 2013). The present chapter aimed to further determine the metabolite fate of the 
remainder of the anthocyanin bolus, as the unidentified metabolites likely play a role in the 
perceived bioactivity of anthocyanins against cardiovascular disease. Until the major 
metabolites present following the consumption of anthocyanin-rich foods are realised, the 
mechanisms associated with their health effects will remain undefined. 
 
In the present study, a total of 17 previously unidentified phase II (nine glucuronidated and 
eight sulfated) metabolites of anthocyanins (Table 5.2) were putatively identified within 
urine samples derived from intervention trials feeding either 500 mg 
13
C-labelled cyanidin-3-
glucoside or 500 mg elderberry derived anthocyanins. O-Glucuronide conjugates are 
reportedly best observed under ESI conditions (Keski-Hynnilä et al., 2002), and in negative 
ionisation mode produce ions that are 176 Da higher than those of non-conjugated 
metabolite. Therefore, the search for the presence of unknown O-glucuronide anthocyanin 
metabolites was initially conducted using non targeted scans including a neutral loss scan 
(Qu et al., 2001) for the m/z loss of 176, scanned over ranges covering  200 to 400 Da and 
400 to 1200 Da. Enhanced MS scans (EMS) over ranges of 100 Da from 100 to 1200 Da 
were also conducted. However, the scans were too general, and signal noise was too high to 
provide good MS spectral scans for the identification of the majority of the low 
concentrations of anthocyanin derived metabolites. Thus a more specific method was 
employed, where targeted MRM methods were developed for the detection of modelled 
conjugates (Table 5.2) and used to trigger an EPI scan using the IDA function, with 
enhanced resolution (ER) scans built into the method to improve peak sensitivity. In contrast 
to the non-targeted survey scans such as a neutral loss scan, a major limitation of MRM-IDA 
methods is their inability to detect unexpected metabolites, which are not included in the 
MRM transitions of predicted metabolites. Thus, the effectiveness of metabolite screening by 
MRM is dependent on a suitable selection of theoretical metabolite ions and their product 
ions (Huang et al., 2010). The present study incorporated both methods in the analysis of 
urine samples, and putatively identified nine glucuronide conjugates.  
 
Following fragmentation, glucuronide conjugates reportedly produce an abundant fragment 
[M-H-176]
-
, corresponding to the neutral loss of glucuronic acid from the deprotonated 
molecule, a less abundant ion at m/z 175, and secondary fragment ions at m/z 113 (resulting 
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from the loss of CO2 and water from the glucuronide ion) and m/z 85 (from the extrusion of 
CO from m/z 113) (Figure 5.14) (Farrell et al., 2011; Keski-Hynnilä et al., 2002; Levsen et 
al., 2005; Qu et al., 2001; Stalmach et al., 2009a; Woodward et al., 2011). The loss of 176 
Da and the formation of m/z 175 and 113 fragments was observed for all nine glucuronides 
putatively identified in the present study and the formation of the less abundant m/z 85 
fragment was observed for six of the glucuronide conjugates (Table 5.2). 
 
Figure 5.14 Example fragmentation of a glucuronyl moiety conjugated to protocatechuic 
acid in negative-ion MS/MS mode.  
 
Adapted from (Levsen et al., 2005). 
 
Conjugations with sulfuric acid consist of the transfer of a sulfate group from 3’-
phosphoadenosine-5'-phosphosulfate (PAPS) in the presence of SULTs forming a molecular 
ion [M-H+80]
-
 (Wu et al., 2011).  Collision-induced fragmentation of the molecular of 
sulfate ester results in a loss of 80 Da, producing an abundant [M-H-SO3]
-
 fragment (Keski-
Hynnilä et al., 2002). Alternatively, the loss of 98 Da from [M-H-H2SO4]
- 
has been reported 
to occur, which is represented by a m/z 97 Da (Levsen et al., 2005). If the charge resides 
with the sulfate group, radical ions at m/z -80 from SO3
-•
 and at m/z -97 from HSO4
-
 may 
form (Figure 5.15) (Boss et al., 1999; Lin et al., 2007). In the present study, all sulfated 
conjugates were identified by the presence of the [M-H+80]
-
 parent ion and the [M-H-80]
-
 
daughter ion. Peaks 8, 13 and 14 also showed the presence of m/z 97, whilst peak 2 formed 
m/z 80. 
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Figure 5.15 Possible fragmentation of sulfuric acid conjugated to 
protocatechuic acid in negative-ion MS/MS mode. 
 
 Adapted from (Boss et al., 1999; Lin et al., 2007). 
 
In negative ion mode phenolic compounds containing a carboxylic group, such as carboxylic 
acids and cinnamic acids are known to produce a deprotonated [M-H]
- 
molecule and a [M-H-
44]
-
 fragment ion via the loss of a CO2 group from the carboxylic acid moiety (Figure 5.16) 
(Sun et al., 2007). This is consistent with the MS
3
 fragmentation of the 11 cinnamic acid 
conjugates identified in the present study, where the conjugates were identified via the loss 
of the conjugated sulfate [M-H-80]
-
, glucuronide [M-H-176]
-
, and carboxylic [M-H-44]
-
 
group. Where present, hydroxyl (OH) groups were cleaved, producing characteristic [M-H-
17]
-
 fragment ions (Figure 5.16) (Liu et al., 2007; Sun et al., 1997). In addition, methoxy 
groups typically show the loss of the methyl CH3 group, providing a [M-H-15]
-
 anion radical 
(Figure 5.16), which was observed for seven of the conjugates identified. 
 
The position of the conjugation groups could not be ascertained in the present study. 
However, recent work into the regioselective sulfation and glucuronidation of phenolics 
indicates that for hydroxycinnamic acids which contain a catechol group, such as caffeic 
acid, the sulfate conjugation preferentially occurs at the 3-OH group, whilst glucuronidation 
occurs at both the 3-OH and 4-OH positions, depending on the UDPDG subgroup  (Wong et 
al., 2010; Wu et al., 2011).  
 
 
OH
O
O
OH
S
O
-
O
O
OH
O
O
-
OH
O
-S
O
O
O
-S
OH
O
O
-SO3
+
[M-H-SO3]
- m/z 80
-H2SO4
m/z 97
  
 
 
150/215 
 
 
Figure 5.16 Proposed MS fragmentation pathway for [M-H]
-
 ions of 1) vanillic acid; 2) 3,4-
dihydroxybenzaldehyde; 3) ferulic acid 
 
 
Due to the absence of commercially available standards, identified metabolites were 
quantified relative to their unconjugated standards, in order to get an approximation of the 
concentrations present. Seven previously unidentified metabolites were identified within 
urine samples derived from the study feeding 500 mg 
13
C5-cyanidin-3-glucoside. A high 
inter-individual variation in metabolite concentration was observed between participants 
(Figure 5.5), with dihydroxycinnamic acid-glucuronide (peak 10) only detected in urine 
derived from three participants. The post ingestion Cmax values ranged from 304 ± 429 nM 
(116 ± 140 µg) for dimethoxyhydroxycinnamic acid-glucuronide (peak 17) to 1307 ± 826 
nM (291 ± 245 µg) for methyl-dihydroxybenzoate-sulfate (peak 2; Table 5.3). These 
concentrations are similar to the maximum concentrations observed for the unconjugated 
phenolic metabolites identified previously (Chapter 3), which ranged from 24 ± 17 nM (6.3 
± 6.5 µg) for 3,4-dihydroxybenzaldehyde to 5.4 ± 13.9 µM (2416 ± 6288 µg) for hippuric 
acid (de Ferrars et al., 2014). However, the time at peak excretion was generally later than 
observed for the unconjugated metabolites, with values ranging from 5-6 h to 24-48 h post 
bolus in the present study, compared to the values of 0-1 h to 24-48 h observed previously 
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(Chapter 3). This is likely due to colonic metabolism playing a significant role in their 
formation.  
 
The recovery of the conjugated metabolites identified within urine from the 
13
C-labelled 
anthocyanin study ranged from 0.03 ± 0.02% for dihydroxyphenylacetic acid-sulfate (peak 
3) to 0.14 ± 0.10% for methyl-dihydroxybenzoate-sulfate (peak 2). Together, the seven 
conjugated metabolites identified accounted for 0.45 ± 0.14% of the given bolus. However, 
this is an estimation due to the lack of commercially available standards which would enable 
accurate quantification.  
 
Fifteen previously unidentified conjugated metabolites were detected within the urine 
samples derived from the intervention feeding 500 mg elderberry derived anthocyanins to 
postmenopausal females. Post ingestion Cmax values ranging from 38 ± 27 nM/mM creatinine 
for dihydroxycinnamic acid-glucuronide (peak 10) to 20.9 ± 15.0 µM/mM creatinine for 
hydroxymethoxycinnamic acid-sulfate (peak 13) were observed within the 2-3h postprandial 
samples following acute (week 0) anthocyanin consumption (Table 5.4). These 
concentrations are generally similar to the concentrations of un-conjugated metabolites 
identified previously following elderberry consumption, which ranged from 145 ± 86 to 
7382 ± 5927 nM/mM creatinine in urine. Likewise, there was also no significant impact of 
12wks continuous dosing on urinary metabolite excretion of the conjugated metabolites 
(Table 5.4). 
 
A number of the metabolites identified within urine samples from the elderberry intervention 
trial were absent from the urine samples of the participant who consumed the isotopically 
labelled anthocyanins. There are several possibilities for this; firstly, the metabolites 
identified may not originate from anthocyanins, but from other phenolic compounds within 
the elderberry extract or the breakfast given. This is plausible, as  phenolic compounds are 
ubiquitous within our diets (Dykes et al., 2007; Schmitzer et al., 2010). For example, green 
tea can provide over 100 mg phenolics /100mL (Kodama et al., 2010) and onions can 
contain 69 mg phenolics/100 g of onion (Yang et al., 2004).  Secondly, the absence of the 
metabolites may results from inter-individual variation between participants, particularly 
because the studies were conducted using two very different population groups 
(postmenopausal women versus men aged 27.8 ± 8.1 y). Thirdly, the elderberry bolus 
contained a range of anthocyanin glycosides in addition to cyanidin-3-glucoside (including 
cyanidin-3-sambubioside, cyanidin-3-sambubioside-5-glucoside and cyanidin-3,5-
diglucoside, Chapter 4), which were not present within the 
13
C-labelled bolus. The presence 
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of more complex sugars may result in the employment of differing metabolic pathways. For 
example, a study feeding blueberries to volunteers with an end ileostomy achieved higher 
recoveries for anthocyanins conjugated to arabinosides than to glucosides (Kahle et al., 
2006). Finally, the conjugated metabolites may be present but at concentrations below the 
detection limit within the 
13
C-labelled urine samples. Further work using synthesised 
standards would be required to confirm these metabolites. 
 
There are certain limitations with this work. Although the metabolites in the present study 
were identified based on the presence of at least three, and in some cases up to eight 
transitions, due to the absence of commercially available standards the identity of the 
metabolites and the position of the conjugation could not be established with certainty. In 
addition, the quantification of metabolites was conducted relative to the closest 
commercially available unconjugated analytical standard. In order to increase the accuracy of 
this data, conjugated standards would need to be synthesised. An alternative approach often 
used within metabolomic studies is to use enzyme hydrolysis to confirm the identity of the 
conjugated compounds. This was attempted in the present study, where following, urine 
samples were evaporated with 10 x 1 mL 50 mM sodium phosphate buffer to remove the 
methanol/acid. Samples were subsequently hydrolysed overnight with 80 μL sulfatase (from 
Aerobacter aerogenes, Type VI, 2-5units/mg protein, 10-20units/ml) or 29.9 μL 
glucuronidase (from Escherichia coli, 20,000,000-60,000,000 units/g protein) and were re-
extracted to remove the buffer from the sample matrix. However, analysis of the samples 
illustrated that the enzymes did not efficiently hydrolyse the conjugated forms of 
protocatechuic acid and vanillic acid. Future work should focus on the hydrolysis of non-
acidified samples prior to SPE.     
 
The present study analysed samples derived from two anthocyanin intervention studies. The 
elderberry intervention study fed 500 mg elderberry derived anthocyanins within 1 g 
elderberry extract. As discussed previously (Chapter 4), the use of an unlabelled 
anthocyanin bolus complicates the elucidation of the anthocyanin derived metabolites as 
phenolic compounds are ubiquitous within plants (Dykes et al., 2007; Schmitzer et al., 2010) 
and were present in the elderberry extract and breakfast (Chapter 4). Whilst only 
metabolites which increased from baseline values were described in the present chapter, it is 
not possible to categorically define the origin of phenolics which were identified within the 
elderberry intervention trial. A further limitation of the present study was that it focused on 
the analysis of urine samples. Whilst plasma provides a better representation for 
bioavailability, urine was selected for analysis because metabolites are generally more 
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concentrated within the urine, which enabled the collection of superior MS
3
 data. In addition, 
the urine analysis should ultimately reflect plasma clearance for the majority of the 
metabolites. Future work should focus on quantifying the levels on conjugated metabolites in 
plasma. 
 
5.5. Conclusion 
Overall, the presence of glucuronide and sulfate conjugates of previously identified 
metabolites indicates a much higher relative anthocyanin bioavailability than previously 
reported. The mechanisms of action and relative importance of these metabolites on risk 
factors associated with cardiovascular disease should be the focus of future anthocyanin 
research.   
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Chapter 6. The effects of select anthocyanin 
metabolites on sVCAM-1 and IL-6 expression 
in HUVECs  
 
6.1. Introduction 
A high consumption of anthocyanins has been associated with a reduced risk of 
cardiovascular disease (CVD) (Cassidy et al., 2011; Mink et al., 2007). Mechanistic studies 
exploring this bioactivity have suggested that this may in part be due to their anti-
inflammatory activity. Inflammation is a complex and necessary defence mechanism 
whereby leukocytes migrate into damaged tissues, to destroy agents which may potentially 
cause further damage (García-Lafuente et al., 2009), however chronic inflammation is 
detrimental to health and has been found to be involved in the development of many 
diseases, including atherosclerosis, diabetes and cancer (Dandona et al., 2004; Epstein et al., 
1999; Libby et al., 2002).  
 
Inflammation drives the formation and progression of atherosclerotic plaques through 
initiating the expression of cell adhesion molecules and cytokines, which leads to the 
recruitment and aggregation of leukocytes (Libby et al., 2002). Vascular cell adhesion 
molecule (VCAM-1) is transcriptionally induced in endothelial cells and plays a key role in 
leukocyte attachment and transmigration. Following pro-atherogenic stimulation and the 
recruitment of leukocytes by selectins (Blankenberg et al., 2003), VCAM-1 participates in 
the firm adhesion of leukocytes to the endothelium, resulting in their immobilisation and 
enabling transmigration of the leukocytes towards the site of tissue damage or infection. 
VCAM-1 also interacts with integrin α4β1, which induces signals within endothelial cells, 
including the activation of NADPH oxidase to catalyse the production of reactive oxygen 
species (ROS), thus triggering change in endothelial cell morphology, and allowing 
leukocyte emigration (Matheny et al., 2000). The adhesion of leukocytes triggers the 
secretion of inflammatory molecules, including cytokines such as interleukin-6 (IL-6), which 
futher perpetuates inflammation.  
  
IL-6 is a pleiotropic cytokine, which is produced at sites of inflammation in order to 
stimulate an immune response to fight infection. IL-6 stimulates the production of 
inflammatory proteins by a diverse range of cells, including T-cells and smooth muscle cells 
(Schuett et al., 2009). IL-6 activates specific intracellular signal transduction pathways, 
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through binding to its receptor (IL-6R), which leads to the recruitment and complexation of 
two gp130 molecules, and perpetuates downstream signalling pathways such as janus kinase 
(JAK) and signal transducer and activator of transcription (STAT), which ultimately lead to 
the transcription of inflammatory genes (Schuett et al., 2009).  
 
Tumor necrosis factor alpha (TNF-α) and CD40L are potent inducers of both VCAM-1 and 
IL-6. TNF-α is a member of a group of cytokines involved in regulating immune cells during 
systemic inflammation. It is predominately produced by activated macrophages and in target 
cells can stimulate the activation of the mitogen activated protein kinases (MAPK) and 
nuclear factor-κB (NF-κB) pathways (Baud et al., 2001). CD40 is a member of the TNF 
receptor family, and is constitutively expressed on many cell types, including endothelial 
cells (Miller et al., 1998) and interacts with CD40L, an activation induced transmembrane 
protein which is expressed on activated T-cells. The ligation between CD40L and CD40 
initiates intracellular signalling, which eventually leads to the transcription of pro-
inflammatory and pro-atherogenic genes, including IL-6 and VCAM-1 (Pamukcu et al., 
2011). 
 
Anthocyanins have been reported to modulate the expression of VCAM-1 and IL-6 in 
humans, mice and endothelial cells (Chao et al., 2013; Kim et al., 2006; Miyazaki et al., 
2008; Nizamutdinova et al., 2009; Speciale et al., 2010; Xia et al., 2009). Humans fed 320 
mg/day anthocyanins for 24 weeks (Zhu et al., 2013) and mice fed purple sweet potato for 
four weeks  (Miyazaki et al., 2008) had significantly lower plasma levels of soluble VCAM-
1 (sVCAM-1). Similarly in vitro, pre-treatment of TNF-α challenged endothelial cells with 
black soybean anthocyanins (Chao et al., 2013; Kim et al., 2006; Nizamutdinova et al., 
2009) and grape seed extract (Sen et al., 2001) has been shown to reduce VCAM-1 
expression. Furthermore, 1, 10 and 100 µM concentrations of cyanidin-3-glucoside and 
peonidin-3-glucoside resulted in a dose-dependent decrease in IL-6 secretion in endothelial 
cells following CD40L stimulation (Xia et al., 2009).  
 
Due to the low bioavailability of parent anthocyanins (Czank et al., 2013; de Ferrars et al., 
2013; Milbury et al., 2002), their protective effects may be due to anti-inflammatory 
activities of their degradation products and metabolites, rather than the direct effect of the 
parent anthocyanins. However, until recently, little was known concerning the bioavailability 
of anthocyanin metabolites, therefore their bioactivity remained relativity unexplored. The 
B-ring degradation product of cyanidin-3-glucoside, protocatechuic acid has previously been 
demonstrated to reduce VCAM-1 protein and mRNA production in TNF-α-induced mouse 
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aortic endothelial cells at concentrations of 20 µM and 40 µM (Wang et al., 2010). In 
addition, mice fed protocatechuic acid for 20 weeks had significantly reduced plasma levels 
of sVCAM-1 (Wang et al., 2010) and vanillic acid has been shown to reduce plasma IL-6 
levels in mice (Kim et al., 2010). Less is known concerning the inflammatory bioactivity of 
the phenylacetic metabolites in human endothelial cells, although they were present at high 
concentrations within urine following anthocyanin consumption (de Ferrars et al., 2013).   
 
The present chapter investigates the anti-inflammatory activity of six previously established 
anthocyanin metabolites (Czank et al., 2013; de Ferrars et al., 2013), namely protocatechuic 
acid, homoprotocatechuic acid and 3,4-dihydroxybenzalehyde and their respective 
methylated counterparts, vanillic acid, homovanillic acid, and vanillin (The aim of the 
present chapter was to investigate the anti-inflammatory activity of protocatechuic acid, 
vanillic acid, homoprotocatechuic acid, homovanillic acid, 3,4-dihydroxybenzaldehyde and 
vanillin at a range of physiologically relevant concentrations (0.01µM to 10 µM) on the 
production of VCAM-1 and IL-6 in human umbilical vein endothelial cells (HUVECs) 
following stimulation with either CD40L or TNF-α. 
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Figure 6.1). Following 500 mg anthocyanin consumption, these compounds have been 
identified in serum at maximum concentrations of  146 ± 74 nM for protocatechuic acid and 
1,845 ± 838 nM for vanillic acid, and in urine at maximum concentrations of  1,945 ± 1,302 
nM for homoprotocatechuic acid, 7,382 ± 5,927 nM for homovanillic acid and 24 ± 7 nM for 
3,4-dihydroxybenzaldehyde (de Ferrars et al., 2013; de Ferrars et al., 2014). These six 
metabolites were selected as the bioactivity of the more prevalent glucuronide and sulfate 
metabolites is currently been undertaken within the Department of Nutrition (unpublished 
data). In addition, these six metabolites were selected to provide an insight into structural 
activity relationships, as the effect of a catechol group versus methylated catechol group and 
of a carboxylic versus phenylacetic versus phenylaldehyde functional group on metabolite 
bioactivity could be explored. 
 
The aim of the present chapter was to investigate the anti-inflammatory activity of 
protocatechuic acid, vanillic acid, homoprotocatechuic acid, homovanillic acid, 3,4-
dihydroxybenzaldehyde and vanillin at a range of physiologically relevant concentrations 
(0.01µM to 10 µM) on the production of VCAM-1 and IL-6 in human umbilical vein 
endothelial cells (HUVECs) following stimulation with either CD40L or TNF-α. 
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Figure 6.1 Structures of anthocyanin metabolites screened for their effect on 
CD40L and TNF-α stimulated VCAM-1 and IL-6 expression in HUVECs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.2. Materials and methods  
6.2.1. Materials and Reagents 
Protocatechuic acid, homoprotocatechuic acid, vanillic acid, homovanillic acid, 3,4-
dihydroxybenzaldehyde and vanillin were purchased from Sigma-Aldrich (Dorset, UK). 
Standards were prepared at concentrations of 200 mM in 100% dimethylsulphoxide (DMSO, 
molecular biology grade) from Sigma-Aldrich (Dorset, UK). Cell proliferation reagent WST-
1 [(4-[3-(4-Iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulphonate)] was 
obtained from Roche Applied Science (Burgess Hill, UK). DuoSet
®
 human VCAM-1 ELISA 
kit and DuoSet
®
 human IL-6 ELISA kit were purchased from R&D systems (Abingdon, 
UK). Lyphilized recombinant human TNF-α (10 µg) was purchased from Invitrogen 
(Paisley, UK). Fibronectin was purchased from Sigma-Aldrich (Dorset, UK), foetal calf 
serum (FCS; heat-inactivated) from was purchased from Biosera (Ringmer, UK), RPMI1640 
media, penicillin/streptomycin, L-Glutamine and fetal bovine serum were purchased from 
PAA (Pasching, Austria), penicillin/streptomycin was purchased from Promocell 
(Heidelberg, Germany) and 1 mg/mL human monoclonal antibody blocking CD40 was 
purchased from Enzo Life Sciences (Exeter, UK). Cryo-preserved, early passage, human 
umbilical vein endothelial cells (HUVECs) from pooled donors, large vessel endothelial cell 
growth medium, trypsin, EDTA and gentamicin and amphotericin B supplements were 
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purchased from Caltag Medsystems (Buckingham, UK). Cryo-preserved D1.1 Jurkat cells 
were generously provided by Dr. Maria O’Connell, Senior Lecturer, Department of 
Pharmacy, University of East Anglia (Norwich, UK). TRIzol
®
 reagent was purchased from 
Invitrogen (Paisley, UK), chloroform and propan-2-ol were purchased from Fisher Scientific 
(Loughborough, UK) and 200 proof ethanol was purchased from Sigma-Aldrich (Dorset, 
UK). Nunclon™ Δ 75cm2 flasks and Nunclon
TM
 ∆ 24 well plates were purchased from 
PAA (Somerset, UK)], 96-well microplates were purchased from BD Falcon® (Oxford, 
UK). 
6.2.2. HUVEC cell culture.  
Cryo-preserved HUVECs from pooled donors were cultured in Nunclon™ Δ 75cm2 flasks 
coated with fibronectin (0.26 μg/cm2), and grown in large vessel endothelial cell growth 
medium (proprietary basal medium formulation supplemented with growth factor and 
antibiotic (gentamicin & amphotericin B) supplements, to a final concentration of 2% v/v 
foetal bovine serum) at 37 °C with 5% CO2. HUVECs were sub-cultured to 90-95% 
confluence before they were split using 0.025% trypsin and 0.01% EDTA. All experiments 
were conducted between passages two to four. 
6.2.3. D1.1 Jurkat cell culture 
D1.1 cells were cultured in Nunclon™ Δ 75 cm2 flasks in RPMI1640 media supplemented 
with 10% foetal bovine serum, 2 mM L-Glutamine (200 mM) and 1% 
penicillin/streptomycin (100 x concentrate). Cell density was calculated using trypan blue (a 
diazo dye which colours dead cells) and the cell density was maintained between 6 x 10
5 
and 
1 x 10
6
 cells/mL.   
6.2.4. Cytotoxicity assay 
Cell viability was assessed using cell proliferation reagent WST-1; the assay was conducted 
using 96-well microplates coated with fibronectin (0.41 μg/cm2), seeded with HUVECs at a 
density of ~20,000 cells/well. Cells were subsequently grown to confluence (~24-48 h at 
37°C and 5% CO2). The culture medium was then aspirated and 100 μL of the treatment 
compounds prepared in supplemented large vessel endothelial cell growth medium at 
concentrations of 0.1, 1, 10, and 100 μM. Controls consisted of wells containing media and 
0.05% DMSO, with no cells (blank), media and cells (control), 0.05% DMSO in media and 
cells (vehicle control) and PBS and cells (negative control). Three replicates were carried out 
for each control and treatment solution. The microplates were incubated for 24 h at 37 °C 
and 5% CO2, after which 10 μL WST-1 reagent was added to each well and the plates were 
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incubated for a further 2 h. Absorbance was then measured at 440 nm with a reference 
wavelength measured at 650 nm using a microplate reader [Fluostar Omega, BMG Labtech 
(Aylesbury, UK)].  
6.2.5. CD40L induced IL-6 and sVCAM1 expression in HUVECS  
HUVECs were cultured as described above and split into 24 well plates coated with 
fibronectin (0.25 μg/cm2) at a seeding density of ~60,000 cells/well. The cells were grown to 
90-95% confluence (~24-48 h at 37°C and 5% CO2), the culture medium was aspirated and 
the HUVECs were co-incubated with CD40L expressing Jurkat D1.1 cells (1 x 10
6 
cells/well) and the treatments (600 μL/well) for 24 h.  All treatment compounds were 
prepared in large vessel endothelial cells growth media at final concentrations of 0.01, 0.1, 1 
and 10 μM. Each experiment contained controls, which consisted of un-stimulated cells 
(media only), D1.1 cells but no treatment compound (positive control) and D1.1 cells 
preincubated for 1 h with 15 µg/mL anti-CD40L antibody (negative control). The plates 
were incubated for 24 h at 37 °C and 5% CO2, after which the media was collected and 
stored in eppendorf tubes and the plates were washed with warm PBS. The media and plates 
were then stored at -80 °C until analysis. 
6.2.6. TNF-α induced IL-6 and sVCAM-1 expression in HUVECS  
HUVECs were cultured as described above and split into 24 well plates coated with 
fibronectin (0.25 μg/cm2) at a seeding density of ~60,000 cells/well. The cells were grown to 
90-95% (~24-48 h at 37 °C and 5% CO2), the culture medium was aspirated and the 
HUVECs were co-incubated for 24 h in 600 μL/well of large vessel endothelial cell growth 
media supplemented with TNF-α (10 ng/mL) and the treatment compounds at concentrations 
of 0.01, 0.1, 1 and 10 μM. Controls consisted of un-stimulated cells (media only) and 10 
ng/mL TNF-α without treatment compounds (positive control). The plates were incubated 
for 24 h at 37 °C and 5% CO2, after which the media was collected and stored in eppendorf 
tubes. The media and plates were then stored at -80 °C until analysis.  
6.2.7. sVCAM1 ELISA 
ELISA for human sVCAM-1 was performed using a DuoSet
® 
kit purchased from R&D 
systems (Abingdon, UK) according to the manufacturer’s instructions. The sensitivity of the 
ELISA was 16.63 pg/mL. Prior to ELISA, samples were centrifuged for 10 min at 4 °C and 
13,000 rpm to pellet the D1.1 cells or any cell debris, and the media from the TNF-α 
stimulated cells was diluted (2/1)  in reagent diluent. The kit used a mouse anti-human 
VCAM-1 capture antibody (2 µg/mL in 1% PBS) and biotinylated sheep anti-human 
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VCAM-1 detection antibody (200 ng/mL in reagent diluent). sVCAM-1 was quantified via 
colorimetric assay, measuring at 450 nm and 570 nm (as reference wavelength) using a 
BMG microplate reader [Fluostar Omega, BMG Labtech (Aylesbury, UK)] 
6.2.8. IL-6 ELISA 
ELISA for human IL-6 was performed using a DuoSet
® 
kit purchased from R&D systems 
(Abingdon, UK) according to the manufacturer’s instructions. The sensitivity of the ELISA 
was 9.38 pg/mL. Prior to ELISA, samples were centrifuged for 10 min at 4 °C and 13,000 
rpm to pellet the D1.1 cells or any cell debris, and the media from the TNF-α stimulated cells 
was diluted (2/1)  in reagent diluent. The kit used a mouse anti-human IL-6 capture antibody 
(2 µg/mL in reagent diluent) and biotinylated goat anti-human IL-6 detection antibody (50 
ng/mL in reagent diluent). IL-6 was quantified via colorimetric assay, measuring at 450 nm 
and 570 nm (as reference wavelength) using a BMG microplate reader [Fluostar Omega, 
BMG Labtech (Aylesbury, UK)] 
6.2.9. RNA extraction 
HUVECs within the stored 24 well plates were homogenised with 500 µL/well TRIzol
®
 and 
the RNA was extracted using 100 µL/sample chloroform. The samples were vortexed and 
centrifuged (12,000 × g for 10 min at 4°C) and 100 µL of the clear aqueous layer was 
collected and vortexed with 250 µL propan-2-ol. The samples were centrifuged again 
(12,000 × g for 10 min at 4°C) and the supernatant was discarded leaving the RNA pellet. 
The pellets were washed with 500 µL of 75% ethanol, vortexed and centrifuged (7,500 × g 
for 5 min at 4°C). The supernatant was discarded and the pellets were air-dried before being 
re-suspended in 20 µL DEPC-treated nuclease-free water, vortexed and heated it at 57.5°C 
for 10 min to aid solubility. The quantification of RNA was performed using a 
NanoDrop
®
2000 spectrophotometer. 
6.2.10. Reverse transcription  
Reverse transcription was carried out using 1 µg of RNA. Initially, any genomic DNA 
contamination was eliminated by incubating the RNA solution with 1 µL/reaction DNase 
reaction buffer, 1 µL/reaction DNase-1 and 0.25 µL/reaction RiboLock RNase inhibitor at 
37°C for 30 min. DNase-1 was then inactivated through the addition of 1 µL/reaction of 50 
mM EDTA along with 1µL/reaction oligo (dT) primers and 1 µL/reaction dNTP PCR mix, 
followed by incubation at 65°C for 10 min. The oligo (dT) primers were subsequently 
annealed through the addition of 4 µL/reaction first strand buffer, 1 µL/reaction RiboLock 
RNase inhibitor, 1 µL/reaction of 100 mM dithiothreitol (DTT) and incubated for 2 min at 
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42°C.  Finally, the reverse transcription of mRNA was conducted by incubating the reaction 
mix with 1 µL/reaction SuperScript
® 
II at 42°C for 50 min, followed by 70°C for 15 min to 
inactivate the SuperScript
® 
II.  The resulting complementary DNA (cDNA) was then diluted 
to a concentration of 5 ng/µL in DEPC-treated nuclease-free water and stored at 4°C until 
required for RT-qPCR 
6.2.11. VCAM-1 and IL-6 RT-qPCR 
The RT-qPCR was conducted using 5 µL/reaction (25 ng) of cDNA mixed with 1 
µL/reaction VCAM-1 primer, 8.33 µL/reaction real time PCR master mix with SYBR
®
 green 
and made up to 20 µL/reaction with 5.67 µL DEPC-treated nuclease-free water. The RT-
qPCR was performed using Applied Biosystems 7500 Real-Time PCR System (Life 
Technologies, Paisley, UK) where the enzymes were activated for 10 min at 95°C followed 
by 50 cycles of denaturation at 95°C for 15 seconds and the data collection took place at 60 
°C for 1 min. The target genes (VCAM-1 or IL-6) were normalised against two geNorm 
housekeeping reference genes, PRDM4 and UBE2D2. The expression of target gene was 
quantified by ΔCt, where ΔCt = Ct target gene / Ct geomean of references gene. The forward and reverse 
primer sequences for VCAM-1 were CAG GCT AAG TTA CAT ATT GAT GAC AT and 
GAG GAA GGG CTG ACC AAG AC respectively and the forward and reverse primer 
sequences for IL-6 were GCA GAA AAC AAC CTG AAC CTT and ACC TCA AAC TCC 
AAA AGA CCA respectively. A melt curve was performed following RT-qPCR to confirm 
that the pure product was amplified. 
6.2.12. Statistical analysis.  
For WST-1 cytotoxicity and ELISA data, analysis of variance (ANOVA) with Tukey post-
hoc test was performed on three biological replicates (with each biological replicate 
representing the mean of two technical replicates) using SPSS for Windows statistical 
software package (version 18.0; IBM, New York, USA) and significance was determined at 
the 5% level. The statistical analysis was conducted on raw data and mean values were 
graphed as percentage of the positive control with error bars representing % coefficient of 
variation (%CV).  
 
For RT-qPCR data, analysis of variance (ANOVA) with Tukey post-hoc test was performed 
on three biological replicates using SPSS and significance was determined at the 5% level. 
Statistical analyses was conducted using normalised (for PRDM4 and UBE2D2 
housekeeping genes) mRNA levels, represented as fold change relative to un-stimulated 
(basal) mRNA levels, with error bars representing SD. 
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6.3.  Results  
6.3.1. Cytotoxicity assay 
Six treatment compounds (protocatechuic acid, homoprotocatechuic acid, vanillic acid, 
homovanillic acid, 3,4-dihydroxybenzaldehyde and vanillin) were screened for cytotoxicity 
at four concentrations (0.1, 1, 10, and 100 μM) (Figure 6.2). No significant effects (p > 0.01) 
on endothelial cell viability were observed following 24 h incubation of HUVECs with the 
vehicle control (0.05% DMSO) or any of the treatment compounds. 
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Figure 6.2 Assessment of cytotoxicity of six treatment compounds using WST-1 following 24 h incubation with cultured HUVECs. 
  
Cell viability (mean absorbance as percentage of mean control absorbance) for control (supplemented culture medium), vehicle control (culture medium with 
0.05% DMSO), negative control (PBS) and 100, 10, 1 and 0.1 μM of treatment compounds. Data shown as mean ± CV, n=3. *Significance p ≤ 0.01 (ANOVA 
with Tukey post-hoc) relative to control incubations. PCA, protocatechuic acid; VA, vanillic acid; 34dhBAL, 3,4-dihydroxybenzaldehyde. 
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6.3.2. CD40L induced sVCAM-1 protein production 
Incubation of HUVECs with CD40L resulted in a 14.7 fold increase in the production of 
sVCAM-1 compared to un-stimulated HUVECs (p<0.01). This was attenuated to basal levels 
when HUVECs were treated with D1.1 cells, which had been pre-incubated with 15 µg/mL 
anti-CD40L antibody (Figure 6.3). 
 
Figure 6.3 sVCAM-1 protein production in CD40L stimulated cells.  
 
 
 
 
 
 
 
 
 
 
HUVECs were co-incubated with CD40L expressing Jurkat D1.1 cells (1 x 
10
6 
cells/well) for 24 h and supernatants were used to quantify sVCAM-1 
protein production via ELISA. All data is expressed as % mean ± %CV 
(n=3) relative to CD40L control. *Significance p ≤ 0.01 (ANOVA with 
Tukey post-hoc) relative to CD40L control.   
 
The effect of six anthocyanin metabolites on sVCAM-1 production in CD40L stimulated 
HUVECs was examined by incubating CD40L with and without treatment compounds at 
0.01, 0.1, 1 and 10 µM for 24 h. Following the co-incubation of HUVECs with CD40L 
expressing Jurkat D1.1 cells and the treatment compounds, all six compounds tested 
demonstrated a significant (p ≤ 0.01) reduction in sVCAM-1 production (Figure 6.4).  The 
largest reduction in sVCAM-1 production was observed for protocatechuic acid at 0.01 µM 
(86.9 ± 20.8%; Figure 6.4A) followed by vanillin (82.5 ± 34.8%; Figure 6.4F) and 
homoprotocatechuic acid (81.8 ± 31.6%; Figure 6.4B) at 10 µM. Vanillic acid (Figure 6.4D) 
and homovanillic acid (Figure 6.4E) only showed a significant reduction in sVCAM-1 
production at the highest concentration tested (10 µM), whilst protocatechuic acid displayed 
a negative dose response and homoprotocatechuic acid, 3,4-dihydroxybenzaldehyde (Figure 
6.4C) and vanillin also showed a significant reduction at the lower concentrations  tested. 
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Figure 6.4 sVCAM-1 protein production following treatment with anthocyanin metabolites in CD40L stimulated cells. 
 
HUVECs were co-incubated with CD40L expressing Jurkat D1.1 cells (1 x 10
6 
cells/well) and the treatment compounds for 24 h and supernatants were 
used to quantify sVCAM-1 protein production via ELISA. All data is expressed as % mean ± %CV (n=3) relative to CD40L control. Significance: 
**p≤0.01 (ANOVA with Tukey post-hoc) relative to CD40L control. a,b,c,dBars for treatments with different superscript letters are significantly different (p 
< 0.05). 34dhBAL, 3,4-dihydroxybenzaldehyde; PCA, protocatechuic acid; VA, vanillic acid.  
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6.3.3.  CD40L induced IL-6 protein production 
Incubation of HUVECs with CD40L resulted in a 1.9 fold increase in the production of IL-6 
compared to un-stimulated HUVECs (p<0.01). This increase was attenuated to basal levels 
when HUVECs were treated with D1.1 cells, which had been pre-incubated with 15 µg/mL 
anti-CD40L antibody (Figure 6.5). 
 
Figure 6.5 IL-6 protein production in CD40L stimulated cells. 
 
 
 
 
 
 
 
 
 
 
HUVECs were co-incubated with CD40L expressing Jurkat D1.1 cells 
(1 x 10
6 
cells/well) for 24 h and supernatants were used to quantify IL-
6 protein production via ELISA. All data is expressed as % mean ± 
%CV (n = 3) relative to CD40L control. *Significance p ≤ 0.01 
(ANOVA with Tukey post-hoc) relative to CD40L control.   
 
The effect of six anthocyanin metabolites on IL-6 production in CD40L stimulated HUVECs 
was examined by incubating CD40L with and without treatment compounds at 0.01, 0.1, 1 
and 10 µM for 24 h. Following the treatment of CD40L challenged HUVECs with the 
anthocyanin metabolites, all six compounds tested demonstrated a significant (p ≤ 0.01) 
reduction in IL-6 production (Figure 6.6). Vanillin (Figure 6.6F) and 3,4-
dihydroxybenzaldehyde (Figure 6.6C) demonstrated the largest reduction in IL-6 production 
at 10 µM (86.4 ± 36.7% and 86.2 ± 9.6% reduction respectively) followed by protocatechuic 
acid at 0.01 µM (79.3 ± 22.0%) (Figure 6.6A). Vanillic acid (Figure 6.6D) and homovanillic 
acid (Figure 6.6E) only showed a reduction in sVCAM-1 production at the highest dose (10 
µM), whilst homoprotocatechuic acid (Figure 6.6B) was bioactive over all four 
concentrations tested. 3,4-Dihydroxybenzaldehyde and vanillin were bioactive at the highest 
(10 µM) and lowest (0.01 µM) concentrations tested, whilst decreasing concentrations of 
protocatechuic acid resulted in significantly (p<0.01) lower levels of IL-6.  
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Figure 6.6 IL-6 protein production following treatment with anthocyanin metabolites in CD40L stimulated cells. 
 
HUVECs were co-incubated with CD40L expressing Jurkat D1.1 cells (1 x 10
6 
cells/well) and the treatment compounds for 24 h and the supernatants were 
used to quantify IL-6 protein production via ELISA. All data is expressed as % mean ± %CV (n=3) relative to CD40L control. Significance: **p≤0.01 
(ANOVA with Tukey post-hoc) relative to CD40L control. 
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Bars for treatments with different superscript letters are significantly different (p < 0.05). 
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6.3.1. TNF-α induced sVCAM-1 protein production 
Incubation of HUVECs with TNF-α resulted in a 25 fold increase in the production of 
sVCAM-1 compared to un-stimulated HUVECs (p<0.01) (Figure 6.7).   
 
Figure 6.7 sVCAM-1 protein production in TNF-α stimulated cells. 
 
 
 
 
 
 
 
 
 
 
 
HUVECs were co-incubated with TNF-α (10 ng/mL) for 24 h and 
supernatants were used to quantify sVCAM-1 protein production via 
ELISA. All data is expressed as % mean ± %CV (n = 3) relative to CD40L 
control. *Significance p≤0.01 (ANOVA with Tukey post-hoc) relative to 
TNF-α control. 
 
The effect of six anthocyanin metabolites on sVCAM-1 production in TNF-α stimulated 
HUVECs was examined by incubating TNF-α stimulated HUVECs with and without 
treatment compounds at 0.01, 0.1, 1 and 10µM for 24 h (Figure 6.8). Following the 
treatment of TNF-α challenged HUVECs with the anthocyanin metabolites, three 
compounds, namely homoprotocatechuic acid (Figure 6.8B), 3,4-dihydroxybenzaldehyde 
(Figure 6.8C), and vanillin (Figure 6.8F) significantly (p≤0.01) reduced sVCAM-1 
production. Two compounds, vanillic acid (Figure 6.8D) and homovanillic acid (Figure 
6.8E) demonstrated a trend (p≤0.2) towards reduced sVCAM-1 production, whilst 
protocatechuic acid (Figure 6.8A) had no significant effect on sVCAM-1 production at any 
concentration. 3,4-Dihydroxybenzaldehyde (83.1 ± 39.2%) demonstrated the largest 
reduction in IL-6 production at 0.01 µM, followed by homoprotocatechuic acid  at 10 µM 
(72.8 ± 20.9%) and homovanillic acid at 1 µM (61.8 ± 51.5%). 
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Figure 6.8 sVCAM-1 protein production following treatment with anthocyanin metabolites in TNF-α stimulated cells. 
 
HUVECs were co-incubated with TNF-α (10 ng/mL) and the treatment compounds for 24 h and supernatants were used to quantify sVCAM-1 protein 
production via ELISA. All data is expressed as % mean ± %CV (n=3) relative to TNF-α control. Significance: †trend, p≤0.2; *p≤0.05; **p≤0.01 (ANOVA 
with Tukey post-hoc) relative to TNF-α control. a,bBars for treatments with different superscript letters are significantly different (p < 0.05). 34dhBAL, 3,4-
dihydroxybenzaldehyde; PCA, protocatechuic acid; VA, vanillic acid. 
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6.3.2. TNF-α induced IL-6 protein production 
Incubation of HUVECs with TNF-α resulted in an eight fold increase in the production of 
IL-6 compared to un-stimulated HUVECs (p<0.01) (Figure 6.9).   
 
Figure 6.9 IL-6 protein production in TNF-α stimulated cells. 
 
HUVECs were co-incubated with TNF-α (10 ng/mL) for 24 h and 
supernatants were used to quantify IL-6 protein production via ELISA. 
All data is expressed as % mean ± %CV (n = 3) relative to CD40L 
control. *Significance p≤0.01 (ANOVA with Tukey post-hoc) relative 
to TNF-α control.  
 
The effect of six anthocyanin metabolites on IL-6 production in TNF-α stimulated HUVECs 
was examined by incubating TNF-α and HUVECs with and without treatment compounds at 
0.01, 0.1, 1 and 10 µM for 24 h. Following the treatment of TNF-α stimulated HUVECs with 
the anthocyanin metabolites, all six compounds tested demonstrated a significant (p ≤ 0.01) 
reduction in IL-6 production (Figure 6.10). Homoprotocatechuic acid (Figure 6.10B) and 
3,4-dihydroxybenzaldehyde (Figure 6.10C) demonstrated the largest reduction in IL-6 
production, of 88.4 ± 42.6% and 85.3 ± 24.4% respectively, followed by homovanillic acid 
(67.2 ± 9.1%) (Figure 6.10E). Vanillin resulted in the smallest reduction in IL-6 (44.8 ± 
21.8) (Figure 6.10F) over the concentrations tested. 
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Figure 6.10 IL-6 protein production following treatment with anthocyanin metabolites in TNF-α stimulated cells. 
HUVECs were co-incubated with TNF-α (10 ng/mL) and the treatment compounds for 24 h and the supernatants were used to quantify IL-6 protein 
production via ELISA. All data is expressed as % mean ± %CV (n=3) relative to TNF-α control. Significance: †trend, p≤0.2; **p≤0.01 (ANOVA with 
Tukey post-hoc) relative to TNF-α control. a,bBars for treatments with different superscript letters are significantly different (p < 0.05). 34dhBAL, 3,4-
dihydroxybenzaldehyde; PCA, protocatechuic acid; VA, vanillic acid. 
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6.3.3. CD40L induced IL-6 and VCAM-1 mRNA.  
A 50.1 ± 3.1 fold increase in sVCAM-1 mRNA levels was observed when HUVECs were 
incubated with CD40L compared to unstimulated cells. This was attenuated to a 5.3 ± 1.7 
fold increase through the addition of 15 µg/mL anti-CD40L antibody (Figure 6.11A).  Three 
of the treatment compounds significantly (p ≤ 0.01) reduced the levels of VCAM-1 mRNA 
at 10 µM. Homoprotocatechuic acid resulted in the smallest increase in mRNA post CD40L 
stimulation (2.9 ± 0.8 fold increase) followed by 3,4-dihydroxybenzaldehyde (15.3 ± 2.5 
fold increase) and vanillin (16.7 ± 7.1 fold increase). However, protocatechuic acid, vanillic 
acid and homovanillic acid had no significant effect. 
 
The incubation of HUVECs with CD40L for 24 h had no significant impact on IL-6 mRNA 
levels compared to untreated or anti-CD40L antibody treated cells (Figure 6.11B).  
However, all compounds, except homoprotocatechuic acid, resulted in a significant (p ≤ 
0.05) decrease in IL-6 mRNA levels compared to CD40 positive control. 
6.3.4. TNF-α induced IL-6 and VCAM-1 mRNA.  
An 824.9 ± 173.5 fold increase in VCAM-1 mRNA levels (p ≤ 0.01) was observed when 
HUVECs were incubated with TNF-α (10 ng/mL) compared to unstimulated cells (Figure 
6.12A). Co-incubation of TNF-α stimulated HUVECs with 10 µM vanillic acid significantly 
(p ≤ 0.01) attenuated the increase in VCAM-1 mRNA production to 144.3 ± 55.1 fold 
increase from baseline. Co-incubation with 10 µM 3,4-dihydroxybenzaldehyde (426.5 ± 
121.5 fold increase from baseline) and vanillin (456.5 ± 280.1 fold increase from baseline)  
indicated a trend (p ≤ 0.2) towards attenuating the increase in TNF-α stimulated VCAM-1 
mRNA production. The remaining compounds (protocatechuic acid, homoprotocatechuic 
acid and homovanillic acid) had no significant impact on VCAM-1 mRNA levels (p > 0.2) 
(Figure 6.12A). 
 
A 3.8 ± 0.1 fold increase in IL-6 mRNA levels was observed when HUVECs were incubated 
with TNF-α (10 ng/mL). Co-incubation of TNF-α stimulated HUVECs with 10 µM vanillic 
acid indicated a trend (p ≤ 0.2) towards attenuating the TNF-α stimulated increase in IL-6 
mRNA levels to a 1.8 ± 0.6 fold increase from baseline. However, the remaining compounds 
had no significant impact on IL-6 mRNA levels (p > 0.2) (Figure 6.12B)  
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Figure 6.11 CD40L induced (A) VCAM-1 and (B) IL-6 mRNA levels following treatment with 
10 µM anthocyanin metabolites.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HUVECs were co-incubated with CD40L expressing Jurkat D1.1 cells (1 x 10
6 
cells/well) for 
24h. Cell lysates were then used to quantify mRNA levels via RT-qPCR. All data was expressed 
relative to un-stimulated (basal) mRNA levels as mean fold ± SD (n=3) Significance: *p≤0.05; 
**p≤0.01 (ANOVA with Tukey post-hoc) relative to CD40L control. 34dhBAL, 3,4-
dihydroxybenzaldehyde; PCA, protocatechuic acid; VA, vanillic acid. 
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Figure 6.12 TNF-α induced (A) VCAM-1 and (B) IL-6 mRNA levels following treatment with 
10 µM anthocyanin metabolites. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TNF-α (10 ng/mL) was co-incubated with or without treatment compounds at 10 µM for 24 h.  
Cell lysates were then used to quantify mRNA levels via RT-qPCR. All data is expressed relative 
to un-stimulated (basal) mRNA levels as mean fold ± SD (n=3). Significance: †trend, p≤0.2; 
**p≤0.01 (ANOVA with Tukey post-hoc) (ANOVA with Tukey post-hoc) relative to TNF-α 
control. 34dhBAL, 3,4-dihydroxybenzaldehyde; PCA, protocatechuic acid; VA, vanillic acid.  
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6.4. Discussion 
Previously in vitro experiments into anthocyanin bioactivity have commonly used treatment 
doses, up to 2.2 mM (1 mg/mL) of anthocyanins (Youdim et al., 2000).  The treatment 
compounds used in the present study have been identified at maximum concentrations of  up 
to 2 µM in serum and urine following the consumption of 500 mg 
13
C-labelled cyanidin-3-
glucoside (de Ferrars et al., 2014). Therefore, the treatment concentrations of 0.01 µM to 1 
µM were chosen based on their physiological relevance, and 10 µM was selected as 
representing a potential maximal obtainable concentration, albeit outside normal dietary 
levels. 
 
There were no significant effects (p > 0.01) of any treatment compound on endothelial cell 
viability following a 24 h incubation of HUVECs with WST-1 reagent (Figure 6.2). This 
confirms that ≤100 µM concentrations of the compounds are not cytotoxic to human 
vascular endothelial cells over a 24 h period, and that the doses used in the present study are 
suitable for the assessment of their vascular biological activity. 
 
Anthocyanins have been shown to reduce the development of inflammation in human  
(Cassidy et al., 2013; Zhu et al., 2013), animal (Miyazaki et al., 2008) and cell models 
(Chao et al., 2013; Kim et al., 2006; Miyazaki et al., 2008; Nizamutdinova et al., 2009; Xia 
et al., 2009). However, bioavailability studies have shown that metabolites of anthocyanins 
are present at much higher concentrations than the anthocyanins themselves (Czank et al., 
2013; de Ferrars et al., 2013). This has led to the hypothesis that anthocyanins may exert 
their bioactive effects through the effects of their metabolites (Kay, 2010). The adhesion of 
circulating leukocytes to the intimal endothelial monolayer is one of the earliest events in the 
development of atherosclerosis, and the process depends upon the complex interactions of 
multiple adhesion molecules and their receptors including VCAM-1, ICAM-1, selectins and 
integrins. IL-6 is a pleiotropic cytokine, whose expression is rapidly induced in response 
cytokines and is associated with a wide range of inflammatory functions, from B-
lymphocyte differentiation to adhesion molecule recruitment  (Schuett et al., 2009). The 
current study focused on the effect of anthocyanin metabolites on sVCAM-1 and IL-6, as 
their inhibition may prevent or attenuate the progression of atherosclerosis through a 
decrease in the recruitment, differentiation and activation of a wide range of inflammatory 
mediators.  
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A key finding of the present study was that all compounds tested significantly reduced the 
production of sVCAM-1 (Figure 6.4) and IL-6 (Figure 6.6) following stimulation of 
HUVECs with CD40L, thus demonstrating that the degradation products and metabolites of 
anthocyanins have anti-inflammatory properties. Protocatechuic acid demonstrated an 
inverse dose dependent response following stimulation of HUVECs with CD40L, resulting 
in decreasing sVCAM-1 and IL-6 production at the lower concentrations. This effect was 
not observed with its methyl or phenylacetic acid derivatives. All other compounds tested 
were most active at the highest concentrations (10 µM) following stimulation with CD40L. 
Furthermore, vanillin and 3,4-dihydroxybenzaldehyde may reflect an inverse U-shaped 
response, decreasing sVCAM-1 and IL-6 levels at the highest (10 µM) and lowest (0.01 µM) 
concentrations tested, thus suggesting these metabolites do not follow a classical linear dose 
response. Previous studies have also suggested precedence in vivo for a non-linear dose 
response for flavonoid activity (Kay et al., 2012; Rodriguez-Mateos et al., 2013).  
 
Little difference in sVCAM-1 and IL-6 production was observed between structures 
containing carboxylic, phenylacetic and benzaldehyde functional groups following CD40L 
stimulation.  In contrast, the effect of methylation of the catechol group generally resulted in 
a decreased bioactivity following CD40L stimulation as protocatechuic acid (87 ± 21%) and 
homoprotocatechuic acid (82 ± 21%) demonstrated a higher maximum reduction in 
sVCAM-1 than vanillic acid (49 ± 9%) and homovanillic acid (48 ± 24%). Furthermore, 
protocatechuic acid, homoprotocatechuic acid and 3,4-dihydroxybenzaldehyde demonstrated 
a significant decrease in sVCAM-1 and IL-6 protein production over a larger range of 
concentrations than their methylated derivatives, thus suggesting the catechol group plays an 
important role in the bioactivity of the metabolite in CD40L stimulated cells. The presence 
of two hydroxyl groups in an ortho position have previously been shown to be important in 
the radical scavenging activity of flavonoids (Pereira et al., 2009; Yokozawa et al., 1998), 
with O-methylation of the catechol group resulting in a significant decrease in anti-oxidant 
activity (Amaral et al., 2009; Cao et al., 1997; Mladěnka et al., 2010). However, to the best 
of the authors knowledge, the effect of a catechol or methylated catechol group on VCAM-1 
or IL-6 production has not previously been investigated in CD40L stimulated cells. 
 
Following TNF-α stimulation, all compounds tested significantly reduced the protein 
production of IL-6 (Figure 6.10). However, only homoprotocatechuic acid, 3,4-
dihydroxybenzaldehyde and vanillin significantly reduced sVCAM-1 levels. Vanillic acid 
and homovanillic acid suggested a trend (p ≤ 0.2) towards reducing sVCAM-1 levels and 
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protocatechuic had no significant effect (Figure 6.8). The effect of methylation of the 
catechol group on the treatment compounds also generally resulted in a decreased bioactivity 
in TNF-α stimulated HUVECs. This effect was most evident for the benzaldehydes, with 
3,4-dihydroxybenzaldehyde demonstrating a higher reduction in sVCAM-1 (83 ± 39%) and  
IL-6 (85 ± 24%) production compared to vanillin (63 ± 16% and 44 ± 22% reduction for 
sVCAM-1 and IL-6 respectively). The enhanced bioactivity of compounds containing a 
catechol group over a methylated-catechol group has been previously observed for 
flavonoids (Spencer et al., 2003; Williams et al., 2004). The functional group also appeared 
to affect the bioactivity of the metabolites, with phenylacetic acids and benzaldehydes 
appearing more bioactive than carboxylic acids following TNF-α stimulation, with 3,4-
dihydroxybenzaldehyde demonstrating the largest reduction in sVCAM-1(83 ± 39%), 
closely followed by homoprotocatechuic acid (73 ± 20%) and protocatechuic acid (38 ± 
21%; Figure 6.8). A similar effect was observed for IL-6 production (Figure 6.8).  
 
Following CD40L stimulation, VCAM-1 mRNA levels in HUVECs were increased 50-fold 
over baseline values (Figure 6.3). Incubation with the three compounds 
(homoprotocatechuic acid, 3,4-dihydroxybenzaldehyde and vanillin) which resulted in the 
largest reduction in sVCAM-1 protein levels at 10 µM following CD40L stimulation, also 
resulted in a significant decrease in VCAM-1 mRNA levels. Similarly, VCAM-1 mRNA 
levels demonstrated an 825-fold increase over baseline values following TNF-α stimulation, 
and co-incubation with vanillic acid significantly (p ≤ 0.01) reduced the levels of VCAM-1 
mRNA, whilst co-incubation with 3,4-dihydroxybenzaldehyde and vanillin indicated a trend 
(p≤0.2) towards the reduction of VCAM-1 mRNA. Together, these results suggest that some 
metabolites reduce VCAM-1 by down regulating the transcription of VCAM-1 mRNA. 
However, little is known concerning the mechanisms by which these treatment compounds 
regulate the expression of sVCAM-1 and IL-6. The down regulation of VCAM-1 mRNA 
production may be mediated by the inhibition of nuclear factor- κB (NF-κB) (Karlsen et al., 
2007; Wang et al., 2010). NF-κB, one of the key transcription factors in mammals, is 
activated by numerous pro-inflammatory stimuli and controls the expression of multiple 
genes involved in inflammatory response and secretion of cytokines and chemokines 
(Bremner et al., 2002). Protocatechuic acid at concentrations of 20 µM and 40 µM has 
previously been reported to suppress TNF-α stimulated VCAM-1 production in mouse aortic 
endothelial cells through the inhibition of TNF-α induced NF-κB activation (Wang et al., 
2010). A decrease in IL-6 expression and inhibition of NF-κB p65 following 
supplementation with vanillic acid was also observed in mice with ulcerative colitis (Figure 
6.13) (Kim et al., 2010). Furthermore, anthocyanins and protocatechuic acid have been 
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shown to suppress lipopolysaccharide (LPS) and CD40L stimulated NF-κB activation 
through inhibiting IκBα phosphorylation and the translocation of NF-κB (p65) into the 
nucleus (Figure 6.13) (Min et al., 2010; Speciale et al., 2010; Xia et al., 2009), although this 
was not observed within HUVECs treated with 100 µM protocatechuic acid (Zhou-Stache et 
al., 2002). Protocatechuic acid has also been shown to reduce the LPS stimulated production 
of inflammatory cytokines through inhibiting the activation of c-Jun N-terminal kinases 
(JNK), extracellular-signal-regulated kinases (ERK) and p38, within the MAPK pathway in 
macrophages (Figure 6.13) (Min et al., 2010). Additionally, anthocyanins have also been 
shown to supress phosphorylation of STAT-3 (Signal Transducer and Activator of 
Transcription-3) but not STAT-1 within the JAK (janus kinase)/STAT activation pathway 
(Nizamutdinova et al., 2009). However, a mechanistic study would be required to elucidate 
the mechanisms by which the metabolites reduced sVCAM-1 and IL-6 levels, which is 
beyond the scope of the present study and should be the focus of future research.  
 
No significant change in VCAM-1 mRNA levels was observed for protocatechuic acid, 
vanillic acid and homovanillic acid following CD40L stimulation (Figure 6.11A) or in 
homoprotocatechuic acid following TNF-α stimulation (Figure 6.12A), despite a significant 
reduction in sVCAM-1 protein production at 10 µM. There are many possibilities to explain 
this. As the current investigation looked at levels of sVCAM-1 rather than membrane bound 
VCAM-1 (Fotis et al., 2012), it is possible that the treatment compounds interfered with the 
proteolytic cleavage of VCAM-1, thus reducing the abundance within the media, but not at 
the mRNA level (CarterandWicks, 2001). Alternatively, the phenolic compounds may act to 
stabilise the mRNA transcripts or may reduce the levels of sVCAM-1 through post-
translational modifications (Carter et al., 2001). 
 
Treatment of HUVECs with CD40L alone (positive control) did not result in up-regulation 
of IL-6 mRNA levels compared to unstimulated cells (Figure 6.11B). Despite this, a 
significant decrease in IL-6 mRNA levels from the CD40L positive control was observed for 
all compounds except homoprotocatechuic acid. The lack of an up-regulation in IL-6 mRNA 
levels, despite up-regulation of IL-6 protein levels following CD40L stimulation may be the 
result of mRNA transcription, translation and degradation prior to 24 h. The peak in protein 
levels observed at 24 h could therefore have been detected following the peak in mRNA 
levels. A time course experiment would be necessary to confirm this hypothesis, which is 
beyond the scope of the present study and is the focus of future work within our laboratory.  
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In contrast a four-fold increase in IL-6 mRNA levels, compared to unstimulated cells, was 
observed following TNF-α stimulation (Figure 6.12B). Co-incubation with vanillic acid 
suggested a trend (p ≤ 0.2) towards attenuating the levels of IL-6 mRNA compared to 
unstimulated cells, however, no other compound significantly affected IL-6 mRNA 
production. As discussed above, this may be due to the phenolic compounds acting through 
stabilisation or other post-translational modifications, such as interfering with the 
glycosylation of IL-6 (Santhanam et al., 1989). 
 
Figure 6.13 Activation of NF-κB and MAPK signalling pathways by CD40-
CD40L and TNF-α.  
 
Adapted from (Bremner et al., 2002; Pamukcu et al., 2011). CD40L, Cluster of 
differentiation 40 ligand; ERK, extracellular-signal-regulated kinases; IKK, 
inhibitory-κB kinase; JNK, c-Jun N-terminal kinases; MAPK, mitogen-
activated protein kinase complex; NF-κB, nuclear factor-κB; P, phosphate; p38, 
mitogen-activated protein kinase;  p50, NF-κB p50 subunit; p65, NF-κB  p65 
subunit; TNF-α, tumour necrosis factor-α; TNFR1, TNF receptor-1; ub, 
ubiquitination.  
 
Whilst the present screening data provides a novel insight into the effect of anthocyanin 
metabolites on the production of sVCAM-1 and IL-6 in vascular endothelial cells, there are 
certain limitations involved with the study. HUVECs are widely used for general research 
into vasculature activity, however an arterial cell type, such as human coronary artery 
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endothelial cells (HCAECs) or human aortic endothelial cells (HAECs) may be more 
relevant for assessing the potential modulatory effects of anthocyanin metabolites on 
sVCAM-1 and IL-6 production (Bouïs et al., 2001). Moreover, experimental results obtained 
from different HUVEC isolates cannot be easily compared to each other because of different 
donor origins (Bouïs et al., 2001). However, HUVECs from a single batch of pooled donors 
were utilised in the present study to minimise this limitation. 
 
There are a number of research areas that should be addressed to progress the present work 
further. Firstly, the anthocyanin metabolites in the present study were co-incubated with the 
stimulus (CD40L or TNF-α). However, in previous anthocyanin bioactivity studies 
HUVECs were pre-incubated with the treatment compounds for 24 h, then washed with PBS 
prior to stimulation (Speciale et al., 2010). The study found that pre-treatment with 
cyanidin-3-glucoside significantly suppressed TNF-α induced endothelial activation 
(Speciale et al., 2010). Future research is needed to establish whether pre-incubation of 
HUVECs with anthocyanin metabolites also results in a protective effect against the 
production of inflammatory biomarkers. Secondly, future research should investigate the 
bioactivity of individual metabolites versus combinations of metabolites in order to establish 
whether anthocyanin metabolites have additive or synergistic bioactive effects. Thirdly, 
future research is required to determine whether the bioactivity of metabolites observed in 
the present study would also be observed following stimulation with other stimuli involved 
in atherosclerosis and CVD, such as oxidised low density lipoprotein (oxLDL) or 
peroxynitrite (ONOO
-
). Similarly, soluble CD40L, which is secreted by activated platelets in 
vivo (Pamukcu et al., 2011), as opposed to D1.1 cell derived CD40L, could be used to 
stimulate the HUVECs and confirm the specificity of the D1.1 cell activity. Fourthly, as 
mention previously, a time-course experiment, where VCAM-1 and IL-6 protein and mRNA 
levels are repeatedly measured over 24 h would provide additional information into the 
mechanisms by which anthocyanin metabolites reduce their production. Finally, the present 
study quantified the production of sVCAM-1, as opposed to membrane bound VCAM-1 
following CD40L and TNF-α stimulation in HUVECs. Although this is a commonly utilised 
method (Zhu et al., 2013) and a clinically relevant biomarker (Carter et al., 2001), it would 
be informative to quantify membrane bound VCAM-1, in order explore the mechanisms by 
which the anthocyanin metabolites decreased sVCAM-1 production.  
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6.5. Conclusion 
In summary, we demonstrate that recently identified, novel metabolites of anthocyanins 
reduce CD40L and TNF-α stimulated expression of the inflammatory markers, sVCAM-1 
and IL-6. Furthermore, the metabolites are bioactive at concentrations that have recently 
been established as physiologically relevant following consumption of an anthocyanin rich 
bolus. Together, this data indicates that the anti-inflammatory effect of anthocyanins are 
likely attributed to their metabolites. This research provides an informative insight into 
understanding how the consumption of anthocyanins may contribute to optimising human 
health through diet.  
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Chapter 7. General Discussion & Future 
Perspectives 
 
Epidemiological evidence (Cassidy et al., 2013; Cassidy et al., 2011; McCullough et al., 
2012) and randomised control trials (Rodriguez-Mateos et al., 2013; Zhu et al., 2011) have 
indicated an association between the consumption of fruits and vegetables rich in 
anthocyanins and a decrease in cardiovascular disease (CVD) risk. However, the low 
bioavailability of anthocyanin glycosides (Manach et al., 2005; Williamson et al., 2005), in 
conjunction with their instability when exposed to physiological pH, suggests anthocyanin 
bioactivity in vivo may be mediated by the presence of their degradation products and 
metabolites.  
 
Until recently, little was known concerning the bioavailability of anthocyanins metabolites, 
primarily due to five main deficiencies within the scientific literature. First, the majority of 
anthocyanin bioavailability studies to date exclusively focused on identifying parent 
anthocyanins and glucuronide, sulfate and methyl conjugates thereof (Bitsch et al., 2004b; 
Mülleder et al., 2002; Wu et al., 2002). Second, there is a lack of intrinsic methods 
developed to identify a wide range of anthocyanin and anthocyanin metabolites. Third, in the 
few studies which aimed to identify phenolic acid metabolites of anthocyanins (Nurmi et al., 
2009; Russell et al., 2009), their elucidation was complicated by use of a boluses containing 
complex anthocyanin and phenolic acid profiles, which often resulted in the failure of 
studies to identify phenolic acids that were not present in the original food source. Fourth, 
the absence of commercially available standards for glucuronide and sulfate conjugates 
limited the positive identification of anthocyanin metabolites. Finally, the lack of 
anthocyanin studies feeding a labelled anthocyanin bolus meant the origin of the identified 
metabolites could not be traced with certainty to the fed anthocyanin.  
 
The present thesis sought to address some of these limitations by developing methods for the 
identification of possible anthocyanin metabolites (Figure 7.1A), and investigating their 
bioavailability in human samples from a study feeding an isotopically labelled (
13
C-labelled 
cyanidin-3-glucoside) anthocyanin bolus and a study feeding a berry (elderberry) derived 
anthocyanin bolus (Figure 7.1B).  
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Figure 7.1 Experimental scheme for the assessment of anthocyanin bioavailability and bioactivity  
 
EE, extraction efficiency; IL-6, interleukin-6; LOD, limit of detection; SPE, solid phase extraction; sVCAM-1, soluble vascular cell adhesion molecule. 
a
Significant (p < 0.01; ANOVA with Tukey post-hoc) decrease in biomarker expression at *one, **two, ***three, ****four of the concentrations examined. 
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Whilst a number of methods have previously been developed for the analysis of flavonoids 
and flavonoid derived phenolics (Kylli et al., 2010; Plazonić et al., 2009; Zhang et al., 
2004), the majority of reported methods for anthocyanin analysis have concentrated on 
quantification of parent anthocyanins and their respective metabolic conjugates. A major 
challenge associated with the development of methods for detecting anthocyanin metabolites 
in vivo relates to the formation of a large diversity of metabolic by-products, whose diversity 
and physicochemical properties make extraction and quantification in complex matrices 
problematic. The present study modelled 112 putative metabolites of anthocyanins based on 
the degradation, phase I, phase II and colonic metabolism of anthocyanins and other 
similarly structured flavonoids from previously published studies (Aura et al., 2005; 
Cheminat et al., 1986; Donovan et al., 1999; Donovan et al., 2002; Fernandes et al., 2008; 
Forester et al., 2008; Kay et al., 2004; Mazza et al., 1987; Mazza et al., 2002; Moridani et 
al., 2001; Williamson et al., 2010; Woodward et al., 2009). Analytical methods (SPE, HPLC 
and MS) were subsequently developed and validated to allow the quantification of 45 
commercially available metabolites. The use of ten synthesised glucuronide and sulfate 
conjugates and structural elucidation using MS
3
 enabled a more extensive search for 
anthocyanin metabolites than previously conducted.  
 
Phenolic compounds are ubiquitous within plants (Dykes et al., 2007; Schmitzer et al., 
2010), and can be formed following the consumption of a wide variety of compounds. For 
example, hippuric acid is formed from the reaction of benzoic acid with glycine, and is a 
common product of protein (Pero, 2010) or dietary polyphenol metabolism (Del Bo’ et al., 
2012; Mulder et al., 2005). Without the use of an isotope marker, previous studies could not 
confirm the origin of identified metabolites. Therefore, the labelled anthocyanin intervention 
(Chapter 3) enabled for the first time, confirmation of the degradation and metabolism of 
anthocyanins in humans into multiple phenolic compounds. 
 
A total of 35 anthocyanin metabolites were identified with biological samples post 
consumption of 500 mg 
13
C-cyanidin-3-glucoside. These included methylated, sulfated and 
glucuronidated conjugates of the parent anthocyanin, anthocyanin degradation products and 
phase II metabolites. Taken together with previous studies investigating the stability and 
absorption of anthocyanins within the gastrointestinal tract (Aura et al., 2005; Crozier et al., 
2010; Del Rio et al., 2013; Fleschhut et al., 2006;  onz lez-Barrio et al., 2010; Hassimotto 
et al., 2008; Keppler et al., 2005), these results suggest that upon ingestion, a small 
proportion (~0.1%) of the anthocyanin dose is absorbed intact within the upper 
gastrointestinal tract and undergoes methylation, sulfation and glucuronidation to some 
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extent. The remaining bolus is likely degraded, followed by significant phase II conjugation, 
particularly methylation to form vanillic acid, sulfation to form protocatechuic acid sulfate, 
and conjugation with glycine to form hippuric acid. The absorption of many of the 
metabolites appeared to follow biphasic serum kinetics, displaying an initial serum peak 
between 0-5 h followed by a second peak after 6-48 h. This indicated that the metabolism 
and absorption likely occurs within different tissues and at different sites within the 
gastrointestinal tract, including the colon. 
 
The elderberry intervention trial was conducted to investigate the bioavailability of 
anthocyanin metabolites following acute (1 x 500 mg) and chronic (500 mg x 12 wks) 
consumption of a food (elderberry) derived anthocyanin bolus. To the best of our knowledge, 
it was the first study to look at postprandial phenolic metabolite excretion following 
sustained anthocyanin dosing. No significant difference in the metabolism or clearance was 
identified following chronic anthocyanin consumption, suggesting there is no alteration in 
metabolic processing following 12 wks repeated dosing. However, the use of an elderberry 
bolus with a simple anthocyanin profile and MS
3
 structural elucidation enabled the largest 
number of metabolic conjugates of elderberry anthocyanins to be identified to date.  
 
To fully understand the bioactivity of anthocyanins, it was first necessary to gain a complete 
understanding of their absorption, distribution and metabolism in vivo and to subsequently 
integrate this understanding into establishing their bioactivity. Chronic inflammation is 
involved with the onset and development of pathological disturbances, including 
arteriosclerosis, diabetes and obesity (García-Lafuente et al., 2009). Therefore, the final part 
of the current thesis aimed to establish the anti-inflammatory bioactivity of six anthocyanin 
metabolites via their effect on soluble vascular adhesion molecule-1 (sVCAM-1) and 
interleukin-6 (IL-6) production in stimulated endothelial cells. sVCAM-1 and IL-6 were 
selected for analysis as they play a pivotal role in inflammation and development of 
atherosclerosis. Their inhibition may prevent or attenuate the progression of atherosclerosis, 
through a decrease in the recruitment, differentiation and activation of a wide range of 
inflammatory mediators. The modulation of VCAM-1 and IL-6 production by anthocyanins 
has been the subject of many previous studies (Chao et al., 2013; Kim et al., 2006; Miyazaki 
et al., 2008; Nizamutdinova et al., 2009; Sen et al., 2001; Zhu et al., 2013), yet little is 
known concerning the bioactivity of the more bioavailable degradation products and 
metabolites. A key finding of the present thesis was that all metabolites tested significantly 
reduced the production of sVCAM-1 and IL-6 at one or more of the concentrations tested, 
following stimulation of HUVECs with CD40L. Furthermore, all compounds significantly 
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reduced the production of IL-6 and three metabolites significantly reduced the production of 
sVCAM-1 following stimulation of HUVECs with tumor necrosis factor-α (TNF-α) (Figure 
7.1C). These results demonstrate that the degradation products and metabolites of 
anthocyanins appear to have anti-inflammatory properties. Metabolites containing a catechol 
group (ortho hydroxy) were significantly (p<0.01) bioactive over a greater number of 
concentrations than those containing a methylated catechol group, following stimulation with 
CD40L. The enhanced bioactivity of the compounds containing a catechol group over a 
methoxy group has been previously observed for flavonoids (Spencer et al., 2003; Williams 
et al., 2004).  
 
7.1. Future perspectives 
The main topics addressed in this thesis were the development and validation of methods for 
the detection of anthocyanin metabolites, the bioavailability and metabolism of anthocyanins 
in humans and the bioactivity of anthocyanin metabolites in vitro (Figure 7.1). In the authors 
opinion, the research topics discussed in the proceeding section must have a predominant 
position in future research. 
 
The present thesis describes the development and validation of methods using solid phase 
extraction (SPE) and HPLC-ESI-MS/MS for the quantification of 45 anthocyanin 
metabolites. The validated methods achieved high extraction efficiencies using SPE in urine 
(88.3 ± 17.8%), serum (86.5 ± 11.1%) and faeces (80.6 ± 20.9%) and limits of detection 
below 100 nM for 34, 35 and 30 of the 45 compounds in urine, serum and faeces 
respectively (Figure 7.1). However, in common with the majority of analytical laboratories, 
the developed SPE method utilised individual cartridges, and was performed off-line, 
therefore making it time-consuming and costly in experiments were large number of samples 
need to be analysed. A further step in the development of analytical methods for anthocyanin 
metabolite analysis would be to optimise a 96 well SPE method or an automated on-line SPE 
method, suitable for the extraction of the metabolites of interest, to enable high throughput 
analysis of samples. Another limitation of the developed HPLC-MS/MS methods was that 
high (>100 nM) limits of detection were observed for 11, 10 and 15 of the compounds within 
the urine, serum and faecal matrices respectively. To improve the detection limits of these 
metabolites, future work should focus on developing methods for GCMS analysis, which can 
result in superior detection for the smaller, volatile phenolic acids, such as benzoic acid or 
benzaldehyde. Furthermore, the development of efficient derivatisation methods will 
improve the detection of analytes by increasing their volatility (Fiamegos et al., 2004; 
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Robbins, 2003). The most common silylating reagents used for the derivatisation of phenolic 
acids are trimethylsilyl deratives (Rechner et al., 2002). The development of these methods 
could ultimately enable the detection of anthocyanin metabolites present in samples below 
the detection limit of the current methodology and enable methods to be developed for 
potential anthocyanin metabolites not indicated in the current study.  
 
Matrix effects, such as ion suppression are caused by the presence of co-eluting, residual 
matrix components competing or interfering with the ionisation of the analyte of interest. 
Matrix effects can alter the response and thus the measured concentration of an analyte of 
interest, leading to erroneous results. The analytical methods described in the present study 
(Chapter 2) corrected for this by utilising matrix matched calibration curves. The described 
methods are therefore more robust and more closely match the recommendations set out by 
the U.S. Department of Health and Human Services Food and Drug Administration (FDA) 
(FDA, 2001) than methods developed previously in the flavonoid field. In order to improve 
these methods further, it would be necessary to use labelled calibration standards within the 
sample to quantify unlabelled analytes. 
  
The isotopically labelled study described in the present thesis (Chapter 3) was the first 
labelled anthocyanin bioavailability study to be conducted in humans and enabled the 
identification of 35 anthocyanin metabolites, which has not previously been possible. In 
addition, 11 sulfate and 13 glucuronide conjugates of these metabolites were putatively 
identified using MS
3 
(Figure 7.1). In order to further this work, it would be necessary 
synthesise these novel metabolites. This would allow their retention time and fragmentation 
pattern to be confirmed with certainty and would enable accurate quantification to be 
performed. 
 
Anthocyanins are speculated to undergo conjugation with glutathione (GSH), as the 
nucleophilic cysteinyl thiol group in GSH is easily added to activated double bonds, such as 
those found on aromatic rings (Levsen et al., 2005). Moreover, the formation of quercetin 
GSH conjugates has been observed in murine hepatic suspensions and GSH related 
metabolites of quercetin degradation products have been observed in  human urine (Hong et 
al., 2006). Therefore, future work should additionally focus on identifying possible 
glutathione conjugates of anthocyanins and their metabolites.  
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A number of anthocyanin bioavailability studies conducted to date have investigated the 
dose response and metabolism of anthocyanins (Carkeet et al., 2008; Charron et al., 2007). 
However, the effect of anthocyanin dose on the bioavailability of anthocyanin metabolites is 
currently unknown. Future bioavailability studies should therefore focus on investigating the 
dose response of anthocyanins. For example, a randomised, double blind, crossover 
intervention trial could be conducted where participants are fed an isotopically labelled 
anthocyanin bolus, containing 250 mg, 500 mg and 1000 mg anthocyanins. Blood, urine, 
faecal and breath samples should be collected at baseline and for ≥72 h post bolus in order to 
ensure the concentrations of identified metabolites return to baseline values. 
 
A key finding of this thesis revealed that all metabolites tested significantly reduced the 
production of sVCAM-1 and IL-6 in HUVECs following stimulation with CD40L. 
Moreover, all metabolites tested significantly reduced the production of IL-6 following 
stimulation with TNF-α. This indicates that the degradation products and metabolites of 
anthocyanins have anti-inflammatory properties and suggests they may be responsible for the 
perceived bioactivity of anthocyanins in vivo. The main challenge for future research is 
therefore to characterise the mechanisms by which anthocyanin metabolites act to reduce 
inflammation. Previous work indicates that anthocyanins and anthocyanin metabolites may 
act via the down regulation of nuclear factor- κB (NF-κB) (Karlsen et al., 2007; Wang et al., 
2010) (Min et al., 2010; Speciale et al., 2010; Xia et al., 2009). Alternatively, anthocyanins 
have been shown to reduce the production of pro-inflammatory molecules through 
interacting with the mitogen activated protein kinases (MAPK) family [extracellular signal 
regulated kinase (ERK), p38 and c-jun NH2-terminal kinase (JNK)] (Hirano et al., 1996; 
Min et al., 2010; Xia et al., 2009). In order to deduce whether the six metabolites 
investigated in the present study reduce inflammation via similar mechanisms, it would be 
necessary to carry out a mechanistic study using a range of inhibitors, such as BAY-11-7082, 
an inhibitor of TNF-α induced phosphorylation of IκB-α, in conjunction with techniques 
such as immunoblotting and flow cytometry to investigate how the metabolites are 
regulating the inflammatory pathways. 
 
In addition to characterising the bioactivity of anthocyanin metabolites in vitro, the activity 
of these compounds could be assessed in human intervention studies, to translate the 
identified effects observed in the cellular model to the human. To date, several randomised 
controlled trials with anthocyanins have been conducted describing decreased levels of pro-
inflammatory cell adhesion molecules and cytokines (Karlsen et al., 2007; Zhu et al., 2013). 
To further investigate the bioactivity of anthocyanin metabolites compared to parent 
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anthocyanins, similar interventions could be performed using anthocyanin degradation 
products and metabolites. For example, an acute phase, randomised, double blind, placebo 
controlled, crossover intervention could be conducted where participants are fed a bolus dose 
(500 mg) of protocatechuic acid, vanillic acid, cyanidin-3-glucoside or placebo. Clinical 
vascular measures, such as endothelial vasodilator function and pulse wave analysis and 
biomarkers of inflammation such as plasma levels of nitric oxide metabolites (nitrite, nitrate 
and thionitrites) and pro-inflammatory cytokines could be investigated in such an 
intervention. 
 
In conclusion, this thesis has contributed to the current literature on anthocyanin 
bioavailability and bioactivity by providing novel insights into the metabolism of 
anthocyanins and giving an indication of their bioactivity in vitro. However, further 
investigations into anthocyanin bioavailability and mechanisms of bioactivity are required to 
explain fully the observed cardioprotective effects of anthocyanins. A long-term goal of this 
work would be to supply nutritionist and clinicians with information on how the 
consumption of anthocyanins can be used to reduce risk factors associated with CVD. 
 
 
 
  
  
 
 
191/215 
 
 
List of Abbreviations 
 
ADME  Absorption, distribution, metabolism and excretion 
ANOVA Analysis of variance 
BH4   Tetrahydrobiopterin 
CG   Cytosolic-β-glucosidase 
C3G   Cyanidin-3-O-glucoside 
CAD  Collision-activated dissociation 
CD40  Cluster of differentiation 40 
CD40L  Cluster of differentiation 40 ligand 
CE  Collision Energy 
CEP  Collision cell entry potential 
Cmax  Maximum concentration 
COMT  Catechol-O-methyltransferase 
CUR  Curtain gas 
CV  Coefficient of variation 
CVD  Cardiovascular disease 
CXP  Collision cell exit potential 
Cy  Cyanidin 
DAD  Diode array detector 
DMSO  Dimethyl sulfoxide 
DP  Declustering potential 
ELISA  Enzyme linked immunosorbent assay 
ERK  Extracellular-signal-regulated kinases; 
ESI  Electrospray ionisation 
eNOS  Endothelial nitric oxide synthase 
EP  Entrance potential 
FMD  Flow mediated dilation 
GIT  Gastrointestinal tract 
GLUT2  Glucose transporter 2 
GS1  Gas 1 
GS2  Gas 2 
GSH  Glutathione 
HPLC  High performance liquid chromatography 
HAEC  Human aortic endothelial cells 
  
 
 
192/215 
 
 
HCAEC Human coronary artery endothelial cells 
HUVEC Human umbilical vein endothelial cells 
ICAM  Intercellular adhesion molecules  
IKK  Inhibitory-κB kinase  
IL-6  Interleukin-6 
iNOS  Inducible nitric oxide synthase 
IRMS  Isotope ratio mass spectrometry 
IS  Ion spray voltage 
JAK   Janus kinase 
JNK  c-Jun-N-terminal kinase 
LDL  Low-density lipoprotein 
LIT  Linear ion trap 
LLE  Liquid-liquid extraction 
LPH  Lactase phlorizin hydrolase 
LPS  Lipopolysaccharide 
NADPH Nicotinamide adenine dinucleotide phosphate (reduced form) 
NF-κB  Nuclear factor kappa B 
NH2  Amine 
NO  Nitric oxide 
NOX  NADPH oxidase 
O2
-
  Superoxide 
ONOO
-
  Peroxynitrite 
oxLDL  Oxidised low-density lipoprotein 
MAPK  Mitogen-activated protein kinase complex  
MCP-1  Monocyte chemoattractant protein-1 
MP   Mobile phase 
mRNA  Messenger ribonucleic acid 
MRP2  multiresistant protein 2 
MS  Mass Spectrometry 
m/z  Mass to charge ratio. 
p38  Mitogen-activated protein kinase subunit 
p50   NF-κB p50 subunit 
p65  NF-κB  p65 subunit 
PAPS  3’-phosphoadenosine-5’-phosphosulfate 
PCA  Protocatechuic acid 
PCR  Polymerase chain reaction 
  
 
 
193/215 
 
 
PECAM-1 Platelet endothelial cellular adhesion molecule-1 
PGA  Phloroglucinaldehyde 
Pl3G  Pelargonidin-3-O-glucoside 
PFP  Pentafluorophenyl 
ROS  Reactive oxygen species 
RP  Reverse phase 
Rt  Retention time 
SD  Standard deviation 
SGLT1  Sodium dependent glucose transporter-1 
SOD  Superoxide dismutase 
SPE  Solid Phase Extraction 
STAT  signal transducer and activator of transcription 
SULT   Sulfotransferase  
Tmsx  Time at maximum concentration 
TMS  Trimethylsilyl 
TNF-α   Tumor necrosis factor alpha  
TNFR1   TNF receptor-1 
TOF  Time of flight 
UDPDG  Uridine 5’-diphospho-glucuronosyl transferase 
VCAM-1 Vascular cell adhesion molecule-1 
WHO  World Health Organisation 
  
 
 
194/215 
 
Bibliography 
 
Amaral S, Mira L, Nogueira J, Silva APd, Helena Florêncio M (2009). Plant extracts 
with anti-inflammatory properties—A new approach for characterization of their 
bioactive compounds and establishment of structure–antioxidant activity 
relationships. Bioorganic & medicinal chemistry 17(5): 1876-1883. 
 
Arts IC, Sesink AL, Hollman PC (2002). Quercetin-3-glucoside is transported by the 
glucose carrier SGLT1 across the brush border membrane of rat small intestine. J 
Nutr 132(9): 2823; author reply 2824. 
 
Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. (2011). 
Enterotypes of the human gut microbiome. Nature 473(7346): 174-180. 
 
Aura AM, Martin-Lopez P, O’Leary KA, Williamson  , Oksman-Caldentey KM, 
Poutanen K, et al. (2005). In vitro metabolism of anthocyanins by human gut 
microflora. Eur J Nutr 44(3): 133-142. 
 
Aura AM, O'Leary KA, Williamson G, Ojala M, Bailey M, Puupponen-Pimiä R, et 
al. (2002). Quercetin derivatives are deconjugated and converted to 
hydroxyphenylacetic acids but not methylated by human fecal flora in vitro. J. Agric. 
Food. Chem. 50(6): 1725-1730. 
 
Azzini E, Bugianesi R, Romano F, Di Venere D, Miccadei S, Durazzo A, et al. 
(2007). Absorption and metabolism of bioactive molecules after oral consumption of 
cooked edible heads of Cynara scolymus L. (cultivar Violetto di Provenza) in human 
subjects: a pilot study. British Journal of Nutrition 97(05): 963-969. 
 
Azzini E, Vitaglione P, Intorre F, Napolitano A, Durazzo A, Foddai MS, et al. 
(2010). Bioavailability of strawberry antioxidants in human subjects. Br. J. Nutr. 
104(8): 1165-1173. 
 
Basu A, Du M, Leyva MJ, Sanchez K, Betts NM, Wu M, et al. (2010). Blueberries 
decrease cardiovascular risk factors in obese men and women with metabolic 
syndrome. The Journal of Nutrition 140(9): 1582-1587. 
 
Baud V, Karin M (2001). Signal transduction by tumor necrosis factor and its 
relatives. Trends in cell biology 11(9): 372-377. 
 
Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. (2006). 
Resveratrol improves health and survival of mice on a high-calorie diet. Nature 
444(7117): 337-342. 
 
Bell DR, Gochenaur K (2006). Direct vasoactive and vasoprotective properties of 
anthocyanin-rich extracts. Journal of Applied Physiology 100(4): 1164-1170. 
 
 
  
 
 
195/215 
 
Berg RD (1996). The indigenous gastrointestinal microflora. Trends in Microbiology 
4(11): 430-435. 
 
Bermúdez-Soto M-J, Tomás-Barberán F-A, Garcia-Conesa M-T (2007). Stability of 
polyphenols in chokeberry (Aronia melanocarpa) subjected to in vitro gastric and 
pancreatic digestion. Food Chemistry 102(3): 865-874. 
 
Bitsch R, Netzel M, Frank T, Strass G, Bitsch I (2004a). Bioavailability and 
biokinetics of anthocyanins from red grape juice and red wine. Journal of 
Biomedicine and Biotechnology 2004(5): 293-298. 
 
Bitsch R, Netzel M, Sonntag S, Strass G, Frank T, Bitsch I (2004b). Urinary 
excretion of cyanidin glucosides and glucuronides in healthy humans after elderberry 
juice ingestion. J. Biomed. Biotechnol. 2004(5): 343-345. 
 
Blankenberg S, Barbaux S, Tiret L (2003). Adhesion molecules and atherosclerosis. 
Atherosclerosis 170(2): 191-203. 
 
Boss B, Richling E, Herderich M, Schreier P (1999). HPLC–ESI–MS/MS analysis of 
sulfated flavor compounds in plants. Phytochemistry 50(2): 219-225. 
 
Bouïs D, Hospers GP, Meijer C, Molema G, Mulder N (2001). Endothelium in vitro: 
A review of human vascular endothelial cell lines for blood vessel-related research. 
Angiogenesis 4(2): 91-102. 
 
Bremner P, Heinrich M (2002). Natural products as targeted modulators of the 
nuclear factor‐KB pathway. Journal of Pharmacy and Pharmacology 54(4): 453-
472. 
 
Bub A, Watzl B, Heeb D, Rechkemmer G, Briviba K (2001). Malvidin-3-glucoside 
bioavailability in humans after ingestion of red wine, dealcoholized red wine and red 
grape juice. European Journal of Nutrition 40(3): 113. 
 
Burton-Freeman B (2010). Postprandial metabolic events and fruit-derived 
phenolics: a review of the science. Br J Nutr 104 Suppl 3: S1-14. 
 
Cao G, Muccitelli HU, Sánchez-Moreno C, Prior RL (2001). Anthocyanins are 
absorbed in glycated forms in elderly women: a pharmacokinetic study. Am. J. Clin. 
Nutr. 73(5): 920-926. 
 
Cao G, Sofic E, Prior RL (1997). Antioxidant and prooxidant behavior of flavonoids: 
structure-activity relationships. Free Radical Biology and Medicine 22(5): 749-760. 
 
Cardona F, Andrés-Lacueva C, Tulipani S, Tinahones FJ, Queipo-Ortuño MI (2013). 
Benefits of polyphenols on gut microbiota and implications in human health. The 
Journal of Nutritional Biochemistry 24(8): 1415-1422. 
 
  
 
 
196/215 
 
Carkeet C, Clevidence BA, Novotny JA (2008). Anthocyanin excretion by humans 
increases linearly with increasing strawberry dose. The Journal of Nutrition 138(5): 
897-902. 
 
Carter RA, Wicks IP (2001). Vascular cell adhesion molecule 1 (CD106): a 
multifaceted regulator of joint inflammation. Arthritis & Rheumatism 44(5): 985-
994. 
 
Cassidy A, Mukamal KJ, Liu L, Franz M, Eliassen AH, Rimm EB (2013). High 
anthocyanin intake is associated with a reduced risk of myocardial infarction in 
young and middle-aged women. Circulation 127(2): 188-196. 
 
Cassidy A, O'Reilly ÉJ, Kay CD, Sampson L, Franz M, Forman J, et al. (2011). 
Habitual intake of flavonoid subclasses and incident hypertension in adults. Am J 
Clin Nutr 93(2): 338-347. 
 
Castañeda-Ovando A, Pacheco-Hernández MdL, Páez-Hernández ME, Rodríguez 
JA, Galán-Vidal CA (2009). Chemical studies of anthocyanins: A review. Food 
Chemistry 113(4): 859-871. 
 
Chalker-Scott L (1999). Environmental significance of anthocyanins in plant stress 
responses. Photochemistry and Photobiology 70(1): 1-9. 
 
Chao P-Y, Chen Y-L, Lin Y-C, Hsu J-I, Lin K-H, Lu Y-F, et al. (2013). Effects of 
black soybean on atherogenic prevention in hypercholesterolemic rabbits and on 
adhesion molecular expression in cultured HAECs. Food and Nutrition 4: 9-21. 
 
Charron CS, Clevidence BA, Britz SJ, Novotny JA (2007). Effect of dose size on 
bioavailability of acylated and nonacylated anthocyanins from red cabbage (Brassica 
oleracea L. Var. capitata). J Agric Food Chem 55(13): 5354-5362. 
 
Cheminat A, Brouillard R (1986). PMR investigation of 3-O-([beta]-d-
glucosyl)malvidin structural transformations in aqueous solutions. Tetrahedron 
Letters 27(37): 4457-4460. 
 
Chun OK, Chung SJ, Song WO (2007). Estimated dietary flavonoid intake and major 
food sources of U.S. adults. J Nutr 137(5): 1244-1252. 
 
Clark LC, Thompson HL (1949). Determination of creatine and creatinine in urine. 
Analytical Chemistry 21(10): 1218-1221. 
 
Crozier A, Del Rio D, Clifford MN (2010). Bioavailability of dietary flavonoids and 
phenolic compounds. Molecular Aspects of Medicine 31(6): 446-467. 
 
Crozier A, Jaganath IB, Clifford MN (2009). Dietary phenolics: chemistry, 
bioavailability and effects on health. Natural product reports 26(8): 1001-1043. 
 
Curtis PJ, Kroon PA, Hollands WJ, Walls R, Jenkins G, Kay CD, et al. (2009). 
Cardiovascular disease risk biomarkers and liver and kidney function are not altered 
  
 
 
197/215 
 
in postmenopausal women after ingesting an elderberry extract rich in anthocyanins 
for 12 weeks. J. Nutr. 139(12): 2266-2271. 
 
Czank C, Cassidy A, Zhang Q, Morrison DJ, Preston T, Kroon PA, et al. (2013). 
Human metabolism and elimination of the anthocyanin, cyanidin-3-glucoside: a 13C-
tracer study. Am. J. Clin. Nutr. 97(5): 995-1003. 
 
Dandona P, Aljada A, Bandyopadhyay A (2004). Inflammation: the link between 
insulin resistance, obesity and diabetes. Trends in immunology 25(1): 4-7. 
 
Das NP, Griffiths LA (1969). Studies on flavonoid metabolism. Metabolism of (+)-
[14C] catechin in the rat and guinea pig. Biochem J 115(4): 831-836. 
 
Day AJ, Cañada FJ, Díaz JC, Kroon PA, McLauchlan R, Faulds CB, et al. (2000). 
Dietary flavonoid and isoflavone glycosides are hydrolysed by the lactase site of 
lactase phlorizin hydrolase. FEBS Letters 468(2-3): 166-170. 
 
de Ferrars RM, Cassidy A, Curtis P, Kay CD (2013). Phenolic metabolites of 
anthocyanins following a dietary intervention study in postmenopausal women. Mol 
Nutr Food Res. 
 
de Ferrars RM, Czank C, Zhang Q, Botting NP, Kroon PA, Cassidy A, et al. (2014). 
The pharmacokinetics of anthocyanins and their metabolites in humans British 
Journal of Pharmacology: TBC. 
 
de Pascual-Teresa S, Moreno DA, Garcia-Viguera C (2010). Flavanols and 
anthocyanins in cardiovascular health: a review of current evidence. Int J Mol Sci 
11(4): 1679-1703. 
 
Del Bo’ C, Riso P, Brambilla A,  ardana C, Rizzolo A, Simonetti P, et al. (2012). 
Blanching improves anthocyanin absorption from highbush blueberry (Vaccinium 
corymbosum L.) purée in healthy human volunteers: A pilot study. J. Agric. Food. 
Chem. 60(36): 9298-9304. 
 
Del Rio D, Borges G, Crozier A (2010). Berry flavonoids and phenolics: 
bioavailability and evidence of protective effects. Br J Nutr 104 Suppl 3: S67-90. 
 
Del Rio D, Rodriguez-Mateos A, Spencer JP, Tognolini M, Borges G, Crozier A 
(2013). Dietary (poly) phenolics in human health: structures, bioavailability, and 
evidence of protective effects against chronic diseases. Antioxidants & redox 
signaling 18(14): 1818-1892. 
 
Donovan JL, Bell JR, Kasim-Karakas S, German JB, Walzem RL, Hansen RJ, et al. 
(1999). Catechin is present as metabolites in human plasma after consumption of red 
wine. J Nutr 129(9): 1662. 
 
Donovan JL, Kasim-Karakas S, German JB, Waterhouse AL (2002). Urinary 
excretion of catechin metabolites by human subjects after red wine consumption. Br 
J Nutr 87(1): 31-37. 
  
 
 
198/215 
 
 
Dykes L, Rooney LW (2007). Phenolic compounds in cereal grains and their health 
benefits. Cereal Foods Worldwide 52(3): 105-111. 
 
Edirisinghe I, Banaszewski K, Cappozzo J, McCarthy D, Burton-Freeman BM 
(2011). Effect of black currant anthocyanins on the activation of endothelial nitric 
oxide synthase (eNOS) in vitro in human endothelial cells. J. Agric. Food. Chem. 
59(16): 8616-8624. 
 
Egert S, Wolffram S, Bosy-Westphal A, Boesch-Saadatmandi C, Wagner AE, Frank 
J, et al. (2008). Daily quercetin supplementation dose-dependently increases plasma 
quercetin concentrations in healthy humans. J. Nutr. 138(9): 1615-1621. 
 
Epstein FH, Ross R (1999). Atherosclerosis—an inflammatory disease. New England 
journal of medicine 340(2): 115-126. 
 
Erdman JW, Jr., Balentine D, Arab L, Beecher G, Dwyer JT, Folts J, et al. (2007). 
Flavonoids and Heart Health: proceedings of the ILSI North America Flavonoids 
Workshop, May 31-June 1, 2005, Washington, DC. J Nutr 137(3): 718S-737S. 
 
Fallingborg J (1999). Intraluminal pH of the human gastrointestinal tract. Dan Med 
Bull 46(3): 183-196. 
 
Faria A, Pestana D, Azevedo J, Martel F, de Freitas V, Azevedo I, et al. (2009). 
Absorption of anthocyanins through intestinal epithelial cells – Putative involvement 
of GLUT2. Mol Nutr Food Res 53(11): 1430-1437. 
 
Farrell T, Poquet L, Dionisi F, Barron D, Williamson G (2011). Characterization of 
hydroxycinnamic acid glucuronide and sulfate conjugates by HPLC-DAD-MS2: 
Enhancing chromatographic quantification and application in Caco-2 cell 
metabolism. Journal of Pharmaceutical and Biomedical Analysis 55(5): 1245-1254. 
 
FDA (2001). Food and drug administration. Guidance for industry: bioanalytical 
method validation. In: US Department of Health and Human Services, Food and 
Drug Administration, Center for Drug Evaluation and Research, Rockville, MD: . 
 
Feild TS, Lee DW, Holbrook NM (2001). Why leaves turn red in autumn. The role 
of anthocyanins in senescing leaves of red-osier dogwood. Plant Physiology 127(2): 
566-574. 
 
Felgines C, Krisa S, Mauray A, Besson C, Lamaison JL, Scalbert A, et al. (2010). 
Radiolabelled cyanidin 3-O-glucoside is poorly absorbed in the mouse. Br J Nutr 
103(12): 1738-1745. 
 
Felgines C, Talavera S, Gonthier MP, Texier O, Scalbert A, Lamaison JL, et al. 
(2003). Strawberry anthocyanins are recovered in urine as glucuro- and 
sulfoconjugates in humans. J Nutr 133(5): 1296-1301. 
 
  
 
 
199/215 
 
Felgines C, Talavera S, Texier O, Gil-Izquierdo A, Lamaison JL, Remesy C (2005). 
Blackberry anthocyanins are mainly recovered from urine as methylated and 
glucuronidated conjugates in humans. J. Agric. Food. Chem. 53(20): 7721-7727. 
 
Feng R, Ni HM, Wang SY, Tourkova IL, Shurin MR, Harada H, et al. (2007). 
Cyanidin-3-rutinoside, a natural polyphenol antioxidant, selectively kills leukemic 
cells by induction of oxidative stress. J Biol Chem 282(18): 13468-13476. 
 
Fernandes I, Azevedo J, Faria A, Calhau C, de Freitas V, Mateus N (2008). 
Enzymatic hemisynthesis of metabolites and conjugates of anthocyanins. J Agric 
Food Chem 57(2): 735-745. 
 
Fiamegos YC, Nanos CG, Vervoort J, Stalikas CD (2004). Analytical procedure for 
the in-vial derivatization—extraction of phenolic acids and flavonoids in methanolic 
and aqueous plant extracts followed by gas chromatography with mass-selective 
detection. Journal of Chromatography A 1041(1): 11-18. 
 
Fleschhut J, Kratzer F, Rechkemmer G, Kulling SE (2006). Stability and 
biotransformation of various dietary anthocyanins in vitro. Eur J Nutr 45(1): 7-18. 
 
Forester SC, Waterhouse AL (2008). Identification of Cabernet Sauvignon 
Anthocyanin Gut Microflora Metabolites. J. Agric. Food. Chem. 56(19): 9299-9304. 
 
Förstermann U, Sessa WC (2012). Nitric oxide synthases: regulation and function. 
European Heart Journal 33(7): 829-837. 
 
Fossen T, Cabrita L, Andersen OM (1998). Colour and stability of pure anthocyanins 
influenced by pH including the alkaline region. Food Chemistry 63(4): 435-440. 
 
Fotis L, Giannakopoulos D, Stamogiannou L, Xatzipsalti M (2012). Intercellular cell 
adhesion molecule-1 and vascular cell adhesion molecule-1 in children. Do they play 
a role in the progression of atherosclerosis. Hormones 11: 140-146. 
 
Freudenthaler S, Meineke I, Schreeb K, Boakye E, Gundert-Remy U, Gleiter C 
(1998). Influence of urine pH and urinary flow on the renal excretion of memantine. 
British journal of clinical pharmacology 46: 541-546. 
 
Gabay C (2006). Interleukin-6 and chronic inflammation. Arthritis research and 
therapy 8(2): S3. 
 
Garcia-Alonso M, Minihane A-M, Rimbach G, Rivas-Gonzalo JC, de Pascual-Teresa 
S (2009). Red wine anthocyanins are rapidly absorbed in humans and affect 
monocyte chemoattractant protein 1 levels and antioxidant capacity of plasma. J. 
Nutr. Biochem. 20(7): 521-529. 
 
García-Lafuente A, Guillamón E, Villares A, Rostagno M, Martínez J (2009). 
Flavonoids as anti-inflammatory agents: implications in cancer and cardiovascular 
disease. Inflamm. Res. 58(9): 537-552. 
 
  
 
 
200/215 
 
Gee JM, DuPont MS, Day AJ, Plumb GW, Williamson G, Johnson IT (2000). 
Intestinal transport of quercetin glycosides in rats involves both deglycosylation and 
interaction with the hexose transport pathway. J Nutr 130(11): 2765-2771. 
 
Gee JM, DuPont MS, Rhodes MJ, Johnson IT (1998). Quercetin glucosides interact 
with the intestinal glucose transport pathway. Free Radic Biol Med 25(1): 19-25. 
 
Gonzalez-Barrio R, Christine E, Crozier A (2011). Colonic Catabolism of 
Ellagitannins, Ellagic acid and Raspberry Anthocyanins: In Vivo and In Vitro 
Studies. Drug Metab Dispos. 
 
 onz lez-Barrio Ro, Borges G, Mullen W, Crozier A (2010). Bioavailability of 
anthocyanins and ellagitannins following consumption of raspberries by healthy 
humans and subjects with an ileostomy. J. Agric. Food. Chem. 58(7): 3933-3939. 
 
Gould KS (2004). Nature's swiss army knife: the diverse protective roles of 
anthocyanins in leaves. Journal of Biomedicine and Biotechnology 2004(5): 314-
320. 
 
Graf BA, Ameho C, Dolnikowski GG, Milbury PE, Chen CY, Blumberg JB (2006). 
Rat gastrointestinal tissues metabolize quercetin. J Nutr 136(1): 39. 
 
Griffiths L, Barrow A (1972). Metabolism of flavonoid compounds in germ-free rats. 
Biochemical Journal 130(4): 1161-1162. 
 
Hämäläinen M, Nieminen R, Vuorela P, Heinonen M, Moilanen E (2007). Anti-
inflammatory effects of flavonoids: genistein, kaempferol, quercetin, and daidzein 
inhibit STAT-1 and NF-κ B activations, whereas flavone, isorhamnetin, naringenin, 
and pelargonidin inhibit only NF-κ B activation along with their inhibitory effect on 
iNOS expression and NO production in activated macrophages. Mediators of 
inflammation 2007. 
 
Harada K, Kano M, Takayanagi T, Yamakawa O, Ishikawa F (2004). Absorption of 
acylated anthocyanins in rats and humans after ingesting an extract of Ipomoea 
batatas purple sweet potato tuber. Bioscience, biotechnology, and biochemistry 
68(7): 1500-1507. 
 
Hassimotto NMA, Genovese MI, Lajolo FM (2008). Absorption and metabolism of 
cyanidin-3-glucoside and cyanidin-3-rutinoside extracted from wild mulberry (Morus 
nigra L.) in rats. Nutr Res 28(3): 198-207. 
 
He J, Wallace TC, Keatley KE, Failla ML, Giusti MMn (2009). Stability of black 
raspberry anthocyanins in the digestive tract lumen and transport efficiency into 
gastric and small intestinal tissues in the rat. J. Agric. Food. Chem. 57(8): 3141-
3148. 
 
Heiss C, Jahn S, Taylor M, Real WM, Angeli FS, Wong ML, et al. (2010). 
Improvement of endothelial function with dietary flavanols is associated with 
  
 
 
201/215 
 
mobilization of circulating angiogenic cells in patients with coronary artery disease. 
J Am Coll Cardiol 56(3): 218-224. 
 
Hertrampf R, Gundert-Remy U, Beckmann J, Hoppe U, Elsäßer W, Stein H (1991). 
Elimination of flecainide as a function of urinary flow rate and pH. European journal 
of clinical pharmacology 41(1): 61-63. 
 
Hirano M, Osada S-i, Aoki T, Hirai S-i, Hosaka M, Inoue J-i, et al. (1996). MEK 
kinase is involved in tumor necrosis factor α-induced NF-κB activation and 
degradation of IκB-α. Journal of Biological Chemistry 271(22): 13234-13238. 
 
Hollands W, Brett GM, Dainty JR, Teucher B, Kroon PA (2008). Urinary excretion 
of strawberry anthocyanins is dose dependent for physiological oral doses of fresh 
fruit. Mol Nutr Food Res 52(10): 1097-1105. 
 
Hollman PC, Bijsman MN, van Gameren Y, Cnossen EP, de Vries JH, Katan MB 
(1999). The sugar moiety is a major determinant of the absorption of dietary 
flavonoid glycosides in man. Free Radic Res 31(6): 569-573. 
 
Hollman PC, de Vries JH, van Leeuwen SD, Mengelers MJ, Katan MB (1995). 
Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy 
volunteers. Am J Clin Nutr 62(6): 1276-1282. 
 
Hollman PCH (2004). Absorption, bioavailability, and metabolism of flavonoids. 
Pharmaceutical Biology 42(s1): 74-83. 
 
Hong Y-J, Mitchell AE (2006). Identification of glutathione-related quercetin 
metabolites in humans. Chemical research in toxicology 19(11): 1525-1532. 
 
Hooper L, Kroon PA, Rimm EB, Cohn JS, Harvey I, Le Cornu KA, et al. (2008). 
Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of 
randomized controlled trials. Am. J. Clin. Nutr. 88(1): 38-50. 
 
Huang J, Bathena SPR, Alnouti Y (2010). Metabolite profiling of praziquantel and 
its analogs during the analysis of in vitro metabolic stability using information-
dependent acquisition on a hybrid triple quadrupole linear ion trap mass 
spectrometer. Drug metabolism and pharmacokinetics 25(5): 487-499. 
 
Ichiyanagi T, Rahman MM, Hatano Y, Konishi T, Ikeshiro Y (2007). Protocatechuic 
acid is not the major metabolite in rat blood plasma after oral administration of 
cyanidin 3-O-[beta]-d-glucopyranoside. Food Chemistry 105(3): 1032-1039. 
 
Ichiyanagi T, Rahman MM, Kashiwada Y, Ikeshiro Y, Shida Y, Hatano Y, et al. 
(2004). Absorption and metabolism of delphinidin 3-O-β-d-glucopyranoside in rats. 
Free Radical Biology and Medicine 36(7): 930-937. 
 
Ichiyanagi T, Shida Y, Rahman MM, Hatano Y, Konishi T (2006). Bioavailability 
and tissue distribution of anthocyanins in bilberry (Vaccinium myrtillus L.) extract in 
rats. J. Agric. Food. Chem. 54(18): 6578-6587. 
  
 
 
202/215 
 
 
Jennings A, Welch AA, Fairweather-Tait SJ, Kay C, Minihane A-M, Chowienczyk 
P, et al. (2012). Higher anthocyanin intake is associated with lower arterial stiffness 
and central blood pressure in women. The American Journal of Clinical Nutrition 
96(4): 781-788. 
 
Jeong J-W, Lee WS, Shin SC, Kim G-Y, Choi BT, Choi YH (2013). Anthocyanins 
downregulate lipopolysaccharide-induced inflammatory responses in BV2 microglial 
cells by suppressing the NF-κB and Akt/MAPKs signaling pathways. International 
journal of molecular sciences 14(1): 1502-1515. 
 
Kahle K, Kraus M, Scheppach W, Ackermann M, Ridder F, Richling E (2006). 
Studies on apple and blueberry fruit constituents: Do the polyphenols reach the colon 
after ingestion? Mol Nutr Food Res 50(4-5): 418-423. 
 
Karlsen A, Retterstøl L, Laake P, Paur I, Kjølsrud-Bøhn S, Sandvik L, et al. (2007). 
Anthocyanins inhibit nuclear factor-κB activation in monocytes and reduce plasma 
concentrations of pro-inflammatory mediators in healthy adults. The Journal of 
Nutrition 137(8): 1951-1954. 
 
Kataoka H, Saito K, Yokoyama A (2010). Sampling and sample preparation for 
clinical and pharmaceutical analysis. In: Pawliszyn J, Lord HL (ed)^(eds). Handbook 
of Sample Preparation, edn. Veinheim Wiley-VCH  Verlag. p^pp 285-313. 
 
Kay CD (2010). The future of flavonoid research. Br. J. Nutr. 104(SupplementS3): 
S91-S95. 
 
Kay CD, Hooper L, Kroon PA, Rimm EB, Cassidy A (2012). Relative impact of 
flavonoid composition, dose and structure on vascular function: A systematic review 
of randomised controlled trials of flavonoid‐rich food products. Mol Nutr Food Res 
56(11): 1605-1616. 
 
Kay CD, Kroon PA, Cassidy A (2009). The bioactivity of dietary anthocyanins is 
likely to be mediated by their degradation products. Mol Nutr Food Res 53(S1): 92-
101. 
 
Kay CD, Mazza G, Holub BJ (2005). Anthocyanins exist in the circulation primarily 
as metabolites in adult men. The Journal of Nutrition 135(11): 2582-2588. 
 
Kay CD, Mazza G, Holub BJ, Wang J (2004). Anthocyanin metabolites in human 
urine and serum. Br. J. Nutr. 91(6): 933-942. 
 
Keppler K, Humpf HU (2005). Metabolism of anthocyanins and their phenolic 
degradation products by the intestinal microflora. Bioorg Med Chem 13(17): 5195-
5205. 
 
Keski-Hynnilä H, Kurkela M, Elovaara E, Antonio L, Magdalou J, Luukkanen L, et 
al. (2002). Comparison of electrospray, atmospheric pressure chemical ionization, 
  
 
 
203/215 
 
and atmospheric pressure photoionization in the identification of apomorphine, 
dobutamine, and entacapone phase II metabolites in biological samples. Analytical 
Chemistry 74(14): 3449-3457. 
 
Kim DH, Jung EA, Sohng IS, Han JA, Kim TH, Han MJ (1998). Intestinal bacterial 
metabolism of flavonoids and its relation to some biological activities. Archives of 
pharmacal research 21(1): 17-23. 
 
Kim HJ, Tsoy I, Park JM, Chung JI, Shin SC, Chang KC (2006). Anthocyanins from 
soybean seed coat inhibit the expression of TNF-α-induced genes associated with 
ischemia/reperfusion in endothelial cell by NF-κB-dependent pathway and reduce rat 
myocardial damages incurred by ischemia and reperfusion in vivo. FEBS letters 
580(5): 1391-1397. 
 
Kim S-J, Kim M-C, Um J-Y, Hong S-H (2010). The beneficial effect of vanillic acid 
on ulcerative colitis. Molecules 15(10): 7208-7217. 
 
Kırca A, Özkan M, Cemeroğlu B (2007). Effects of temperature, solid content and 
pH on the stability of black carrot anthocyanins. Food Chemistry 101(1): 212-218. 
 
Kodama DH, Gonçalves AEdSS, Lajolo FM, Genovese MI (2010). Flavonoids, total 
phenolics and antioxidant capacity: comparison between commercial green tea 
preparations. Food Science and Technology (Campinas) 30(4): 1077-1082. 
 
Koli R, Erlund I, Jula A, Marniemi J, Mattila P, Alfthan G (2010). Bioavailability of 
various polyphenols from a diet containing moderate amounts of berries. J. Agric. 
Food. Chem. 58(7): 3927-3932. 
 
Kottra G, Daniel H (2007). Flavonoid glycosides are not transported by the human 
Na+/glucose transporter when expressed in Xenopus laevis oocytes, but effectively 
inhibit electrogenic glucose uptake. J Pharmacol Exp Ther 322(2): 829-835. 
 
Kraemer-Schafhalter A, Fuchs H, Pfannhauser W (1998). Solid-phase extraction 
(SPE)—a comparison of 16 materials for the purification of anthocyanins from 
aronia melanocarpa var Nero. Journal of the Science of Food and Agriculture 78(3): 
435-440. 
 
Kurilich AC, Clevidence BA, Britz SJ, Simon PW, Novotny JA (2005). Plasma and 
urine responses are lower for acylated vs nonacylated anthocyanins from raw and 
cooked purple carrots. J. Agric. Food. Chem. 53(16): 6537-6542. 
 
Kylli P, Nohynek L, Puupponen-Pimia R, Westerlund-Wikstro m B, McDougall G, 
Stewart D, et al. (2010). Rowanberry phenolics: Compositional analysis and 
bioactivities. J Agric Food Chem. 
 
Lapidot T, Harel S, Granit R, Kanner J (1998). Bioavailability of red wine 
anthocyanins as detected in human urine. J. Agric. Food. Chem. 46(10): 4297-4302. 
 
  
 
 
204/215 
 
Lee J, Ebeler SE, Zweigenbaum JA, Mitchell AE (2012). UHPLC-(ESI)QTOF 
MS/MS profiling of quercetin metabolites in human plasma postconsumption of 
applesauce enriched with apple peel and onion. J. Agric. Food. Chem. 60(34): 8510-
8520. 
 
Levsen K, Schiebel HM, Behnke B, Dotzer R, Dreher W, Elend M, et al. (2005). 
Structure elucidation of phase II metabolites by tandem mass spectrometry: an 
overview. J Chromatogr A 1067(1-2): 55-72. 
 
Libby P, Ridker PM, Maseri A (2002). Inflammation and atherosclerosis. Circulation 
105(9): 1135-1143. 
 
Lin S-J, Shyue S-K, Shih M-C, Chu T-H, Chen Y-H, Ku H-H, et al. (2007). 
Superoxide dismutase and catalase inhibit oxidized low-density lipoprotein-induced 
human aortic smooth muscle cell proliferation: Role of cell-cycle regulation, 
mitogen-activated protein kinases, and transcription factors. Atherosclerosis 190(1): 
124-134. 
 
Liu A-H, Guo H, Ye M, Lin Y-H, Sun J-H, Xu M, et al. (2007). Detection, 
characterization and identification of phenolic acids in Danshen using high-
performance liquid chromatography with diode array detection and electrospray 
ionization mass spectrometry. Journal of Chromatography A 1161(1–2): 170-182. 
 
Manach C, Williamson G, Morand C, Scalbert A, Remesy C (2005). Bioavailability 
and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. 
Am. J. Clin. Nutr. 81(1 Suppl): 230S-242S. 
 
Manzano S, Williamson G (2010). Polyphenols and phenolic acids from strawberry 
and apple decrease glucose uptake and transport by human intestinal Caco-2 cells. 
Mol Nutr Food Res 54(12): 1773-1780. 
 
Marks SC, Mullen W, Borges G, Crozier A (2009). Absorption, metabolism, and 
excretion of cider dihydrochalcones in healthy humans and subjects with an 
ileostomy. J Agric Food Chem 57(5): 2009-2015. 
 
Matheny HE, Deem TL, Cook-Mills JM (2000). Lymphocyte migration through 
monolayers of endothelial cell lines involves VCAM-1 signaling via endothelial cell 
NADPH oxidase. The Journal of Immunology 164(12): 6550-6559. 
 
Matsumoto H, Inaba H, Kishi M, Tominaga S, Hirayama M, Tsuda T (2001). Orally 
administered delphinidin 3-rutinoside and cyanidin 3-rutinoside are directly absorbed 
in rats and humans and appear in the blood as the intact forms. J Agric Food Chem 
49(3): 1546-1551. 
 
Mazza G, Brouillard R (1987). Recent developments in the stabilization of 
anthocyanins in food products. Food Chemistry 25(3): 207-225. 
 
Mazza G, Cacace JE, Kay CD (2004). Methods of analysis for anthocyanins in plants 
and biological fluids. J AOAC Int 87(1): 129-145. 
  
 
 
205/215 
 
 
Mazza G, Kay CD, Cottrell T, Holub BJ (2002). Absorption of anthocyanins from 
blueberries and serum antioxidant status in human subjects. J Agric Food Chem 
50(26): 7731-7737. 
 
McCullough ML, Peterson JJ, Patel R, Jacques PF, Shah R, Dwyer JT (2012). 
Flavonoid intake and cardiovascular disease mortality in a prospective cohort of US 
adults. Am J Clin Nutr 95(2): 454-464. 
 
McDougall GJ, Dobson P, Smith P, Blake A, Stewart D (2005a). Assessing potential 
bioavailability of raspberry anthocyanins using an in vitro digestion system. J. Agric. 
Food. Chem. 53(15): 5896-5904. 
 
McDougall GJ, Fyffe S, Dobson P, Stewart D (2007). Anthocyanins from red 
cabbage - stability to simulated gastrointestinal digestion. Phytochemistry 68(9): 
1285-1294. 
 
McDougall GJ, Fyffe S, Dobson P, Stewart D (2005b). Anthocyanins from red wine 
- Their stability under simulated gastrointestinal digestion. Phytochemistry 66(21): 
2540-2548. 
 
McGhie TK, Ainge GD, Barnett LE, Cooney JM, Jensen DJ (2003). Anthocyanin 
glycosides from berry fruit are absorbed and excreted unmetabolized by both humans 
and rats. J Agric Food Chem 51(16): 4539-4548. 
 
McGhie TK, Walton MC (2007). The bioavailability and absorption of anthocyanins: 
towards a better understanding. Mol Nutr Food Res 51(6): 702-713. 
 
Milbury PE, Cao G, Prior RL, Blumberg J (2002). Bioavailablility of elderberry 
anthocyanins. Mech. Ageing Dev. 123(8): 997-1006. 
 
Milbury PE, Vita JA, Blumberg JB (2010). Anthocyanins are bioavailable in humans 
following an acute dose of cranberry juice. The Journal of Nutrition 140(6): 1099-
1104. 
 
Millburn P, Smith R, Williams R (1967). Biliary excretion of foreign compounds. 
Biphenyl, stilboestrol and phenolphthalein in the rat: molecular weight, polarity and 
metabolism as factors in biliary excretion. Biochem. J 105: 1275-1281. 
 
Miller DL, Yaron R, Yellin MJ (1998). CD40L-CD40 interactions regulate 
endothelial cell surface tissue factor and thrombomodulin expression. Journal of 
Leukocyte Biology 63(3): 373-379. 
 
Miller KC, Mack G, Knight KL (2009). Electrolyte and plasma changes after 
ingestion of pickle juice, water, and a common carbohydrate-electrolyte solution. 
Journal of athletic training 44(5): 454. 
 
  
 
 
206/215 
 
Min S-W, Ryu S-N, Kim D-H (2010). Anti-inflammatory effects of black rice, 
cyanidin-3-O-β-D-glycoside, and its metabolites, cyanidin and protocatechuic acid. 
International immunopharmacology 10(8): 959-966. 
 
Mink PJ, Scrafford CG, Barraj LM, Harnack L, Hong CP, Nettleton JA, et al. (2007). 
Flavonoid intake and cardiovascular disease mortality: a prospective study in 
postmenopausal women. Am. J. Clin. Nutr. 85(3): 895-909. 
 
Miyazaki K, Makino K, Iwadate E, Deguchi Y, Ishikawa F (2008). Anthocyanins 
from purple sweet potato Ipomoea batatas cultivar ayamurasaki suppress the 
development of atherosclerotic lesions and both enhancements of oxidative stress 
and soluble vascular cell adhesion molecule-1 in apolipoprotein E-deficient mice. J. 
Agric. Food. Chem. 56(23): 11485-11492. 
 
Miyazawa T, Nakagawa K, Kudo M, Muraishi K, Someya K (1999). Direct intestinal 
absorption of red fruit anthocyanins, cyanidin-3-glucoside and cyanidin-3,5-
diglucoside, into rats and humans. J. Agric. Food. Chem. 47(3): 1083-1091. 
 
Mladěnka P, Zatloukalov  L, Filipský T, Hrdina R (2010). Cardiovascular effects of 
flavonoids are not caused only by direct antioxidant activity. Free Radical Biology 
and Medicine 49(6): 963-975. 
 
Moridani MY, Scobie H, Salehi P, O'Brien PJ (2001). Catechin metabolism: 
glutathione conjugate formation catalyzed by tyrosinase, peroxidase, and cytochrome 
p450. Chem Res Toxicol 14(7): 841-848. 
 
Mulder TP, Rietveld AG, van Amelsvoort JM (2005). Consumption of both black tea 
and green tea results in an increase in the excretion of hippuric acid into urine. Am. J. 
Clin. Nutr. 81(1): 256S-260S. 
 
Mülleder U, Murkovic M, Pfannhauser W (2002). Urinary excretion of cyanidin 
glycosides. J. Biochem. Biophys. Methods 53(1-3): 61-66. 
 
Mullen W, Borges G, Donovan JL, Edwards CA, Serafini M, Lean MEJ, et al. 
(2009). Milk decreases urinary excretion but not plasma pharmacokinetics of cocoa 
flavan-3-ol metabolites in humans. Am J Clin Nutr 89(6): 1784. 
 
Mullen W, Edwards CA, Serafini M, Crozier A (2008a). Bioavailability of 
pelargonidin-3-O-glucoside and Its metabolites in humans following the ingestion of 
strawberries with and without cream. J. Agric. Food. Chem. 56(3): 713-719. 
 
Mullen W, Graf BA, Caldwell ST, Hartley RC, Duthie GG, Edwards CA, et al. 
(2002). Determination of flavonol metabolites in plasma and tissues of rats by 
HPLC-radiocounting and tandem mass spectrometry following oral ingestion of [2-
14C] quercetin-4'-glucoside. J Agric Food Chem 50(23): 6902-6909. 
 
Mullen W, Rouanet J-M, Auger C, Teiss dre P-L, Caldwell ST, Hartley RC, et al. 
(2008b). Bioavailability of [2-14C]quercetin-4′-glucoside in rats. J. Agric. Food. 
Chem. 56(24): 12127-12137. 
  
 
 
207/215 
 
 
Murkovic M, Mülleder U, Adam U, Pfannhauser W (2001). Detection of 
anthocyanins from elderberry juice in human urine. J. Sci. Food Agric. 81(9): 934-
937. 
 
Mutlib AE (2008). Application of stable isotope-labeled compounds in metabolism 
and in metabolism-mediated toxicity studies. Chemical research in toxicology 21(9): 
1672-1689. 
 
Nardini M, Forte M, Vrhovsek U, Mattivi F, Viola R, Scaccini C (2009). White wine 
phenolics are absorbed and extensively metabolized in humans. Journal of 
Agricultural and Food Chemistry 57(7): 2711-2718. 
 
Nardini M, Natella F, Scaccini C, Ghiselli A (2006). Phenolic acids from beer are 
absorbed and extensively metabolized in humans. The Journal of Nutritional 
Biochemistry 17(1): 14-22. 
 
Netzel M, Strass G, Herbst M, Dietrich H, Bitsch R, Bitsch I, et al. (2005). The 
excretion and biological antioxidant activity of elderberry antioxidants in healthy 
humans. Food Research International 38(8): 905-910. 
 
Neveu V, Perez-Jiménez J, Vos F, Crespy V, du Chaffaut L, Mennen L, et al. (2010). 
Phenol-Explorer: an online comprehensive database on polyphenol contents in foods. 
Database 2010. 
 
Nizamutdinova IT, Kim YM, Chung JI, Shin SC, Jeong Y-K, Seo HG, et al. (2009). 
Anthocyanins from black soybean seed coats preferentially inhibit TNF-α-mediated 
induction of VCAM-1 over ICAM-1 through the regulation of GATAs and IRF-1. J. 
Agric. Food. Chem. 57(16): 7324-7330. 
 
Nurmi T, Mursu J, Heinonen M, Nurmi A, Hiltunen R, Voutilainen S (2009). 
Metabolism of berry anthocyanins to phenolic acids in humans. J. Agric. Food. 
Chem. 57(6): 2274-2281. 
 
Ohnishi R, Ito H, Kasajima N, Kaneda M, Kariyama R, Kumon H, et al. (2006). 
Urinary excretion of anthocyanins in humans after cranberry juice ingestion. 
Bioscience, biotechnology, and biochemistry 70(7): 1681-1687. 
 
Ovaskainen M-L, Törrönen R, Koponen JM, Sinkko H, Hellström J, Reinivuo H, et 
al. (2008). Dietary intake and major food sources of polyphenols in finnish adults. 
The Journal of Nutrition 138(3): 562-566. 
 
Pamukcu B, Lip GY, Snezhitskiy V, Shantsila E (2011). The CD40-CD40L system 
in cardiovascular disease. Annals of medicine 43(5): 331-340. 
 
Passamonti S, Vrhovsek U, Mattivi F (2002). The interaction of anthocyanins with 
bilitranslocase. Biochemical and Biophysical Research Communications 296(3): 
631-636. 
 
  
 
 
208/215 
 
Passamonti S, Vrhovsek U, Vanzo A, Mattivi F (2003). The stomach as a site for 
anthocyanins absorption from food. FEBS Lett 544(1-3): 210-213. 
 
Patras A, Brunton NP, O'Donnell C, Tiwari BK (2010). Effect of thermal processing 
on anthocyanin stability in foods; mechanisms and kinetics of degradation. Trends in 
Food Science & Technology 21(1): 3-11. 
 
Pereira D, Valentão P, Pereira J, Andrade P (2009). Phenolics: from chemistry to 
biology. Molecules 14(6): 2202-2211. 
 
Pérez-Vicente A, Gil-Izquierdo A, García-Viguera C (2002). In vitro gastrointestinal 
digestion study of pomegranate juice phenolic compounds, anthocyanins, and 
bitamin C. J. Agric. Food. Chem. 50(8): 2308-2312. 
 
Pergola C, Rossi A, Dugo P, Cuzzocrea S, Sautebin L (2006). Inhibition of nitric 
oxide biosynthesis by anthocyanin fraction of blackberry extract. Nitric oxide 15(1): 
30-39. 
 
Pero RW (2010). Health consequences of catabolic synthesis of hippuric acid in 
humans. Current Clinical Pharmacology 5(1): 67-73. 
 
Piffaut B, Kader F, Girardin M, Metche M (1994). Comparative degradation 
pathways of malvidin 3,5-diglucoside after enzymatic and thermal treatments. Food 
Chemistry 50(2): 115-120. 
 
Piskula MK, Terao J (1998). Accumulation of (−)-epicatechin metabolites in rat 
plasma after oral administration and distribution of conjugation enzymes in rat 
tissues. The Journal of Nutrition 128(7): 1172-1178. 
 
Plazonić A, Bucar F, Maleš Ž, Mornar A, Nigović B, Kujundžić N (2009). 
Identification and quantification of flavonoids and phenolic acids in burr parsley 
(Caucalis platycarpos L.), using high-performance liquid chromatography with diode 
array detection and electrospray ionization mass spectrometry. Molecules 14(7): 
2466-2490. 
 
Proudfoot AT, Krenzelok EP, Brent J, Vale JA (2003). Does urine alkalinization 
increase salicylate elimination? If so, why? Toxicological reviews 22(3): 129-136. 
 
Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. (2010). A 
human gut microbial gene catalogue established by metagenomic sequencing. Nature 
464(7285): 59-65. 
 
Qu J, Wang Y, Luo G, Wu Z (2001). Identification and determination of 
glucuronides and their aglycones in Erigeron breviscapus by liquid chromatography–
tandem mass spectrometry. Journal of Chromatography A 928(2): 155-162. 
 
Ramassamy C (2006). Emerging role of polyphenolic compounds in the treatment of 
neurodegenerative diseases: A review of their intracellular targets. European Journal 
of Pharmacology 545(1): 51-64. 
  
 
 
209/215 
 
 
Rechner AR, Kuhnle G, Bremner P, Hubbard GP, Moore KP, Rice-Evans CA 
(2002). The metabolic fate of dietary polyphenols in humans. Free Radical Biology 
and Medicine 33(2): 220-235. 
 
Riches Z, Stanley EL, Bloomer JC, Coughtrie MWH (2009). Quantitative evaluation 
of the expression and activity of five major sulfotransferases (SULTs) in human 
tissues: the SULT “pie”. Drug Metabolism and Disposition 37(11): 2255-2261. 
 
Rissanen TH, Voutilainen S, Virtanen JK, Venho B, Vanharanta M, Mursu J, et al. 
(2003). Low intake of fruits, berries and vegetables is associated with excess 
mortality in men: the Kuopio Ischaemic Heart Disease Risk Factor (KIHD) Study. 
The Journal of Nutrition 133(1): 199-204. 
 
Robbins RJ (2003). Phenolic acids in foods: an overview of analytical methodology. 
J. Agric. Food. Chem. 51(10): 2866-2887. 
 
Rodriguez-Mateos A, Rendeiro C, Bergillos-Meca T, Tabatabaee S, George TW, 
Heiss C, et al. (2013). Intake and time dependence of blueberry flavonoid–induced 
improvements in vascular function: a randomized, controlled, double-blind, 
crossover intervention study with mechanistic insights into biological activity. Am. J. 
Clin. Nutr. 
 
Roy S, Hawes E, Midha K (1987). Influence of urinary pH on the disposition of 
methoxyphenamine and three metabolites in humans. Journal of pharmaceutical 
sciences 76(6): 427-432. 
 
Russell WR, Scobbie L, Labat A, Duthie GG (2009). Selective bio-availability of 
phenolic acids from Scottish strawberries. Mol. Nutr. Food Res. 53(S1): S85-S91. 
 
Santhanam U, Ghrayeb J, Sehgal PB, May LT (1989). Post-translational 
modifications of human interleukin-6. Archives of Biochemistry and Biophysics 
274(1): 161-170. 
 
Sasaki R, Nishimura N, Hoshino H, Isa Y, Kadowaki M, Ichi T, et al. (2007). 
Cyanidin 3-glucoside ameliorates hyperglycemia and insulin sensitivity due to 
downregulation of retinol binding protein 4 expression in diabetic mice. Biochemical 
Pharmacology 74(11): 1619-1627. 
 
Saxholt E, Christensen AT, Møller A, Hartkopp HB, Hess Ygil K, Hels OH ( 2008). 
Danish food composition databank, revision 7. Database. 
 
Schmitzer V, Veberic R, Slatnar A, Stampar F (2010). Elderberry (Sambucus nigra 
L.) wine: a product rich in health promoting compounds. J. Agric. Food. Chem. 
58(18): 10143-10146. 
 
Schuett H, Luchtefeld M, Grothusen C, Grote K, Schieffer B (2009). How much is 
too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost 
102(2): 215-222. 
  
 
 
210/215 
 
 
Seeram NP, Bourquin LD, Nair MG (2001). Degradation products of cyanidin 
glycosides from tart cherries and their bioactivities. J. Agric. Food. Chem. 49(10): 
4924-4929. 
 
Selma MaV, Esp n JC, Tom s-Barber n FA (2009). Interaction between phenolics 
and gut microbiota: role in human health. J. Agric. Food. Chem. 57(15): 6485-6501. 
 
Sen CK, Bagchi D (2001). Regulation of inducible adhesion molecule expression in 
human endothelial cells by grape seed proanthocyanidin extract. Molecular and 
cellular biochemistry 216(1-2): 1-7. 
 
Sesso HD, Gaziano JM, Jenkins DJ, Buring JE (2007). Strawberry intake, lipids, C-
reactive protein, and the risk of cardiovascular disease in women. J Am Coll Nutr 
26(4): 303-310. 
 
Shaked-Sachray L, Weiss D, Reuveni M, Nissim-Levi A, Oren-Shamir M (2002). 
Increased anthocyanin accumulation in aster flowers at elevated temperatures due to 
magnesium treatment. Physiologia Plantarum 114(4): 559-565. 
 
Shirley BW (1996). Flavonoid biosynthesis:‘new’functions for an ‘old’pathway. 
Trends in Plant Science 1(11): 377-382. 
 
Speciale A, Canali R, Chirafisi J, Saija A, Virgili F, Cimino F (2010). Cyanidin-3-O-
glucoside protection against TNF-α-induced endothelial dysfunction: involvement of 
nuclear factor-κB signaling. J. Agric. Food. Chem. 58(22): 12048-12054. 
 
Spencer J, Kuhnle G, Williams R, Rice-Evans C (2003). Intracellular metabolism 
and bioactivity of quercetin and its in vivo metabolites. Biochem. J 372: 173-181. 
 
Stalmach A, Mullen W, Barron D, Uchida K, Yokota T, Cavin C, et al. (2009a). 
Metabolite profiling of hydroxycinnamate derivatives in plasma and urine after the 
ingestion of coffee by humans: identification of biomarkers of coffee consumption. 
Drug Metab Disp 37(8): 1749. 
 
Stalmach A, Mullen W, Pecorari M, Serafini M, Crozier A (2009b). Bioavailability 
of C-linked dihydrochalcone and flavanone glucosides in humans following 
ingestion of unfermented and fermented rooibos teas. J Agric Food Chem 57(15): 
7104-7111. 
 
Sun J, Liang F, Bin Y, Li P, Duan C (2007). Screening non-colored phenolics in red 
wines using liquid chromatography/ultraviolet and mass spectrometry/mass 
spectrometry libraries. Molecules 12(3): 679-693. 
 
Sun RX, Lu ZY, Wijdenes J, Brochier J, Hertog C, Rossi JF, et al. (1997). Large 
scale and clinical grade purification of syndecan-1+ malignant plasma cells. J 
Immunol Methods 205(1): 73-79. 
 
  
 
 
211/215 
 
Talavéra S, Felgines C, Texier O, Besson C, Gil-Izquierdo A, Lamaison J-L, et al. 
(2005). Anthocyanin metabolism in rats and their distribution to digestive area, 
kidney, and brain. J. Agric. Food. Chem. 53(10): 3902-3908. 
 
Talavéra S, Felgines C, Texier O, Besson C, Lamaison JL, Remesy C (2003). 
Anthocyanins are efficiently absorbed from the stomach in anesthetized rats. J Nutr 
133(12): 4178-4182. 
 
Talavéra S, Felgines C, Texier O, Besson C, Manach C, Lamaison J-L, et al. (2004). 
Anthocyanins are efficiently absorbed from the small intestine in rats. The Journal of 
Nutrition 134(9): 2275-2279. 
 
Tarozzi A, Morroni F, Hrelia S, Angeloni C, Marchesi A, Cantelli-Forti G, et al. 
(2007). Neuroprotective effects of anthocyanins and their in vivo metabolites in SH-
SY5Y cells. Neuroscience Letters 424(1): 36-40. 
 
Toromanović J, Kovač-Bešović E, Šapčanin A, Tahirović I, Rimpapa Z (2008). 
Urinary hippuric acid after ingestion of edible fruits. Bosnian Journal of Basic 
Medical Sciences 8(1): 38-43. 
 
Tsuda T (2011). Dietary anthocyanin-rich plants: Biochemical basis and recent 
progress in health benefits studies. Mol Nutr Food Res 56(1): 159-170. 
 
Tsuda T, Horio F, Osawa T (1999). Absorption and metabolism of cyanidin 3-O-
beta-D-glucoside in rats. FEBS Lett 449(2-3): 179-182. 
 
Valentova K, Stejskal D, Bednar P, Vostalova J, Cihalik C, Vecerova R, et al. 
(2007). Biosafety, antioxidant status, and metabolites in urine after consumption of 
dried cranberry juice in healthy women: a pilot double-blind placebo-controlled trial. 
J. Agric. Food. Chem. 55(8): 3217-3224. 
 
Vauzour D, Vafeiadou K, Rodriguez-Mateos A, Rendeiro C, Spencer JP (2008). The 
neuroprotective potential of flavonoids: a multiplicity of effects. Genes Nutr 3(3-4): 
115-126. 
 
Veberic R, Jakopic J, Stampar F, Schmitzer V (2009). European elderberry 
(Sambucus nigra L.) rich in sugars, organic acids, anthocyanins and selected 
polyphenols. Food Chemistry 114(2): 511-515. 
 
Vitaglione P, Donnarumma G, Napolitano A, Galvano F, Gallo A, Scalfi L, et al. 
(2007). Protocatechuic acid is the major human metabolite of cyanidin-glucosides. J. 
Nutr. 137(9): 2043-2048. 
 
Walgren RA, Lin JT, Kinne RK, Walle T (2000). Cellular uptake of dietary 
flavonoid quercetin 4'-beta-glucoside by sodium-dependent glucose transporter 
SGLT1. J Pharmacol Exp Ther 294(3): 837-843. 
 
Wallace TC (2011). Anthocyanins in cardiovascular disease. Advances in Nutrition: 
An International Review Journal 2(1): 1-7. 
  
 
 
212/215 
 
 
Walle T, Walle UK, Halushka PV (2001). Carbon dioxide is the major metabolite of 
quercetin in humans. The Journal of Nutrition 131(10): 2648-2652. 
 
Wang D, Wei X, Yan X, Jin T, Ling W (2010). Protocatechuic acid, a metabolite of 
anthocyanins, inhibits monocyte adhesion and reduces atherosclerosis in 
apolipoprotein E-deficient mice. J. Agric. Food. Chem. 58(24): 12722-12728. 
 
Wang D, Zou T, Yang Y, Yan X, Ling W (2011). Cyanidin-3-O-β-glucoside with the 
aid of its metabolite protocatechuic acid, reduces monocyte infiltration in 
apolipoprotein E-deficient mice. Biochemical Pharmacology 82(7): 713-719. 
 
Wang Q, Xia M, Liu C, Guo H, Ye Q, Hu Y, et al. (2008). Cyanidin-3-O-β-glucoside 
inhibits iNOS and COX-2 expression by inducing liver X receptor alpha activation in 
THP-1 macrophages. Life Sciences 83(5–6): 176-184. 
 
Wang Y, Ho CT (2009). Metabolism of flavonoids. Forum Nutr 61: 64-74. 
 
Weber J, Van Zanten A (1991). Interferences in current methods for measurements 
of creatinine. Clinical chemistry 37(5): 695-700. 
 
Williams RJ, Spencer JPE, Rice-Evans C (2004). Flavonoids: antioxidants or 
signalling molecules? Free Radical Biology and Medicine 36(7): 838-849. 
 
Williamson G, Clifford MN (2010). Colonic metabolites of berry polyphenols: the 
missing link to biological activity? British Journal of Nutrition 104(S3): S48-S66. 
 
Williamson G, Manach C (2005). Bioavailability and bioefficacy of polyphenols in 
humans. II. Review of 93 intervention studies. Am J Clin Nutr 81(1 Suppl): 243S-
255S. 
 
Winter J, Moore L, Dowell V, Bokkenheuser V (1989). C-ring cleavage of 
flavonoids by human intestinal bacteria. Applied and environmental microbiology 
55(5): 1203-1208. 
 
Wittemer SM, Ploch M, Windeck T, Müller SC, Drewelow B, Derendorf H, et al. 
(2005). Bioavailability and pharmacokinetics of caffeoylquinic acids and flavonoids 
after oral administration of Artichoke leaf extracts in humans. Phytomedicine 12(1–
2): 28-38. 
 
Wolffram S, Block M, Ader P (2002). Quercetin-3-glucoside is transported by the 
glucose carrier SGLT1 across the brush border membrane of rat small intestine. J 
Nutr 132(4): 630-635. 
 
Wong CC, Meinl W, Glatt H-R, Barron D, Stalmach A, Steiling H, et al. (2010). In 
vitro and in vivo conjugation of dietary hydroxycinnamic acids by UDP-
glucuronosyltransferases and sulfotransferases in humans. The Journal of Nutritional 
Biochemistry 21(11): 1060-1068. 
 
  
 
 
213/215 
 
Woodward G, Kroon P, Cassidy A, Kay C (2009). Anthocyanin stability and 
recovery: Implications for the analysis of clinical and experimental samples. J Agr 
Food Chem 57(12): 5271-5278. 
 
Woodward GM, Needs PW, Kay CD (2011). Anthocyanin derived phenolic acids 
form glucuronides following simulated gastrointestinal digestion and microsomal 
glucuronidation. Mol Nutr Food Res 55(3): 378-386. 
 
Wu B, Basu S, Meng S, Wang X, Hu M (2011). Regioselective sulfation and 
glucuronidation of phenolics: Insights into the structural basis. Current Drug 
Metabolism 12(9): 900-916. 
 
Wu X, Beecher GR, Holden JM, Haytowitz DB, Gebhardt SE, Prior RL (2006). 
Concentrations of anthocyanins in common foods in the United States and estimation 
of normal consumption. J Agric Food Chem 54(11): 4069-4075. 
 
Wu X, Cao G, Prior RL (2002). Absorption and metabolism of anthocyanins in 
elderly women after consumption of elderberry or blueberry. J. Nutr. 132(7): 1865-
1871. 
 
Wu X, Gu L, Prior RL, McKay S (2004). Characterization of anthocyanins and 
proanthocyanidins in some cultivars of Ribes, Aronia, and Sambucus and their 
antioxidant capacity. J Agric Food Chem 52(26): 7846-7856. 
 
Wu X, Pittman HE, Mckay S, Prior RL (2005). Aglycones and sugar moieties alter 
anthocyanin absorption and metabolism after berry consumption in weanling pigs. 
The Journal of Nutrition 135(10): 2417-2424. 
 
Xia M, Ling W, Zhu H, Ma J, Wang Q, Hou M, et al. (2009). Anthocyanin 
attenuates CD40-mediated endothelial cell activation and apoptosis by inhibiting 
CD40-induced MAPK activation. Atherosclerosis 202(1): 41-47. 
 
Xu J-W, Ikeda K, Yamori Y (2004a). Cyanidin-3-glucoside regulates 
phosphorylation of endothelial nitric oxide synthase. FEBS Letters 574(1-3): 176-
180. 
 
Xu J-W, Ikeda K, Yamori Y (2004b). Upregulation of enndothelial nitric oxide 
synthase by cyanidin-3-glucoside, a typical anthocyanin pigment. Hypertension 
44(2): 217-222. 
 
Yang J, Meyers KJ, van der Heide J, Liu RH (2004). Varietal differences in phenolic 
content and antioxidant and antiproliferative activities of onions. Journal of 
Agricultural and Food Chemistry 52(22): 6787-6793. 
 
Yokozawa T, Chen CP, Dong E, Tanaka T, Nonaka G-I, Nishioka I (1998). Study on 
the inhibitory effect of tannins and flavonoids against the 1,1-diphenyl-2-
picrylhydrazyl radical. Biochemical Pharmacology 56(2): 213-222. 
 
  
 
 
214/215 
 
Youdim KA, Martin A, Joseph JA (2000). Incorporation of the elderberry 
anthocyanins by endothelial cells increases protection against oxidative stress. Free 
Radical Biology and Medicine 29(1): 51-60. 
 
Zamora-Ros R, Andres-Lacueva C, Lamuela-Raventos RM, Berenguer T, Jakszyn P, 
Barricarte A, et al. (2010). Estimation of dietary sources and flavonoid intake in a 
Spanish adult population (EPIC-Spain). J Am Diet Assoc 110(3): 390-398. 
 
Zhang K, Zuo Y (2004). GC-MS determination of flavonoids and phenolic and 
benzoic acids in human plasma after consumption of cranberry juice. J. Agric. Food. 
Chem. 52(2): 222-227. 
 
Zhang L, Zuo Z, Lin G (2007). Intestinal and hepatic glucuronidation of flavonoids. 
Molecular Pharmaceutics 4(6): 833-845. 
 
Zhang Q, Botting NP, Kay CD (2011). A gram scale synthesis of a multi-13C-
labelled anthocyanin, [6,8,10,3[prime or minute],5[prime or minute]-13C5]cyanidin-
3-glucoside, for use in oral tracer studies in humans. Chemical Communications 
47(38): 10596-10598. 
 
Zhang Q, Raheem KS, Botting NP, Slawin AMZ, Kay CD, O'Hagan D (2012). 
Flavonoid metabolism: the synthesis of phenolic glucuronides and sulfates 
as candidate metabolites for bioactivity studies of dietary flavonoids. Tetrahedron 
68(22): 4194-4201. 
 
Zhang Y, Huo M, Zhou J, Xie S (2010). PKSolver: An add-in program for 
pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Computer 
Methods and Programs in Biomedicine 99(3): 306-314. 
 
Zhou-Stache J, Buettner R, Artmann G, Mittermayer C, Bosserhoff A (2002). 
Inhibition of TNF-α induced cell death in human umbilical vein endothelial cells and 
Jurkat cells by protocatechuic acid. Medical and Biological Engineering and 
Computing 40(6): 698-703. 
 
Zhu Y, Ling W, Guo H, Song F, Ye Q, Zou T, et al. (2013). Anti-inflammatory 
effect of purified dietary anthocyanin in adults with hypercholesterolemia: A 
randomized controlled trial. Nutrition, Metabolism and Cardiovascular Diseases 
23(9): 843-849. 
 
Zhu Y, Xia M, Yang Y, Liu F, Li Z, Hao Y, et al. (2011). Purified anthocyanin 
supplementation improves endothelial function via NO-cGMP activation in 
hypercholesterolemic individuals. Clin Chem 57(11): 1524-1533. 
 
 
 
  
  
 
 
215/215 
 
Appendix 1. Food exclusion list and suggested 
alternatives for
 13
C-cyanidin-3-glucoside 
intervention study. 
For 7 days preceding the study day: 
*Consume no more than a combined intake of 10 portions per week from the foods (berries, 
fruits, vegetables, and other) identified in the “FOODS TO LIMIT‟ category.  
** If a rare food source in not on the list and you are not sure if you can eat it, a good rule of 
thumb is, “if it‟s red or blue, then it‟s not for you”.  
 
Food to Exclude from the 
Diet 
Foods to Limit 
(*Refer to note regarding 
amount of foods permitted) 
Suggested alternatives 
(Unlimited intake) 
FRUITS 
Blueberries Gooseberries Banana 
Blackcurrant Orange Kiwi 
Bilberry Red apples Green apples 
Redcurrant  Grapefruit 
Elderberry  Pear 
Chokeberry  Avocado 
Blackberry  Melon 
Raspberry  Pineapple 
Cherry  Apricots 
Strawberry  Lemon 
Cranberry  Clementine 
Pomegranate  Melon 
Red/purple/blue grape  Green grapes 
Plum   
Red or blood orange   
VEGETABLES 
Aubergine/Eggplant Black bean White onion 
Red onion Purple basil Green / white cabbage 
Red cabbage Purple corn Broccoli 
Red/purple potato Olives Carrots 
Purple carrots  Courgette 
BEVERAGES 
Juices derived from any above 
listed berries, fruits or 
vegetables 
Tea (green or black) 
Coffee 
Ideally, no more than a combined 
total of 2 drinks a day of tea and 
coffee. 
Fruit juices derived from 
non-berry sources 
e.g. Green apple juice etc. 
White wine 
Red wine  
Port  
Sherry 
Alcohol 
-Ideally, no more than a 
combined total of 10 units per 
week of alcohol. 
Milk  
Water  
Carbonated drinks e.g. 
Coca-cola, Sprite 
OTHER 
Jams, sauces or dessert toppings 
derived from any above listed 
berries or fruits 
Purple corn tortillas or crisps 
Peanut skins  
Rhubarb 
Non-berry derived 
desserts, ice-creams and 
crisps 
Cheesecakes or desserts made 
from any above listed berries or 
fruits 
  
